Germany	O	O
Heidelberg	O	O
Germany	O	O
Prostate	O	O
bed	O	O
irradiation	O	O
with	O	O
alternative	O	O
radio	O	O
-	O	O
oncological	O	O
approaches	O	O
(	O	O
PAROS	O	O
)	O	O
-a	O	O
prospective	B-study_type	B-study_type
,	I-study_type	I-study_type
multicenter	I-study_type	I-study_type
and	I-study_type	I-study_type
randomized	I-study_type	I-study_type
phase	I-study_type	I-study_type
III	I-study_type	I-study_type
trial	I-study_type	I-study_type
27	O	O
September	O	O
2018	O	O
.	O	O
27	O	O
September	O	O
2018	O	O
.	O	O
27	O	O
September	O	O
2018	O	O
.	O	O
10.1186	O	O
/	O	O
s13014	O	O
-	O	O
019	O	O
-	O	O
1325-x	O	O
Received	O	O
:	O	O
21	O	O
February	O	O
2019	O	O
Accepted	O	O
:	O	O
26	O	O
June	O	O
2019	O	O

The	O	O
primary	O	O
endpoint	O	O
is	O	O
defined	O	O
as	O	O
the	O	O
change	O	O
in	O	O
the	O	O
bowel	O	O
-	O	O
score	O	O
according	O	O
to	O	O
EORTC	O	O
QLQ	O	O
-	O	O
PR25	O	O
from	O	O
baseline	O	O
to	O	O
12	O	O
weeks	O	O
after	O	O
start	O	O
of	O	O
proton	B-arm_description	O
therapy	I-arm_description	O
compared	O	O
to	O	O
photon	B-arm_description	O
irradiation	I-arm_description	O
.	O	O

The	O	O
trial	O	O
is	O	O
a	O	O
prospective	B-study_type	B-study_type
,	I-study_type	I-study_type
multicenter	I-study_type	I-study_type
,	I-study_type	I-study_type
randomized	I-study_type	I-study_type
phase	I-study_type	I-study_type
III	I-study_type	I-study_type
trial	I-study_type	I-study_type
of	O	O
patients	O	O
with	O	O
operated	O	O
prostate	O	O
carcinoma	O	O
and	O	O
is	O	O
planned	O	O
to	O	O
enroll	O	O
897	O	O
patients	O	O
with	O	O
localized	O	O
prostate	O	O
cancer	O	O
after	O	O
prostatectomy	O	O
.	O	O
Patients	O	O
will	O	O
be	O	O
randomized	O	O
to	O	O
one	O	O
of	O	O
the	O	O
three	O	O
arms	O	O
:	O	O
nRT	B-arm_description	B-arm_description
with	I-arm_description	O
photons	I-arm_description	O
,	O	O
hRT	O	O
with	O	O
photons	O	O
or	O	O
hRT	O	O
with	O	O
protons	O	O
.	O	O
Total	O	O
dose	O	O
is	O	O
70.0	B-arm_dosage	O
Gy	I-arm_dosage	O
in	I-arm_dosage	O
35	I-arm_dosage	O
fractions	I-arm_dosage	O
for	O	O
nRT	B-arm_description	B-arm_description
with	I-arm_description	O
photons	I-arm_description	O
(	O	O
arm	O	B-arm_description
1	O	O
)	O	O
,	O	O
57.0	B-arm_dosage	O
Gy	I-arm_dosage	O
in	I-arm_dosage	O
19	I-arm_dosage	O
fractions	I-arm_dosage	O
for	O	O
hRT	B-arm_description	O
with	I-arm_description	O
photons	I-arm_description	O
(	O	O
arm	O	B-arm_description
2	O	O
)	O	O
and	O	O
57.0	B-arm_dosage	O
Gy	I-arm_dosage	O
relative	O	O
biological	O	O
effectiveness	O	O
(	O	O
RBE	O	O
)	O	O
in	B-arm_dosage	O
19	I-arm_dosage	O
fractions	I-arm_dosage	O
for	O	O
hRT	B-arm_description	O
with	I-arm_description	O
protons	I-arm_description	O
(	O	O
arm	O	B-arm_description
3	O	O
)	O	O
,	O	O
respectively	O	O
(	O	O
Fig	O	O
.	O	O
1	O	O
)	O	O
.	O	O
The	O	O
study	O	O
was	O	O
designed	O	O
as	O	O
a	O	O
multicenter	B-study_type	B-study_type
trial	I-study_type	I-study_type
in	O	O
at	O	O
least	O	O
seven	O	O
radio	O	O
oncological	O	O
centers	O	O
in	O	O
Germany	O	O
and	O	O
is	O	O
conducted	O	O
in	O	O
accordance	O	O
with	O	O
the	O	O
Declaration	O	O
of	O	O
Helsinki	O	O
and	O	O
the	O	O
guidelines	O	O
of	O	O
Good	O	O
Clinical	O	O
Practice	O	O
in	O	O
their	O	O
current	O	O
versions	O	O
.	O	O
Before	O	O
trial	O	O
initiation	O	O
,	O	O
the	O	O
study	O	O
was	O	O
approved	O	O
by	O	O
the	O	O
local	O	O
institutional	O	O
review	O	O
board	O	O
and	O	O
the	O	O
expert	O	O
committee	O	O
of	O	O
the	O	O
German	O	O
Society	O	O
of	O	O
Radiation	O	O
Oncology	O	O
.	O	O
Written	O	O
informed	O	O
consent	O	O
will	O	O
be	O	O
obtained	O	O
from	O	O
all	O	O
patients	O	O
prior	O	O
to	O	O
inclusion	O	O
into	O	O
the	O	O
trial	O	O
.	O	O

Biochemical	O	O
failure	O	O
is	O	O
defined	O	O
as	O	O
two	O	O
consecutive	O	O
increases	O	O
of	O	O
PSA	O	O
from	O	O
nadir	O	O
according	O	O
to	O	O
national	O	O
guidelines	O	O
[	O	O
14][15][16][17	O	O
]	O	O
.	O	O
bPFS	O	O
is	O	O
defined	O	O
as	O	O
time	O	O
from	O	O
first	O	O
diagnosis	O	O
to	O	O
biochemical	O	O
failure	O	O
.	O	O
OS	O	O
is	O	O
defined	O	O
as	O	O
time	O	O
from	O	O
the	O	O
first	O	O
diagnosis	O	O
to	O	O
death	O	O
from	O	O
any	O	O
course	O	O
.	O	O
If	O	O
the	O	O
respective	O	O
event	O	O
has	O	O
been	O	O
observed	O	O
,	O	O
the	O	O
patient	O	O
is	O	O
censored	O	O
at	O	O
the	O	O
date	O	O
of	O	O
the	O	O
last	O	O
follow	O	O
-	O	O
up	O	O
examination	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
considered	O	O
the	O	O
following	O	O
eligibility	O	O
criteria	O	O
for	O	O
patients	O	O
:	O	O
histologically	O	O
proven	O	O
peripheral	O	O
stage	O	O
I	O	O
NSCLC	O	O
,	O	O
diagnosed	O	O
in	O	O
line	O	O
with	O	O
TNM	O	O
Classification	O	O
of	O	O
the	O	O
Union	O	O
for	O	O
International	O	O
Cancer	O	O
Control	O	O
's	O	O
(	O	O
7th	O	O
Edition	O	O
)	O	O
;	O	O
inoperable	O	O
,	O	O
or	O	O
refusal	O	O
of	O	O
surgery	O	O
;	O	O
a	O	O
measurable	O	O
tumor	O	O
;	O	O
and	O	O
an	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
's	O	O
scale	O	O
performance	O	O
status	O	O
between	O	O
0	O	O
and	O	O
2	O	O
.	O	O
The	O	O
following	O	O
were	O	O
set	O	O
as	O	O
exclusion	O	O
criteria	O	O
:	O	O
a	O	O
previous	O	O
history	O	O
of	O	O
radiotherapy	O	O
anywhere	O	O
near	O	O
the	O	O
target	O	O
volume	O	O
;	O	O
chemotherapy	O	O
within	O	O
the	O	O
month	O	O
prior	O	O
to	O	O
C	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
ion	I-arm_description	I-arm_description
RT	I-arm_description	I-arm_description
;	O	O
a	O	O
life	O	O
expectancy	O	O
estimated	O	O
to	O	O
be	O	O
≤6	O	O
months	O	O
;	O	O
a	O	O
second	O	O
active	O	O
cancer	O	O
;	O	O
interstitial	O	O
pneumonitis	O	O
;	O	O
or	O	O
an	O	O
intractable	O	O
infectious	O	O
disease	O	O
in	O	O
the	O	O
region	O	O
of	O	O
the	O	O
target	O	O
volume	O	O
.	O	O
Each	O	O
patient	O	O
's	O	O
eligibility	O	O
was	O	O
confirmed	O	O
at	O	O
a	O	O
joint	O	O
conference	O	O
involving	O	O
medical	O	O
oncologists	O	O
,	O	O
thoracic	O	O
surgeons	O	O
,	O	O
and	O	O
radiation	O	O
oncologists	O	O
.	O	O

Depending	O	O
on	O	O
the	O	O
tumor	O	O
location	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
immobilized	O	O
in	O	O
the	O	O
supine	O	O
or	O	O
prone	O	O
position	O	O
using	O	O
a	O	O
thermoplastic	O	O
shell	O	O
(	O	O
Shellfitter	O	O
;	O	O
Sanyo	O	O
Polymer	O	O
Industrial	O	O
)	O	O
with	O	O
a	O	O
pillow	O	O
made	O	O
of	O	O
water	O	O
-	O	O
sclerogenic	O	O
polymers	O	O
(	O	O
Moldcare	O	O
;	O	O
ALCARE	O	O
)	O	O
.	O	O
To	O	O
achieve	O	O
a	O	O
suitable	O	O
posture	O	O
for	O	O
oblique	O	O
beam	O	O
irradiation	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
rotated	O	O
±	O	O
15	O	O
°	O	O
to	O	O
the	O	O
superior	O	O
-	O	O
inferior	O	O
axis	O	O
.	O	O
Subsequently	O	O
,	O	O
computed	O	O
tomography	O	O
(	O	O
CT	O	O
)	O	O
was	O	O
run	O	O
in	O	O
2-mm	O	O
slices	O	O
with	O	O
two	O	O
different	O	O
body	O	O
positions	O	O
.	O	O
A	O	O
respiratory	O	O
-	O	O
gated	O	O
CT	O	O
image	O	O
was	O	O
obtained	O	O
after	O	O
exhaling	O	O
.	O	O
This	O	O
was	O	O
followed	O	O
by	O	O
a	O	O
four	O	O
-	O	O
dimensional	O	O
CT	O	O
scan	O	O
to	O	O
account	O	O
for	O	O
respiratory	O	O
motion	O	O
,	O	O
reconstructing	O	O
four	O	O
-	O	O
dimensional	O	O
images	O	O
for	O	O
each	O	O
phase	O	O
of	O	O
respiration	O	O
.	O	O

We	O	O
calculated	O	O
local	O	O
control	O	O
rates	O	O
or	O	O
survival	O	O
times	O	O
starting	O	O
with	O	O
the	O	O
first	O	O
day	O	O
of	O	O
C	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
ion	I-arm_description	I-arm_description
RT	I-arm_description	I-arm_description
administration	O	O
.	O	O
The	O	O
Kaplan	O	O
-	O	O
Meier	O	O
method	O	O
was	O	O
applied	O	O
to	O	O
determine	O	O
the	O	O
defined	O	O
endpoints	O	O
(	O	O
local	O	O
control	O	O
rate	O	O
,	O	O
OS	O	O
rate	O	O
,	O	O
and	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
rate	I-arm_efficacy_metric	O
)	O	O
.	O	O
For	O	O
purposes	O	O
of	O	O
sample	O	O
size	O	O
calculation	O	O
,	O	O
we	O	O
hypothesized	O	O
that	O	O
the	O	O
2-year	O	O
local	O	O
control	O	O
rate	O	O
of	O	O
stage	O	O
I	O	O
NSCLC	O	O
would	O	O
be	O	O
60	O	O
%	O	O
by	O	O
conventionally	O	O
fractionated	O	O
radiation	O	O
therapy	O	O
with	O	O
photons	O	O
and	O	O
90	O	O
%	O	O
by	O	O
C	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
ion	I-arm_description	I-arm_description
RT	I-arm_description	I-arm_description
.	O	O
Using	O	O
the	O	O
normal	O	O
approximation	O	O
,	O	O
we	O	O
calculated	O	O
that	O	O
35	O	O
patients	O	O
would	O	O
be	O	O
needed	O	O
for	O	O
80	O	O
%	O	O
power	O	O
and	O	O
95	O	O
%	O	O
confidence	O	O
.	O	O
In	O	O
the	O	O
univariate	O	O
analyses	O	O
,	O	O
we	O	O
applied	O	O
log	O	O
-	O	O
rank	O	O
tests	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
age	O	O
group	O	O
,	O	O
sex	O	O
,	O	O
histological	O	O
type	O	O
,	O	O
performance	O	O
status	O	O
,	O	O
T	O	O
stage	O	O
of	O	O
TNM	O	O
classification	O	O
,	O	O
operability	O	O
,	O	O
and	O	O
smoking	O	O
history	O	O
on	O	O
the	O	O
study	O	O
's	O	O
endpoints	O	O
.	O	O
P	O	O
-	O	O
values	O	O
of	O	O
lower	O	O
than	O	O
0.05	O	O
were	O	O
considered	O	O
as	O	O
statistically	O	O
significant	O	O
.	O	O
All	O	O
tests	O	O
were	O	O
performed	O	O
two	O	O
-	O	O
tailed	O	O
with	O	O
JMP	O	O
version	O	O
12.2.0	O	O
(	O	O
SAS	O	O
Institute	O	O
Inc	O	O
)	O	O
.	O	O

30	O	O
Duke	O	O
Medicine	O	O
Circle	O	O
,	O	O
Room	O	O
#	O	O
0050	O	O
,	O	O
Durham	O	O
Box	O	O
3216	O	O
27705	O	O
NC	O	O
USA	O	O
HerbertIHurwitz	B-authors	B-authors
Genentech	O	O
,	O	O
Inc	O	O
94080	O	O
South	O	O
San	O	O
Francisco	O	O
CA	O	O
USA	O	O

HTG	O	O
Molecular	O	O
Diagnostics	O	O
,	O	O
Leadiant	O	O
Biosciences	O	O
,	O	O
MedPacto	O	O
Inc.	O	O
,	O	O
Novartis	O	O
,	O	O
Seattle	O	O
Genetics	O	O
,	O	O
and	O	O
Tracon	O	O
Pharma	O	O
.	O	O
Dr.	B-authors	O
Strickler	I-authors	O
discloses	O	O
receiving	O	O
research	O	O
funding	O	O
from	O	O
Seattle	O	O
Genetics	O	O
,	O	O
Exelixis	O	O
,	O	O
Amgen	O	O
,	O	O
AbbVie	O	O
,	O	O
Genentech	O	O
/	O	O
Roche	O	O
,	O	O
and	O	O
Sanofi	O	O
Genzyme	O	O
.	O	O
Additionally	O	O
,	O	O
Dr.	B-authors	O
Strickler	I-authors	O
performs	O	O
consulting	O	O
and	O	O
honoraria	O	O
work	O	O
for	O	O
Amgen	O	O

Of	O	O
the	O	O
63	O	O
patients	O	O
that	O	O
accrued	O	O
to	O	O
the	O	O
study	O	O
,	O	O
a	O	O
total	O	O
of	O	O
31	O	O
tumor	O	O
samples	O	O
yielded	O	O
sufficient	O	O
RNA	O	O
for	O	O
reverse	O	O
-	O	O
transcription	O	O
.	O	O
Expression	O	O
levels	O	O
of	O	O
VEGF	O	O
-	O	O
A	O	O
,	O	O
VEGF	O	O
-	O	O
C	O	O
,	O	O
VEGF	O	O
-	O	O
D	O	O
,	O	O
PlGF	O	O
,	O	O
NRP1	O	O
,	O	O
and	O	O
NRP2	O	O
were	O	O
quantified	O	O
using	O	O
preformulated	O	O
TaqMan	O	O
real	O	O
-	O	O
time	O	O
PCR	O	O
assays	O	O
and	O	O
TaqMan	O	O
Gene	O	O
Expression	O	O
Master	O	O
Mix	O	O
(	O	O
Applied	O	O
Biosystems	O	O
,	O	O
Foster	O	O
City	O	O
,	O	O
CA	O	O
)	O	O
in	O	O
10	O	O
μl	O	O
reactions	O	O
according	O	O
to	O	O
the	O	O
manufacturer	O	O
's	O	O
instructions	O	O
.	O	O
All	O	O
assays	O	O
were	O	O
run	O	O
in	O	O
duplicate	O	O
.	O	O
If	O	O
the	O	O
standard	O	O
deviation	O	O
(	O	O
SD	O	O
)	O	O
in	O	O
cycle	O	O
thresholds	O	O
(	O	O
CT	O	O
)	O	O
between	O	O
replicate	O	O
wells	O	O
was	O	O
>	O	O
0.5	O	O
then	O	O
the	O	O
reaction	O	O
was	O	O
rerun	O	O
.	O	O
If	O	O
the	O	O
rerun	O	O
data	O	O
improved	O	O
replicate	O	O
consistency	O	O
(	O	O
SD	O	O
<	O	O
0.5	O	O
)	O	O
,	O	O
then	O	O
the	O	O
rerun	O	O
data	O	O
was	O	O
used	O	O
.	O	O
Gene	O	O
expressions	O	O
levels	O	O
were	O	O
normalized	O	O
to	O	O
β	O	O
-	O	O
actin	O	O
using	O	O
the	O	O
ΔCT	O	O
method	O	O
.	O	O
Gene	O	O
-	O	O
specific	O	O
assays	O	O
are	O	O
listed	O	O
in	O	O
Additional	O	O
file	O	O
1	O	O
:	O	O
Table	O	O
S1	O	O
.	O	O

Within	O	O
the	O	O
expansion	O	O
cohort	O	O
,	O	O
forty	O	O
-	O	O
five	O	O
patients	O	O
(	O	O
90	O	O
%	O	O
)	O	O
had	O	O
experienced	O	O
disease	O	O
progression	O	O
on	O	O
bevacizumab	O	B-arm_description
prior	O	O
to	O	O
enrollment	O	O
.	O	O
One	O	O
patient	O	O
had	O	O
received	O	O
ziv	O	B-arm_description
-	O	I-arm_description
aflibercept	O	I-arm_description
prior	O	O
to	O	O
enrollment	O	O
(	O	O
in	O	O
combination	O	O
with	O	O
FOLFIRI	O	B-arm_description
)	O	O
,	O	O
and	O	O
this	O	O
patient	O	O
experienced	O	O
disease	O	O
progression	O	O
.	O	O

Endpoints	O	O
included	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
OS	O	O
,	O	O
overall	O	O
response	O	O
rate	O	O
(	O	O
ORR	O	O
)	O	O
,	O	O
improvement	O	O
in	O	O
hematologic	O	O
parameters	O	O
,	O	O
patient	O	O
-	O	O
reported	O	O
outcomes	O	O
,	O	O
and	O	O
safety	O	O
.	O	O
Long	O	O
-	O	O
term	O	O
PD	O	O
and	O	O
response	O	O
were	O	O
assessed	O	O
by	O	O
the	O	O
investigator	O	O
per	O	O
2008	O	O
International	O	O
Workshop	O	O
on	O	O
CLL	O	O
(	O	O
iwCLL	O	O
)	O	O
criteria	O	O
[	O	O
12	O	O
]	O	O
.	O	O
Long	O	O
-	O	O
term	O	O
safety	O	O
data	O	O
are	O	O
reported	O	O
for	O	O
patients	O	O
who	O	O
were	O	O
initially	O	O
randomized	O	O
to	O	O
ibrutinib	B-arm_description	B-arm_description
.	O	O
Nonhematologic	O	O
adverse	O	O
events	O	O
(	O	O
AEs	O	O
)	O	O
were	O	O
graded	O	O
using	O	O
Common	O	O
Terminology	O	O
Criteria	O	O
for	O	O
Adverse	O	O
Events	O	O
,	O	O
v4.03	O	O
[	O	O
13	O	O
]	O	O
.	O	O
Hematologic	O	O
AEs	O	O
were	O	O
graded	O	O
using	O	O
iwCLL	O	O
criteria	O	O
[	O	O
12	O	O
]	O	O
.	O	O

With	O	O
a	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
5	O	O
years	O	O
(	O	O
up	O	O
to	O	O
66	O	O
months	O	O
)	O	O
,	O	O
the	O	O
ORR	O	O
including	O	O
partial	O	O
response	O	O
with	O	O
lymphocytosis	O	O
was	O	O
92	O	O
%	O	O
for	O	O
patients	O	O
treated	O	O
with	O	O
ibrutinib	B-arm_description	B-arm_description
compared	O	O
with	O	O
37	O	O
%	O	O

Treatment	O	O
discontinuations	O	O
decreased	O	O
over	O	O
time	O	O
on	O	O
ibrutinib	B-arm_description	B-arm_description
,	O	O
with	O	O
7	O	O
%	O	O
of	O	O
patients	O	O
discontinuing	O	O
because	O	O
of	O	O
AEs	O	B-arm_description
in	O	O
years	O	O
0	O	O
-	O	O
1	O	O
,	O	O
6	O	O
%	O	O
in	O	O
years	O	O
1	O	O
-	O	O
2	O	O
,	O	O
5	O	O
%	O	O
in	O	O
years	O	O
2	O	O
-	O	O
3	O	O
,	O	O
6	O	O
%	O	O
in	O	O
years	O	O
3	O	O
-	O	O
4	O	O
,	O	O
and	O	O
1	O	O
%	O	O
in	O	O
years	O	O
4	O	O
-	O	O
5	O	O
(	O	O
Supplementary	O	O
Fig	O	O
.	O	O
6	O	O
)	O	O
.	O	O
Thirtyeight	O	O
patients	O	O
experienced	O	O
AEs	O	O
leading	O	O
to	O	O
discontinuation	O	O
of	O	O
ibrutinib	B-arm_description	B-arm_description
;	O	O
those	O	O
reported	O	O
in	O	O
≥2	O	O
patients	O	O
were	O	O
atrial	O	O
fibrillation	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
,	O	O
and	O	O
palpitations	O	O
,	O	O
pneumonia	O	O
,	O	O
and	O	O
worsening	O	O
CLL	O	O
(	O	O
n	O	O
=	O	O
2	O	O
each	O	O
)	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
2	O	O
deaths	O	O
with	O	O
unknown	O	O
cause	O	O
.	O	O

At	O	O
the	O	O
time	O	O
of	O	O
data	O	O
cutoff	O	O
,	O	O
23	O	O
patients	O	O
randomized	O	O
to	O	O
ibrutinib	B-arm_description	B-arm_description
died	O	O
(	O	O
8	O	O
while	O	O
on	O	O
treatment	O	O
)	O	O
;	O	O
4	O	O
due	O	O
to	O	O
PD	O	O
(	O	O
all	O	O
were	O	O
aged	O	O
≥70	O	O
years	O	O
)	O	O
.	O	O
One	O	O
AE	O	O
of	O	O
pneumonia	O	O
was	O	O
considered	O	O
possibly	O	O
related	O	O
to	O	O
ibrutinib	O	B-arm_description
.	O	O
There	O	O
were	O	O
six	O	O
patients	O	O
for	O	O
whom	O	O
cause	O	O
of	O	O
death	O	O
was	O	O
unknown	O	O
,	O	O
and	O	O
of	O	O
the	O	O
remaining	O	O
,	O	O
there	O	O
were	O	O
two	O	O
infections	O	O
,	O	O
three	O	O
second	O	O
malignancies	O	O
,	O	O
and	O	O
one	O	O
each	O	O
reported	O	O
as	O	O
multiorgan	O	O
failure	O	O
,	O	O
heart	O	O
attack	O	O
,	O	O
sudden	O	O
death	O	O
,	O	O
heart	O	O
failure	O	O
,	O	O
sepsis	O	O
,	O	O
pulmonary	O	O
fibrosis	O	O
,	O	O
and	O	O
septic	O	O
shock	O	O
(	O	O
Supplementary	O	O
Fig	O	O
.	O	O
7	O	O
)	O	O
.	O	O

Randomised	B-study_type	O
phase	I-study_type	B-study_type
II	I-study_type	I-study_type
trial	I-study_type	I-study_type
of	O	O
mFOLFOX6	B-arm_description	B-arm_description
plus	I-arm_description	I-arm_description
bevacizumab	I-arm_description	B-arm_description
versus	O	O
mFOLFOX6	B-arm_description	B-arm_description
plus	I-arm_description	I-arm_description
cetuximab	I-arm_description	I-arm_description
as	O	O
first	O	O
-	O	O
line	O	O
treatment	O	O
for	O	O
colorectal	O	O
liver	O	O
metastasis	O	O
(	O	O
ATOM	O	O
trial	O	O
)	O	O
EijiOki	B-authors	B-authors
okieiji@surg2.med.kyushu-u.ac.jp	O	B-authors

Japan	O	O
Fukuoka	O	O
Japan	O	O
Randomised	B-study_type	B-study_type
phase	I-study_type	I-study_type
II	I-study_type	I-study_type
trial	I-study_type	I-study_type
of	O	O
mFOLFOX6	B-arm_description	B-arm_description
plus	I-arm_description	I-arm_description
bevacizumab	I-arm_description	B-arm_description
versus	O	O
mFOLFOX6	B-arm_description	B-arm_description
plus	I-arm_description	I-arm_description
cetuximab	I-arm_description	I-arm_description
as	O	O
first	O	O
-	O	O
line	O	O
treatment	O	O
for	O	O
colorectal	O	O
liver	O	O
metastasis	O	O
(	O	O
ATOM	O	O
trial	O	O
)	O	O
9	O	O
July	O	O
2019	O	O
9	O	O
July	O	O
2019	O	O
9	O	O
July	O	O
2019	O	O
10.1038	O	O
/	O	O
s41416	O	O
-	O	O
019	O	O
-	O	O
0518	O	O
-	O	O
2	O	O
Received	O	O
:	O	O
16	O	O
March	O	O
2019	O	O
Revised	O	O
:	O	O
12	O	O
June	O	O
2019	O	O
Accepted	O	O
:	O	O
20	O	O
June	O	O
2019	O	O

Patients	O	O
received	O	O
either	O	O
mFOLFOX6	B-arm_description	B-arm_description
plus	I-arm_description	I-arm_description
BEV	I-arm_description	I-arm_description
(	B-arm_dosage	O
BEV	I-arm_dosage	B-arm_dosage
5	I-arm_dosage	I-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
kg	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	O
followed	I-arm_dosage	O
by	I-arm_dosage	O
oxaliplatin	B-arm_dosage	B-arm_description
85	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
l	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
leucovorin	I-arm_dosage	O
200	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
and	I-arm_dosage	O
bolus	I-arm_dosage	O
infusion	I-arm_dosage	O
of	I-arm_dosage	O
fluorouracil	I-arm_dosage	O
400	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	O
Day	I-arm_dosage	O
1	I-arm_dosage	O
and	I-arm_dosage	O
continuous	I-arm_dosage	O
fluorouracil	I-arm_dosage	O
infusion	I-arm_dosage	O
2400	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	O
Day	I-arm_dosage	O
1	I-arm_dosage	O
through	I-arm_dosage	O
Day	I-arm_dosage	O
2	I-arm_dosage	O
)	I-arm_dosage	O
or	O	O
mFOLFOX6	B-arm_description	B-arm_description
plus	O	I-arm_description
CET	B-arm_description	I-arm_description
(	O	O
CET	O	B-arm_dosage
400	B-arm_dosage	I-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
as	I-arm_dosage	O
the	I-arm_dosage	O
initial	I-arm_dosage	O
dose	I-arm_dosage	O
and	I-arm_dosage	O
250	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
as	I-arm_dosage	O
the	I-arm_dosage	O
subsequent	I-arm_dosage	O
doses	I-arm_dosage	O
on	I-arm_dosage	O
Days	I-arm_dosage	O
1	I-arm_dosage	O
and	I-arm_dosage	O
8	I-arm_dosage	O
,	O	O
followed	O	O
by	O	O
mFOLFOX6	O	B-arm_description
)	O	O
,	O	O
no	B-arm_dosage	O
later	I-arm_dosage	O
than	I-arm_dosage	O
2	I-arm_dosage	O
weeks	I-arm_dosage	O
after	I-arm_dosage	O
enrolment	I-arm_dosage	O
in	I-arm_dosage	O
the	I-arm_dosage	O
study	I-arm_dosage	O
.	O	O
Study	O	O
treatments	O	O
were	O	O
continued	O	O
in	O	O
2-week	O	O
cycles	O	O
until	O	O
disease	O	O
progression	O	O
.	O	O
In	O	O
accordance	O	O
with	O	O
the	O	O
Response	O	O
Evaluation	O	O
Criteria	O	O
In	O	O
Solid	O	O
Tumours	O	O
version	O	O
1.1	O	O
,	O	O
the	O	O
same	O	O
methods	O	O
were	O	O
used	O	O
to	O	O
perform	O	O
tumour	O	O
assessment	O	O
at	O	O
baseline	O	O
and	O	O
every	O	O
subsequent	O	O
8	O	O
weeks	O	O
using	O	O
torso	O	O
contrast	O	O
-	O	O
enhanced	O	O
computed	O	O
tomography	O	O
(	O	O
CT	O	O
)	O	O
,	O	O
liver	O	O
contrast	O	O
-	O	O
enhanced	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
,	O	O
or	O	O
whole	O	O
-	O	O
body	O	O
non	O	O
-	O	O
contrast	O	O
CT	O	O
.	O	O
The	O	O
tumour	O	O
histopathological	O	O
response	O	O
rate	O	O
was	O	O
defined	O	O
as	O	O
the	O	O
proportion	O	O
of	O	O
patients	O	O
with	O	O
grade	O	O
≥Ib	O	O
in	O	O
accordance	O	O
with	O	O
the	O	O
following	O	O
definition	O	O
:	O	O
grade	O	O
0	O	O
,	O	O
no	O	O
necrosis	O	O
in	O	O
the	O	O
tumour	O	O
;	O	O
grade	O	O
1a	O	O
,	O	O
necrosis	O	O
in	O	O
<	O	O
33.3	O	O
%	O	O
of	O	O
the	O	O
tumour	O	O
;	O	O
grade	O	O
1b	O	O
,	O	O
necrosis	O	O
in	O	O
33.3	O	O
-	O	O
66.6	O	O
%	O	O
of	O	O
the	O	O
tumour	O	O
;	O	O
grade	O	O
2	O	O
,	O	O
necrosis	O	O
in	O	O
66.6-<100	O	O
%	O	O
of	O	O
the	O	O
tumour	O	O
;	O	O
and	O	O
grade	O	O
3	O	O
,	O	O
necrosis	O	O
in	O	O
100	O	O
%	O	O
of	O	O
the	O	O
tumour	O	O
.	O	O

The	O	O
primary	O	O
endpoint	O	O
was	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
as	O	O
assessed	O	O
by	O	O
the	O	O
Independent	O	O
Central	O	O
Review	O	O
Committee	O	O
(	O	O
IRC	O	O
)	O	O
.	O	O
The	O	O
cases	O	O
were	O	O
not	O	O
censored	O	O
at	O	O
the	O	O
time	O	O
of	O	O
liver	O	O
resection	O	O
.	O	O
Recurrence	O	O
was	O	O
considered	O	O
to	O	O
be	O	O
a	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
event	O	O
in	O	O
patients	O	O
who	O	O
underwent	O	O
liver	O	O
resection	O	O
after	O	O
protocol	O	O
treatment	O	O
.	O	O
Secondary	O	O
endpoints	O	O
included	O	O
response	O	O
rate	O	O
,	O	O
tumour	O	O
shrinkage	O	O
at	O	O
week	O	O
8	O	O
,	O	O
liver	O	O
resection	O	O
rate	O	O
,	O	O
time	O	O
to	O	O
treatment	O	O
failure	O	O
,	O	O
OS	O	O
,	O	O
quality	O	O
of	O	O
life	O	O
,	O	O
and	O	O
adverse	O	O
events	O	O
(	O	O
AEs	O	O
)	O	O
.	O	O

Phase	B-study_type	B-study_type
II	I-study_type	I-study_type
trial	I-study_type	I-study_type
of	O	O
AKT	O	B-arm_description
inhibitor	O	O
MK-2206	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
breast	O	O
cancer	O	O
who	O	O
have	O	O
tumors	O	O
with	O	O
PIK3CA	B-arm_description	B-arm_description
or	I-arm_description	I-arm_description
AKT	I-arm_description	I-arm_description
mutations	I-arm_description	I-arm_description
,	O	O
and/or	O	O
PTEN	B-arm_description	B-arm_description
loss	I-arm_description	I-arm_description
/	I-arm_description	I-arm_description
PTEN	I-arm_description	I-arm_description
mutation	I-arm_description	I-arm_description
Phase	B-study_type	B-study_type
II	I-study_type	I-study_type
trial	I-study_type	I-study_type
of	O	O
AKT	O	B-arm_description
inhibitor	O	I-arm_description
MK-2206	O	B-arm_description
in	O	O
patients	O	O
with	O	O
advanced	O	O
breast	O	O
cancer	O	O
who	O	O
have	O	O
tumors	O	O
with	O	O
PIK3CA	B-arm_description	B-arm_description
or	I-arm_description	I-arm_description
AKT	I-arm_description	I-arm_description
mutations	I-arm_description	I-arm_description
,	O	O
and/or	O	O
PTEN	B-arm_description	B-arm_description
loss	I-arm_description	I-arm_description
/	I-arm_description	I-arm_description
PTEN	I-arm_description	I-arm_description
mutation	I-arm_description	I-arm_description
YanXing	B-authors	I-arm_description

The	O	O
Sheikh	O	O
Khalifa	O	O
Bin	O	O
Zayed	O	O
Al	O	O
Nahyan	O	O
Institute	O	O
for	O	O
Personalized	O	O
Cancer	O	O
Therapy	O	O
,	O	O
The	O	O
University	O	O
of	O	O
Texas	O	O
MD	O	O
Anderson	O	O
Cancer	O	O
Center	O	O
77030	O	O
Houston	O	O
TX	O	O
USA	O	O
Breast	O	O
Surgical	O	O
Oncology	O	O

Phase	B-study_type	B-study_type
II	I-study_type	I-study_type
trial	I-study_type	I-study_type
of	O	O
AKT	O	O
inhibitor	O	O
MK-2206	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
breast	O	O
cancer	O	O
who	O	O
have	O	O
tumors	O	O
with	O	O
PIK3CA	B-arm_description	B-arm_description
or	I-arm_description	I-arm_description
AKT	I-arm_description	I-arm_description
mutations	I-arm_description	I-arm_description
,	O	O
and/or	O	O
PTEN	B-arm_description	B-arm_description
loss	I-arm_description	I-arm_description
/	I-arm_description	I-arm_description
PTEN	I-arm_description	I-arm_description
mutation	I-arm_description	I-arm_description

Deaconess	O	O
Medical	O	O
Center	O	O
and	O	O
Dana	O	O
Farber	O	O
Harvard	O	O
Cancer	O	O
Center	O	O
02215	O	O
Beth	O	O
,	O	O
Boston	O	O
MA	O	O
Israel	O	O
,	O	O
USA	O	O
LewisCCantley	B-authors	O
Cornell	O	O
University	O	O
14850	O	O
Ithaca	O	O
NY	O	O
USA	O	O
GordonBMills	B-authors	B-authors
Systems	O	O
Biology	O	O

The	O	O
Sheikh	O	O
Khalifa	O	O
Bin	O	O
Zayed	O	O
Al	O	O
Nahyan	O	O
Institute	O	O
for	O	O
Personalized	O	O
Cancer	O	O
Therapy	O	O
,	O	O
The	O	O
University	O	O
of	O	O
Texas	O	O
MD	O	O
Anderson	O	O
Cancer	O	O
Center	O	O
77030	O	O
Houston	O	O
TX	O	O
USA	O	O
Breast	O	O
Surgical	O	O
Oncology	O	O

Phase	B-study_type	B-study_type
II	I-study_type	I-study_type
trial	I-study_type	I-study_type
of	O	O
AKT	O	O
inhibitor	O	O
MK-2206	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
breast	O	O
cancer	O	O
who	O	O
have	O	O
tumors	O	O
with	O	O
PIK3CA	B-arm_description	B-arm_description
or	I-arm_description	I-arm_description
AKT	I-arm_description	I-arm_description
mutations	I-arm_description	I-arm_description
,	O	O
and/or	O	O
PTEN	B-arm_description	B-arm_description
loss	I-arm_description	I-arm_description
/	I-arm_description	I-arm_description
PTEN	I-arm_description	I-arm_description
mutation	I-arm_description	I-arm_description

The	O	O
Sheikh	O	O
Khalifa	O	O
Bin	O	O
Zayed	O	O
Al	O	O
Nahyan	O	O
Institute	O	O
for	O	O
Personalized	O	O
Cancer	O	O
Therapy	O	O
,	O	O
The	O	O
University	O	O
of	O	O
Texas	O	O
MD	O	O
Anderson	O	O
Cancer	O	O
Center	O	O
77030	O	O
Houston	O	O
TX	O	O
USA	O	O
Breast	O	O
Surgical	O	O
Oncology	O	O

The	O	O
Sheikh	O	O
Khalifa	O	O
Bin	O	O
Zayed	O	O
Al	O	O
Nahyan	O	O
Institute	O	O
for	O	O
Personalized	O	O
Cancer	O	O
Therapy	O	O
,	O	O
The	O	O
University	O	O
of	O	O
Texas	O	O
MD	O	O
Anderson	O	O
Cancer	O	O
Center	O	O
77030	O	O
Houston	O	O
TX	O	O
USA	O	O
Breast	O	O
Surgical	O	O
Oncology	O	O

We	O	O
present	O	O
here	O	O
the	O	O
results	O	O
of	O	O
a	O	O
biomarker	B-study_type	O
-	I-study_type	O
selected	I-study_type	O
phase	I-study_type	B-study_type
II	I-study_type	I-study_type
breast	I-study_type	O
cancer	I-study_type	O
trial	I-study_type	O
of	O	O
MK-2206	O	O
.	O	O
Further	O	O
,	O	O
we	O	O
present	O	O
results	O	O
of	O	O
correlative	O	O
studies	O	O
including	O	O
assessment	O	O
of	O	O
pathway	O	O
inhibition	O	O
in	O	O
circulating	O	O
biomarkers	O	O
and	O	O
pre	O	O
-	O	O
treatment	O	O
and	O	O
on	O	O
-	O	O
treatment	O	O
biopsies	O	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
-	O	O
depth	O	O
characterization	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
response	O	O
to	O	O
MK-2206	O	O
.	O	O

"	O	O
Phase	B-study_type	B-study_type
II	I-study_type	I-study_type
Trial	I-study_type	I-study_type
of	O	O
AKT	O	B-arm_description
Inhibitor	O	O
MK-2206	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
breast	O	O
cancer	O	O
who	O	O
have	O	O
tumors	O	O
with	O	O
a	O	O
PIK3CA	B-arm_description	B-arm_description
mutation	I-arm_description	I-arm_description
,	I-arm_description	O
or	I-arm_description	O
an	I-arm_description	O
AKT	I-arm_description	B-arm_description
mutation	I-arm_description	I-arm_description
,	O	O
and/or	O	O
PTEN	B-arm_description	B-arm_description
loss	I-arm_description	I-arm_description
/	I-arm_description	I-arm_description
PTEN	I-arm_description	I-arm_description
mutation	I-arm_description	I-arm_description
"	O	O
(	O	O
NCT01277757	O	O
)	O	O
was	O	O
a	O	O
phase	O	B-study_type
II	O	I-study_type
trial	O	I-study_type
sponsored	O	O
by	O	O
The	O	O
Cancer	O	O
Therapy	O	O
Evaluation	O	O
Program	O	O
and	O	O
conducted	O	O
by	O	O
the	O	O
American	O	O
Academy	O	O
of	O	O
Cancer	O	O
Research	O	O
Stand	O	O
Up	O	O
to	O	O
Cancer	O	O
PI3	O	O
K	O	O
Dream	O	O
Team	O	O
.	O	O
This	O	O
multicenter	B-study_type	B-study_type
trial	I-study_type	I-study_type
accrued	O	O
in	O	O
five	O	O
centers	O	O
:	O	O
MD	O	O
Anderson	O	O
Cancer	O	O
Center	O	O
(	O	O
lead	O	O
organization	O	O
)	O	O
,	O	O
Dana	O	O
-	O	O
Farber	O	O
Cancer	O	O
Institute	O	O
,	O	O
Beth	O	O
Israel	O	O
Deaconess	O	O
Medical	O	O
Center	O	O
,	O	O
Columbia	O	O
University	O	O
Medical	O	O
Center	O	O
,	O	O
and	O	O
Vanderbilt	O	O
-	O	O
Ingram	O	O
Cancer	O	O
Center	O	O
.	O	O

Secondary	O	O
objectives	O	O
included	O	O
(	O	O
1	O	O
)	O	O
determining	O	O
the	O	O
6-month	B-arm_efficacy_metric	O
progression	I-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
(	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
)	O	O
,	O	O
(	O	O
2	O	O
)	O	O
determining	O	O
baseline	O	O
molecular	O	O
markers	O	O
that	O	O
may	O	O
predict	O	O
clinical	O	O
outcome	O	O
,	O	O
(	O	O
3	O	O
)	O	O
establishing	O	O
pharmacodynamic	O	O
markers	O	O
in	O	O
blood	O	O
and	O	O
tumor	O	O
tissue	O	O
that	O	O
may	O	O
predict	O	O
outcome	O	O
,	O	O
and	O	O
(	O	O
4	O	O
)	O	O
determining	O	O
safety	O	O
and	O	O
tolerability	O	O
of	O	O
MK-2206	O	O
in	O	O
previously	O	O
treated	O	O
patients	O	O
with	O	O
advanced	O	O
breast	O	O
cancer	O	O
.	O	O

Tumor	O	O
biopsies	O	O
(	O	O
core	O	O
biopsies	O	O
and	O	O
fine	O	O
needle	O	O
aspirates	O	O
)	O	O
were	O	O
obtained	O	O
pretreatment	O	O
and	O	O
on	O	O
day	O	O
16	O	O
(	O	O
1	O	O
day	O	O
after	O	O
third	O	O
weekly	O	O
treatment	O	O
)	O	O
.	O	O
IHC	O	O
was	O	O
performed	O	O
on	O	O
core	O	O
biopsies	O	O
.	O	O
PTEN	B-arm_description	B-arm_description
IHC	O	O
was	O	O
performed	O	O
in	O	O
the	O	O
MD	O	O
Anderson	O	O
CLIA	O	O
clinical	O	O
laboratory	O	O
.	O	O
PTEN	B-arm_description	B-arm_description
IHC	O	O
was	O	O
performed	O	O
using	O	O
monoclonal	O	O
mouse	O	O
anti	O	O
-	O	O
Human	O	O
PTEN	B-arm_description	O
antibody	O	O
Clone	O	O
6H2.1	O	O
from	O	O
Dako	O	O
at	O	O
1:100	O	O
dilution	O	O
.	O	O
In	O	O
previous	O	O
studies	O	O
,	O	O
we	O	O
had	O	O
already	O	O
demonstrated	O	O
that	O	O
PTEN	B-arm_description	B-arm_description
loss	I-arm_description	O
by	O	O
IHC	O	O
is	O	O
associated	O	O
with	O	O
PI3	O	O
K	O	O
pathway	O	O
activation	O	O
[	O	O
7	O	O
]	O	O
.	O	O
PTEN	B-arm_description	O
staining	O	O
was	O	O
evaluated	O	O
by	O	O
assessing	O	O
both	O	O
intensity	O	O
and	O	O
percent	O	O
positivity	O	O
of	O	O
staining	O	O
.	O	O
Both	O	O
nuclear	O	O
and	O	O
cytoplasmic	O	O
staining	O	O
were	O	O
evaluated	O	O
.	O	O
Staining	O	O
of	O	O
normal	O	O
cells	O	O
such	O	O
as	O	O
benign	O	O
breast	O	O
epithelium	O	O
,	O	O
stromal	O	O
cells	O	O
and/or	O	O
endothelial	O	O
cells	O	O
was	O	O
evaluated	O	O
as	O	O
an	O	O
internal	O	O
control	O	O
.	O	O
Any	O	O
tumor	O	O
nuclear	O	O
or	O	O
cytoplasmic	O	O
staining	O	O
showing	O	O
similar	O	O
intensity	O	O
with	O	O
internal	O	O
control	O	O
cells	O	O
was	O	O
considered	O	O
positive	O	O
staining	O	O
(	O	O
no	O	O
PTEN	B-arm_description	O
loss	I-arm_description	O
)	O	O
.	O	O
Complete	O	O
lack	O	O
of	O	O
staining	O	O
or	O	O
faint	O	O
staining	O	O
(	O	O
cytoplasmic	O	O
or	O	O
nuclear	O	O
)	O	O
in	O	O
up	O	O
to	O	O
50	O	O
%	O	O
of	O	O
tumor	O	O
cells	O	O
was	O	O
considered	O	O
as	O	O
PTEN	B-arm_description	B-arm_description
loss	I-arm_description	O
.	O	O
If	O	O
there	O	O
was	O	O
no	O	O
staining	O	O
in	O	O
internal	O	O
control	O	O
cells	O	O
,	O	O
the	O	O
staining	O	O
was	O	O
considered	O	O
to	O	O
be	O	O
inconclusive	O	O
.	O	O

Pre	O	O
-	O	O
treatment	O	O
and	O	O
on	O	O
-	O	O
treatment	O	O
core	O	O
biopsies	O	O
were	O	O
also	O	O
assessed	O	O
for	O	O
pAKT	O	O
Ser473	O	O
(	O	O
1:50	O	O
)	O	O
,	O	O
pS6	O	O
Ser235/236	O	O
(	O	O
1:50	O	O
)	O	O
,	O	O
and	O	O
pS6	O	O
Ser240/244	O	O
(	O	O
1:200	O	O
;	O	O
all	O	O
from	O	O
Cell	O	O
Signaling	O	O
,	O	O
Danvers	O	O
,	O	O
MA	O	O
)	O	O
as	O	O
previously	O	O
described	O	O
[	O	O
7	O	O
]	O	O
.	O	O
The	O	O
Refine	O	O
Polymer	O	O
Detection	O	O
kit	O	O
was	O	O
used	O	O
for	O	O
immunostaining	O	O
,	O	O
with	O	O
3,3-diaminobenzidine	O	O
serving	O	O
as	O	O
chromagen	O	O
.	O	O
Slides	O	O
were	O	O
counterstained	O	O
with	O	O
Mayer	O	O
's	O	O
hematoxylin	O	O
.	O	O
Antibodies	O	O
were	O	O
evaluated	O	O
with	O	O
known	O	O
positive	O	O
and	O	O
negative	O	O
tissue	O	O
controls	O	O
.	O	O

Samples	O	O
were	O	O
evaluated	O	O
by	O	O
reverse	O	O
phase	O	O
protein	O	O
arrays	O	O
(	O	O
RPPA	O	O
)	O	O
to	O	O
assess	O	O
PI3	O	O
K	O	O
activation	O	O
status	O	O
as	O	O
previously	O	O
described	O	O
[	O	O
7][8][9	O	O
]	O	O
.	O	O
Fine	O	O
-	O	O
needle	O	O
aspiration	O	O
biopsy	O	O
samples	O	O
were	O	O
obtained	O	O
at	O	O
pre	O	O
-	O	O
and	O	O
post	O	O
-	O	O
treatment	O	O
from	O	O
patients	O	O
and	O	O
were	O	O
frozen	O	O
immediately	O	O
.	O	O
Among	O	O
24	O	O
patients	O	O
who	O	O
had	O	O
biopsies	O	O
,	O	O
one	O	O
patient	O	O
was	O	O
excluded	O	O
because	O	O
there	O	O
was	O	O
no	O	O
tumor	O	O
in	O	O
samples	O	O
for	O	O
H&E	O	O
analysis	O	O
of	O	O
core	O	O
biopsies	O	O
.	O	O
Fifteen	O	O
patients	O	O
had	O	O
paired	O	O
pre	O	O
-	O	O
and	O	O
post	O	O
-	O	O
treatment	O	O
samples	O	O
available	O	O
,	O	O
while	O	O
eight	O	O
patients	O	O
had	O	O
pre	O	O
-	O	O
treatment	O	O
samples	O	O
only	O	O
.	O	O
Peripheral	O	O
blood	O	O
mononuclear	O	O
cells	O	O
(	O	O
PBMCs	O	O
)	O	O
and	O	O
platelet	O	O
enriched	O	O
plasma	O	O
(	O	O
PRP	O	O
)	O	O
were	O	O
evaluated	O	O
by	O	O
RPPA	O	O
at	O	O
the	O	O
following	O	O
time	O	O
points	O	O
:	O	O
at	O	O
screening	O	O
,	O	O
C1-D1	O	O
(	O	O
pretreatment	O	O
)	O	O
,	O	O
C1-D1	O	O
(	O	O
post	O	O
-	O	O
treatment	O	O
)	O	O
,	O	O
and	O	O
C1-D2	O	O
.	O	O

The	O	O
RPPA	O	O
raw	O	O
data	O	O
were	O	O
normalized	O	O
by	O	O
loading	O	O
control	O	O
by	O	O
the	O	O
RPPA	O	O
core	O	O
and	O	O
log2	O	O
transformed	O	O
.	O	O
A	O	O
linear	O	O
mixed	O	O
effects	O	O
(	O	O
LME	O	O
)	O	O
model	O	O
was	O	O
used	O	O
to	O	O
assess	O	O
the	O	O
differences	O	O
in	O	O
protein	O	O
expression	O	O
between	O	O
time	O	O
points	O	O
on	O	O
a	O	O
protein	O	O
-	O	O
by	O	O
-	O	O
protein	O	O
basis	O	O
.	O	O
The	O	O
LME	O	O
model	O	O
includes	O	O
the	O	O
fixed	O	O
effect	O	O
of	O	O
time	O	O
point	O	O
(	O	O
two	O	O
pre	O	O
-	O	O
treatment	O	O
:	O	O
early	O	O
,	O	O
C1D1	O	O
:	O	O
pre	O	O
-	O	O
treatment	O	O
;	O	O
two	O	O
post	O	O
-	O	O
treatment	O	O
:	O	O
C1D1	O	O
:	O	O
post	O	O
-	O	O
treatment	O	O
,	O	O
C1D2	O	O
)	O	O
and	O	O
random	O	O
effect	O	O
of	O	O
the	O	O
patient	O	O
.	O	O
To	O	O
account	O	O
for	O	O
multiple	O	O
testing	O	O
,	O	O
we	O	O
estimated	O	O
the	O	O
false	O	O
discovery	O	O
rates	O	O
(	O	O
FDR	O	O
)	O	O
of	O	O
the	O	O
overall	O	O
test	O	O
of	O	O
the	O	O
model	O	O
using	O	O
the	O	O
Benjamini	O	O
-	O	O
Hochberg	O	O
method	O	O
[	O	O
10	O	O
]	O	O
.	O	O
The	O	O
modified	O	O
Z	O	O
-	O	O
scores	O	O
of	O	O
9	O	O
important	O	O
PI3	O	O
K	O	O
pathway	O	O
biomarkers	O	O
were	O	O
calculated	O	O
and	O	O
used	O	O
to	O	O
compute	O	O
the	O	O
composite	O	O
PI3	O	O
K	O	O
pathway	O	O
activity	O	O
score	O	O
.	O	O
The	O	O
modified	O	O
Z	O	O
-	O	O
score	O	O
proposed	O	O
by	O	O
Iglewicz	O	O
and	O	O
Hoaglin	O	O
[	O	O
11	O	O
]	O	O
was	O	O
calculated	O	O
based	O	O
on	O	O
the	O	O
median	O	O
of	O	O
expression	O	O
and	O	O
absolute	O	O
deviation	O	O
about	O	O
the	O	O
median	O	O
.	O	O
We	O	O
defined	O	O
the	O	O
patient	O	O
's	O	O
composite	O	O
PI3	O	O
K	O	O
pathway	O	O
activity	O	O
score	O	O
as	O	O
the	O	O
sum	O	O
of	O	O
the	O	O
modified	O	O
Z	O	O
-	O	O
scores	O	O
of	O	O
phospho	O	O
-	O	O
protein	O	O
of	O	O
pAKT	O	O
,	O	O
4E	O	O
-	O	O
BP1	O	O
,	O	O
S6	O	O
K	O	O
,	O	O
and	O	O
S6	O	O
(	O	O
i.e.	O	O
,	O	O
PI3	O	O
K	O	O
score	O	O
=	O	O
pS6	O	O
S240/244	O	O
+	O	O
pS6	O	O
S235/236	O	O
+	O	O
pS6	O	O
K	O	O
T389	O	O
+	O	O
p4E	O	O
-	O	O
BP1	O	O
S65	O	O
+	O	O
p4E	O	O
-	O	O
BP1	O	O
T37/46	O	O
+	O	O
p	O	O
-	O	O
mTOR	O	O
S2448	O	O
+	O	O
pPRAS40	O	O
T246	O	O
+	O	O
pAKT	O	O
S473	O	O
+	O	O
pAKT	O	O
T308	O	O
)	O	O
.	O	O
The	O	O
LME	O	O
model	O	O
described	O	O
above	O	O
was	O	O
used	O	O
to	O	O
compare	O	O
the	O	O
PI3	O	O
K	O	O
activity	O	O
scores	O	O
between	O	O
pre	O	O
-	O	O
and	O	O
post	O	O
-	O	O
treatment	O	O
.	O	O

CLIA	O	O
DNA	O	O
analysis	O	O
was	O	O
performed	O	O
initially	O	O
using	O	O
the	O	O
Sanger	O	O
sequencing	O	O
,	O	O
and	O	O
then	O	O
transitioned	O	O
to	O	O
mass	O	O
spectroscopy	O	O
-	O	O
based	O	O
multiplex	O	O
assay	O	O
to	O	O
assess	O	O
the	O	O
mutational	O	O
status	O	O
of	O	O
hotspot	O	O
regions	O	O
in	O	O
11	O	O
genes	O	O
(	O	O
Sequenom	O	O
)	O	O
or	O	O
with	O	O
next	O	O
-	O	O
generation	O	O
sequencing	O	O
using	O	O
the	O	O
Ion	O	O
Ampliseq	O	O
46	O	O
Gene	O	O
Cancer	O	O
Panel	O	O
(	O	O
Life	O	O
Technologies	O	O
)	O	O
to	O	O
assess	O	O
hotspot	O	O
mutations	O	O
in	O	O
PIK3CA	B-arm_description	O
and	I-arm_description	O
AKT1	I-arm_description	O
genes	O	O
as	O	O
previously	O	O
described	O	O
[	O	O
12	O	O
]	O	O
.	O	O
Through	O	O
the	O	O
course	O	O
of	O	O
the	O	O
trial	O	O
,	O	O
genomic	O	O
testing	O	O
became	O	O
more	O	O
comprehensive	O	O
and	O	O
frequently	O	O
performed	O	O
at	O	O
individual	O	O
institutions	O	O
.	O	O
Testing	O	O
performed	O	O
on	O	O
alternate	O	O
CLIA	O	O
platforms	O	O
was	O	O
allowed	O	O
.	O	O
Genomic	O	O
testing	O	O
was	O	O
performed	O	O
on	O	O
available	O	O
archival	O	O
tissue	O	O
;	O	O
testing	O	O
on	O	O
either	O	O
primary	O	O
tumors	O	O
or	O	O
metastatic	O	O
biopsies	O	O
was	O	O
allowed	O	O
,	O	O
but	O	O
testing	O	O
on	O	O
most	O	O
recent	O	O
samples	O	O
was	O	O
encouraged	O	O
.	O	O

1	O	O
×	O	O
10	O	O
7	O	O
ZR75	O	O
-	O	O
1	O	O
breast	O	O
cancer	O	O
cells	O	O
were	O	O
inoculated	O	O
in	O	O
the	O	O
mammary	O	O
fat	O	O
pads	O	O
of	O	O
female	O	O
nu	O	O
/	O	O
nu	O	O
mice	O	O
(	O	O
Department	O	O
of	O	O
Experimental	O	O
Oncology	O	O
,	O	O
MD	O	O
Anderson	O	O
)	O	O
.	O	O
Mice	O	O
were	O	O
subcutaneously	O	O
implanted	O	O
with	O	O
17β	O	O
-	O	O
estradiol	O	O
pellets	O	O
(	O	O
Innovative	O	O
Research	O	O
of	O	O
America	O	O
)	O	O
.	O	O
Mice	O	O
bearing	O	O
ZR75	O	O
-	O	O
1	O	O
xenografts	O	O
were	O	O
randomized	O	O
into	O	O
3	O	O
groups	O	O
(	O	O
vehicle	O	O
,	O	O
MK-2206	O	O
240	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
or	O	O
480	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
n	O	O
=	O	O
5	O	O
-	O	O
6	O	O
)	O	O
.	O	O
Tumor	O	O
measurements	O	O
were	O	O
followed	O	O
to	O	O
assess	O	O
antitumor	O	O
efficacy	O	O
,	O	O
and	O	O
RPPA	O	O
was	O	O
utilized	O	O
to	O	O
assess	O	O
the	O	O
effect	O	O
on	O	O
cell	O	O
signaling	O	O
as	O	O
described	O	O
above	O	O
.	O	O
All	O	O
animal	O	O
experiments	O	O
were	O	O
approved	O	O
by	O	O
the	O	O
MD	O	O
Anderson	O	O
Cancer	O	O
Center	O	O
Animal	O	O
Care	O	O
and	O	O
Use	O	O
Committee	O	O
.	O	O
Table	O	O
1	O	O
summarizes	O	O
patient	O	O
characteristics	O	O
.	O	O
The	O	O
median	O	O
age	O	O
was	O	O
51	O	O
years	O	O
(	O	O
range	O	O
30	O	O
-	O	O
73	O	O
years	O	O
)	O	O
.	O	O
Fifteen	O	O
patients	O	O
had	O	O
ER	O	O
or	O	O
PR	O	O
-	O	O
positive	O	O
disease	O	O
(	O	O
HR	O	O
-	O	O
positive	O	O
)	O	O
,	O	O
three	O	O
had	O	O
HER2-positive	O	O
disease	O	O
,	O	O
and	O	O
nine	O	O
had	O	O
triple	O	O
-	O	O
negative	O	O
breast	O	O
cancer	O	O
(	O	O
TNBC	O	O
)	O	O
.	O	O
A	O	O
median	O	O
number	O	O
of	O	O
previous	O	O
lines	O	O
of	O	O
therapy	O	O
was	O	O
six	O	O
(	O	O
range	O	O
2	O	O
-	O	O
9	O	O
)	O	O
.	O	O
Four	O	O
patients	O	O
had	O	O
previously	O	O
received	O	O
everolimus	O	O
.	O	O

Twenty	O	O
-	O	O
seven	O	O
patients	O	O
received	O	O
MK-2206	B-arm_description	B-arm_description
treatment	O	O
:	O	O
18	O	O
patients	O	O
were	O	O
treated	O	O
on	O	O
the	O	O
PIK3CA	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
AKT1	I-arm_description	I-arm_description
mutation	I-arm_description	I-arm_description
arm	I-arm_description	I-arm_description
(	O	I-arm_description
cohort	O	I-arm_description
A)-13	O	I-arm_description
had	O	O
PIK3CA	B-arm_description	B-arm_description
mutations	O	I-arm_description
,	O	O
4	O	O
had	O	O
AKT1	B-arm_description	B-arm_description
mutations	O	I-arm_description
,	O	O
and	O	O
one	O	O
had	O	O
a	O	O
PIK3CA	B-arm_description	B-arm_description
mutation	O	I-arm_description
as	O	O
well	O	O
as	O	O
PTEN	O	B-arm_description
loss	O	I-arm_description
.	O	O
Nine	O	O
patients	O	O
were	O	O
enrolled	O	O
on	O	O
the	O	O
PTEN	B-arm_description	B-arm_description
mutation	I-arm_description	I-arm_description
/	I-arm_description	I-arm_description
loss	I-arm_description	I-arm_description
arm	I-arm_description	I-arm_description
(	O	I-arm_description
cohort	O	I-arm_description
B	O	I-arm_description
)	O	O
:	O	O
4	O	O
with	O	O
PTEN	B-arm_description	B-arm_description
mutations	I-arm_description	I-arm_description
and	O	O
5	O	O
with	O	O
PTEN	B-arm_description	B-arm_description
loss	I-arm_description	I-arm_description
by	O	O
IHC	O	O
.	O	O

PI3	O	O
K	O	O
pathway	O	O
activation	O	O
was	O	O
also	O	O
assessed	O	O
by	O	O
IHC	O	O
for	O	O
pAKT	O	O
S473	O	O
,	O	O
pS6	O	O
S235/236	O	O
,	O	O
pS6	O	O
S240/244	O	O
,	O	O
and	O	O
p4EBP1	O	O
T70	O	O
(	O	O
Fig	O	O
.	O	O
3	O	O
)	O	O
.	O	O
Overall	O	O
in	O	O
the	O	O
study	O	O
,	O	O
no	O	O
difference	O	O
in	O	O
IRS	O	O
score	O	O
was	O	O
observed	O	O
between	O	O
paired	O	O
baseline	O	O
and	O	O
ontreatment	O	O
samples	O	O
based	O	O
on	O	O
Wilcoxon	O	O
signed	O	O
-	O	O
rank	O	O
tests	O	O
(	O	O
Fig	O	O
.	O	O
3a	O	O
)	O	O
.	O	O
Notably	O	O
,	O	O
IHC	O	O
did	O	O
reveal	O	O
pathway	O	O
inhibition	O	O
in	O	O
the	O	O
two	O	O
patients	O	O
who	O	O
evidenced	O	O
clinical	O	O
benefit	O	O
(	O	O
Fig	O	O
.	O	O
3b	O	O
)	O	O
.	O	O

The	O	O
primary	O	O
endpoint	O	O
is	O	O
the	O	O
ORR	O	O
.	O	O
The	O	O
secondary	O	O
endpoints	O	O
are	O	O
progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
(	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
)	O	O
,	O	O
duration	O	O
of	O	O
response	O	O
,	O	O
proportion	O	O
of	O	O
disease	O	O
control	O	O
,	O	O
and	O	O
safety	O	O
.	O	O

12	O	O
.	O	O
No	O	O
interstitial	O	O
pneumonia	O	O
or	O	O
history	O	O
of	O	O
interstitial	O	O
pneumonia	O	O
13	O	O
.	O	O
Patients	O	O
or	O	O
their	O	O
family	O	O
members	O	O
who	O	O
signed	O	O
the	O	O
informed	O	O
consent	O	O
14	O	O
.	O	O
Female	O	O
patients	O	O
of	O	O
childbearing	O	O
age	O	O
who	O	O
agreed	O	O
to	O	O
use	O	O
contraceptives	O	O
(	O	O
such	O	O
as	O	O
intrauterine	O	O
devices	O	O
,	O	O
birth	O	O
control	O	O
pills	O	O
,	O	O
or	O	O
condoms	O	O
)	O	O
in	O	O
the	O	O
study	O	O
period	O	O
and	O	O
for	O	O
six	O	O
months	O	O
after	O	O
the	O	O
end	O	O
of	O	O
the	O	O
drug	O	O
treatment	O	O
;	O	O
the	O	O
serum	O	O
or	O	O
urine	O	O
test	O	O
indicated	O	O
no	O	O
pregnancy	O	O
in	O	O
the	O	O
seven	O	O
days	O	O
prior	O	O
to	O	O
the	O	O
study	O	O
,	O	O
and	O	O
patients	O	O
who	O	O
were	O	O
not	O	O
lactating	O	O
;	O	O
male	O	O
patients	O	O
who	O	O
agreed	O	O
to	O	O
use	O	O
contraception	O	O
during	O	O
the	O	O
study	O	O
period	O	O
and	O	O
for	O	O
six	O	O
months	O	O
after	O	O
the	O	O
end	O	O
of	O	O
the	O	O
study	O	O
period	O	O
.	O	O

1	O	O
.	O	O
Previously	O	O
used	O	O
anlotinib	B-arm_description	B-arm_description
or	O	O
S-1	B-arm_description	O
2	O	O
.	O	O
Small	O	O
-	O	O
cell	O	O
lung	O	O
cancer	O	O
(	O	O
including	O	O
small	O	O
-	O	O
cell	O	O
carcinoma	O	O
and	O	O
non	O	O
-	O	O
small	O	O
-	O	O
cell	O	O
carcinoma	O	O
mixed	O	O
lung	O	O
cancer	O	O
)	O	O

Adverse	O	O
events	O	O
were	O	O
recorded	O	O
in	O	O
accordance	O	O
with	O	O
the	O	O
requirements	O	O
of	O	O
Medical	O	O
Dictionary	O	O
for	O	O
Regulatory	O	O
Activities	O	O
(	O	O
Med	O	O
DRA	O	O
)	O	O
.	O	O
The	O	O
severity	O	O
of	O	O
adverse	O	O
events	O	O
was	O	O
graded	O	O
according	O	O
to	O	O
the	O	O
National	O	O
Cancer	O	O
Institute	O	O
Common	O	O
Terminology	O	O
Criteria(NCI	O	O
-	O	O
CTC	O	O
)	O	O
.	O	O
The	O	O
toxicity	O	O
of	O	O
the	O	O
treatment	O	O
,	O	O
including	O	O
acute	O	O
and	O	O
chronic	O	O
toxicity	O	O
,	O	O
was	O	O
evaluated	O	O
during	O	O
treatment	O	O
and	O	O
follow	O	O
-	O	O
up	O	O
(	O	O
Table	O	O
1).Any	O	O
serious	O	O
adverse	O	O
drug	O	O
reaction	O	O
was	O	O
promptly	O	O
reported	O	O
to	O	O
the	O	O
hospital	O	O
ethics	O	O
committee	O	O
.	O	O
PFS	O	B-arm_efficacy_metric
was	O	O
defined	O	O
as	O	O
the	O	O
date	O	O
from	O	O
randomization	O	O
to	O	O
tumor	O	O
progression	O	O
or	O	O
death	O	O
.	O	O
Duration	O	O
of	O	O
response	O	O
was	O	O
assessed	O	O
in	O	O
patients	O	O
who	O	O
achieved	O	O
a	O	O
response	O	O
and	O	O
was	O	O
defined	O	O
as	O	O
the	O	O
time	O	O
from	O	O
the	O	O
date	O	O
of	O	O
the	O	O
first	O	O
documented	O	O
response	O	O
to	O	O
the	O	O
date	O	O
of	O	O
the	O	O
documented	O	O
progression	O	O
or	O	O
death	O	O
from	O	O
any	O	O
cause	O	O
.	O	O
Disease	O	O
control	O	O
was	O	O
defined	O	O
as	O	O
the	O	O
proportion	O	O
of	O	O
patients	O	O
who	O	O
achieved	O	O
a	O	O
CR	O	O
,	O	O
PR	O	O
,	O	O
or	O	O
SD	O	O
.	O	O

A	O	O
phase	B-study_type	B-study_type
2	I-study_type	I-study_type
study	I-study_type	I-study_type
of	O	O
an	O	O
oral	O	O
mTORC1	B-arm_description	O
/	I-arm_description	O
mTORC2	I-arm_description	O
kinase	I-arm_description	O
inhibitor	I-arm_description	O
(	O	O
CC-223	O	O
)	O	O
for	O	O
non	O	O
-	O	O
pancreatic	O	O
neuroendocrine	O	O
tumors	O	O
with	O	O
or	O	O
without	O	O
carcinoid	O	O
symptoms	O	O

Tumors	O	O
were	O	O
restaged	O	O
by	O	O
the	O	O
principal	O	O
investigator	O	O
at	O	O
each	O	O
site	O	O
using	O	O
computed	O	O
tomography	O	O
(	O	O
CT	O	O
)	O	O
,	O	O
positron	O	O
emission	O	O
tomography	O	O
(	O	O
PET)-CT	O	O
,	O	O
or	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
scans	O	O
after	O	O
every	O	O
2	O	O
cycles	O	O
through	O	O
cycle	O	O
6	O	O
,	O	O
and	O	O
every	O	O
3	O	O
cycles	O	O
thereafter	O	O
,	O	O
using	O	O
Response	O	O
Evaluation	O	O
Criteria	O	O
In	O	O
Solid	O	O
Tumors	O	O
(	O	O
RECIST	O	O
)	O	O
version	O	O
1.1	O	O
criteria	O	O
for	O	O
response	O	O
[	O	O
14	O	O
]	O	O
.	O	O

Blood	O	O
for	O	O
PK	O	O
analysis	O	O
was	O	O
drawn	O	O
on	O	O
day	O	B-arm_dosage
1	O	I-arm_dosage
pre	O	I-arm_dosage
-	O	I-arm_dosage
dose	O	I-arm_dosage
and	O	O
for	O	O
up	O	O
to	O	O
48	O	B-arm_dosage
hours	O	I-arm_dosage
post	O	I-arm_dosage
-	O	I-arm_dosage
dose	O	I-arm_dosage
,	O	O
and	O	O
then	O	O
on	O	O
day	O	B-arm_dosage
15	O	I-arm_dosage
up	O	I-arm_dosage
to	O	I-arm_dosage
8	O	I-arm_dosage
hours	O	I-arm_dosage
post	O	I-arm_dosage
-	O	I-arm_dosage
dose	O	I-arm_dosage
.	O	O
Urine	O	B-arm_description
on	O	O
day	O	B-arm_description
1	O	O
was	O	O
collected	O	O
within	O	O
30	O	O
minutes	O	O
prior	O	O
to	O	O
dosing	O	O
and	O	O
at	O	O
intervals	O	O
up	O	O
to	O	O
24	O	O
hours	O	O
post	O	O
-	O	O
dose	O	O
.	O	O
Samples	O	O
were	O	O
assayed	O	O
for	O	O
CC-223	B-arm_description	B-arm_description
and	O	O
the	O	O
principal	O	O
active	O	O
metabolite	O	O
(	O	O
M1	O	O
)	O	O
using	O	O
validated	O	O
chiral	O	O
liquid	O	O
chromatography	O	O
mass	O	O
spectrometry	O	O
.	O	O
CC-223	B-arm_description	B-arm_description
PK	O	O
parameters	O	O
were	O	O
calculated	O	O
using	O	O
dosing	O	O
and	O	O
sample	O	O
collection	O	O
times	O	O
.	O	O
Noncompartmental	O	O
PK	O	O
analysis	O	O
was	O	O
performed	O	O
used	O	O
WinNonlin	O	O
Enterprise	O	O
version	O	O
5.2	O	O
Model	O	O
200	O	O
and	O	O
Model	O	O
210	O	O
(	O	O
Certara	O	O
,	O	O
Princeton	O	O
,	O	O
NJ	O	O
)	O	O
.	O	O

This	O	O
phase	B-study_type	B-study_type
1/2	I-study_type	I-study_type
study	I-study_type	I-study_type
was	O	O
not	O	O
powered	O	O
for	O	O
inferential	O	O
statistics	O	O
and	O	O
mostly	O	O
descriptive	O	O
statistics	O	O
were	O	O
used	O	O
.	O	O
All	O	O
patients	O	O
dosed	O	O
with	O	O
CC-223	B-arm_description	B-arm_description
were	O	O
included	O	O
in	O	O
the	O	O
safety	O	O
analysis	O	O
.	O	O
The	O	O
efficacy	O	O
analysis	O	O
included	O	O
all	O	O
patients	O	O
completing	O	O
at	O	O
least	O	O
one	O	O
cycle	O	O
of	O	O
drug	O	O
who	O	O
had	O	O
both	O	O
baseline	O	O
and	O	O
one	O	O
post	O	O
-	O	O
baseline	O	O
tumor	O	O
efficacy	O	O
assessment	O	O
,	O	O
unless	O	O
otherwise	O	O
specified	O	O
.	O	O
Categorical	O	O
baseline	O	O
variables	O	O
including	O	O
tumor	O	O
type	O	O
-	O	O
specific	O	O
characteristics	O	O
were	O	O
summarized	O	O
using	O	O
frequency	O	O
counts	O	O
and	O	O
percentage	O	O
.	O	O
Continuous	O	O
demographic	O	O
and	O	O
baseline	O	O
characteristic	O	O
variables	O	O
were	O	O
summarized	O	O
by	O	O
descriptive	O	O
statistics	O	O
.	O	O
A	O	O
Wilcoxon	O	O
signed	O	O
rank	O	O
test	O	O
was	O	O
used	O	O
to	O	O
analyse	O	O
change	O	O
from	O	O
baseline	O	O
in	O	O
serum	O	O
hormone	O	O
levels	O	O
at	O	O
selected	O	O
scheduled	O	O
visits	O	O
.	O	O

Relationship	O	O
between	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
and	O	O
NET	O	O
-	O	O
specific	O	O
assessments	O	O
such	O	O
as	O	O
serum	O	O
hormone	O	O
levels	O	O
and	O	O
carcinoid	O	O
symptoms	O	O
were	O	O
investigated	O	O
.	O	O
The	O	O
Kaplan	O	O
-	O	O
Meier	O	O
estimate	O	O
of	O	O
median	B-arm_efficacy_metric	B-arm_efficacy_metric
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
with	O	O
its	O	O
two	O	O
-	O	O
sided	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
was	O	O
provided	O	O
for	O	O
each	O	O
baseline	O	O
category	O	O
of	O	O
the	O	O
selected	O	O
biomarkers	O	O
.	O	O
Kaplan	O	O
-	O	O
Meier	O	O
plots	O	O
of	O	O
PFS	O	B-arm_efficacy_metric
were	O	O
created	O	O
by	O	O
category	O	O
.	O	O
The	O	O
raw	O	O
P	O	O
value	O	O
of	O	O
the	O	O
log	O	O
rank	O	O
test	O	O
comparing	O	O
survival	O	O
distribution	O	O
of	O	O
PFS	O	B-arm_efficacy_metric
between	O	O
categories	O	O
was	O	O
also	O	O
provided	O	O
.	O	O

Of	O	O
the	O	O
47	O	O
patients	O	O
,	O	O
41	O	O
completed	O	O
at	O	O
least	O	O
one	O	O
cycle	O	O
of	O	O
CC-223	B-arm_description	B-arm_description
,	O	O
had	O	O
at	O	O
least	O	O
one	O	O
restaging	O	O
,	O	O
and	O	O
were	O	O
thus	O	O
evaluable	O	O
for	O	O
efficacy	O	O
.	O	O
By	O	O
investigator	O	O
assessment	O	O
,	O	O
no	O	O
patient	O	O
had	O	O
a	O	O
complete	O	O
response	O	O
(	O	O
CR	O	O
)	O	O
,	O	O
3	O	O
patients	O	O
(	O	O
7.3	O	O
%	O	O
)	O	O
had	O	O
a	O	O
partial	O	O
response	O	O
(	O	O
PR	O	O
)	O	O
,	O	O
34	O	O
(	O	O
82.9	O	O
%	O	O
)	O	O
showed	O	O
stable	O	O
disease	O	O
(	O	O
SD	O	O
)	O	O
,	O	O
1	O	O
(	O	O
2.4	O	O
%	O	O
)	O	O
had	O	O
progressive	O	O
disease	O	O
(	O	O
PD	O	O
)	O	O
,	O	O
and	O	O
for	O	O
3	O	O
(	O	O
7.3	O	O
%	O	O
)	O	O
the	O	O
assessment	O	O
was	O	O
not	O	O
done	O	O
.	O	O
Thus	O	O
,	O	O
the	O	O
objective	O	O
response	O	O
rate	O	O
(	O	O
CR+PR	O	O
)	O	O
was	O	O
7.3	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
1.5	O	O
-	O	O
19.9	O	O
%	O	O
)	O	O
and	O	O
the	O	O
disease	O	O
control	O	O
rate	O	O
(	O	O
CR+PR+SD	O	O
)	O	O
was	O	O
90.2	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
76.9	O	O
-	O	O
97.3	O	O
%	O	O
)	O	O
.	O	O
It	O	O
is	O	O
noteworthy	O	O
that	O	O
tumor	O	O
shrinkage	O	O
of	O	O
any	O	O
magnitude	O	O
relative	O	O
to	O	O
baseline	O	O
was	O	O
observed	O	O
in	O	O
73.2	O	O
%	O	O
patients	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
57.1	O	O
-	O	O
85.8	O	O
%	O	O
)	O	O
(	O	O
Fig	O	O
2	O	O
)	O	O
.	O	O
Duration	O	O
of	O	O
response	O	O
for	O	O
the	O	O
three	O	O
patients	O	O
with	O	O
PR	O	O
was	O	O
125	O	O
,	O	O
253	O	O
+	O	O
(	O	O
no	O	O
PD	O	O
reported	O	O
)	O	O
,	O	O
and	O	O
401	O	O
days	O	O
.	O	O
The	O	O
median	O	O
duration	O	O
of	O	O
SD	O	O
was	O	O
long	O	O
and	O	O
lasted	O	O
297	O	O
days	O	O
(	O	O
min	O	O
50	O	O
days	O	O
,	O	O
max	O	O
1519	O	O
days	O	O
)	O	O
.	O	O
Duration	O	O
of	O	O
SD	O	O
was	O	O
longer	O	O
than	O	O
a	O	O
year	O	O
in	O	O
17	O	O
patients	O	O
.	O	O
Median	B-arm_efficacy_metric	O
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
for	O	O
the	O	O
treated	O	O
population	O	O
was	O	O
19.5	B-arm_efficacy_results	O
months	I-arm_efficacy_results	O
(	I-arm_efficacy_results	O
95	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
CI	I-arm_efficacy_results	O
10.4	I-arm_efficacy_results	O
-	I-arm_efficacy_results	O
28.5	I-arm_efficacy_results	O
months	I-arm_efficacy_results	O
)	I-arm_efficacy_results	O
with	O	O
rates	B-arm_efficacy_results	O
at	I-arm_efficacy_results	O
6	I-arm_efficacy_results	O
and	I-arm_efficacy_results	O
10	I-arm_efficacy_results	O
months	I-arm_efficacy_results	O
of	I-arm_efficacy_results	O
85	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
and	I-arm_efficacy_results	O
64	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
,	O	O
respectively	O	O
;	O	O
median	O	O
OS	O	O
was	O	O
not	O	O
assessable	O	O
(	O	O
OS	O	O
rate	O	O
at	O	O
48	O	O
weeks	O	O
was	O	O
0.97	O	O
)	O	O
(	O	O
Fig	O	O
3	O	O
)	O	O
.	O	O

Impact	O	O
of	O	O
circulating	O	O
tumor	O	O
DNA	O	O
mutant	O	O
allele	O	O
fraction	O	O
on	O	O
prognosis	O	O
in	O	O
RAS	O	O
-	O	O
mutant	O	O
metastatic	O	O
colorectal	O	O
cancer	O	O
Impact	O	O
of	O	O
circulating	O	O
tumor	O	O
DNA	O	O
mutant	O	O
allele	O	O
fraction	O	O
on	O	O
prognosis	O	O
in	O	O
RAS	O	O
-	O	O
mutant	O	O
metastatic	O	O
colorectal	O	O
cancer	O	O
ElenaElez	B-authors	B-authors

Spain	O	O
Cellex	O	O
Building	O	O
,	O	O
C/	O	O
Natzaret	O	O
115	O	O
-	O	O
117	O	O
08035	O	O
Barcelona	O	O
Spain	O	O
Impact	O	O
of	O	O
circulating	O	O
tumor	O	O
DNA	O	O
mutant	O	O
allele	O	O
fraction	O	O
on	O	O
prognosis	O	O
in	O	O
RAS	O	O
-	O	O
mutant	O	O
metastatic	O	O
colorectal	O	O
cancer	O	O
10.1002/1878	O	O
-	O	O
0261.12547	O	O
Received	O	O
21	O	O
October	O	O
2018	O	O
,	O	O
revised	O	O
11	O	O
May	O	O
2019	O	O
,	O	O
accepted	O	O
15	O	O
July	O	O
2019	O	O
,	O	O
available	O	O
online	O	O
31	O	O
July	O	O
2019	O	O

This	O	O
multicentric	O	O
study	O	O
included	O	O
both	O	O
retrospective	O	O
and	O	O
prospective	O	O
patients	O	O
:	O	O
Retrospective	O	O
patients	O	O
were	O	O
recruited	O	O
from	O	O
two	O	O
Spanish	O	O
hospitals	O	O
(	O	O
Vall	O	O
d'Hebron	O	O
University	O	O
Hospital	O	O
and	O	O
Catalan	O	O
Institute	O	O
of	O	O
Oncology	O	O
,	O	O
Duran	O	O
I	O	O
Reynals	O	O
)	O	O
;	O	O
prospective	O	O
patients	O	O
were	O	O
recruited	O	O
from	O	O
the	O	O
Vall	O	O
d'Hebron	O	O
University	O	O
Hospital	O	O
only	O	O
.	O	O
Additionally	O	O
,	O	O
an	O	O
independent	O	O
cohort	O	O
of	O	O
first	O	O
-	O	O
line	O	O
patients	O	O
derived	O	O
from	O	O
the	O	O
CAPRI	B-study_type	O
-	I-study_type	O
GOIM	I-study_type	O
trial	I-study_type	O
(	O	O
registration	O	O
number	O	O
:	O	O
2009	O	O
-	O	O
014041	O	O
-	O	O
81	O	O
)	O	O
were	O	O
also	O	O
included	O	O
.	O	O
The	O	O
study	O	O
was	O	O
approved	O	O
by	O	O
the	O	O
ethics	O	O
committee	O	O
of	O	O
all	O	O
hospitals	O	O
,	O	O
and	O	O
all	O	O
patients	O	O
signed	O	O
written	O	O
informed	O	O
consent	O	O
.	O	O
This	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
accordance	O	O
with	O	O
the	O	O
Declaration	O	O
of	O	O
Helsinki	O	O
and	O	O
Good	O	O
Clinical	O	O
Practice	O	O
guidelines	O	O
.	O	O

Blood	O	O
samples	O	O
(	O	O
4	O	O
mL	O	O
)	O	O
were	O	O
collected	O	O
in	O	O
CellSaveÒ	O	O
Preservative	O	O
Tubes	O	O
(	O	O
Menarini	O	O
-	O	O
Silicon	O	O
Biosystems	O	O
,	O	O
Bologna	O	O
,	O	O
Italy	O	O
)	O	O
,	O	O
and	O	O
plasma	O	O
was	O	O
isolated	O	O
within	O	O
48	O	O
h.	O	O
For	O	O
nontrial	O	O
patients	O	O
,	O	O
10	O	O
mL	O	O
of	O	O
blood	O	O
was	O	O
collected	O	O
in	O	O
EDTA	O	O
tubes	O	O
and	O	O
plasma	O	O
was	O	O
isolated	O	O
within	O	O
1	O	O
h.	O	O
A	O	O
two	O	O
-	O	O
step	O	O
centrifugation	O	O
was	O	O
performed	O	O
with	O	O
blood	O	O
initially	O	O
centrifuged	O	O
for	O	O
10	O	O
min	O	O
at	O	O
1600	O	O
g	O	O
at	O	O
room	O	O
temperature	O	O
.	O	O
Supernatant	O	O
was	O	O
collected	O	O
,	O	O
avoiding	O	O
the	O	O
buffy	O	O
coat	O	O
,	O	O
and	O	O
then	O	O
centrifuged	O	O
again	O	O
for	O	O
10	O	O
min	O	O
at	O	O
room	O	O
temperature	O	O
at	O	O
3000	O	O
g	O	O
to	O	O
remove	O	O
remaining	O	O
cells	O	O
.	O	O
Plasma	O	O
supernatant	O	O
was	O	O
transferred	O	O
into	O	O
a	O	O
1.5-mL	O	O
tube	O	O
and	O	O
stored	O	O
at	O	O
À80	O	O
°	O	O
C	O	O
until	O	O
use	O	O
.	O	O

In	O	O
the	O	O
first	O	O
-	O	O
line	O	O
setting	O	O
,	O	O
using	O	O
an	O	O
optimized	O	O
MAF	O	B-arm_description
cutoff	O	O
of	O	O
5.8	O	O
%	O	O
,	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
not	O	O
significantly	O	O
better	O	O
in	O	O
samples	B-arm_description	O
with	I-arm_description	O
MAF	I-arm_description	B-arm_description
<	I-arm_description	O
5.8	I-arm_description	O
%	I-arm_description	O
(	O	O
Fig	O	O
.	O	O
2A	O	O
)	O	O
;	O	O
however	O	O
,	O	O
a	O	O
trend	O	O
toward	O	O
lower	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
observed	O	O
in	O	O
samples	B-arm_description	O
with	I-arm_description	O
a	I-arm_description	O
higher	I-arm_description	O
MAF	I-arm_description	B-arm_description
.	O	O
The	O	O
difference	O	O
in	O	O
median	B-arm_efficacy_metric	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
between	O	O
patients	O	O
with	O	O
RAS	B-arm_description	O
-	I-arm_description	O
mutant	I-arm_description	O
samples	I-arm_description	O
with	I-arm_description	O
MAF	I-arm_description	B-arm_description
<	I-arm_description	O
5.8	I-arm_description	O
%	I-arm_description	O
(	O	O
N	O	O
=	O	O
10	O	O
)	O	O
and	O	O
those	B-arm_description	O
with	I-arm_description	O
MAF	I-arm_description	B-arm_description
≥	I-arm_description	O
5.8	I-arm_description	O
%	I-arm_description	O
was	O	O
10.7	B-arm_efficacy_results	O
months	I-arm_efficacy_results	O
vs	O	O
7.0	B-arm_efficacy_results	O
months	I-arm_efficacy_results	O
with	O	O
an	O	O
HR	B-arm_efficacy_results	O
of	I-arm_efficacy_results	O
2.2	I-arm_efficacy_results	O
(	I-arm_efficacy_results	O
95	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
CI	I-arm_efficacy_results	O
:	I-arm_efficacy_results	O
0.94	I-arm_efficacy_results	O
-	I-arm_efficacy_results	O
7.20	I-arm_efficacy_results	O
;	I-arm_efficacy_results	O
P	I-arm_efficacy_results	O
=	I-arm_efficacy_results	O
0.06	I-arm_efficacy_results	O
)	I-arm_efficacy_results	O
.	O	O

Our	O	O
data	O	O
strongly	O	O
support	O	O
that	O	O
RAS	O	O
MAFs	O	O
have	O	O
independent	O	O
prognostic	O	O
value	O	O
for	O	O
CRC	O	O
survival	O	O
and	O	O
that	O	O
,	O	O
along	O	O
with	O	O
tumor	O	O
and	O	O
patient	O	O
characteristics	O	O
,	O	O
could	O	O
provide	O	O
a	O	O
useful	O	O
noninvasive	O	O
decision	O	O
-	O	O
making	O	O
tool	O	O
in	O	O
the	O	O
first	O	O
-	O	O
line	O	O
setting	O	O
.	O	O
After	O	O
demonstrating	O	O
the	O	O
feasibility	O	O
for	O	O
implementing	O	O
liquid	O	O
biopsies	O	O
in	O	O
routine	O	O
care	O	O
(	O	O
Grasselli	O	O
et	O	O
al	O	O
.	O	O
,	O	O
2017	O	O
)	O	O
,	O	O
we	O	O
propose	O	O
RAS	O	O
MAFs	O	O
as	O	O
a	O	O
novel	O	O
independent	O	O
prognostic	O	O
biomarker	O	O
for	O	O
mCRC	O	O
.	O	O
AIRC	O	O
(	O	O
Associazione	O	O
Italiana	O	O
per	O	O
la	O	O
Ricerca	O	O
sul	O	O
cancro	O	O
)	O	O
.	O	O
This	O	O
research	O	O
project	O	O
was	O	O
supported	O	O
by	O	O
ESMO	O	O
[	O	O
Translational	O	O
Research	O	O
Fellowship	O	O
]	O	O
with	O	O
the	O	O
aid	O	O
of	O	O
a	O	O
grant	O	O
from	O	O
Amgen	O	O
.	O	O
Any	O	O
views	O	O
,	O	O
opinions	O	O
,	O	O
findings	O	O
,	O	O
conclusions	O	O
,	O	O
or	O	O
recommendations	O	O
expressed	O	O
in	O	O
this	O	O
material	O	O
are	O	O
those	O	O
solely	O	O
of	O	O
the	O	O
author(s	O	O
)	O	O
and	O	O
do	O	O
not	O	O
necessarily	O	O
reflect	O	O
those	O	O
of	O	O
ESMO	O	O
or	O	O
Amgen	O	O
.	O	O
This	O	O
work	O	O
was	O	O
supported	O	O
partially	O	O
by	O	O
the	O	O
Instituto	O	O
de	O	O
Salud	O	O
Carlos	O	O
III	O	O
(	O	O
Ministerio	O	O
de	O	O
Econom	O	O
ıa	O	O
y	O	O
Competitividad	O	O
)	O	O
and	O	O
'	O	O
Fondo	O	O
Europeo	O	O
de	O	O
Desarrollo	O	O
Regional	O	O
(	O	O
FEDER	O	O
)	O	O
,	O	O
una	O	O
manera	O	O
de	O	O
hacer	O	O
Europa	O	O
'	O	O
grants	O	O
[	O	O
FIS	O	O
PI12	O	O
-	O	O
01589	O	O
to	O	O
RS	O	O
]	O	O
and	O	O
RETICC	O	O
Cancer	O	O
.	O	O
The	O	O
funders	O	O
had	O	O
no	O	O
role	O	O
in	O	O
study	O	O
design	O	O
,	O	O
data	O	O
collection	O	O
and	O	O
analysis	O	O
,	O	O
decision	O	O
to	O	O
publish	O	O
,	O	O
or	O	O
preparation	O	O
of	O	O
the	O	O
manuscript	O	O
.	O	O

JT	B-authors	O
has	O	O
served	O	O
in	O	O
a	O	O
consulting	O	O
or	O	O
advisory	O	O
role	O	O
for	O	O
Amgen	O	O
,	O	O
Boehringer	O	O
Ingelheim	O	O
,	O	O
Celgene	O	O
,	O	O
Chugai	O	O
,	O	O
ImClone	O	O
,	O	O
Lilly	O	O
,	O	O
Merck	O	O
,	O	O
S.L.	O	O
,	O	O
Madrid	O	O
,	O	O
Merck	O	O
Serono	O	O
,	O	O
Millennium	O	O
Pharmaceuticals	O	O
,	O	O
Inc.	O	O
,	O	O
Novartis	O	O
,	O	O
Roche	O	O
,	O	O
Sanofi	O	O
,	O	O
and	O	O
Taiho	O	O
.	O	O
RS	B-authors	O
has	O	O
served	O	O
in	O	O
a	O	O
consulting	O	O
or	O	O
advisory	O	O
role	O	O
for	O	O
Amgen	O	O
,	O	O
Merck	O	O
,	O	O
S.L.	O	O
,	O	O
Madrid	O	O
,	O	O
and	O	O
Roche	O	O
Dx	O	O
and	O	O
obtained	O	O
research	O	O
funding	O	O
from	O	O
Roche	O	O
Dx	O	O
.	O	O
AV	B-authors	O
has	O	O
served	O	O
in	O	O
a	O	O
consulting	O	O
or	O	O
advisory	O	O
role	O	O
for	O	O
Merck	O	O
,	O	O
S.L.	O	O
,	O	O
Madrid	O	O
,	O	O
Merck	O	O
Serono	O	O
,	O	O
and	O	O
Sysmex	O	O
.	O	O
All	O	O
remaining	O	O
authors	O	O
have	O	O
declared	O	O
no	O	O
conflicts	O	O
of	O	O
interest	O	O
.	O	O

The	O	O
Christie	O	O
NHS	O	O
Foundation	O	O
Trust	O	O
Manchester	O	O
UK	O	O
PhDMargheritaCarucci	B-authors	B-authors
DrRobertHJones	B-authors	B-authors
robert.hugh.jones@wales.nhs.uk	O	B-authors
CatrinCox	B-authors	B-authors
RachelButler	B-authors	B-authors
FouadAlchami	B-authors	B-authors
Tracie	B-authors	B-authors
-	I-authors	I-authors
AnnMadden	I-authors	B-authors
CatherineBale	B-authors	B-authors
PavelBezecny	B-authors	B-authors
JohnathanJoffe	B-authors	B-authors
SarahMoon	B-authors	B-authors
ChrisTwelves	B-authors	B-authors
RamachandranVenkitaraman	B-authors	B-authors
SimonWaters	B-authors	B-authors
AndrewFoxley	B-authors	B-authors
Joffe	B-authors	B-authors
FRCP	O	B-authors
)	O	O

robert.hugh.jones@wales.nhs.uk	O	O
DrRobertHJones	B-authors	B-authors
Dr	B-authors	B-authors
Robert	I-authors	B-authors
H	I-authors	I-authors
Jones	I-authors	I-authors
robert.hugh.jones@wales.nhs.uk	O	B-authors
CatrinCox	B-authors	B-authors
CatrinCox	B-authors	B-authors
Catrin	B-authors	B-authors
Cox	I-authors	I-authors
RachelButler	B-authors	B-authors
RachelButler	B-authors	B-authors
Rachel	B-authors	B-authors
Butler	I-authors	I-authors
FouadAlchami	B-authors	B-authors
FouadAlchami	B-authors	B-authors
Fouad	B-authors	B-authors
Alchami	I-authors	B-authors
Tracie	B-authors	B-authors
-	I-authors	I-authors
AnnMadden	I-authors	B-authors
Tracie	B-authors	B-authors
-	I-authors	I-authors
AnnMadden	I-authors	B-authors
Tracie	B-authors	B-authors
-	I-authors	I-authors
Ann	I-authors	B-authors
Madden	I-authors	I-authors
CatherineBale	B-authors	B-authors
CatherineBale	B-authors	B-authors
Catherine	B-authors	B-authors
Bale	I-authors	I-authors
PavelBezecny	B-authors	B-authors
PavelBezecny	B-authors	B-authors
Pavel	B-authors	B-authors
Bezecny	I-authors	I-authors
JohnathanJoffe	B-authors	B-authors
JohnathanJoffe	B-authors	B-authors
Johnathan	B-authors	B-authors
Joffe	I-authors	B-authors
SarahMoon	B-authors	B-authors
SarahMoon	B-authors	B-authors
Sarah	B-authors	B-authors
Moon	I-authors	I-authors
ChrisTwelves	B-authors	B-authors
ChrisTwelves	B-authors	B-authors
Chris	B-authors	B-authors
Twelves	I-authors	I-authors
RamachandranVenkitaraman	B-authors	B-authors
RamachandranVenkitaraman	B-authors	B-authors
Ramachandran	B-authors	B-authors
Venkitaraman	I-authors	B-authors
SimonWaters	B-authors	B-authors
SimonWaters	B-authors	B-authors
Simon	B-authors	B-authors
Waters	I-authors	I-authors
AndrewFoxley	B-authors	B-authors
Joffe	B-authors	B-authors
FRCP	O	B-authors
)	O	O

Capivasertib	O	O
(	O	O
AZD5363	O	O
)	O	O
is	O	O
a	O	O
potent	O	O
and	O	O
selective	O	O
inhibitor	O	O
of	O	O
the	O	O
three	O	O
AKT	O	O
isoforms	O	O
.	O	O
Preclinical	O	O
data	O	O
show	O	O
synergistic	O	O
activity	O	O
with	O	O
fulvestrant	O	O
in	O	O
both	O	O
endocrinesensitive	O	O
and	O	O
endocrineresistant	O	O
models	O	O
of	O	O
oestrogen	O	O
receptorpositive	O	O
breast	O	O
cancer	O	O
.	O	O
12	O	O
Preliminary	O	O
clinical	O	O
activity	O	O
was	O	O
seen	O	O
with	O	O
capivasertib	O	O
monotherapy	O	O
in	O	O
heavily	O	O
pretreated	O	O
patients	O	O
with	O	O
AKT1mutant	O	O
solid	O	O
cancers	O	O
,	O	O
including	O	O
oestrogen	O	O
receptorpositive	O	O
breast	O	O
cancer	O	O
,	O	O
but	O	O
very	O	O
low	O	O
singleagent	O	O
activity	O	O
in	O	O
patients	O	O
with	O	O
PIK3CAmutant	O	O
breast	O	O
and	O	O
gynaeco	O	O
logical	O	O
cancers	O	O
.	O	O
13,14	O	O
In	O	O
the	O	O
phase	O	O
2	O	O
BEECH	O	O
trial	O	O
,	O	O
capivasertib	O	O
did	O	O
not	O	O
enhance	O	O
the	O	O
efficacy	O	O
of	O	O
paclitaxel	O	O
in	O	O
oestrogen	O	O
receptorpositive	O	O
advanced	O	O
breast	O	O
cancer	O	O
,	O	O
although	O	O
endocrine	O	O
therapy	O	O
was	O	O
not	O	O
permitted	O	O
in	O	O
this	O	O
study	O	O
as	O	O
is	O	O
standard	O	O
practice	O	O
.	O	O
15	O	O
In	O	O
a	O	O
phase	O	B-study_type
1b	O	I-study_type
study	O	I-study_type
,	O	O
we	O	O
determined	O	O
the	O	O
capivasertib	O	O
dose	O	O
to	O	O
be	O	O
used	O	O
in	O	O
combination	O	O
with	O	O
fulvestrant	O	O
was	O	O
400	O	O
mg	O	O
twice	O	O
daily	O	O
for	O	O
4	O	O
days	O	O
then	O	O
3	O	O
days	O	O
off	O	O
in	O	O
a	O	O
weekly	O	O
schedule	O	O
.	O	O
16	O	O
In	O	O
the	O	O
phase	B-study_type	B-study_type
2	I-study_type	I-study_type
FAKTION	O	I-study_type
trial	B-study_type	I-study_type
,	O	O
we	O	O
assessed	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
capivasertib	B-arm_description	O
plus	B-arm_description	O
fulvestrant	I-arm_description	O
in	O	O
post	O	O
menopausal	O	O
women	O	O
with	O	O
aromatase	O	O
inhibitorresistant	O	O
,	O	O
oestrogen	O	O
receptorpositive	O	O
,	O	O
HER2negative	O	O
advanced	O	O
or	O	O
metastatic	O	O
breast	O	O
cancer	O	O
.	O	O
Furthermore	O	O
,	O	O
the	O	O
relative	O	O
efficacy	O	O
of	O	O
the	O	O
treatment	O	O
combination	O	O
in	O	O
participants	O	O
with	O	O
and	O	O
without	O	O
alteration	O	O
of	O	O
the	O	O
PI3	O	O
K	O	O
pathway	O	O
was	O	O
assessed	O	O
.	O	O

Baseline	O	O
PTEN	O	O
status	O	O
was	O	O
assessed	O	O
centrally	O	O
at	O	O
the	O	O
University	O	O
Hospital	O	O
Wales	O	O
Cellular	O	O
Pathology	O	O
Department	O	O
(	O	O
Cardiff	O	O
,	O	O
UK	O	O
)	O	O
.	O	O
Freshly	O	O
cut	O	O
sections	O	O
(	O	O
5	O	O
µm	O	O
thick	O	O
)	O	O
were	O	O
taken	O	O
from	O	O
each	O	O
formalinfixed	O	O
paraffin	O	O
embedded	O	O
tumour	O	O
block	O	O
.	O	O
The	O	O
first	O	O
section	O	O
was	O	O
stained	O	O
with	O	O
haematoxylin	O	O
and	O	O
eosin	O	O
to	O	O
identify	O	O
the	O	O
area	O	O
of	O	O
greatest	O	O
tumour	O	O
density	O	O
and	O	O
tumour	O	O
percentage	O	O
,	O	O
and	O	O
the	O	O
rest	O	O
was	O	O
made	O	O
available	O	O
for	O	O
DNA	O	O
extraction	O	O
and	O	O
whole	O	O
section	O	O
immunohistochemistry	O	O
.	O	O
Immunohistochemistry	O	O
was	O	O
prepared	O	O
using	O	O
DAKO	O	O
(	O	O
Ely	O	O
,	O	O
UK	O	O
)	O	O
PTEN	O	O
Monoclonal	O	O
Mouse	O	O
AntiHumanClone	O	O
(	O	O
code	O	O
M3627	O	O
)	O	O
,	O	O
with	O	O
antigen	O	O
retrieval	O	O
done	O	O
with	O	O
high	O	O
pH	O	O
DAKO	O	O
Target	O	O
Retrieval	O	O
Solution	O	O
and	O	O
the	O	O
DAKO	O	O
Autostainer	O	O
Link	O	O
48	O	O
automated	O	O
strainer	O	O
with	O	O
a	O	O
predetection	O	O
dilution	O	O
of	O	O
1:100	O	O
.	O	O
The	O	O
validation	O	O
study	O	O
and	O	O
full	O	O
protocol	O	O
for	O	O
the	O	O
PTEN	O	O
immunohistochemistry	O	O
detection	O	O
have	O	O
been	O	O
published	O	O
previously	O	O
.	O	O
18	O	O
The	O	O
PTEN	O	O
protein	O	O
expression	O	O
was	O	O
docu	O	O
mented	O	O
using	O	O
a	O	O
numeric	O	O
intensity	O	O
score	O	O
of	O	O
the	O	O
cyto	O	O
plasmic	O	O
staining	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
surrounding	O	O
stroma	O	O
and	O	O
macrophages	O	O
(	O	O
0	O	O
:	O	O
null	O	O
;	O	O
1	O	O
:	O	O
weak	O	O
;	O	O
2	O	O
:	O	O
moderate	O	O
;	O	O
and	O	O
3	O	O
:	O	O
strong	O	O
)	O	O
.	O	O
The	O	O
protocol	O	O
definition	O	O
of	O	O
PTEN	O	B-arm_description
loss	O	O
,	O	O
for	O	O
inclusion	O	O
of	O	O
a	O	O
patient	O	O
in	O	O
the	O	O
altered	O	O
pathway	O	O
subgroup	O	O
,	O	O
was	O	O
either	O	O
immunohistochemistry	O	O
0	O	O
or	O	O
weak	O	O
PTEN	O	O
staining	O	O
in	O	O
less	O	O
than	O	O
10	O	O
%	O	O
of	O	O
cancer	O	O
cells	O	O
.	O	O

The	O	O
protocol	O	O
specified	O	O
that	O	O
pathway	O	O
alteration	O	O
was	O	O
defined	O	O
as	O	O
either	O	O
a	O	O
hotspot	O	O
mutation	O	O
detected	O	O
by	O	O
digital	O	O
droplet	O	O
PCR	O	O
(	O	O
ddPCR	O	O
)	O	O
on	O	O
PIK3CA	O	B-arm_description
exons	O	O
9	O	O
or	O	O
20	O	O
in	O	O
tumour	O	O
tissue	O	O
or	O	O
blood	O	O
or	O	O
an	O	O
immuno	O	O
histochemistry	O	O
null	O	O
status	O	O
for	O	O
PTEN	O	B-arm_description
in	O	O
tumour	O	O
tissue	O	O
(	O	O
primary	O	O
tumour	O	O
or	O	O
metastatic	O	O
biopsy	O	O
)	O	O
.	O	O
The	O	O
method	O	O
of	O	O
mutational	O	O
analysis	O	O
changed	O	O
from	O	O
pyrosequencing	O	O
to	O	O
ddPCR	O	O
during	O	O
the	O	O
trial	O	O
(	O	O
from	O	O
Nov	O	O
9	O	O
,	O	O
2016	O	O
)	O	O
,	O	O
which	O	O
provided	O	O
greater	O	O
sensitivity	O	O
to	O	O
detect	O	O
mutations	O	O
.	O	O
14	O	O
patients	O	O
who	O	O
were	O	O
categorised	O	O
as	O	O
nonaltered	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
pyrosequencing	O	O
analysis	O	O
had	O	O
insufficient	O	O
material	O	O
to	O	O
carry	O	O
out	O	O
a	O	O
repeat	O	O
ddPCR	O	O
analysis	O	O
.	O	O
Tissue	O	O
DNA	O	O
and	O	O
cellfree	O	O
DNA	O	O
were	O	O
analysed	O	O
by	O	O
ddPCR	O	O
using	O	O
the	O	O
BioRad	O	O
(	O	O
Watford	O	O
,	O	O
UK	O	O
)	O	O
QX	O	O
200	O	O
system	O	O
.	O	O
Samples	O	O
were	O	O
analysed	O	O
for	O	O
the	O	O
common	O	O
PIK3CA	O	B-arm_description
exon	O	O
9	O	O
and	O	O
20	O	O
mutations	O	O
(	O	O
reference	O	O
sequence	O	O
NM_006218.2	O	O
)	O	O
.	O	O

Between	O	O
March	O	O
16	O	O
,	O	O
2015	O	O
,	O	O
and	O	O
March	O	O
6	O	O
,	O	O
2018	O	O
,	O	O
183	O	O
patients	O	O
were	O	O
screened	O	O
for	O	O
eligibility	O	O
and	O	O
140	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
fulvestrant	B-arm_description	B-arm_description
plus	O	I-arm_description
capivasertib	B-arm_description	I-arm_description
(	O	O
n=69	O	O
[	O	O
49	O	O
%	O	O
]	O	O
)	O	O
or	O	O
fulvestrant	B-arm_description	B-arm_description
plus	O	I-arm_description
placebo	B-arm_description	I-arm_description
(	O	O
n=71	O	O
[	O	O
51	O	O
%	O	O
]	O	O
;	O	O
figure	O	O
1	O	O
)	O	O
.	O	O
All	O	O
randomly	O	O
assigned	O	O
participants	O	O
were	O	O
included	O	O
in	O	O
primary	O	O
efficacy	O	O
and	O	O
safety	O	O
analyses	O	O
.	O	O
Participants	O	O
were	O	O
followed	O	O
up	O	O
until	O	O
all	O	O
had	O	O
had	O	O
at	O	O
least	O	O
6	O	O
months	O	O
followup	O	O
and	O	O
the	O	O
minimum	O	O
98	O	O
disease	O	O
progression	O	O
events	O	O
required	O	O
for	O	O
analysis	O	O
were	O	O
confirmed	O	O
.	O	O
Median	B-arm_efficacy_metric	O
progressionfree	I-arm_efficacy_metric	B-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
followup	O	O
was	O	O
4•9	O	O
months	O	O
(	O	O
IQR	O	O
1•6	O	O
-	O	O
11•6	O	O
)	O	O
.	O	O
Treatment	O	O
groups	O	O
were	O	O
well	O	O
balanced	O	O
for	O	O
baseline	O	O
characteristics	O	O
(	O	O
table	O	O
1	O	O
)	O	O
.	O	O

RHJ	B-authors	O
,	O	O
SJH	B-authors	O
,	O	O
AC	B-authors	O
,	O	O
and	O	O
AF	B-authors	O
were	O	O
responsible	O	O
for	O	O
study	O	O
design	O	O
,	O	O
and	O	O
RHJ	B-authors	O
,	O	O
SJH	B-authors	O
,	O	O
AC	B-authors	O
,	O	O
and	O	O
MC	B-authors	O
for	O	O
writing	O	O
of	O	O
the	O	O
manuscript	O	O
.	O	O
MC	B-authors	O
and	O	O
TAM	B-authors	O
were	O	O
responsible	O	O
for	O	O
trial	O	O
management	O	O
,	O	O
coordination	O	O
,	O	O
and	O	O
conduct	O	O
.	O	O
RHJ	B-authors	O
,	O	O
SJH	B-authors	O
,	O	O
CB	B-authors	O
,	O	O
PB	B-authors	O
,	O	O
JJ	B-authors	O
,	O	O
SM	B-authors	O
,	O	O
CT	B-authors	O
,	O	O
RV	B-authors	O
,	O	O
and	O	O
SW	B-authors	O
were	O	O
responsible	O	O
for	O	O
patient	O	O
accrual	O	O
,	O	O
trial	O	O
conduct	O	O
,	O	O
and	O	O
obtaining	O	O
the	O	O
data	O	O
.	O	O
RB	B-authors	O
and	O	O
FA	B-authors	O
were	O	O
responsible	O	O
for	O	O
the	O	O
analysis	O	O
of	O	O
biological	O	O
samples	O	O
.	O	O
AC	B-authors	O
,	O	O
RHJ	B-authors	O
,	O	O
and	O	O
SJH	B-authors	O
wrote	O	O
the	O	O
statistical	O	O
analysis	O	O
plan	O	O
.	O	O
CC	B-authors	O
and	O	O
AC	B-authors	O
analysed	O	O
the	O	O
data	O	O
and	O	O
produced	O	O
the	O	O
results	O	O
and	O	O
figures	O	O
.	O	O
All	O	O
authors	O	O
interpreted	O	O
the	O	O
data	O	O
and	O	O
reviewed	O	O
the	O	O
draft	O	O
and	O	O
final	O	O
versions	O	O
of	O	O
the	O	O
manuscript	O	O
.	O	O

Therapy	O	O
of	O	O
nodal	O	O
Follicular	O	O
Lymphoma	O	O
(	O	O
WHO	O	O
grade	O	O
1/2	O	O
)	O	O
in	O	O
clinical	O	O
stage	O	O
I	O	O
/	O	O
II	O	O
using	O	O
response	O	O
adapted	O	O
Involved	B-arm_description	B-arm_description
Site	I-arm_description	I-arm_description
Radiotherapy	I-arm_description	I-arm_description
in	O	O
combination	O	O
with	O	O
Obinutuzumab	B-arm_description	B-arm_description
(	I-arm_description	I-arm_description
Gazyvaro	I-arm_description	B-arm_description
)	I-arm_description	O
-GAZAI	O	O
Trial	O	O
(	O	O
GAZyvaro	O	O
and	O	O
response	O	O
adapted	O	O
Involvedsite	O	B-arm_description
Radiotherapy	O	I-arm_description
)	O	O
:	O	O
a	O	O
study	B-study_type	B-study_type
protocol	I-study_type	I-study_type
for	I-study_type	I-study_type
a	I-study_type	I-study_type
single	I-study_type	I-study_type
-	I-study_type	I-study_type
arm	I-study_type	I-study_type
,	I-study_type	I-study_type
non	I-study_type	I-study_type
-	I-study_type	I-study_type
randomized	I-study_type	I-study_type
,	I-study_type	I-study_type
open	I-study_type	I-study_type
,	I-study_type	I-study_type
national	I-study_type	I-study_type
,	I-study_type	I-study_type
multi	I-study_type	I-study_type
-	I-study_type	I-study_type
center	I-study_type	I-study_type
phase	I-study_type	I-study_type
II	I-study_type	I-study_type
trial	I-study_type	I-study_type

Also	O	O
,	O	O
rituximab	O	O
may	O	O
enhance	O	O
radiosensitivity	O	O
of	O	O
lymphoma	O	O
cells	O	O
and	O	O
thus	O	O
may	O	O
improve	O	O
the	O	O
efficacy	O	O
of	O	O
RT	O	O
[	O	O
20	O	O
]	O	O
.	O	O
Additionally	O	O
,	O	O
rituximab	O	O
maintenance	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
prolong	O	O
progression	O	B-arm_efficacy_metric
-	O	I-arm_efficacy_metric
free	O	I-arm_efficacy_metric
survival	O	I-arm_efficacy_metric
(	O	O
PFS	O	B-arm_efficacy_metric
)	O	O
after	O	O
first	O	O
-	O	O
line	O	O
therapy	O	O
of	O	O
advanced	O	O
stage	O	O
FL	O	O
[	O	O
21	O	O
]	O	O
and	O	O
therefore	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
elimination	O	O
of	O	O
minimal	O	O
disease	O	O
that	O	O
is	O	O
not	O	O
covered	O	O
by	O	O
the	O	O
radiation	O	O
field	O	O
.	O	O

MRD	O	O
will	O	O
be	O	O
analyzed	O	O
initially	O	O
,	O	O
at	O	O
week	O	O
18	O	O
,	O	O
and	O	O
at	O	O
months	O	O
6	O	O
,	O	O
12	O	O
,	O	O
18	O	O
,	O	O
and	O	O
24	O	O
using	O	O
the	O	O
markers	O	O
t(14:18	O	O
)	O	O
PCR	O	O
for	O	O
MBR	O	O
,	O	O
3′mbr	O	O
,	O	O
5′mcr	O	O
,	O	O
and	O	O
MCR	O	O
;	O	O
clonal	O	O
IGH	O	O
rearrangements	O	O
(	O	O
FR1	O	O
-	O	O
3	O	O
)	O	O
;	O	O
and	O	O
clonal	O	O
IGL	O	O
rearrangements	O	O
(	O	O
IGK	O	O
and	O	O
Kappa	O	O
-	O	O
KDE	O	O
)	O	O
.	O	O

Calculation	O	O
of	O	O
the	O	O
number	O	O
of	O	O
patients	O	O
to	O	O
be	O	O
recruited	O	O
is	O	O
based	O	O
on	O	O
the	O	O
ITT	O	O
population	O	O
.	O	O
The	O	O
primary	O	O
endpoint	O	O
is	O	O
the	O	O
rate	O	O
of	O	O
metabolic	O	O
CR	O	O
in	O	O
week	O	O
18	O	O
in	O	O
patients	O	O
with	O	O
initially	O	O
remaining	O	O
lymphoma	O	O
after	O	O
the	O	O
diagnostic	O	O
surgery	O	O
as	O	O
judged	O	O
by	O	O
FDG	O	O
-	O	O
PET	O	O
/	O	O
CT	O	O
.	O	O
Given	O	O
the	O	O
morphologic	O	O
CR	O	O
rate	O	O
of	O	O
37%-84	O	O
%	O	O
after	O	O
LDRT	O	O
documented	O	O
in	O	O
the	O	O
literature	O	O
and	O	O
a	O	O
lack	O	O
of	O	O
data	O	O
for	O	O
metabolic	O	O
CR	O	O
after	O	O
LDRT	O	O
,	O	O
a	O	O
CR	O	O
rate	O	O
of	O	O
60	O	O
%	O	O
is	O	O
assumed	O	O
.	O	O
If	O	O
50	O	O
patients	O	O
enter	O	O
the	O	O
FDG	O	O
-	O	O
PET	O	O
/	O	O
CT	O	O
and	O	O
the	O	O
observed	O	O
metabolic	O	O
CR	O	O
rate	O	O
amounts	O	O
to	O	O
60	O	O
%	O	O
,	O	O
the	O	O
half	O	O
width	O	O
of	O	O
the	O	O
asymptotic	O	O
twosided	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
amounts	O	O
to	O	O
about	O	O
±13.5	O	O
%	O	O
.	O	O
Based	O	O
on	O	O
the	O	O
experience	O	O
of	O	O
the	O	O
MIR	O	O
trial	O	O
,	O	O
a	O	O
general	O	O
dropout	O	O
rate	O	O
of	O	O
10	O	O
%	O	O
is	O	O
assumed	O	O
,	O	O
and	O	O
about	O	O
30	O	O
%	O	O
of	O	O
the	O	O
included	O	O
patients	O	O
will	O	O
not	O	O
have	O	O
remaining	O	O
lymphoma	O	O
after	O	O
initial	O	O
surgery	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
owing	O	O
to	O	O
stage	O	O
shifting	O	O
to	O	O
stage	O	O
III	O	O
/	O	O
IV	O	O
disease	O	O
,	O	O
a	O	O
dropout	O	O
rate	O	O
of	O	O
about	O	O
15	O	O
%	O	O
after	O	O
the	O	O
initial	O	O
FDG	O	O
-	O	O
PET	O	O
/	O	O
CT	O	O
is	O	O
expected	O	O
.	O	O

A	O	O
clinical	B-study_type	B-study_type
study	I-study_type	I-study_type
of	O	O
traditional	O	O
Chinese	O	O
medicine	O	O
prolonging	O	O
the	O	O
survival	O	O
of	O	O
advanced	O	O
gastric	O	O
cancer	O	O
patients	O	O
by	O	O
regulating	O	O
the	O	O
immunosuppressive	O	O
cell	O	O
population	O	O
A	O	O
study	O	B-study_type
protocol	O	I-study_type
for	O	O
a	O	O
multicenter	B-study_type	B-study_type
,	I-study_type	I-study_type
randomized	I-study_type	I-study_type
controlled	I-study_type	I-study_type
trail	I-study_type	I-study_type
A	O	I-study_type
clinical	B-study_type	I-study_type
study	I-study_type	I-study_type
of	O	O
traditional	O	O
Chinese	O	O
medicine	O	O
prolonging	O	O
the	O	O
survival	O	O
of	O	O
advanced	O	O
gastric	O	O
cancer	O	O
patients	O	O
by	O	O
regulating	O	O
the	O	O
immunosuppressive	O	O
cell	O	O
population	O	O
A	O	O
study	O	B-study_type
protocol	O	I-study_type
for	O	O
a	O	O
multicenter	B-study_type	B-study_type
,	I-study_type	I-study_type
randomized	I-study_type	I-study_type
controlled	I-study_type	I-study_type
trail	I-study_type	I-study_type
BSXiaotingPan	B-authors	B-authors

Traditional	O	O
Chinese	O	O
Medicine	O	O
Hospital	O	O
of	O	O
Zhangjiagang	O	O
,	O	O
d	O	O
Changzhou	O	O
TCM	O	O
Hospital	O	O
,	O	O
e	O	O
Traditional	O	O
Chinese	O	O
Medicine	O	O
Hospital	O	O
of	O	O
Kunshan	O	O
,	O	O
f	O	O
Jiangsu	O	O
Cancer	O	O
Hospital	O	O
,	O	O
g	O	O
Nanjing	O	O
Drum	O	O
Tower	O	O
Hospital	O	O
China	O	O
MSShenlinLiu	B-authors	B-authors

Nanjing	O	O
MSQingminSun	B-authors	B-authors
MS	O	B-authors
Qingmin	B-authors	B-authors
Sun	I-authors	B-authors
sunqingminnjmu@163.com	O	I-authors
The	O	O
Affiliated	O	O
Hospital	O	O
of	O	O
Nanjing	O	O
University	O	O
of	O	O
Chinese	O	O
Medicine	O	O
,	O	O
Jiangsu	O	O
Province	O	O
Hospital	O	O
of	O	O
Chinese	O	O
Medicine	O	O
,	O	O
b	O	O
No	O	O
.	O	O
1	O	O
Clinical	O	O
Medical	O	O
College	O	O

Gastric	O	O
cancer	O	O
(	O	O
GC	O	O
)	O	O
is	O	O
an	O	O
important	O	O
disease	O	O
with	O	O
high	O	O
morbidity	O	O
and	O	O
mortality	O	O
globally	O	O
,	O	O
which	O	O
ranks	O	O
the	O	O
fifth	O	O
most	O	O
frequently	O	O
diagnosed	O	O
cancer	O	O
and	O	O
the	O	O
third	O	O
leading	O	O
cause	O	O
of	O	O
cancer	O	O
death	O	O
.	O	O
In	O	O
2018	O	O
,	O	O
over	O	O
1,000,000	O	O
new	O	O
cases	O	O
were	O	O
diagnosed	O	O
with	O	O
GC	O	O
and	O	O
approximately	O	O
783,000	O	O
deaths	O	O
(	O	O
equating	O	O
to	O	O
1	O	O
in	O	O
12	O	O
deaths	O	O
worldwide	O	O
)	O	O
.	O	O
[	O	O
1	O	O
]	O	O
Most	O	O
patients	O	O
(	O	O
>	O	O
70	O	O
%	O	O
)	O	O
with	O	O
GC	O	O
are	O	O
diagnosed	O	O
at	O	O
the	O	O
advanced	O	O
stage	O	O
,	O	O
[	O	O
2	O	O
]	O	O
as	O	O
a	O	O
consequence	O	O
,	O	O
it	O	O
shows	O	O
a	O	O
disappointing	O	O
result	O	O
.	O	O
[	O	O
3,4	O	O
]	O	O
Accumulating	O	O
evidence	O	O
shows	O	O
that	O	O
only	O	O
5	O	O
%	O	O
of	O	O
patients	O	O
with	O	O
metastatic	O	O
cancer	O	O
are	O	O
still	O	O
alive	O	O
5	O	O
years	O	O
after	O	O
diagnosis	O	O
.	O	O
[	O	O
5	O	O
]	O	O
In	O	O
recent	O	O
years	O	O
,	O	O
immune	O	O
microenvironment	O	O
has	O	O
been	O	O
increasingly	O	O
valued	O	O
for	O	O
its	O	O
crucial	O	O
role	O	O
in	O	O
the	O	O
process	O	O
of	O	O
GC	O	O
onset	O	O
and	O	O
progression	O	O
.	O	O
[	O	O
6][7][8	O	O
]	O	O
Although	O	O
surgical	O	O
resection	O	O
,	O	O
chemotherapy	O	O
,	O	O
radiotherapy	O	O
,	O	O
biologic	O	O
therapeutic	O	O
agents	O	O
,	O	O
and	O	O
other	O	O
measures	O	O
have	O	O
been	O	O
used	O	O
to	O	O
improve	O	O
the	O	O
therapeutic	O	O
efficacy	O	O
of	O	O
GC	O	O
,	O	O
[	O	O
9	O	O
]	O	O
the	O	O
prognosis	O	O
is	O	O
still	O	O
dismal	O	O
.	O	O
[	O	O
10	O	O
]	O	O
Thus	O	O
,	O	O
it	O	O
is	O	O
important	O	O
to	O	O
explore	O	O
new	O	O
strategies	O	O
to	O	O
prolong	O	O
the	O	O
survival	O	O
,	O	O
improve	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
of	O	O
the	O	O
advanced	O	O
GC	O	O
patients	O	O
.	O	O
Fortunately	O	O
,	O	O
traditional	O	O
Chinese	O	O
medicine	O	O
(	O	O
TCM	O	O
)	O	O
has	O	O
its	O	O
unique	O	O
advantages	O	O
in	O	O
preventing	O	O
and	O	O
treating	O	O
GC	O	O
[	O	O
11,12	O	O
]	O	O
and	O	O
it	O	O
also	O	O
has	O	O
an	O	O
efficacy	O	O
in	O	O
improving	O	O
immune	O	O
function	O	O
.	O	O
[	O	O
13	O	O
]	O	O
The	O	O
JPYZXZ	O	B-arm_description
decoction	O	O
is	O	O
a	O	O
traditional	O	O
Chinese	O	O
herbal	O	O
formulation	O	O
created	O	O
by	O	O
Professor	O	O
Shenlin	O	O
Liu	O	O
,	O	O
the	O	O
national	O	O
famous	O	O
Chinese	O	O
Physician	O	O
.	O	O
JPYZXZ	O	O
decoction	O	O
is	O	O
composed	O	O
of	O	O
12	O	O
kinds	O	O
of	O	O
Chinese	O	O
herbal	O	O
medicine	O	O
,	O	O
as	O	O
is	O	O
shown	O	O
in	O	O
Table	O	O
1	O	O
.	O	O
Our	O	O

The	O	O
datasets	O	O
generated	O	O
during	O	O
and/or	O	O
analyzed	O	O
during	O	O
the	O	O
current	O	O
study	O	O
are	O	O
not	O	O
publicly	O	O
available	O	O
,	O	O
but	O	O
are	O	O
available	O	O
from	O	O
the	O	O
corresponding	O	O
author	O	O
on	O	O
reasonable	O	O
request	O	O
.	O	O

A	O	O
total	O	O
of	O	O
210	O	O
patients	O	O
with	O	O
advanced	O	O
GC	O	O
will	O	O
be	O	O
recruited	O	O
in	O	O
this	O	O
clinical	O	O
trail	O	O
.	O	O
The	O	O
purpose	O	O
,	O	O
benefits	O	O
and	O	O
potential	O	O
risks	O	O
of	O	O
this	O	O
trail	O	O
and	O	O
other	O	O
information	O	O
will	O	O
be	O	O
informed	O	O
to	O	O
the	O	O
patients	O	O
in	O	O
detail	O	O
.	O	O
All	O	O
the	O	O
patients	O	O
participating	O	O
in	O	O
this	O	O
trail	O	O
are	O	O
entirely	O	O
voluntary	O	O
,	O	O
and	O	O
they	O	O
can	O	O
also	O	O
withdraw	O	O
at	O	O
any	O	O
time	O	O
during	O	O
the	O	O
whole	O	O
trail	O	O
without	O	O
any	O	O
consequence	O	O
.	O	O
Written	O	O
consent	O	O
will	O	O
be	O	O
obtained	O	O
from	O	O
each	O	O
eligibility	O	O
patient	O	O
before	O	O
them	O	O
participating	O	O
in	O	O
the	O	O
study	O	O
.	O	O
(	O	O
1	O	O
)	O	O
Patients	O	O
who	O	O
is	O	O
unable	O	O
to	O	O
swallow	O	O
oral	O	O
medications	O	O
including	O	O
with	O	O
digestive	O	O
tract	O	O
obstruction	O	O
and	O	O
jejunostomy	O	O
;	O	O
(	O	O
2	O	O
)	O	O
Patients	O	O
with	O	O
symptomatic	O	O
brain	O	O
metastasis	O	O
or	O	O
mental	O	O
disorder	O	O
;	O	O
(	O	O
3	O	O
)	O	O
Patients	O	O
with	O	O
severe	O	O
cardiovascular	O	O
disease	O	O
,	O	O
chronic	O	O
liver	O	O
disease	O	O
,	O	O
kidney	O	O
disease	O	O
or	O	O
blood	O	O
disease	O	O
;	O	O
(	O	O
4	O	O
)	O	O
Patients	O	O
whose	O	O
laboratory	O	O
examination	O	O
before	O	O
enrollment	O	O
is	O	O
abnormal	O	O
according	O	O
to	O	O
the	O	O
following	O	O
criteria	O	O
:	O	O
Blood	O	O
routine	O	O
examination	O	O
:	O	O
ANC	O	O
<	O	O
2.0	O	O
Â	O	O
10	O	O
9	O	O
/L	O	O
,	O	O
Hb	O	O
<	O	O
90	O	O
g	O	O
/	O	O
L	O	O
,	O	O
PLT	O	O
<	O	O
80	O	O
Â	O	O
10	O	O
9	O	O
/L	O	O
,	O	O
Renal	O	O
function	O	O
:	O	O
Cr	O	O
>	O	O
1.5	O	O
Â	O	O
upper	O	O
normal	O	O
limit	O	O
(	O	O
UNL	O	O
)	O	O
;	O	O
2.5.2	O	O
.	O	O
The	O	O
treatment	O	O
group	O	O
.	O	O
Total	O	O
of	O	O
140	O	O
patients	O	O
in	O	O
the	O	O
treatment	O	O
group	O	O
will	O	O
be	O	O
treated	O	O
with	O	O
chemotherapy	B-arm_description	O
combined	O	O
with	O	O
JPYZXZ	B-arm_description	B-arm_description
decoction	O	O
.	O	O
The	O	O
chemotherapy	B-arm_description	O
regimens	O	O
will	O	O
be	O	O
the	O	O
same	O	O
as	O	O
the	O	O
control	B-arm_description	O
group	I-arm_description	O
and	O	O
the	O	O
JPYZXZ	B-arm_description	B-arm_description
decoction	O	O
,	O	O
available	O	O
in	O	O
the	O	O
forms	O	O
of	O	O
granules	O	O
,	O	O
should	O	O
be	O	O
taken	O	O
at	B-arm_dosage	O
least	I-arm_dosage	O
6	B-arm_dosage	O
months	I-arm_dosage	O
,	O	O
per	O	O
bag	O	O
twice	B-arm_dosage	O
daily	I-arm_dosage	O
,	O	O
add	O	O
boiled	O	O
water	O	O
in	O	O
it	O	O
and	O	O
mix	O	O
up	O	O
it	O	O
,	O	O
150	B-arm_dosage	O
ml	I-arm_dosage	O
each	I-arm_dosage	O
time	I-arm_dosage	O
.	O	O

The	O	O
time	O	O
-	O	O
points	O	O
of	O	O
assessment	O	O
is	O	O
listed	O	O
in	O	O
Table	O	O
2	O	O
.	O	O
2.6.1	O	O
.	O	O
Primary	O	O
outcomes	O	O
.	O	O
The	O	O
primary	O	O
outcomes	O	O
include	O	O
1year	O	O
survival	O	O
rate	O	O
,	O	O
progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
,	O	O
and	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
.	O	O
One	O	O
-	O	O
year	O	O
survival	O	O
rate	O	O
=	O	O
(	O	O
the	O	O
number	O	O
of	O	O
patients	O	O
still	O	O
alive	O	O
after	O	O
1	O	O
year	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
/	O	O
the	O	O
total	O	O
number	O	O
of	O	O
patients	O	O
followed	O	O
up	O	O
)	O	O
Â	O	O
100	O	O
%	O	O
.	O	O
Progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
means	O	O
the	O	O
time	O	O
from	O	O
the	O	O
start	O	O
of	O	O
treatment	O	O
to	O	O
recurrence	O	O
or	O	O
death	O	O
due	O	O
to	O	O
any	O	O
causes	O	O
.	O	O
OS	O	O
is	O	O
the	O	O
time	O	O
from	O	O
the	O	O
beginning	O	O
of	O	O
diagnosis	O	O
to	O	O
death	O	O
for	O	O
any	O	O
causes	O	O
.	O	O
All	O	O
of	O	O
the	O	O
indicators	O	O
will	O	O
be	O	O
calculated	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
trail	O	O
.	O	O

Considering	O	O
20	O	O
%	O	O
of	O	O
the	O	O
drop	O	O
rate	O	O
,	O	O
allocating	O	O
patients	O	O
at	O	O
a	O	O
ratio	O	O
of	O	O
2:1	O	O
,	O	O
the	O	O
total	O	O
sample	O	O
size	O	O
is	O	O
210	O	O
(	O	O
140	O	O
in	O	O
chemotherapy	B-arm_description	O
plus	O	O
JPYZXZ	B-arm_description	B-arm_description
group	O	I-arm_description
and	O	O
70	O	O
in	O	O
chemotherapy	B-arm_description	B-arm_description
alone	I-arm_description	I-arm_description
group	O	I-arm_description
)	O	O
.	O	O

Avelumab	B-arm_description	B-arm_description
monotherapy	O	O
as	O	O
first	O	O
-	O	O
line	O	O
or	O	O
second	O	O
-	O	O
line	O	O
treatment	O	O
in	O	O
patients	O	O
with	O	O
metastatic	O	O
renal	O	O
cell	O	O
carcinoma	O	O
:	O	O
phase	B-study_type	B-study_type
Ib	I-study_type	I-study_type
results	I-study_type	I-study_type
from	O	O
the	O	O
JAVELIN	O	O
Solid	O	O
Tumor	O	O
trial	O	O
Avelumab	B-arm_description	B-arm_description
monotherapy	O	O
as	O	O
first	O	O
-	O	O
line	O	O
or	O	O
second	O	O
-	O	O
line	O	O
treatment	O	O
in	O	O
patients	O	O
with	O	O
metastatic	O	O
renal	O	O
cell	O	O
carcinoma	O	O
:	O	O
phase	B-study_type	B-study_type
Ib	I-study_type	I-study_type
results	I-study_type	I-study_type
from	O	O
the	O	O
JAVELIN	O	O
Solid	O	O
Tumor	O	O
trial	O	O
UlkaVaishampayan	B-authors	B-authors

Avelumab	B-arm_description	B-arm_description
monotherapy	O	O
as	O	O
first	O	O
-	O	O
line	O	O
or	O	O
second	O	O
-	O	O
line	O	O
treatment	O	O
in	O	O
patients	O	O
with	O	O
metastatic	O	O
renal	O	O
cell	O	O
carcinoma	O	O
:	O	O
phase	B-study_type	B-study_type
Ib	I-study_type	I-study_type
results	I-study_type	I-study_type
from	O	O
the	O	O
JAVELIN	O	O
Solid	O	O
Tumor	O	O
trial	O	O

4100	O	O
John	O	O
R.	O	O
Street	O	O
48201	O	O
Detroit	O	O
MI	O	O
USA	O	O
PatrickSchöffski	B-authors	B-authors
General	O	O
Medical	O	O
Oncology	O	O
Leuven	O	O
Cancer	O	O
Institute	O	O
University	O	O
Hospitals	O	O
Leuven	O	O
Leuven	O	O
Belgium	O	O
AlainRavaud	B-authors	B-authors
Medical	O	O
Oncology	O	O
Bordeaux	O	O
University	O	O
Hospital	O	O
Bordeaux	O	O
France	O	O
ChristianBorel	B-authors	B-authors
Medical	O	O
Oncology	O	O

4100	O	O
John	O	O
R.	O	O
Street	O	O
48201	O	O
Detroit	O	O
MI	O	O
USA	O	O
PatrickSchöffski	B-authors	B-authors
General	O	O
Medical	O	O
Oncology	O	O
Leuven	O	O
Cancer	O	O
Institute	O	O
University	O	O
Hospitals	O	O
Leuven	O	O
Leuven	O	O
Belgium	O	O
AlainRavaud	B-authors	B-authors
Medical	O	O
Oncology	O	O
Bordeaux	O	O
University	O	O
Hospital	O	O
Bordeaux	O	O
France	O	O
ChristianBorel	B-authors	B-authors
Medical	O	O
Oncology	O	O

Horovice	O	O
Oncology	O	O
Clinic	O	O
,	O	O
Nemocnice	O	O
Rudolfa	O	O
a	O	O
Stefanie	O	O
Benešov	O	O
,	O	O
a.	O	O
s	O	O
,	O	O
Benešov	O	O
,	O	O
Czech	O	O
Republic	O	O
.	O	O
10	O	O
Merck	O	O
Serono	O	O
Pharmaceutical	O	O
R&D	O	O
Co	O	O
Beijing	O	O
China	O	O
DongliZhou	B-authors	B-authors
SilkeGuenther	B-authors	B-authors
Merck	O	O
KGaA	O	O
Darmstadt	O	O
Germany	O	O
MarcisBajars	B-authors	B-authors

Horovice	O	O
Oncology	O	O
Clinic	O	O
,	O	O
Nemocnice	O	O
Rudolfa	O	O
a	O	O
Stefanie	O	O
Benešov	O	O
,	O	O
a.	O	O
s	O	O
,	O	O
Benešov	O	O
,	O	O
Czech	O	O
Republic	O	O
.	O	O
10	O	O
Merck	O	O
Serono	O	O
Pharmaceutical	O	O
R&D	O	O
Co	O	O
Beijing	O	O

In	O	O
the	O	O
1	B-arm_description	O
L	I-arm_description	O
and	O	O
2	B-arm_description	O
L	I-arm_description	O
subgroups	O	O
,	O	O
respectively	O	O
,	O	O
the	O	O
ORR	O	O
was	O	O
16.1	O	O
%	O	O
(	O	O
CR	O	O
,	O	O
n	O	O
=	O	O
1	O	O
[	O	O
1.6	O	O
%	O	O
]	O	O
;	O	O
PR	O	O
,	O	O
n	O	O
=	O	O
9	O	O
[	O	O
14.5	O	O
%	O	O
]	O	O
)	O	O
and	O	O
10.0	O	O
%	O	O
(	O	O
PR	O	O
,	O	O
n	O	O
=	O	O
2	O	O
)	O	O
(	O	O
seven	O	O
patients	O	O
(	O	O
35.0	O	O
%	O	O
)	O	O
had	O	O
serious	O	O
AEs	O	O
,	O	O
which	O	O
were	O	O
related	O	O
to	O	O
treatment	O	O
in	O	O
two	O	O
patients	O	O
(	O	O
3.2	O	O
%	O	O
)	O	O
in	O	O
the	O	O
1	O	B-arm_description
L	O	O
subgroup	O	O
(	O	O
grade	O	O
3	O	O
colitis	O	O
and	O	O
grade	O	O
2	O	O
hyperthermia	O	O
,	O	O
both	O	O
n	O	O
=	O	O
1	O	O
)	O	O
.	O	O
Four	O	O
patients	O	O
(	O	O
6.5	O	O
%	O	O
)	O	O
in	O	O
the	O	O
1	B-arm_description	B-arm_description
L	I-arm_description	O
subgroup	O	O
and	O	O
two	O	O
patients	O	O
(	O	O
10.0	O	O
%	O	O
)	O	O
in	O	O
the	O	O
2	B-arm_description	B-arm_description
L	I-arm_description	O
subgroup	O	O
had	O	O
an	O	O
AE	O	B-arm_description
leading	O	O
to	O	O
death	O	O
(	O	O
none	O	O
treatment	O	O
related	O	O
)	O	O
.	O	O

and	O	O
Pfizer	O	O
,	O	O
outside	O	O
the	O	O
submitted	O	O
work	O	O
;	O	O
personal	O	O
fees	O	O
from	O	O
Novartis	O	O
,	O	O
Millennium	O	O
Pharmaceuticals	O	O
,	O	O
Takeda	O	O
,	O	O
Veridex	O	O
and	O	O
the	O	O
Institute	O	O
of	O	O
Cancer	O	O
Research	O	O
(	O	O
ICR	O	O
)	O	O
,	O	O
outside	O	O
the	O	O
submitted	O	O
work	O	O
;	O	O
grants	O	O
from	O	O
AstraZeneca	O	O
,	O	O
Arno	O	O
Therapeutics	O	O
,	O	O
Innocrin	O	O
Pharma	O	O
and	O	O
Veridex	O	O
,	O	O
outside	O	O
the	O	O
submitted	O	O
work	O	O
;	O	O
received	O	O
a	O	O
share	O	O
of	O	O
this	O	O
income	O	O
through	O	O
the	O	O
ICR	O	O
's	O	O
Rewards	O	O
to	O	O
Discoverers	O	O
Scheme	O	O
.	O	O
SC	B-authors	O
reports	O	O
personal	O	O
fees	O	O
from	O	O
Janssen	O	O
Pharmaceutical	O	O
,	O	O
outside	O	O
the	O	O
submitted	O	O
work	O	O
.	O	O
WC	B-authors	O
reports	O	O
personal	O	O
fees	O	O
from	O	O
Janssen	O	O
and	O	O
other	O	O
from	O	O
Bayer	O	O
outside	O	O
the	O	O
submitted	O	O
work	O	O
.	O	O
DPD	B-authors	O
reports	O	O
other	O	O
from	O	O
UK	O	O
NWClarke	B-authors	B-authors
noel.clarke@christie.nhs.uk	O	O
Department	O	O
of	O	O
Urology	O	O

All	O	O
procedures	O	O
relating	O	O
to	O	O
administration	O	O
and	O	O
reporting	O	O
of	O	O
docetaxel	O	B-arm_description
as	O	O
a	O	O
research	O	O
treatment	O	O
have	O	O
been	O	O
reported	O	O
previously	O	O
[	O	O
1	O	O
]	O	O
.	O	O
In	O	O
brief	O	O
,	O	O
patients	O	O
were	O	O
randomised	O	O
to	O	O
lifelong	O	O
ADT	B-arm_description	O
with	O	O
or	O	O
without	O	O
six	B-arm_dosage	O
cycles	I-arm_dosage	O
of	O	O
docetaxel	B-arm_description	B-arm_description
(	B-arm_dosage	O
75	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
)	I-arm_dosage	O
given	O	O
3-weekly	B-arm_dosage	O
with	O	O
prednisolone	O	O
5	B-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
twice	I-arm_dosage	I-arm_dosage
daily	I-arm_dosage	I-arm_dosage
during	I-arm_dosage	O
the	I-arm_dosage	O
18-week	I-arm_dosage	O
period	I-arm_dosage	O
of	I-arm_dosage	O
therapy	I-arm_dosage	O
.	O	O

A	O	O
sensitivity	O	O
analysis	O	O
was	O	O
undertaken	O	O
without	O	O
the	O	O
M1	O	O
patients	O	O
retrospectively	O	O
found	O	O
not	O	O
to	O	O
have	O	O
met	O	O
all	O	O
of	O	O
the	O	O
strict	O	O
protocol	O	O
eligibility	O	O
criteria	O	O
,	O	O
mostly	O	O
concerning	O	O
a	O	O
review	O	O
of	O	O
baseline	O	O
blood	O	O
pressure	O	O
measurements	O	O
.	O	O
Removing	O	O
these	O	O
120	O	O
patients	O	O
(	O	O
11	O	O
%	O	O
)	O	O
did	O	O
not	O	O
change	O	O
the	O	O
primary	O	O
outcome	O	O
measure	O	O
results	O	O
HR	O	O
¼	O	O
0.81	O	O
(	O	O
95	O	B-arm_efficacy_results
%	O	I-arm_efficacy_results
CI	O	I-arm_efficacy_results
0.68	O	I-arm_efficacy_results
-	O	I-arm_efficacy_results
0.96	O	I-arm_efficacy_results
;	O	I-arm_efficacy_results
P	O	I-arm_efficacy_results
¼	O	I-arm_efficacy_results
0.013	O	I-arm_efficacy_results
)	O	O
.	O	O

Apatinib	B-arm_description	B-arm_description
in	O	O
patients	O	O
with	O	O
extensive	O	O
-	O	O
stage	O	O
small	O	O
-	O	O
cell	O	O
lung	O	O
cancer	O	O
after	O	O
second	O	O
-	O	O
line	O	O
or	O	O
third	O	O
-	O	O
line	O	O
chemotherapy	O	O
:	O	O
a	O	O
phase	B-study_type	B-study_type
II	I-study_type	I-study_type
,	I-study_type	I-study_type
singlearm	I-study_type	I-study_type
,	I-study_type	I-study_type
multicentre	I-study_type	I-study_type
,	I-study_type	I-study_type
prospective	I-study_type	I-study_type
study	I-study_type	I-study_type
YanjunXu	B-authors	B-authors

The	O	O
study	O	O
protocol	O	O
was	O	O
approved	O	O
by	O	O
the	O	O
relevant	O	O
institutional	O	O
review	O	O
board	O	O
or	O	O
ethics	O	O
committee	O	O
at	O	O
each	O	O
medical	O	O
centre	O	O
,	O	O
and	O	O
it	O	O
was	O	O
conducted	O	O
in	O	O
accordance	O	O
with	O	O
the	O	O
Declaration	O	O
of	O	O
Helsinki	O	O
and	O	O
Good	O	O
Clinical	O	O
Practice	O	O
guidelines	O	O
,	O	O
as	O	O
defined	O	O
by	O	O
the	O	O
International	O	O
Conference	O	O
on	O	O
Harmonisation	O	O
.	O	O
All	O	O
enrolled	O	O
patients	O	O
provided	O	O
written	O	O
informed	O	O
consent	O	O
before	O	O
any	O	O
study	O	O
-	O	O
specific	O	O
procedures	O	O
were	O	O
performed	O	O
.	O	O

The	O	O
following	O	O
three	O	O
populations	O	O
were	O	O
analysed	O	O
:	O	O
the	O	O
full	O	O
analysis	O	O
set	O	O
(	O	O
FAS	O	O
)	O	O
,	O	O
the	O	O
per	O	O
-	O	O
protocol	O	O
set	O	O
(	O	O
PPS	O	O
)	O	O
and	O	O
the	O	O
safety	O	O
analysis	O	O
set	O	O
(	O	O
SAS	O	O
)	O	O
.	O	O
The	O	O
FAS	O	O
consisted	O	O
of	O	O
all	O	O
enrolled	O	O
patients	O	O
who	O	O
received	O	O
at	O	O
least	O	O
one	O	O
dose	O	O
of	O	O
study	O	O
medication	O	O
according	O	O
to	O	O
the	O	O
intention	O	O
-	O	O
totreat	O	O
(	O	O
ITT	O	O
)	O	O
principle	O	O
.	O	O
The	O	O
PPS	O	O
referred	O	O
to	O	O
a	O	O
subset	O	O
of	O	O
the	O	O
patients	O	O
in	O	O
the	O	O
FAS	O	O
who	O	O
were	O	O
compliant	O	O
with	O	O
the	O	O
protocol	O	O
and	O	O
without	O	O
any	O	O
major	O	O
protocol	O	O
violations	O	O
(	O	O
including	O	O
violation	O	O
of	O	O
study	O	O
entry	O	O
criteria	O	O
)	O	O
.	O	O
The	O	O
SAS	O	O
included	O	O
all	O	O
enrolled	O	O
patients	O	O
who	O	O
received	O	O
at	O	O
least	O	O
one	O	O
dose	O	O
of	O	O
the	O	O
study	O	O
medication	O	O
,	O	O
though	O	O
not	O	O
those	O	O
without	O	O
any	O	O
safety	O	O
data	O	O
.	O	O
Patients	O	O
'	O	O
baseline	O	O
characteristics	O	O
were	O	O
summarised	O	O
for	O	O
the	O	O
ITT	O	O
population	O	O
.	O	O
The	O	O
efficacy	O	O
analysis	O	O
was	O	O
performed	O	O
in	O	O
both	O	O
the	O	O
ITT	O	O
and	O	O
PPS	O	O
populations	O	O
.	O	O
Safety	O	O
data	O	O
were	O	O
explored	O	O
in	O	O
the	O	O
SAS	O	O
.	O	O

Objective	O	O
response	O	O
and	O	O
disease	O	O
control	O	O
rate	O	O
were	O	O
evaluated	O	O
via	O	O
the	O	O
binomial	O	O
response	O	O
rate	O	O
and	O	O
the	O	O
corresponding	O	O
two	O	O
-	O	O
sided	O	O
95	O	O
%	O	O
exact	O	O
confidence	O	O
intervals	O	O
(	O	O
CIs	O	O
)	O	O
,	O	O
using	O	O
the	O	O
Clopper	O	O
-	O	O
Pearson	O	O
method	O	O
.	O	O
The	O	O
Kaplan	O	O
-	O	O
Meier	O	O
method	O	O
was	O	O
used	O	O
to	O	O
estimate	O	O
progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
and	O	O
overall	O	O
survival	O	O
,	O	O
and	O	O
median	O	O
values	O	O
were	O	O
estimated	O	O
with	O	O
two	O	O
-	O	O
sided	O	O
95	O	O
%	O	O
CIs	O	O
by	O	O
using	O	O
the	O	O
Brookmeyer	O	O
-	O	O
Crowley	O	O
method	O	O
.	O	O
Cox	O	O
proportional	O	O
-	O	O
hazards	O	O
regression	O	O
models	O	O
were	O	O
used	O	O
for	O	O
univariate	O	O
and	O	O
multivariate	O	O
analysis	O	O
to	O	O
identify	O	O
the	O	O
potential	O	O
factors	O	O
associated	O	O
with	O	O
clinical	O	O
outcomes	O	O
.	O	O
A	O	O
p	O	O
-	O	O
value	O	O
(	O	O
two	O	O
-	O	O
sided	O	O
)	O	O
<	O	O
0.05	O	O
was	O	O
considered	O	O
statistically	O	O
significant	O	O
.	O	O
All	O	O
analyses	O	O
were	O	O
performed	O	O
with	O	O
SPSS	O	O
®	O	O
22.0	O	O
.	O	O
The	O	O
study	O	O
was	O	O
registered	O	O
with	O	O
ClinicalTrials.gov	O	O
(	O	O
NCT02945852	O	O
)	O	O
.	O	O

The	O	O
SAS	O	O
included	O	O
the	O	O
entire	O	O
40	O	O
patients	O	O
,	O	O
and	O	O
all	O	O
experienced	O	O
AEs	O	O
related	O	O
to	O	O
apatinib	O	B-arm_description
treatment	O	O
.	O	O
AEs	O	O
of	O	O
clinical	O	O
significance	O	O
,	O	O
as	O	O
selected	O	O
by	O	O
the	O	O
investigators	O	O
,	O	O
are	O	O
summarised	O	O
in	O	O
Table	O	O
3	O	O
.	O	O
The	O	O
most	O	O
commonly	O	O
observed	O	O
grade	O	O
3	O	O
or	O	O
greater	O	O
AEs	O	O
were	O	O
hypertension	O	O
(	O	O
25	O	O
%	O	O
;	O	O
10/40	O	O
)	O	O
,	O	O
hand	O	O
-	O	O
foot	O	O
syndrome	O	O
(	O	O
10	O	O
%	O	O
;	O	O
4/40	O	O
)	O	O
,	O	O
increased	O	O
Lgamma	O	O
glutamyltransferase	O	O
(	O	O
10	O	O
%	O	O
;	O	O
4/40	O	O
)	O	O
,	O	O
increased	O	O
aspartate	O	O
transaminase	O	O
(	O	O
7.5	O	O
%	O	O
;	O	O
3/40	O	O
)	O	O
and	O	O
thrombocytopenia	O	O
(	O	O
7.5	O	O
%	O	O
;	O	O
3/40	O	O
)	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
one	O	O
patient	O	O
required	O	O
hospitalisation	O	O
for	O	O
the	O	O
management	O	O
of	O	O
grade	O	O
4	O	O
neutropenia	O	O
.	O	O
No	O	O
grade	O	O
5	O	O
AEs	O	O
were	O	O
reported	O	O
,	O	O
and	O	O
no	O	O
unexpected	O	O
AEs	O	O
were	O	O
observed	O	O
during	O	O
the	O	O
study	O	O
.	O	O

Dosage	O	O
reduction	O	O
of	O	O
apatinib	O	O
was	O	O
required	O	O
in	O	O
15	O	O
patients	O	O
(	O	O
37.5	O	O
%	O	O
)	O	O
during	O	O
the	O	O
therapy	O	O
with	O	O
following	O	O
reasons	O	O
:	O	O
11	O	O
cases	O	O
(	O	O
73.3	O	O
%	O	O
)	O	O
of	O	O
hand	O	O
-	O	O
foot	O	O
syndrome	O	O
,	O	O
10	O	O
(	O	O
66.7	O	O
%	O	O
)	O	O
cases	O	O
of	O	O
hypertension	O	O
,	O	O
one	O	O
(	O	O
6.7	O	O
%	O	O
)	O	O
case	O	O
of	O	O
proteinuria	O	O
one	O	O
(	O	O
6.7	O	O
%	O	O
)	O	O
case	O	O
of	O	O
mucositis	O	O
,	O	O
one	O	O
(	O	O
6.7	O	O
%	O	O
)	O	O
case	O	O
of	O	O
thrombocytopenia	O	O
and	O	O
one	O	O
(	O	O
6.7	O	O
%	O	O
)	O	O
case	O	O
of	O	O
impaired	O	O
liver	O	O
function	O	O
.	O	O
Of	O	O
note	O	O
,	O	O
10	O	O
of	O	O
the	O	O
15	O	O
patients	O	O
(	O	O
66.7	O	O
%	O	O
)	O	O
needed	O	O
dosage	O	O
reduction	O	O
due	O	O
to	O	O
two	O	O
(	O	O
60	O	O
%	O	O
;	O	O
n	O	O
=	O	O
9	O	O
)	O	O
or	O	O
three	O	O
(	O	O
6.7	O	O
%	O	O
;	O	O
n	O	O
=	O	O
1	O	O
)	O	O
toxic	O	O
reactions	O	O
.	O	O
Treatment	O	O
had	O	O
to	O	O
be	O	O
stopped	O	O
due	O	O
to	O	O
intolerable	O	O
toxic	O	O
reactions	O	O
for	O	O
four	O	O
patients	O	O
,	O	O
one	O	O
for	O	O
fatigue	O	O
,	O	O
two	O	O
cases	O	O
for	O	O
hand	O	O
-	O	O
foot	O	O
syndrome	O	O
and	O	O
one	O	O
case	O	O
for	O	O
proteinuria	O	O
.	O	O
The	O	O
reasons	O	O
for	O	O
apatinib	B-arm_description	O
dose	O	O
reduction	O	O
are	O	O
summarised	O	O
in	O	O
Supplementary	O	O
Table	O	O
1	O	O
.	O	O

Cediranib	O	B-arm_description
(	O	O
AstraZeneca	O	O
,	O	O
Cheshire	O	O
,	O	O
United	O	O
Kingdom	O	O
)	O	O
,	O	O
an	O	O
oral	O	O
tyrosine	O	O
kinase	O	O
inhibitor	O	O
of	O	O
VEGFR	O	O
1,2,3	O	O
and	O	O
PDGFR	O	O
has	O	O
been	O	O
evaluated	O	O
in	O	O
mesothelioma	O	O
as	O	O
monotherapy	O	O
and	O	O
in	O	O
combination	O	O
with	O	O
chemotherapy	O	O
.	O	O
Southwest	O	O
Oncology	O	O
Group	O	O
trial	O	O
SWOG	O	O
0509	O	O
reported	O	O
a	O	O
9	O	O
%	O	O
response	O	O
rate	O	O
and	O	O
34	O	O
%	O	O
disease	O	O
stabilization	O	O
with	O	O
cediranib	O	O
in	O	O
patients	O	O
with	O	O
previously	O	O
treated	O	O
mesothelioma	O	O
.	O	O
10	O	O
We	O	O
theorized	O	O
that	O	O
targeting	O	O
VEGFR	O	O
and	O	O
PDGFR	O	O
would	O	O
enhance	O	O
chemotherapy	O	O
efficacy	O	O
and	O	O
potentially	O	O
bypass	O	O
resistance	O	O
mechanisms	O	O
of	O	O
high	O	O
VEGF	O	O
ligand	O	O
secretion	O	O
.	O	O
11	O	O
SWOG	O	O
0905	O	O
was	O	O
thus	O	O
designed	O	O
as	O	O
a	O	O
phase	O	B-study_type
I	O	I-study_type
and	O	O
II	O	O
front	O	O
-	O	O
line	O	O
trial	O	O
.	O	O
The	O	O
phase	O	O
I	O	O
trial	O	O
established	O	O
the	O	O
maximum	O	O
tolerated	O	O
dose	O	O
of	O	O
cediranib	O	O
at	O	O
20	O	O
mg	O	O
per	O	O
day	O	O
when	O	O
combined	O	O
with	O	O
cisplatin	O	O
-	O	O
pemetrexed	O	O
.	O	O
12	O	O
Median	O	O
RECIST	O	O
v1.1	O	O
PFS	O	B-arm_efficacy_metric
was	O	O
12.8	O	O
months	O	O
,	O	O
median	O	O
modified	O	O
RECIST	O	O
(	O	O
mRECIST	O	O
)	O	O
PFS	O	B-arm_efficacy_metric
was	O	O
8.6	O	O
months	O	O
,	O	O
and	O	O
median	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
was	O	O
16.2	O	O
months	O	O
.	O	O
12	O	O
Here	O	O
,	O	O
we	O	O
report	O	O
the	O	O
results	O	O
of	O	O
the	O	O
randomized	B-study_type	O
phase	I-study_type	B-study_type
II	I-study_type	I-study_type
SWOG	I-study_type	O
0905	I-study_type	O
trial	I-study_type	O
.	O	O

Patients	O	O
were	O	O
randomly	O	O
assigned	O	O
with	O	O
equal	O	O
probability	O	O
(	O	O
1:1	O	O
)	O	O
between	O	O
cisplatin	B-arm_description	B-arm_description
-	O	I-arm_description
pemetrexed	B-arm_description	I-arm_description
with	O	O
cediranib	B-arm_description	B-arm_description
versus	O	O
placebo	B-arm_description	B-arm_description
.	O	O
Randomization	O	O
was	O	O
stratified	O	O
by	O	O
PS	O	O
(	O	O
0	O	O
to	O	O
1	O	O
v	O	O
2	O	O
)	O	O
and	O	O
histology	O	O
(	O	O
epithelioid	O	O
v	O	O
biphasic	O	O
or	O	O
sarcomatoid	O	O
)	O	O
using	O	O
a	O	O
dynamic	O	O
balancing	O	O
algorithm	O	O
.	O	O
15	O	O
Patients	O	O
were	O	O
enrolled	O	O
via	O	O
a	O	O
Web	O	O
-	O	O
based	O	O
application	O	O
and	O	O
simultaneous	O	O
randomization	O	O
was	O	O
performed	O	O
by	O	O
a	O	O
computer	O	O
program	O	O
.	O	O
Patients	O	O
and	O	O
investigators	O	O
were	O	O
blinded	O	O
to	O	O
the	O	O
treatment	O	O
arm	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
cediranib	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
received	O	O
fewer	O	O
cycles	O	O
of	O	O
chemotherapy	O	O
(	O	O
median	O	O
,	O	O
four	O	O
v	O	O
six	O	O
;	O	O
P	O	O
=	O	O
.41	O	O
)	O	O
and	O	O
fewer	O	O
days	O	O
of	O	O
cediranib	O	B-arm_description
/	O	I-arm_description
placebo	O	B-arm_description
use	O	O
(	O	O
median	O	O
,	O	O
80	O	O
days	O	O
v	O	O
124	O	O
days	O	O
;	O	O
P	O	O
=	O	O
.31	O	O
;	O	O
Appendix	O	O
Table	O	O
A1	O	O
,	O	O
The	O	O
addition	B-arm_description	O
of	I-arm_description	O
cediranib	I-arm_description	B-arm_description
to	I-arm_description	O
chemotherapy	I-arm_description	O
led	O	O
to	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
treatment	O	O
-	O	O
related	O	O
adverse	O	O
events	O	O
compared	O	O
with	O	O
placebo	B-arm_description	B-arm_description
(	O	O
100	O	O
%	O	O
v	O	O
91	O	O
%	O	O
;	O	O
P	O	O
=	O	O
.06	O	O
)	O	O
.	O	O
Toxicities	O	O
(	O	O
any	O	O
grade	O	O
;	O	O
Table	O	O
3	O	O
)	O	O
that	O	O
were	O	O
higher	O	O
in	O	O
the	O	O
cediranib	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
were	O	O
anorexia	O	O
(	O	O
21	O	O
%	O	O
)	O	O
,	O	O
and	O	O
myelosuppression	O	O
(	O	O
44	O	O
%	O	O
v	O	O
30	O	O
%	O	O
)	O	O
.	O	O
There	O	O
were	O	O
two	O	O
cases	O	O
of	O	O
sinus	O	O
bradycardia	O	O
and	O	O
one	O	O
of	O	O
supraventricular	O	O
tachycardia	O	O
in	O	O
the	O	O
cediranib	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
compared	O	O
with	O	O
none	O	O
in	O	O
the	O	O
placebo	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
.	O	O
The	O	O
cediranib	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
was	O	O
associated	O	O
with	O	O
69	O	O
%	O	O
grade	O	O
3	O	O
and	O	O
4	O	O
toxicities	O	O
compared	O	O
with	O	O
57	O	O
%	O	O
in	O	O
the	O	O
placebo	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
(	O	O
P	O	O
=	O	O
.13	O	O
)	O	O
.	O	O
Four	O	O
deaths	O	O
occurred	O	O
:	O	O
two	O	O
in	O	O
the	O	O
cediranib	B-arm_description	B-arm_description
and	O	O
one	O	O
in	O	O
the	O	O
placebo	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
from	O	O
respiratory	O	O
failure	O	O
,	O	O
and	O	O
one	O	O
sudden	O	O
death	O	O
in	O	O
the	O	O
placebo	B-arm_description	B-arm_description
arm	I-arm_description	O
.	O	O

South	O	O
Korea	O	O
81	O	O
,	O	O
Irwon	O	O
-	O	O
ro	O	O
,	O	O
Gangnam	O	O
-	O	O
gu	O	O
06351	O	O
Seoul	O	O
South	O	O
Korea	O	O
Division	O	O
of	O	O
Hematology	O	O
and	O	O
Oncology	O	O
Department	O	O
of	O	O
Medicine	O	O
Samsung	O	O
Medical	O	O
Center	O	O

South	O	O
Korea	O	O
Division	O	O
of	O	O
Hematology	O	O
and	O	O
Oncology	O	O
Department	O	O
of	O	O
Medicine	O	O
Samsung	O	O
Medical	O	O
Center	O	O
Sungkyunkwan	O	O
University	O	O
School	O	O
of	O	O
Medicine	O	O
81	O	O
,	O	O
Irwon	O	O
-	O	O
ro	O	O
,	O	O
Gangnam	O	O
-	O	O
gu	O	O
06351	O	O
Seoul	O	O

South	O	O
Korea	O	O
Division	O	O
of	O	O
Hematology	O	O
and	O	O
Oncology	O	O
Department	O	O
of	O	O
Medicine	O	O
Samsung	O	O
Medical	O	O
Center	O	O
Sungkyunkwan	O	O
University	O	O
School	O	O
of	O	O
Medicine	O	O
81	O	O
,	O	O
Irwon	O	O
-	O	O
ro	O	O
,	O	O
Gangnam	O	O
-	O	O
gu	O	O
06351	O	O
Seoul	O	O

Epstein	O	O
-	O	O
Barr	O	O
virus	O	O
(	O	O
EBV)-positive	O	O
,	O	O
diffuse	O	O
large	O	O
B	O	O
cell	O	O
lymphoma	O	O
(	O	O
DLBCL	O	O
)	O	O
is	O	O
an	O	O
EBV	O	O
-	O	O
positive	O	O
,	O	O
monoclonal	O	O
,	O	O
large	O	O
B	O	O
cell	O	O
lymphoproliferative	O	O
disorder	O	O
mainly	O	O
seen	O	O
in	O	O
individuals	O	O
older	O	O
than	O	O
50	O	O
years	O	O
of	O	O
age	O	O
[	O	O
1,2	O	O
]	O	O
.	O	O
Previous	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
EBV	O	O
-	O	O
positive	O	O
DLBCL	O	O
is	O	O
mainly	O	O
correlated	O	O
with	O	O
high	O	O
-	O	O
intermediate	O	O
/	O	O
high	O	O
International	O	O
Prognostic	O	O
Index	O	O
(	O	O
IPI	O	O
)	O	O
scores	O	O
,	O	O
advanced	O	O
disease	O	O
stage	O	O
(	O	O
III	O	O
/	O	O
IV	O	O
)	O	O
at	O	O
diagnosis	O	O
,	O	O
and	O	O
inferior	O	O
outcomes	O	O
in	O	O
comparison	O	O
with	O	O
EBV	O	O
-	O	O
negative	O	O
DLBCL	O	O
[	O	O
3,4	O	O
]	O	O
.	O	O

This	O	O
study	O	O
was	O	O
an	O	O
open	B-study_type	B-study_type
-	I-study_type	I-study_type
label	I-study_type	I-study_type
,	I-study_type	I-study_type
single	I-study_type	I-study_type
-	I-study_type	I-study_type
arm	I-study_type	I-study_type
,	I-study_type	I-study_type
prospective	I-study_type	I-study_type
multicenter	I-study_type	I-study_type
clinical	I-study_type	I-study_type
trial	I-study_type	I-study_type
for	O	O
evaluating	O	O
the	O	O
efficacy	O	O
and	O	O
toxicity	O	O
of	O	O
I	O	B-arm_description
-	O	O
RCHOP	B-arm_description	B-arm_description
in	O	O
subjects	O	O
with	O	O
newly	O	O
diagnosed	O	O
,	O	O
chemotherapy	O	O
-	O	O
naïve	O	O
,	O	O
EBV	O	O
-	O	O
positive	O	O
DLBCL	O	O
.	O	O
We	O	O
defined	O	O
EBV	O	O
positivity	O	O
as	O	O
a	O	O
finding	O	O
of	O	O
20	O	O
%	O	O
or	O	O
more	O	O
of	O	O
EBV	O	O
-	O	O
encoded	O	O
RNA	O	O
in	O	O
situ	O	O
hybridization	O	O
-	O	O
positive	O	O
tumor	O	O
cells	O	O
among	O	O
total	O	O
tumor	O	O
cells	O	O
during	O	O
pathology	O	O
evaluation	O	O
[	O	O
2	O	O
]	O	O
.	O	O
Ibrutinib	B-arm_description	B-arm_description
(	O	O
560	B-arm_dosage	B-arm_dosage
mg/	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
)	O	O
was	O	O
administrated	O	O
orally	B-arm_dosage	O
and	O	O
RCHOP	B-arm_description	B-arm_description
(	O	O
rituximab	B-arm_description	B-arm_description
375	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	O
cyclophosphamide	B-arm_description	O
750	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	O
doxorubicin	B-arm_description	B-arm_description
50	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
vincristine	B-arm_description	I-arm_dosage
1.4	I-arm_dosage	I-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
(	I-arm_dosage	I-arm_dosage
maximum	I-arm_dosage	I-arm_dosage
total	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
mg	I-arm_dosage	I-arm_dosage
)	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
and	I-arm_dosage	O
oral	I-arm_dosage	O
prednisone	B-arm_description	O
100	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
5	I-arm_dosage	I-arm_dosage
)	O	O
therapy	O	O
was	O	O
administered	O	O
intravenously	B-arm_dosage	O
every	I-arm_dosage	O
21	I-arm_dosage	O
days	I-arm_dosage	O
,	O	O
respectively	O	O
,	O	O
until	O	O
the	O	O
end	O	O
of	O	O
6	B-arm_dosage	O
cycles	I-arm_dosage	O
or	O	O
progression	O	O
or	O	O
unacceptable	O	O
toxicity	O	O
were	O	O
observed	O	O
.	O	O

Patients	O	O
had	O	O
to	O	O
fulfill	O	O
the	O	O
following	O	O
criteria	O	O
to	O	O
be	O	O
included	O	O
in	O	O
this	O	O
research	O	O
:	O	O
(	O	O
1	O	O
)	O	O
histologically	O	O
confirmed	O	O
EBV	O	O
-	O	O
positive	O	O
DLBCL	O	O
without	O	O
central	O	O
nervous	O	O
system	O	O
involvement	O	O
;	O	O
(	O	O
2	O	O
)	O	O
aged	O	O
19	O	O
years	O	O
or	O	O
older	O	O
;	O	O
(	O	O
3	O	O
)	O	O
no	O	O
previous	O	O
treatment	O	O
for	O	O
DLBCL	O	O
,	O	O
although	O	O
we	O	O
allowed	O	O
the	O	O
usage	O	O
of	O	O
prednisolone	B-arm_description	O
100	O	O
mg	O	O
or	O	O
equivalent	O	O
dosage	O	O
of	O	O
any	O	O
type	O	O
of	O	O
steroid	O	O
(	O	O
for	O	O
a	O	O
maximum	O	O
of	O	O
7	O	O
days	O	O
)	O	O
and	O	O
radiation	O	O
for	O	O
reducing	O	O
symptoms	O	O
related	O	O
with	O	O
mass	O	O
effect	O	O
;	O	O
(	O	O
4	O	O
)	O	O
one	O	O
or	O	O
more	O	O
measurable	O	O
lesions	O	O
;	O	O
(	O	O
5	O	O
)	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
(	O	O
ECOG	O	O
)	O	O
performance	O	O
status	O	O
of	O	O
0	O	O
to	O	O
2	O	O
;	O	O
and	O	O
(	O	O
6	O	O
)	O	O
adequate	O	O
organ	O	O
function	O	O
.	O	O
The	O	O
exclusion	O	O
criteria	O	O
included	O	O
any	O	O
life	O	O
-	O	O
threatening	O	O
illness	O	O
,	O	O
medical	O	O
condition	O	O
,	O	O
or	O	O
organ	O	O
system	O	O
dysfunction	O	O
that	O	O
could	O	O
compromise	O	O
the	O	O
subject	O	O
's	O	O
safety	O	O
,	O	O
according	O	O
to	O	O
the	O	O
investigator	O	O
's	O	O
opinion	O	O
.	O	O
Written	O	O
informed	O	O
consent	O	O
was	O	O
obtained	O	O
from	O	O
each	O	O
patient	O	O
prior	O	O
to	O	O
study	O	O
enrollment	O	O
.	O	O
This	O	O
study	O	O
was	O	O
approved	O	O
by	O	O
the	O	O
institutional	O	O
review	O	O
board	O	O
of	O	O
each	O	O
institution	O	O
and	O	O
conducted	O	O
in	O	O
accordance	O	O
with	O	O
the	O	O
tenets	O	O
of	O	O
the	O	O
Declaration	O	O
of	O	O
Helsinki	O	O
.	O	O
This	O	O
trial	O	O
was	O	O
registered	O	O
at	O	O
www.ClinicalTrials.gov	O	O
as	O	O
NCT02670616	O	O
.	O	O

The	O	O
primary	O	O
endpoint	O	O
of	O	O
this	O	O
research	O	O
was	O	O
the	O	O
objective	O	O
response	O	O
rate	O	O
(	O	O
ORR	O	O
)	O	O
based	O	O
on	O	O
the	O	O
proportion	O	O
of	O	O
complete	O	O
response	O	O
(	O	O
CR	O	O
)	O	O
and	O	O
partial	O	O
response	O	O
(	O	O
PR	O	O
)	O	O
.	O	O
Secondary	O	O
endpoints	O	O
included	O	O
toxicity	O	O
,	O	O
progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
(	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
)	O	O
,	O	O
and	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
.	O	O
Adverse	O	O
events	O	O
(	O	O
AEs	O	O
)	O	O
were	O	O
assessed	O	O
according	O	O
to	O	O
the	O	O
Common	O	O
Terminology	O	O
Criteria	O	O
for	O	O
Adverse	O	O
Events	O	O
version	O	O
4.0	O	O
.	O	O

Between	O	O
September	O	O
2016	O	O
and	O	O
August	O	O
2019	O	O
,	O	O
24	O	O
patients	O	O
were	O	O
enrolled	O	O
from	O	O
10	O	O
institutes	O	O
.	O	O
The	O	O
cutoff	O	O
date	O	O
for	O	O
analysis	O	O
was	O	O
March	O	O
2019	O	O
,	O	O
and	O	O
the	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
was	O	O
7.9	O	O
months	O	O
,	O	O
with	O	O
six	O	O
death	O	O
events	O	O
(	O	O
25	O	O
%	O	O
)	O	O
.	O	O
Sixteen	O	O
patients	O	O
(	O	O
67	O	O
%	O	O
)	O	O
finished	O	O
6	O	O
cycles	O	O
of	O	O
chemotherapy	O	O
.	O	O
In	O	O
the	O	O
48	O	O
patients	O	O
who	O	O
were	O	O
confirmed	O	O
to	O	O
have	O	O
EBV	O	O
-	O	O
positive	O	O
DLBCL	O	O
at	O	O
Samsung	O	O
Medical	O	O
Center	O	O
for	O	O
the	O	O
purpose	O	O
of	O	O
the	O	O
matched	O	O
case	O	O
-	O	O
control	O	O
study	O	O
,	O	O
baseline	O	O
clinical	O	O
characteristics	O	O
were	O	O
balanced	O	O
comparatively	O	O
among	O	O
both	O	O
the	O	O
I	O	B-arm_description
-	O	O
RCHOP	B-arm_description	B-arm_description
(	O	O
n	O	O
=	O	O
24	O	O
)	O	O
and	O	O
RCHOP	B-arm_description	B-arm_description
(	O	O
n	O	O
=	O	O
24	O	O
)	O	O
groups	O	O
(	O	O
Table	O	O
1	O	O
)	O	O
.	O	O
The	O	O
median	O	O
ages	O	O
were	O	O
58	O	O
years	O	O
(	O	O
range	O	O
,	O	O

Median	B-arm_efficacy_metric	B-arm_description
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
(	O	O
20.6	B-arm_efficacy_results	O
months	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
95	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
CI	I-arm_efficacy_results	O
non	I-arm_efficacy_results	O
-	I-arm_efficacy_results	O
evaluable	I-arm_efficacy_results	O
vs.	O	O
35.3	B-arm_efficacy_results	O
months	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
95	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
CI	I-arm_efficacy_results	O
0.0	I-arm_efficacy_results	O
-	I-arm_efficacy_results	O
86.9	I-arm_efficacy_results	O
;	I-arm_efficacy_results	O
p	I-arm_efficacy_results	O
=	I-arm_efficacy_results	O
0.46	I-arm_efficacy_results	O
)	O	O
and	O	O
median	O	B-arm_description
OS	O	O
(	O	O
20.9	O	O
months	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
0.6	O	O
-	O	O
41.2	O	O
vs.	O	O
48.1	O	O
months	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
NR	O	O
;	O	O
p	O	O
=	O	O
0.72	O	O
)	O	O
according	O	O
to	O	O
I	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
RCHOP	I-arm_description	I-arm_description
and	O	O
RCHOP	B-arm_description	B-arm_description
were	O	O
not	O	O
significantly	O	O
different	O	O
(	O	O
Fig	O	O
.	O	O
2a	O	O
and	O	O
b	O	O
)	O	O
.	O	O
Based	O	O
on	O	O
the	O	O
one	O	O
-	O	O
year	O	O
survival	O	O
analysis	O	O
,	O	O
one	O	O
-	O	O
year	O	O
OS	O	O
(	O	O
33.3	O	O
%	O	O
vs.	O	O
58.3	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0.15	O	O
)	O	O
and	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
(	O	O
29.2	B-arm_efficacy_results	O
%	I-arm_efficacy_results	O
vs.	O	O
36.8	B-arm_efficacy_results	O
%	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
p	I-arm_efficacy_results	O
=	I-arm_efficacy_results	O
0.24	I-arm_efficacy_results	O
)	O	O
were	O	O
not	O	O
correlated	O	O
with	O	O
more	O	O
favorable	O	O
outcomes	O	O
in	O	O
I	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
RCHOP	I-arm_description	I-arm_description
than	O	O
in	O	O
RCHOP	B-arm_description	B-arm_description
among	O	O
all	O	O
patients	O	O
.	O	O
In	O	O
line	O	O
with	O	O
age	O	O
-	O	O
based	O	O
case	O	O
-	O	O
control	O	O
comparisons	O	O
,	O	O
in	O	O
patients	O	O
aged	O	O
younger	O	O
than	O	O
65	O	O
years	O	O
,	O	O
the	O	O
median	B-arm_efficacy_metric	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
(	O	O
NR	B-arm_efficacy_results	O
vs.	O	O
92.2	B-arm_efficacy_results	O
months	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
95	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
CI	I-arm_efficacy_results	O
9.8	I-arm_efficacy_results	O
-	I-arm_efficacy_results	O
176.0	I-arm_efficacy_results	O
;	I-arm_efficacy_results	O
p	I-arm_efficacy_results	O
=	I-arm_efficacy_results	O
0.68	I-arm_efficacy_results	O
)	O	O
and	O	O
OS	O	O
(	O	O
NR	O	O
vs.	O	O
NR	O	O
;	O	O
p	O	O
=	O	O
0.45	O	O
)	O	O
showed	O	O
a	O	O
superior	O	O
tendency	O	O
in	O	O
the	O	O
I	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
RCHOP	I-arm_description	I-arm_description
group	O	I-arm_description
(	O	O
Fig	O	O
.	O	O
2c	O	O
and	O	O
d	O	O
)	O	O
.	O	O
In	O	O
patients	O	O
aged	O	O
older	O	O
than	O	O
65	O	O
years	O	O
,	O	O
the	O	O
survival	O	O
benefit	O	O
was	O	O
lower	O	O
in	O	O
the	O	O
I	O	B-arm_description
-	O	I-arm_description
RCHOP	O	I-arm_description
group	O	I-arm_description
because	O	O
of	O	O
the	O	O
large	O	O
number	O	O
of	O	O
patients	O	O
terminated	O	O
during	O	O
the	O	O
initial	O	O
treatment	O	O
(	O	O
Figs	O	O
.	O	O
2e	O	O
,	O	O
f	O	O
,	O	O
and	O	O
3	O	O
)	O	O
.	O	O

Weekly	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
versus	O	O
3-weekly	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
for	O	O
newly	O	O
diagnosed	O	O
ovarian	O	O
cancer	O	O
(	O	O
ICON8	O	O
)	O	O
:	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
results	O	O
of	O	O
a	O	O
phase	B-study_type	B-study_type
3	I-study_type	I-study_type
,	I-study_type	I-study_type
randomised	I-study_type	I-study_type
,	I-study_type	I-study_type
controlled	I-study_type	I-study_type
trial	I-study_type	I-study_type
Weekly	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
versus	O	O
3-weekly	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
for	O	O
newly	O	O
diagnosed	O	O
ovarian	O	O
cancer	O	O
(	O	O
ICON8	O	O
)	O	O
:	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
results	O	O
of	O	O
a	O	O
phase	B-study_type	B-study_type
3	I-study_type	I-study_type
,	I-study_type	I-study_type
randomised	I-study_type	I-study_type
,	I-study_type	I-study_type
controlled	I-study_type	I-study_type
trial	I-study_type	I-study_type
21	O	O
July	O	O
2020	O	O
21	O	O
July	O	O
2020	O	O
MScAdrianDCook	B-authors	O

Weekly	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
versus	O	O
3-weekly	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
for	O	O
newly	O	O
diagnosed	O	O
ovarian	O	O
cancer	O	O
(	O	O
ICON8	O	O
)	O	O
:	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
results	O	O
of	O	O
a	O	O
phase	B-study_type	B-study_type
3	I-study_type	I-study_type
,	I-study_type	I-study_type
randomised	I-study_type	I-study_type
,	I-study_type	I-study_type
controlled	I-study_type	I-study_type
trial	I-study_type	I-study_type

Jane	B-authors	B-authors
Hook	I-authors	I-authors
,	O	O
Elizabeth	B-authors	B-authors
C	I-authors	I-authors
James	I-authors	I-authors
,	O	O
Ian	B-authors	B-authors
R	I-authors	I-authors
White	I-authors	I-authors
,	O	O
Timothy	B-authors	B-authors
Perren	I-authors	I-authors
,	O	O
Rosemary	B-authors	B-authors
Lord	I-authors	I-authors
,	O	O
Graham	O	B-authors
Dark	O	I-authors
,	O	O
Helena	B-authors	B-authors
M	I-authors	I-authors
Earl	I-authors	I-authors
,	O	O
Marcia	B-authors	B-authors
Hall	I-authors	I-authors
,	O	O
Richard	B-authors	B-authors
Kaplan	I-authors	I-authors
,	O	O
Jonathan	B-authors	B-authors
A	I-authors	I-authors
Ledermann	I-authors	I-authors
Andrew	B-authors	B-authors
R	I-authors	I-authors
Clamp	I-authors	B-authors

Weekly	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
versus	O	O
3-weekly	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
for	O	O
newly	O	O
diagnosed	O	O
ovarian	O	O
cancer	O	O
(	O	O
ICON8	O	O
)	O	O
:	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
results	O	O
of	O	O
a	O	O
phase	B-study_type	B-study_type
3	I-study_type	I-study_type
,	I-study_type	I-study_type
randomised	I-study_type	I-study_type
,	I-study_type	I-study_type
controlled	I-study_type	I-study_type
trial	I-study_type	I-study_type
MScAdrianDCook	B-authors	B-authors
MScAdrianDCook	B-authors	B-authors
MSc	B-authors	B-authors
Adrian	I-authors	B-authors
D	I-authors	B-authors
Cook	I-authors	I-authors
MScECJames	B-authors	B-authors
MScECJames	B-authors	B-authors
MSc	O	B-authors
E	B-authors	B-authors
C	I-authors	B-authors
James	I-authors	B-authors
ProfIRWhite	B-authors	B-authors
ProfIRWhite	B-authors	B-authors
Prof	O	B-authors
I	B-authors	B-authors
R	I-authors	B-authors
White	I-authors	I-authors
JHook	B-authors	B-authors
JHook	B-authors	B-authors
J	B-authors	B-authors
Hook	I-authors	I-authors
MBBchir	B-authors	B-authors
MBBchir	B-authors	B-authors
M	O	B-authors
B	B-authors	I-authors
Bchir	I-authors	B-authors
DrSarahPBlagden	B-authors	B-authors
sarah.blagden@oncology.ox.ac.uk	O	B-authors

Prof	O	O
C	O	O
Poole	O	O
MB	O	O
BChir	O	O
)	O	O
;	O	O
Maggie	O	O
Keswick	O	O
Jencks	O	O
Cancer	O	O
Caring	O	O
Centres	O	O
Trust	O	O
,	O	O
London	O	O
,	O	O
UK	O	O
(	O	O
L	O	O
Howells	O	O
M	O	O
App	O	O
Sci	O	O
)	O	O
;	O	O
Ovarian	O	O
Cancer	O	O
Action	O	O
Research	O	O
Centre	O	O
University	O	O
Hospital	O	O
Coventry	O	O
Imperial	O	O
College	O	O
London	O	O
Perth	O	O

Prof	O	O
C	O	O
Poole	O	O
MB	O	O
BChir	O	O
)	O	O
;	O	O
Maggie	O	O
Keswick	O	O
Jencks	O	O
Cancer	O	O
Caring	O	O
Centres	O	O
Trust	O	O
,	O	O
London	O	O
,	O	O
UK	O	O
(	O	O
L	O	O
Howells	O	O
M	O	O
App	O	O
Sci	O	O
)	O	O
;	O	O
Ovarian	O	O
Cancer	O	O
Action	O	O
Research	O	O
Centre	O	O
University	O	O
Hospital	O	O
Coventry	O	O
Imperial	O	O
College	O	O
London	O	O
Perth	O	O

UK	O	O
Prof	O	O
T	B-authors	B-authors
Perren	I-authors	B-authors
MD	O	O
)	O	O
Department	O	O
of	O	O
Oncology	O	O
,	O	O
Clatterbridge	O	O
Cancer	O	O
Centre	O	O
Department	O	O
of	O	O
Oncology	O	O
Department	O	O
of	O	O
Medical	O	O
Oncology	O	O
(	O	O
Prof	O	O
M	B-authors	O
Hall	I-authors	O
PhD	O	O
)	O	O
;	O	O
UCL	O	O
Cancer	O	O
Centre	O	O
Institute	O	O
G	B-authors	O
Dark	I-authors	O
MBBS	O	O
)	O	O
;	O	O
NIHR	O	O
Cambridge	O	O
Biomedical	O	O
Research	O	O
Centre	O	O
,	O	O
Cambridge	O	O
,	O	O
UK	O	O
(	O	O
Prof	O	B-authors
H	B-authors	B-authors
M	I-authors	I-authors
Earl	I-authors	I-authors
PhD	O	O
Newcastle	O	O
University	O	O
Mount	O	O
Vernon	O	O
Cancer	O	O
Centre	O	O
Newcastle	O	O

UK	O	O
OX3	O	O
7LE	O	O
Oxford	O	O
UK	O	O
Weekly	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
versus	O	O
3-weekly	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
for	O	O
newly	O	O
diagnosed	O	O
ovarian	O	O
cancer	O	O
(	O	O
ICON8	O	O
)	O	O
:	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
results	O	O
of	O	O
a	O	O
phase	B-study_type	B-study_type
3	I-study_type	I-study_type
,	I-study_type	I-study_type
randomised	I-study_type	I-study_type
,	I-study_type	I-study_type
controlled	I-study_type	I-study_type
trial	I-study_type	I-study_type
21	O	O
July	O	O
2020	O	O
21	O	O
July	O	O
2020	O	O
21	O	O
July	O	O
2020	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
ICON8	O	O
is	O	O
the	O	O
largest	O	O
study	O	O
to	O	O
date	O	O
of	O	O
weekly	O	O
treatment	O	O
for	O	O
primary	O	O
ovarian	O	O
cancer	O	O
.	O	O
The	O	O
study	O	O
showed	O	O
no	O	O
progression	B-arm_efficacy_metric	O
-	I-arm_efficacy_metric	O
free	I-arm_efficacy_metric	O
survival	I-arm_efficacy_metric	O
advantage	O	O
for	O	O
patients	O	O
receiving	O	O
dosedense	O	O
paclitaxel	O	O
-	O	O
containing	O	O
chemotherapy	O	O
compared	O	O
with	O	O
3-weekly	O	O
carboplatin	O	O
and	O	O
paclitaxel	O	O
.	O	O
The	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
results	O	O
show	O	O
that	O	O
,	O	O
although	O	O
the	O	O
global	O	O
quality	O	O
of	O	O
life	O	O
of	O	O
patients	O	O
was	O	O
similar	O	O
between	O	O
the	O	O
three	O	O
treatment	O	O
groups	O	O
at	O	O
9	O	O
months	O	O
,	O	O
those	O	O
receiving	O	O
dose	O	O
-	O	O
dense	O	O
paclitaxel	O	O
had	O	O
poorer	O	O
quality	O	O
of	O	O
life	O	O
during	O	O
chemotherapy	O	O
treatment	O	O
,	O	O
with	O	O
more	O	O
severe	O	O
peripheral	O	O
neuropathy	O	O
that	O	O
lasted	O	O
for	O	O
up	O	O
to	O	O
18	O	O
months	O	O
.	O	O

In	O	O
the	O	O
UK	O	O
,	O	O
ethical	O	O
approval	O	O
was	O	O
granted	O	O
by	O	O
the	O	O
London	O	O
-	O	O
Chelsea	O	O
research	O	O
ethics	O	O
committee	O	O
.	O	O
The	O	O
trial	O	O
also	O	O
received	O	O
ethical	O	O
approval	O	O
from	O	O
appropriate	O	O
national	O	O
or	O	O
local	O	O
institutional	O	O
review	O	O
boards	O	O
in	O	O
other	O	O
jurisdictions	O	O
.	O	O
The	O	O
protocol	O	O
can	O	O
be	O	O
found	O	O
online	O	O
.	O	O

The	O	O
sample	O	O
size	O	O
of	O	O
ICON8	O	O
was	O	O
determined	O	O
to	O	O
detect	O	O
a	O	O
hazard	O	O
ratio	O	O
of	O	O
0•75	O	O
in	O	O
progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
between	O	O
groups	B-arm_description	B-arm_description
1	I-arm_description	I-arm_description
and	O	I-arm_description
2	B-arm_description	I-arm_description
,	O	O
and	O	O
groups	B-arm_description	B-arm_description
1	I-arm_description	I-arm_description
and	O	I-arm_description
3	B-arm_description	I-arm_description
,	O	O
with	O	O
two	O	O
-	O	O
sided	O	O
2•5	O	O
%	O	O
significance	O	O
and	O	O
90	O	O
%	O	O
power	O	O
.	O	O
For	O	O
quality	O	O
of	O	O
life	O	O
,	O	O
a	O	O
retrospective	O	O
power	O	O
calculation	O	O
showed	O	O
that	O	O
the	O	O
study	O	O
had	O	O
90	O	O
%	O	O
power	O	O
to	O	O
detect	O	O
a	O	O
difference	O	O
between	O	O
groups	O	O
of	O	O
5	O	O
points	O	O
in	O	O
global	O	O
quality	O	O
of	O	O
life	O	O
using	O	O
the	O	O
SD	O	O
observed	O	O
in	O	O
group	B-arm_description	B-arm_description
1	I-arm_description	O
.	O	O
The	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
study	O	O
adhered	O	O
to	O	O
the	O	O
null	O	O
hypothesis	O	O
of	O	O
the	O	O
main	O	O
ICON8	O	O
study	O	O
-	O	O
no	O	O
expected	O	O
difference	O	O
in	O	O
quality	O	O
of	O	O
life	O	O
between	O	O
the	O	O
three	O	O
randomised	O	O
treatment	O	O
groups	O	O
.	O	O
A	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
expert	O	O
panel	O	O
(	O	O
comprised	O	O
of	O	O
LH	O	O
,	O	O
CP	O	O
,	O	O
SPB	O	O
,	O	O
and	O	O
RK	O	O
)	O	O
,	O	O
invited	O	O
by	O	O
the	O	O
trial	O	O
management	O	O
group	O	O
,	O	O
convened	O	O
on	O	O
June	O	O
9	O	O
,	O	O
2016	O	O
,	O	O
to	O	O
define	O	O
the	O	O
primary	O	O
,	O	O
secondary	O	O
,	O	O
and	O	O
exploratory	O	O
endpoints	O	O
.	O	O

It	O	O
is	O	O
also	O	O
the	O	O
timepoint	O	O
in	O	O
ICON8	O	O
at	O	O
which	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
and	O	O
hence	O	O
data	O	O
collection	O	O
,	O	O
changed	O	O
from	O	O
6-weekly	O	O
to	O	O
3-monthly	O	O
.	O	O
The	O	O
co	O	O
-	O	O
primary	O	O
endpoints	O	O
of	O	O
cross	O	O
-	O	O
sectional	O	O
and	O	O
longitudinal	O	O
changes	O	O
in	O	O
global	O	O
health	O	O
score	O	O
are	O	O
complementary	O	O
-	O	O
longitudinal	O	O
analysis	O	O
compares	O	O
patient	O	O
experience	O	O
across	O	O
the	O	O
whole	O	O
9-month	O	O
period	O	O
and	O	O
crosssectional	O	O
analysis	O	O
compares	O	O
scores	O	O
at	O	O
the	O	O
9-month	O	O
timepoint	O	O
.	O	O
Thus	O	O
,	O	O
longitudinal	O	O
analysis	O	O
makes	O	O
better	O	O
use	O	O
of	O	O
the	O	O
data	O	O
and	O	O
is	O	O
the	O	O
preferred	O	O
method	O	O
,	O	O
whereas	O	O
crosssectional	O	O
analysis	O	O
provides	O	O
a	O	O
post	O	O
-	O	O
treatment	O	O
snapshot	O	O
.	O	O

We	O	O
assessed	O	O
the	O	O
potential	O	O
effect	O	O
of	O	O
missing	O	O
data	O	O
on	O	O
the	O	O
co	O	O
-	O	O
primary	O	O
outcome	O	O
using	O	O
imputation	O	O
to	O	O
model	O	O
the	O	O
following	O	O
scenarios	O	O
:	O	O
scenario	O	O
1	O	O
,	O	O
a	O	O
global	O	O
score	O	O
of	O	O
0	O	O
was	O	O
imputed	O	O
for	O	O
patients	O	O
who	O	O
died	O	O
within	O	O
9	O	O
months	O	O
of	O	O
enrolment	O	O
;	O	O
scenarios	O	O
2	O	O
-	O	O
4	O	O
,	O	O
all	O	O
patients	O	O
alive	O	O
and	O	O
without	O	O
progression	O	O
at	O	O
9	O	O
months	O	O
but	O	O
missing	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
data	O	O
were	O	O
assigned	O	O
a	O	O
score	O	O
,	O	O
starting	O	O
respectively	O	O
with	O	O
the	O	O
mean	O	O
9-month	O	O
score	O	O
,	O	O
then	O	O
the	O	O
mean	O	O
score	O	O
minus	O	O
10	O	O
points	O	O
,	O	O
then	O	O
mean	O	O
minus	O	O
20	O	O
;	O	O
scenario	O	O
5	O	O
,	O	O
a	O	O
global	O	O
score	O	O
of	O	O
0	O	O
was	O	O
imputed	O	O
for	O	O
patients	O	O
who	O	O
died	O	O
within	O	O
9	O	O
months	O	O
,	O	O
all	O	O
other	O	O
patients	O	O
(	O	O
including	O	O
those	O	O
with	O	O
disease	O	O
progression	O	O
)	O	O
with	O	O
a	O	O
baseline	O	O
global	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
score	O	O
but	O	O
missing	O	O
their	O	O
9-month	O	O
global	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
score	O	O
were	O	O
assigned	O	O
the	O	O
mean	O	O
9-month	O	O
score	O	O
.	O	O
The	O	O
rationale	O	O
for	O	O
scenarios	O	O
2	O	O
-	O	O
4	O	O
was	O	O
that	O	O
patients	O	O
might	O	O
have	O	O
missed	O	O
submitting	O	O
their	O	O
questionnaires	O	O
due	O	O
to	O	O
illness	O	O
,	O	O
in	O	O
which	O	O
case	O	O
a	O	O
lower	O	O
quality	O	O
of	O	O
life	O	O
would	O	O
be	O	O
expected	O	O
.	O	O
All	O	O
analyses	O	O
were	O	O
done	O	O
on	O	O
an	O	O
intention	O	O
-	O	O
to	O	O
-	O	O
treat	O	O
basis	O	O
with	O	O
Stata	O	O
version	O	O
15.0	O	O
.	O	O
The	O	O
trial	O	O
is	O	O
registered	O	O
on	O	O
ClinicalTrials.gov	O	O
,	O	O
NCT01654146	O	O
and	O	O
ISRCTN	O	O
Registry	O	O
,	O	O
ISRCTN10356387	O	O
.	O	O

We	O	O
observed	O	O
evidence	O	O
of	O	O
better	O	O
emotional	O	O
functioning	O	O
(	O	O
QLQ	O	O
-	O	O
C30	O	O
)	O	O
with	O	O
weekly	O	O
treatment	O	O
(	O	O
group	B-arm_description	B-arm_description
3	I-arm_description	O
)	O	O
than	O	O
with	O	O
3-weekly	O	O
treatment	O	O
(	O	O
group	B-arm_description	B-arm_description
1	I-arm_description	I-arm_description
)	O	O
using	O	O
cross	O	O
-	O	O
sectional	O	O
analysis	O	O
;	O	O
however	O	O
,	O	O
it	O	O
did	O	O
not	O	O
meet	O	O
the	O	O
threshold	O	O
for	O	O
clinical	O	O
significance	O	O
(	O	O
table	O	O
3	O	O
;	O	O
figure	O	O
2	O	O
)	O	O
.	O	O
Longitudinal	O	O
analysis	O	O
revealed	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
emotional	O	O
functioning	O	O
between	O	O
study	O	O
groups	O	O
(	O	O
table	O	O
3	O	O
;	O	O
figure	O	O
2	O	O
)	O	O
.	O	O
We	O	O
found	O	O
no	O	O
difference	O	O
in	O	O
social	O	O
functioning	O	O
(	O	O
QLQ	O	O
-	O	O
C30	O	O
)	O	O
between	O	O
treatment	O	O
groups	O	O
using	O	O
either	O	O
cross	O	O
-	O	O
sectional	O	O
or	O	O
longitudinal	O	O
analyses	O	O
(	O	O
table	O	O
3	O	O
;	O	O
figure	O	O
2	O	O
)	O	O
.	O	O
We	O	O
observed	O	O
no	O	O
difference	O	O
in	O	O
fatigue	O	O
(	O	O
QLQ	O	O
-	O	O
C30	O	O
)	O	O
between	O	O
groups	O	O
by	O	O
cross	O	O
-	O	O
sectional	O	O
analysis	O	O
;	O	O
although	O	O
fatigue	O	O
scores	O	O
were	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
weekly	O	O
(	O	O
group	B-arm_description	B-arm_description
2	I-arm_description	O
)	O	O
and	O	O
3-weekly	O	O
(	O	O
group	B-arm_description	B-arm_description
1	I-arm_description	O
)	O	O
treatment	O	O
groups	O	O
by	O	O
longitudinal	O	O
analysis	O	O
,	O	O
they	O	O
did	O	O
not	O	O
meet	O	O
the	O	O
threshold	O	O
for	O	O
clinical	O	O
signifi	O	O
cance	O	O
(	O	O
table	O	O
3	O	O
;	O	O
figure	O	O
2	O	O
)	O	O
.	O	O
By	O	O
cross	O	O
-	O	O
sectional	O	O
analysis	O	O
,	O	O
peripheral	O	O
neuropathy	O	O
scores	O	O
(	O	O
QLQ	O	O
-	O	O
OV28	O	O
)	O	O
were	O	O
statisti	O	O
cally	O	O
and	O	O
clinically	O	O
significantly	O	O
different	O	O
between	O	O
group	B-arm_description	B-arm_description
2	I-arm_description	I-arm_description
and	O	O
group	B-arm_description	B-arm_description
1	I-arm_description	I-arm_description
;	O	O
however	O	O
,	O	O
there	O	O
was	O	O
no	O	O
difference	O	O
by	O	O
longitudinal	O	O
analysis	O	O
(	O	O
table	O	O
3	O	O
;	O	O
figure	O	O
2	O	O
)	O	O
.	O	O
Data	O	O
are	O	O
n	O	O
(	O	O
%	O	O
)	O	O
,	O	O
mean	O	O
(	O	O
SD	O	O
)	O	O
,	O	O
or	O	O
mean	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
)	O	O
,	O	O
unless	O	O
otherwise	O	O
indicated	O	O
.	O	O
Group	B-arm_description	B-arm_description
1	I-arm_description	O
=	O	O
standard	O	O
three	O	O
-	O	O
weekly	O	O
carboplatin	O	O
and	O	O
paclitaxel	O	O
.	O	O
Group	B-arm_description	B-arm_description
2	I-arm_description	O
=	O	O
three	O	O
-	O	O
weekly	O	O
carboplatin	O	O
and	O	O
weekly	O	O
dose	O	O
-	O	O
dense	O	O
paclitaxel	O	O
.	O	O
Group	B-arm_description	B-arm_description
3	I-arm_description	O
=	O	O
weekly	O	O
carboplatin	O	O
and	O	O
weekly	O	O
dose	O	O
-	O	O
dense	O	O
paclitaxel	O	O
.	O	O
*	O	O
From	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
,	O	O
calculated	O	O
from	O	O
mixed	O	O
effects	O	O
regression	O	O
model	O	O
.	O	O
†Adjusted	O	O
for	O	O
baseline	O	O
.	O	O

We	O	O
did	O	O
a	O	O
post	O	B-study_type
-	O	I-study_type
hoc	O	I-study_type
analysis	O	O
to	O	O
assess	O	O
concordance	O	O
between	O	O
self	O	O
-	O	O
reported	O	O
peripheral	O	O
neuropathy	O	O
from	O	O
the	O	O
quality	O	O
-	O	O
of	O	O
-	O	O
life	O	O
questionnaires	O	O
and	O	O
clinician	O	O
-	O	O
assessed	O	O
peripheral	O	O
neuropathy	O	O
reported	O	O
during	O	O
the	O	O
treatment	O	O
period	O	O
;	O	O
there	O	O
was	O	O
good	O	O
agreement	O	O
between	O	O
the	O	O
measures	O	O
(	O	O
appendix	O	O
p	O	O
12	O	O
)	O	O
.	O	O
Sensitivity	O	O
analyses	O	O
to	O	O
assess	O	O
the	O	O
potential	O	O
effect	O	O
of	O	O
missing	O	O
data	O	O
did	O	O
not	O	O
alter	O	O
our	O	O
interpretation	O	O
of	O	O
the	O	O
data	O	O
(	O	O
appendix	O	O
p	O	O
13	O	O
)	O	O
.	O	O

Adjuvant	O	O
intensity	O	O
modulated	O	O
wholeabdominal	B-arm_description	B-arm_description
radiation	I-arm_description	O
therapy	I-arm_description	O
for	O	O
high	O	O
-	O	O
risk	O	O
patients	O	O
with	O	O
ovarian	O	O
cancer	O	O
FIGO	O	O
stage	O	O
III	O	O
:	O	O
final	O	B-study_type
results	B-study_type	I-study_type
of	I-study_type	I-study_type
a	I-study_type	I-study_type
prospective	I-study_type	I-study_type
phase	I-study_type	I-study_type
2	I-study_type	I-study_type
study	I-study_type	I-study_type

Department	O	O
of	O	O
Obstetrics	O	O
and	O	O
Gynecology	O	O
,	O	O
Klinikum	O	O
Hanau	O	O
,	O	O
Academic	O	O
Teaching	O	O
Hospital	O	O
of	O	O
the	O	O
Medical	O	O
Faculty	O	O
of	O	O
the	O	O
Goethe	O	O
University	O	O
of	O	O
Frankfurt	O	O
/	O	O
Main	O	O
Hanau	O	O
Germany	O	O
SonjaKatayama	B-authors	B-authors
2,3,6,7	O	O

Department	O	O
of	O	O
Obstetrics	O	O
and	O	O
Gynecology	O	O
,	O	O
Klinikum	O	O
Hanau	O	O
,	O	O
Academic	O	O
Teaching	O	O
Hospital	O	O
of	O	O
the	O	O
Medical	O	O
Faculty	O	O
of	O	O
the	O	O
Goethe	O	O
University	O	O
of	O	O
Frankfurt	O	O
/	O	O
Main	O	O
Hanau	O	O
Germany	O	O
SonjaKatayama	B-authors	B-authors
2,3,6,7	O	O

Department	O	O
of	O	O
Obstetrics	O	O
and	O	O
Gynecology	O	O
,	O	O
Klinikum	O	O
Hanau	O	O
,	O	O
Academic	O	O
Teaching	O	O
Hospital	O	O
of	O	O
the	O	O
Medical	O	O
Faculty	O	O
of	O	O
the	O	O
Goethe	O	O
University	O	O
of	O	O
Frankfurt	O	O
/	O	O
Main	O	O
Hanau	O	O

Germany	O	O
Department	O	O
of	O	O
Obstetrics	O	O
and	O	O
Gynecology	O	O
,	O	O
Klinikum	O	O
Hanau	O	O
,	O	O
Academic	O	O
Teaching	O	O
Hospital	O	O
of	O	O
the	O	O
Medical	O	O
Faculty	O	O
of	O	O
the	O	O
Goethe	O	O
University	O	O
of	O	O
Frankfurt	O	O
/	O	O
Main	O	O
Hanau	O	O

First	O	O
-	O	O
line	O	O
treatment	O	O
of	O	O
advanced	O	O
ovarian	O	O
cancer	O	O
patients	O	O
consists	O	O
of	O	O
radical	O	O
cytoreductive	O	O
surgery	O	O
(	O	O
"	O	O
no	O	O
residual	O	O
tumor	O	O
"	O	O
)	O	O
and	O	O
a	O	O
platinum	O	O
-	O	O
and	O	O
taxane	O	O
-	O	O
based	O	O
chemotherapy	O	O
(	O	O
6	O	O
cycles	O	O
of	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
in	O	O
combination	O	O
with	O	O
paclitaxel	O	O
175	O	O
mg	O	O
/	O	O
m	O	O
2	O	O
)	O	O
[	O	O
5][6][7][8][9][10][11][12][13][14][15][16][17][18	O	O
]	O	O
.	O	O
Simultaneous	O	O
followed	O	O
by	O	O
consolidative	O	O
administration	O	O
of	O	O
bevacizumab	O	O
for	O	O
12	O	O
-	O	O
15	O	O
months	O	O
can	O	O
be	O	O
considered	O	O
in	O	O
stage	O	O
IIIB	O	O
-	O	O
IV	O	O
patients	O	O
with	O	O
high	O	O
risk	O	O
for	O	O
recurrence	O	O
,	O	O
accepting	O	O
reduced	O	O
quality	O	O
of	O	O
life	O	O
[	O	O
19][20][21	O	O
]	O	O
.	O	O

We	O	O
enrolled	O	O
15	O	O
patients	O	O
with	O	O
GBM	O	B-arm_description
or	O	O
variants	O	O
in	O	O
Stage	O	O
1	O	O
(	O	O
Table	O	O
1	O	O
)	O	O
between	O	O
July	O	O
2015	O	O
and	O	O
June	O	O
2017	O	O
.	O	O
Median	O	O
age	O	O
was	O	O
61	O	O
(	O	O
range	O	O
27	O	O
-	O	O
74	O	O
)	O	O
and	O	O
median	O	O
KPS	O	O
was	O	O
80	O	O
(	O	O
range	O	O
70	O	O
-	O	O
90	O	O
)	O	O
.	O	O
The	O	O
median	O	O
number	O	O
of	O	O
prior	O	O
therapies	O	O
was	O	O
2	O	O
(	O	O
range	O	O
2	O	O
-	O	O
4	O	O
)	O	O
and	O	O
the	O	O
median	O	O
time	O	O
between	O	O
last	O	O
bevacizumab	O	B-arm_description
dose	O	O
and	O	O
first	O	O
ponatinib	B-arm_description	B-arm_description
dose	O	O
was	O	O
34	O	O
days	O	O
(	O	O
range	O	O
20	O	O
-	O	O
92	O	O
)	O	O
.	O	O
At	O	O
the	O	O
time	O	O
of	O	O
study	O	O
enrollment	O	O
,	O	O
GBM	O	O
with	O	O
oligodendroglial	O	O
features	O	O
(	O	O
GBMO	O	O
)	O	O
was	O	O
a	O	O
recognized	O	O
GBM	O	O
variant	O	O
by	O	O
the	O	O
World	O	O
Health	O	O
Organization	O	O
(	O	O
WHO	O	O
)	O	O
Classification	O	O
of	O	O
Tumors	O	O
.	O	O
Upon	O	O
central	O	O
review	O	O
,	O	O
one	O	O
patient	O	O
had	O	O
a	O	O
GBMO	O	O
with	O	O
1p/19q	O	O
loss	O	O
(	O	O
which	O	O
would	O	O
be	O	O
classified	O	O
as	O	O
an	O	O
anaplastic	O	O
oligodendroglioma	O	O
by	O	O
updated	O	O
WHO	O	O
2016	O	O
criteria	O	O
15	O	O
)	O	O
.	O	O

As	O	O
none	O	O
of	O	O
the	O	O
patients	O	O
achieved	O	O
PFS3	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
the	O	O
study	O	O
was	O	O
permanently	O	O
closed	O	O
after	O	O
the	O	O
first	O	O
stage	O	O
(	O	O
Table	O	O
2	O	O
)	O	O
.	O	O
The	O	O
longest	O	O
time	O	O
to	O	O
progression	O	O
observed	O	O
was	O	O
84	O	O
days	O	O
.	O	O
Median	B-arm_efficacy_metric	B-arm_description
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
28	B-arm_efficacy_results	O
days	I-arm_efficacy_results	O
[	I-arm_efficacy_results	O
95	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
CI	I-arm_efficacy_results	O
27	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
30	I-arm_efficacy_results	O
]	I-arm_efficacy_results	O
and	O	O
median	O	O
OS	O	O
was	O	O
98	O	O
days	O	O
[	O	O
95	O	O
%	O	O
CI	O	O
56	O	O
,	O	O
257	O	O
]	O	O
.	O	O
There	O	O
were	O	O
no	O	O
complete	O	O
or	O	O
partial	O	O
responses	O	O
seen	O	O
and	O	O
SD	O	O
was	O	O
the	O	O
best	O	O
response	O	O
in	O	O
two	O	O
patients	O	O
(	O	O
13.7	O	O
%	O	O
)	O	O
.	O	O
Toxicities	O	O
on	O	O
study	O	O
were	O	O
as	O	O
expected	O	O
for	O	O
ponatinib	B-arm_description	B-arm_description
with	O	O
fatigue	O	O
,	O	O
increased	O	O
lipase	O	O
,	O	O
and	O	O
hypertension	O	O
as	O	O
the	O	O
most	O	O
common	O	O
AEs	O	O
(	O	O
Table	O	O
3	O	O
)	O	O
.	O	O
Two	O	O
patients	O	O
were	O	O
dose	O	O
reduced	O	O
,	O	O
one	O	O
due	O	O
to	O	O
grade	O	O
3	O	O
lipase	O	O
and	O	O
the	O	O
other	O	O
due	O	O
to	O	O
recurrent	O	O
grade	O	O
2	O	O
diarrhea	O	O
.	O	O
One	O	O
patient	O	O
was	O	O
taken	O	O
off	O	O
study	O	O
due	O	O
to	O	O
unacceptable	O	O
toxicity	O	O
(	O	O
grade	O	O
3	O	O
bullous	O	O
dermatitis	O	O
occurring	O	O
during	O	O
the	O	O
first	O	O
cycle	O	O
)	O	O
.	O	O
Another	O	O
patient	O	O
withdrew	O	O
consent	O	O
from	O	O
study	O	O
participation	O	O
,	O	O
also	O	O
during	O	O
the	O	O
first	O	O
cycle	O	O
of	O	O
treatment	O	O
.	O	O

LEE	B-authors	O
Et	O	O
aL	O	O
comparative	O	O
genomic	O	O
hybridization	O	O
harbored	O	O
evidence	O	O
of	O	O
FGFR	O	O
-	O	O
TACC	O	O
fusions	O	O
.	O	O
In	O	O
summary	O	O
,	O	O
ponatinib	B-arm_description	O
has	O	O
limited	O	O
efficacy	O	O
in	O	O
patients	O	O
with	O	O
bevacizumab	O	O
-	O	O
resistant	O	O
GBM	O	O
.	O	O
The	O	O
circulating	O	O
biomarker	O	O
data	O	O
suggest	O	O
that	O	O
immunomodulation	O	O
may	O	O
have	O	O
played	O	O
a	O	O
role	O	O
in	O	O
resistance	O	O
to	O	O
treatment	O	O
,	O	O
although	O	O
further	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
clarify	O	O
the	O	O
interplay	O	O
between	O	O
angiogenesis	O	O
and	O	O
these	O	O
immune	O	O
cytokines	O	O
.	O	O
It	O	O
is	O	O
unclear	O	O
if	O	O
ponatinib	O	O
could	O	O
be	O	O
beneficial	O	O
in	O	O
bevacizumab	O	O
-	O	O
naïve	O	O
patients	O	O
or	O	O
in	O	O
patients	O	O
whose	O	O
GBM	O	O
harbors	O	O
a	O	O
FGFR	O	O
-	O	O
TACC	O	O
fusion	O	O
as	O	O
neither	O	O
of	O	O
these	O	O
populations	O	O
were	O	O
examined	O	O
in	O	O
this	O	O
study	O	O
.	O	O
Given	O	O
ponatinib	B-arm_description	O
's	O	O
cumulative	O	O
cardiovascular	O	O
toxicity	O	O
,	O	O
potentially	O	O
limited	O	O
penetration	O	O
across	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
,	O	O
and	O	O
the	O	O
recent	O	O
drug	O	O
development	O	O
of	O	O
selective	O	O
brain	O	O
penetrant	O	O
FGFR	O	O
inhibitors	O	O
,	O	O
further	O	O
evaluation	O	O
of	O	O
ponatinib	B-arm_description	O
in	O	O
GBMs	O	O
with	O	O
FGFR	O	O
-	O	O
TACC	O	O
fusion	O	O
is	O	O
not	O	O
recommended	O	O
.	O	O

Daratumumab	O	B-arm_description
plus	O	I-arm_description
bortezomib	O	I-arm_description
,	O	I-arm_description
melphalan	O	I-arm_description
,	O	I-arm_description
and	O	I-arm_description
prednisone	O	I-arm_description
in	O	O
East	O	O
Asian	O	O
patients	O	O
with	O	O
non	O	O
-	O	O
transplant	O	O
multiple	O	O
myeloma	O	O
:	O	O
subanalysis	O	O
of	O	O
the	O	O
randomized	B-study_type	B-study_type
phase	I-study_type	I-study_type
3	I-study_type	I-study_type
ALCYONE	I-study_type	I-study_type
trial	I-study_type	I-study_type
Daratumumab	O	B-arm_description
plus	O	I-arm_description
bortezomib	O	I-arm_description
,	O	I-arm_description
melphalan	O	I-arm_description
,	O	I-arm_description
and	O	I-arm_description
prednisone	O	I-arm_description
in	O	O
East	O	O
Asian	O	O
patients	O	O
with	O	O
non	O	O
-	O	O
transplant	O	O
multiple	O	O
myeloma	O	O
:	O	O
subanalysis	O	O
of	O	O
the	O	O
randomized	B-study_type	B-study_type
phase	I-study_type	I-study_type
3	I-study_type	I-study_type
ALCYONE	I-study_type	I-study_type
trial	I-study_type	I-study_type
16	O	O
October	O	O
2019	O	O
16	O	O
October	O	O
2019	O	O
TomoakiFujisaki	B-authors	B-authors

Daratumumab	O	B-arm_description
plus	O	I-arm_description
bortezomib	O	B-arm_description
,	O	O
melphalan	O	O
,	O	O
and	O	O
prednisone	O	O
in	O	O
East	O	O
Asian	O	O
patients	O	O
with	O	O
non	O	O
-	O	O
transplant	O	O
multiple	O	O
myeloma	O	O
:	O	O
subanalysis	O	O
of	O	O
the	O	O
randomized	B-study_type	B-study_type
phase	I-study_type	B-study_type
3	I-study_type	I-study_type
ALCYONE	I-study_type	I-study_type
trial	I-study_type	I-study_type
16	O	O
October	O	O
2019	O	O

Japan	O	O
67	O	O
Asahi	O	O
-	O	O
machi	O	O
830	O	O
-	O	O
0011	O	O
Kurume	O	O
Japan	O	O
Daratumumab	O	B-arm_description
plus	O	I-arm_description
bortezomib	O	I-arm_description
,	O	I-arm_description
melphalan	O	I-arm_description
,	O	I-arm_description
and	O	I-arm_description
prednisone	O	O
in	O	O
East	O	O
Asian	O	O
patients	O	O
with	O	O
non	O	O
-	O	O
transplant	O	O
multiple	O	O
myeloma	O	O
:	O	O
subanalysis	O	O
of	O	O
the	O	O
randomized	B-study_type	B-study_type
phase	I-study_type	I-study_type
3	I-study_type	I-study_type
ALCYONE	I-study_type	O
trial	I-study_type	O
16	O	O
October	O	O
2019	O	O
16	O	O
October	O	O
2019	O	O
16	O	O
October	O	O
2019	O	O
10.1007	O	O
/	O	O
s00277	O	O
-	O	O
019	O	O
-	O	O
03794	O	O
-	O	O
9	O	O
Received	O	O
:	O	O
19	O	O
August	O	O
2019	O	O
/	O	O
Accepted	O	O
:	O	O
29	O	O
August	O	O
2019	O	O
#	O	O
The	O	O
Author(s	O	O
)	O	O
2019	O	O

Bortezomib	O	O
,	O	O
melphalan	O	O
,	O	O
and	O	O
prednisone	O	O
(	O	O
VMP	O	O
)	O	O
was	O	O
approved	O	O
based	O	O
on	O	O
the	O	O
VISTA	O	O
trial	O	O
in	O	O
non	O	O
-	O	O
transplant	O	O
newly	O	O
diagnosed	O	O
multiple	O	O
myeloma	O	O
(	O	O
NDMM	O	O
)	O	O
patients	O	O
and	O	O
remains	O	O
as	O	O
one	O	O
of	O	O
several	O	O
standard	O	O
-	O	O
of	O	O
-	O	O
care	O	O
regimens	O	O
for	O	O
non	O	O
-	O	O
transplant	O	O
NDMM	O	O
[	O	O
14	O	O
]	O	O
.	O	O
The	O	O
randomized	O	B-study_type
,	O	I-study_type
open	O	I-study_type
-	O	I-study_type
label	O	I-study_type
,	O	I-study_type
phase	O	I-study_type
3	O	I-study_type
ALCYONE	O	O
study	O	O
compared	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
daratumumab	O	O
in	O	O
combination	O	O
with	O	O
VMP	O	B-arm_description
(	O	O
D	O	B-arm_description
-	O	I-arm_description
VMP	O	I-arm_description
)	O	O
versus	O	O
VMP	O	B-arm_description
alone	O	O
in	O	O
patients	O	O
with	O	O
NDMM	O	O
who	O	O
were	O	O
considered	O	O
ineligible	O	O
for	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
(	O	O
ASCT	O	O
)	O	O
[	O	O
15	O	O
]	O	O
.	O	O
Interim	O	O
results	O	O
that	O	O
were	O	O
reported	O	O
after	O	O
a	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
16.5	O	O
months	O	O
showed	O	O
a	O	O
significant	O	O
improvement	O	O
in	O	O
the	O	O
primary	O	O
endpoint	O	O
of	O	O
progression	O	B-arm_efficacy_metric
-	O	I-arm_efficacy_metric
free	O	I-arm_efficacy_metric
survival	O	I-arm_efficacy_metric
(	O	O
PFS	O	B-arm_efficacy_metric
)	O	O
with	O	O
D	O	B-arm_description
-	O	I-arm_description
VMP	O	I-arm_description
versus	O	O
VMP	O	B-arm_description
,	O	O
along	O	O
with	O	O
significant	O	O
improvements	O	O
in	O	O
response	O	O
and	O	O
minimal	O	O
residual	O	O
disease	O	O
(	O	O
MRD)-negativity	O	O
rates	O	O
at	O	O
a	O	O
10	O	O
−5	O	O
sensitivity	O	O
threshold	O	O
.	O	O
Overall	O	O
,	O	O
D	O	B-arm_description
-	O	I-arm_description
VMP	O	I-arm_description
was	O	O
associated	O	O
with	O	O
a	O	O
toxicity	O	O
profile	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
VMP	O	B-arm_description
;	O	O
while	O	O
grade	O	O
3	O	O
and	O	O
4	O	O
infections	O	O
were	O	O
more	O	O
commonly	O	O
seen	O	O
with	O	O
D	O	B-arm_description
-	O	I-arm_description
VMP	O	I-arm_description
relative	O	O
to	O	O
VMP	O	B-arm_description
alone	O	O
,	O	O
rates	O	O
of	O	O
discontinuations	O	O
due	O	O
to	O	O
infection	O	O
were	O	O
comparable	O	O
(	O	O
0.9	O	O
%	O	O
vs	O	O
1.4	O	O
%	O	O
for	O	O
D	O	B-arm_description
-	O	I-arm_description
VMP	O	I-arm_description
and	O	O
VMP	O	B-arm_description
,	O	O
respectively	O	O
)	O	O
.	O	O
Based	O	O
on	O	O
these	O	O
results	O	O
,	O	O
D	O	B-arm_description
-	O	I-arm_description
VMP	O	I-arm_description
has	O	O
been	O	O
approved	O	O
in	O	O
the	O	O
USA	O	O
,	O	O
European	O	O
Union	O	O
,	O	O
and	O	O
Brazil	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
NDMM	O	O
who	O	O
are	O	O
ineligible	O	O
for	O	O
ASCT	O	O
[	O	O
12	O	O
]	O	O
.	O	O

Analysis	O	O
populations	O	O
in	O	O
ALCYONE	O	O
included	O	O
intent	O	O
-	O	O
to	O	O
-	O	O
treat	O	O
(	O	O
ITT	O	O
)	O	O
and	O	O
safety	O	O
populations	O	O
.	O	O
The	O	O
ITT	O	O
population	O	O
was	O	O
defined	O	O
as	O	O
all	O	O
patients	O	O
randomized	O	O
into	O	O
the	O	O
study	O	O
.	O	O
This	O	O
population	O	O
was	O	O
used	O	O
for	O	O
all	O	O
primary	O	O
efficacy	O	O
endpoints	O	O
,	O	O
key	O	O
secondary	O	O
endpoints	O	O
,	O	O
and	O	O
all	O	O
analyses	O	O
of	O	O
disposition	O	O
,	O	O
demographic	O	O
,	O	O
and	O	O
baseline	O	O
disease	O	O
characteristics	O	O
.	O	O
The	O	O
safety	O	O
population	O	O
included	O	O
all	O	O
treated	O	O
patients	O	O
who	O	O
had	O	O
at	O	O
least	O	O
1	O	O
administration	O	O
of	O	O
study	O	O
drug	O	O
and	O	O
was	O	O
used	O	O
for	O	O
all	O	O
safety	O	O
analyses	O	O
and	O	O
all	O	O
analyses	O	O
of	O	O
treatment	O	O
compliance	O	O
and	O	O
exposure	O	O
.	O	O
East	O	O
Asian	O	O
patients	O	O
from	O	O
the	O	O
ITT	O	O
and	O	O
safety	O	O
populations	O	O
of	O	O
ALCYONE	O	O
were	O	O
used	O	O
for	O	O
this	O	O
report	O	O
.	O	O

Lung	O	O
cancer	O	O
is	O	O
the	O	O
most	O	O
common	O	O
type	O	O
of	O	O
cancer	O	O
and	O	O
the	O	O
leading	O	O
cause	O	O
of	O	O
cancer	O	O
death	O	O
.	O	O
[	O	O
1	O	O
]	O	O
Non	O	O
-	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
(	O	O
NSCLC	O	O
)	O	O
accounts	O	O
for	O	O
75	O	O
%	O	O
to80	O	O
%	O	O
of	O	O
lung	O	O
cancer	O	O
,	O	O
and	O	O
the	O	O
5-year	O	O
survival	O	O
rate	O	O
is	O	O
about	O	O
15	O	O
%	O	O
.	O	O
[	O	O
2	O	O
]	O	O
The	O	O
main	O	O
pathological	O	O
types	O	O
of	O	O
NSCLC	O	O
are	O	O
adenocarcinoma	O	O
(	O	O
32	O	O
%	O	O
-40	O	O
%	O	O
)	O	O
,	O	O
squamous	O	O
cell	O	O
carcinoma	O	O
(	O	O
25	O	O
%	O	O
-30	O	O
%	O	O
)	O	O
,	O	O
and	O	O
large	O	O
cell	O	O
carcinoma	O	O
(	O	O
8	O	O
%	O	O
-16	O	O
%	O	O
)	O	O
.	O	O
[	O	O
3	O	O
]	O	O
About	O	O
70	O	O
%	O	O
of	O	O
lung	O	O
cancer	O	O
patients	O	O
are	O	O
at	O	O
an	O	O
advanced	O	O
stage	O	O
when	O	O
they	O	O
are	O	O
first	O	O
diagnosed	O	O
,	O	O
and	O	O
surgery	O	O
therapy	O	O
is	O	O
n't	O	O
available	O	O
for	O	O
which	O	O
.	O	O
Chemotherapy	O	O
,	O	O
radiotherapy	O	O
,	O	O
targeted	O	O
therapy	O	O
,	O	O
and	O	O
immunotherapy	O	O
can	O	O
be	O	O
selected	O	O
as	O	O
treatments	O	O
for	O	O
stage	O	O
IIIB	O	O
/	O	O
IV	O	O
NSCLC	O	O
,	O	O
platinum	O	O
-	O	O
based	O	O
doublets	O	O
chemotherapy	O	O
is	O	O
the	O	O
main	O	O
option	O	O
among	O	O
which	O	O
.	O	O
However	O	O
,	O	O
the	O	O
effective	O	O
rate	O	O
of	O	O
each	O	O
chemotherapy	O	O
regimen	O	O
varies	O	O
from	O	O
20	O	O
%	O	O
to	O	O
30	O	O
%	O	O
,	O	O
and	O	O
progress	O	O
-	O	O
free	O	O
survival	O	O
(	O	O
PFS	O	B-arm_efficacy_metric
)	O	O
is	O	O
only	O	O
a	O	O
few	O	O
months	O	O
.	O	O
[	O	O
4][5][6	O	O
]	O	O
Also	O	O
,	O	O
adverse	O	O
events	O	O
such	O	O
as	O	O
marrow	O	O
suppression	O	O
,	O	O
nausea	O	O
,	O	O
vomiting	O	O
can	O	O
decrease	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
(	O	O
QOL	O	O
)	O	O
of	O	O
patients	O	O
.	O	O
[	O	O
7	O	O
]	O	O
It	O	O
is	O	O
necessary	O	O
to	O	O
find	O	O
an	O	O
effective	O	O
and	O	O
safe	O	O
treatment	O	O
for	O	O
advanced	O	O
NSCLC	O	O
.	O	O

Initially	O	O
,	O	O
many	O	O
elderly	O	O
patients	O	O
with	O	O
advanced	O	O
lung	O	O
cancer	O	O
chose	O	O
Cancer	O	O
Green	O	O
Therapy	O	O
(	O	O
cryoablation	O	O
combined	O	O
with	O	O
TCM	O	B-arm_description
)	O	O
for	O	O
better	O	O
QOL	O	O
.	O	O
However	O	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
survival	O	O
was	O	O
longer	O	O
than	O	O
that	O	O
we	O	O
had	O	O
expected	O	O
during	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
visit	O	O
.	O	O
Later	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
retrospective	O	O
analysis	O	O
and	O	O
screened	O	O
186	O	O
patients	O	O
who	O	O
underwent	O	O
cryoablation	O	O
plus	O	O
TCM	O	O
in	O	O
our	O	O
department	O	O
between	O	O
2005	O	O
and	O	O
2013	O	O
.	O	O
119	O	O
cases	O	O
were	O	O
followed	O	O
up	O	O
in	O	O
2014	O	O
.	O	O
Among	O	O
them	O	O
,	O	O
82	O	O
cases	O	O
were	O	O
advanced	O	O
NSCLC	O	O
patients	O	O
,	O	O
the	O	O
average	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
of	O	O
them	O	O
is	O	O
18	O	O
months	O	O
,	O	O
almost	O	O
double	O	O
as	O	O
that	O	O
in	O	O
NCCN	O	O
guidelines	O	O
(	O	O
8	O	O
-	O	O
10	O	O
months	O	O
)	O	O
.	O	O
[	O	O
19,20	O	O
]	O	O
The	O	O
present	O	O
multi	B-study_type	B-study_type
-	I-study_type	I-study_type
center	I-study_type	I-study_type
,	I-study_type	I-study_type
prospective	I-study_type	I-study_type
,	I-study_type	I-study_type
randomized	I-study_type	I-study_type
controlled	I-study_type	I-study_type
trial	I-study_type	I-study_type
is	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
Cancer	O	O
Green	O	O
Therapy	O	O
(	O	O
cryoablation	B-arm_description	O
combined	I-arm_description	O
with	I-arm_description	O
TCM	I-arm_description	O
)	O	O
,	O	O
setting	O	O
chemotherapy	B-arm_description	O
as	I-arm_description	O
the	I-arm_description	O
control	I-arm_description	O
treatment	I-arm_description	O
.	O	O
We	O	O
hope	O	O
that	O	O
,	O	O
through	O	O
this	O	O
rigorously	O	O
designed	O	O
study	O	O
,	O	O
we	O	O
can	O	O
provide	O	O
scientific	O	O
and	O	O
objective	O	O
assessments	O	O
for	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
cryoablation	B-arm_description	O
combined	I-arm_description	O
with	I-arm_description	O
TCM	I-arm_description	B-arm_description
for	O	O
stage	O	O
IIIB	O	O
/	O	O
IV	O	O
NSCLC	O	O
patients	O	O
and	O	O
possibly	O	O
offer	O	O
the	O	O
world	O	O
an	O	O
alternative	O	O
treatment	O	O
.	O	O

The	O	O
trial	O	O
is	O	O
a	O	O
multi	B-study_type	B-study_type
-	I-study_type	I-study_type
center	I-study_type	I-study_type
,	I-study_type	I-study_type
prospective	I-study_type	I-study_type
,	I-study_type	I-study_type
randomized	I-study_type	I-study_type
controlled	I-study_type	I-study_type
trial	I-study_type	I-study_type
.	O	O
The	O	O
flowchart	O	O
of	O	O
the	O	O
study	O	O
is	O	O
presented	O	O
in	O	O
Figure	O	O
1	O	O
.	O	O

(	O	O
2	O	O
)	O	O
Objective	O	O
remission	O	O
rate	O	O
(	O	O
ORR	O	O
)	O	O
:	O	O
Enhanced	O	O
CT	O	O
of	O	O
the	O	O
chest	O	O
will	O	O
be	O	O
performed	O	O
at	O	O
the	O	O
baseline	O	O
period	O	O
and	O	O
the	O	O
end	O	O
of	O	O
therapy	O	O
.	O	O
The	O	O
therapeutic	O	O
effect	O	O
will	O	O
be	O	O
evaluated	O	O
as	O	O
complete	O	O
response	O	O
(	O	O
CR	O	O
)	O	O
,	O	O
partial	O	O
response	O	O
(	O	O
PR	O	O
)	O	O
,	O	O
stability	O	O
disease	O	O
(	O	O
SD	O	O
)	O	O
,	O	O
and	O	O
progressive	O	O
disease	O	O
(	O	O
PD	O	O
)	O	O
according	O	O
to	O	O
Response	O	O
Evaluation	O	O
Criteria	O	O
in	O	O
Solid	O	O
Tumors	O	O
(	O	O
RECIST	O	O
)	O	O
.	O	O
ORR	O	O
will	O	O
be	O	O
defined	O	O
as	O	O
the	O	O
percentage	O	O
of	O	O
CR	O	O
and	O	O
PR	O	O
cases	O	O
in	O	O
patients	O	O
.	O	O
(	O	O
3	O	O
)	O	O
QOL	O	O
:	O	O
QOL	O	O
will	O	O
refer	O	O
to	O	O
the	O	O
European	O	O
Organization	O	O
for	O	O
Research	O	O
and	O	O
Treatment	O	O
of	O	O
Cancer	O	O
Quality	O	O
Life	O	O
Questionnaire	O	O
Core	O	O
30	O	O
scale	O	O
and	O	O
lung	O	O
cancer	O	O
-	O	O
specific	O	O
LC13	O	O
scale	O	O
.	O	O

David	O	O
Geffen	O	O
School	O	O
of	O	O
Medicine	O	O
at	O	O
UCLA	O	O
Los	O	O
Angeles	O	O
CA	O	O
USA	O	O
JorgeMouro	B-authors	B-authors
Celgene	O	O
Corporation	O	O
Summit	O	O
NJ	O	O
USA	O	O
WilliamEPierceall	B-authors	B-authors
Celgene	O	O
Corporation	O	O
Summit	O	O
NJ	O	O
USA	O	O
FaizaZafar	B-authors	B-authors
Celgene	O	O
Corporation	O	O
Summit	O	O
NJ	O	O
USA	O	O
WeiyuanChung	B-authors	B-authors
Celgene	O	O
Corporation	O	O
Summit	O	O
NJ	O	O
USA	O	O
ShankarSrinivasan	B-authors	B-authors
Celgene	O	O
Corporation	O	O
Summit	O	O
NJ	O	O
USA	O	O
AmitAgarwal	B-authors	B-authors
Celgene	O	O
Corporation	O	O
Summit	O	O
NJ	O	O
USA	O	O
NizarJBahlis	B-authors	B-authors
University	O	O
of	O	O
Calgary	O	O
Calgary	O	O
AB	O	O
Canada	O	O
JohnTheurer	O	B-authors

Patients	O	O
received	O	O
pomalidomide	B-arm_description	B-arm_description
plus	O	O
low	B-arm_description	O
-	I-arm_description	O
dose	I-arm_description	O
dexamethasone	I-arm_description	O
in	O	O
28-day	O	B-arm_dosage
cycles	O	I-arm_dosage
until	O	O
PD	O	O
or	O	O
unacceptable	O	O
toxicity	O	O
.	O	O
Pomalidomide	B-arm_description	B-arm_description
at	O	B-arm_dosage
a	O	I-arm_dosage
dose	O	I-arm_dosage
of	O	I-arm_dosage
4	B-arm_dosage	I-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
was	I-arm_dosage	I-arm_dosage
given	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
to	I-arm_dosage	I-arm_dosage
21	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	I-arm_dosage
each	I-arm_dosage	I-arm_dosage
28-day	I-arm_dosage	I-arm_dosage
cycle	I-arm_dosage	I-arm_dosage
.	O	O
Dexamethasone	B-arm_description	B-arm_description
at	O	B-arm_dosage
a	O	I-arm_dosage
dose	O	I-arm_dosage
of	O	I-arm_dosage
40	B-arm_dosage	I-arm_dosage
mg/	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
(	O	I-arm_dosage
20	B-arm_dosage	I-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
for	O	I-arm_dosage
patients	B-arm_description	O
>	I-arm_description	O
75	I-arm_description	O
years	I-arm_description	O
of	I-arm_description	O
age	I-arm_description	O
)	O	O
was	O	O
given	O	B-arm_dosage
on	O	I-arm_dosage
days	B-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
8	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
15	I-arm_dosage	I-arm_dosage
and	I-arm_dosage	I-arm_dosage
22	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	I-arm_dosage
each	I-arm_dosage	I-arm_dosage
28-day	I-arm_dosage	I-arm_dosage
cycle	I-arm_dosage	I-arm_dosage
.	O	O
Both	O	O
agents	O	O
were	O	O
administered	O	O
orally	O	O
.	O	O
Dose	O	O
interruptions	O	O
and	O	O
reductions	O	O
were	O	O
permitted	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

Safety	O	O
monitoring	O	O
included	O	O
pregnancy	O	O
testing	O	O
and	O	O
counselling	O	O
,	O	O
physical	O	O
examination	O	O
,	O	O
clinical	O	O
laboratory	O	O
evaluations	O	O
,	O	O
venous	O	O
thromboembolism	O	O
monitoring	O	O
and	O	O
electrocardiograms	O	O
.	O	O
AEs	O	O
were	O	O
coded	O	O
according	O	O
to	O	O
the	O	O
Medical	O	O
Dictionary	O	O
for	O	O
Regulatory	O	O
Activities	O	O
(	O	O
version	O	O
20.0	O	O
;	O	O
https://www.meddra	O	O
.	O	O
org/	O	O
)	O	O
and	O	O
graded	O	O
according	O	O
to	O	O
the	O	O
National	O	O
Cancer	O	O
Institute	O	O
Common	O	O
Terminology	O	O
Criteria	O	O
for	O	O
Adverse	O	O
Events	O	O
,	O	O
version	O	O
4.03	O	O
(	O	O
https://www.eortc.be/services/doc/ctc/CTCAE_4.03	O	O
_	O	O
2010-06-14_QuickReference_5x7.pdf	O	O
)	O	O
.	O	O
If	O	O
a	O	O
patient	O	O
experienced	O	O
the	O	O
same	O	O
AE	O	O
multiple	O	O
times	O	O
,	O	O
only	O	O
the	O	O
event	O	O
with	O	O
the	O	O
worst	O	O
severity	O	O
was	O	O
counted	O	O
.	O	O
SPMs	O	O
were	O	O
monitored	O	O
as	O	O
events	O	O
of	O	O
interest	O	O
.	O	O

Median	B-arm_efficacy_metric	B-arm_description
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
12Á2	B-arm_efficacy_results	O
months	I-arm_efficacy_results	O
in	O	O
the	O	O
ITT	B-arm_description	O
population	I-arm_description	O
(	O	O
Fig	O	O
4	O	O
)	O	O
.	O	O
The	O	O
1-and	B-arm_efficacy_metric	O
2-year	I-arm_efficacy_metric	O
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
rates	I-arm_efficacy_metric	O
were	O	O
50Á2	B-arm_efficacy_results	O
%	I-arm_efficacy_results	O
and	I-arm_efficacy_results	O
29Á8	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
,	O	O
respectively	O	O
.	O	O
Median	B-arm_efficacy_metric	B-arm_description
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
in	O	O
the	O	O
efficacy	B-arm_description	O
-	I-arm_description	O
evaluable	I-arm_description	O
(	I-arm_description	O
EE	I-arm_description	O
)	I-arm_description	O
population	I-arm_description	O
was	O	O
also	O	O
12Á2	B-arm_efficacy_results	O
months	I-arm_efficacy_results	O
,	O	O
and	O	O
1-and	B-arm_efficacy_metric	O
2-year	I-arm_efficacy_metric	O
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
rates	I-arm_efficacy_metric	O
for	O	O
the	O	O
EE	B-arm_description	O
population	I-arm_description	O
were	O	O
similar	O	O
to	O	O
those	O	O
in	O	O
the	O	O
ITT	O	O
population	O	O
(	O	O
52Á1	B-arm_efficacy_results	O
%	I-arm_efficacy_results	O
and	I-arm_efficacy_results	O
30Á9	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
,	O	O
respectively	O	O
)	O	O
.	O	O
Median	B-arm_efficacy_metric	B-arm_description
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
in	O	O
patients	O	O
who	O	O
achieved	O	O
MR	O	O
and	O	O
≥PR	O	O
was	O	O
13Á9	O	O
and	O	O
28Á5	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O
In	O	O
the	O	O
prior	O	B-arm_description
-	O	I-arm_description
bortezomib	O	I-arm_description
subgroup	O	O
,	O	O
median	B-arm_efficacy_metric	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
7Á9	O	O
months	O	O
.	O	O
In	O	O
both	O	O
the	O	O
ITT	O	O
and	O	O
EE	B-arm_description	O
populations	I-arm_description	O
,	O	O
median	O	B-arm_efficacy_metric
TTP	O	B-arm_description
was	O	O
13Á8	O	O
months	O	O
.	O	O
Median	O	O
TTP	O	B-arm_description
was	O	O
8Á7	O	O
months	O	O
in	O	O
the	O	O
prior	O	B-arm_description
-	O	I-arm_description
bortezomib	O	I-arm_description
subgroup	O	O
.	O	O
Follow	O	O
-	O	O
up	O	O
for	O	O
OS	O	O
is	O	O
ongoing	O	O
.	O	O
At	O	O
the	O	O
time	O	O
of	O	O
data	O	O
cut	O	O
-	O	O
off	O	O
,	O	O
median	O	B-arm_description
OS	O	O
was	O	O
41Á7	O	O
months	O	O
in	O	O
both	O	O
the	O	O
ITT	O	O
and	O	O
EE	B-arm_description	O
populations	I-arm_description	O
.	O	O
The	O	O
1-and	O	O
2-year	O	O
OS	O	O
rates	O	O
were	O	O
89Á3	O	O
%	O	O
and	O	O
76Á6	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
ITT	O	O
population	O	O
,	O	O
and	O	O
92Á5	O	O
%	O	O
and	O	O
79Á1	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
EE	B-arm_description	O
population	I-arm_description	O
.	O	O
In	O	O
the	O	O
prior	O	B-arm_description
-	O	O
bortezomib	O	O
subgroup	O	O
,	O	O
median	O	B-arm_description
OS	O	O
was	O	O
38Á6	O	O
months	O	O
.	O	O

Oral	O	O
S-1	O	O
with	O	O
24-h	O	O
Infusion	O	O
of	O	O
Irinotecan	O	O
plus	O	O
Bevacizumab	O	B-arm_description
versus	O	O
FOLFIRI	B-arm_description	B-arm_description
plus	O	O
Bevacizumab	O	B-arm_description
as	O	O
First	O	O
-	O	O
Line	O	O
Chemotherapy	O	O
for	O	O
Metastatic	O	O
Colorectal	O	O
Cancer	O	O
:	O	O
An	O	O
Open	B-study_type	B-study_type
-	I-study_type	I-study_type
Label	I-study_type	I-study_type
Randomized	I-study_type	I-study_type
Phase	I-study_type	I-study_type
II	I-study_type	I-study_type
Trial	I-study_type	I-study_type
Oral	O	O
S-1	O	O
with	O	O
24-h	O	O
Infusion	O	O
of	O	O
Irinotecan	O	O
plus	O	O
Bevacizumab	O	B-arm_description
versus	O	O
FOLFIRI	B-arm_description	B-arm_description
plus	O	O
Bevacizumab	O	B-arm_description
as	O	O
First	O	O
-	O	O
Line	O	O
Chemotherapy	O	O
for	O	O
Metastatic	O	O
Colorectal	O	O
Cancer	O	O
:	O	O
An	O	O
Open	B-study_type	B-study_type
-	I-study_type	I-study_type
Label	I-study_type	I-study_type
Randomized	I-study_type	I-study_type
Phase	I-study_type	I-study_type
II	I-study_type	I-study_type
Trial	I-study_type	I-study_type
May	O	O
29	O	O
,	O	O
2020	O	O
May	O	O
29	O	O
,	O	O
2020	O	O
MDSotaroSadahiro	B-authors	B-authors

Bevacizumab	B-arm_description	B-arm_description
was	O	O
given	O	O
to	O	O
patients	O	O
who	O	O
had	O	O
grade	O	O
2	O	O
or	O	O
lower	O	O
hypertension	O	O
,	O	O
proteinuria	O	O
(	O	O
protein	O	O
≤1	O	O
+	O	O
or	O	O
<	O	O
2	O	O
g	O	O
of	O	O
protein	O	O
per	O	O
24-h	O	O
urine	O	O
collection	O	O
)	O	O
,	O	O
and	O	O
grade	O	O
1	O	O
or	O	O
lower	O	O
bleeding	O	O
,	O	O
with	O	O
no	O	O
evidence	O	O
of	O	O
thrombosis	O	O
or	O	O
embolism	O	O
.	O	O
Treatment	O	O
was	O	O
discontinued	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
any	O	O
of	O	O
the	O	O
following	O	O
conditions	O	O
:	O	O
gastrointestinal	O	O
perforation	O	O
,	O	O
grade	O	O
3	O	O
or	O	O
higher	O	O
hypertension	O	O
,	O	O
bleeding	O	O
,	O	O
thrombosis	O	O
or	O	O
embolism	O	O
,	O	O
hypersensitivity	O	O
,	O	O
and	O	O
grade	O	O
4	O	O
or	O	O
higher	O	O
proteinuria	O	O
.	O	O
Treatment	O	O
was	O	O
delayed	O	O
for	O	O
up	O	O
to	O	O
1	O	O
week	O	O
if	O	O
any	O	O
of	O	O
these	O	O
requirements	O	O
was	O	O
not	O	O
satisfied	O	O
.	O	O

Randomized	B-study_type	B-study_type
phase	I-study_type	I-study_type
III	I-study_type	I-study_type
study	I-study_type	I-study_type
(	O	I-study_type
ADMYRE	O	O
)	O	O
of	O	O
plitidepsin	B-arm_description	B-arm_description
in	O	O
combination	B-arm_description	O
with	I-arm_description	O
dexamethasone	I-arm_description	B-arm_description
vs.	O	O
dexamethasone	B-arm_description	B-arm_description
alone	I-arm_description	O
in	O	O
patients	O	O
with	O	O
relapsed	O	O
/	O	O
refractory	O	O
multiple	O	O
myeloma	O	O
Randomized	B-study_type	B-study_type
phase	I-study_type	I-study_type
III	I-study_type	I-study_type
study	I-study_type	I-study_type
(	O	O
ADMYRE	O	O
)	O	O
of	O	O
plitidepsin	B-arm_description	B-arm_description
in	O	O
combination	B-arm_description	O
with	I-arm_description	O
dexamethasone	I-arm_description	B-arm_description
vs.	O	O
dexamethasone	B-arm_description	B-arm_description
alone	I-arm_description	O
in	O	O
patients	O	O
with	O	O
relapsed	O	O
/	O	O
refractory	O	O
multiple	O	O
myeloma	O	O
25	O	O
June	O	O
2019	O	O
25	O	O
June	O	O
2019	O	O
IvanSpicka	B-authors	B-authors

Randomized	B-study_type	B-study_type
phase	I-study_type	I-study_type
III	I-study_type	I-study_type
study	I-study_type	I-study_type
(	O	O
ADMYRE	O	O
)	O	O
of	O	O
plitidepsin	B-arm_description	B-arm_description
in	O	O
combination	B-arm_description	O
with	I-arm_description	O
dexamethasone	I-arm_description	B-arm_description
vs.	O	O
dexamethasone	B-arm_description	B-arm_description
alone	I-arm_description	O
in	O	O
patients	O	O
with	O	O
relapsed	O	O
/	O	O
refractory	O	O
multiple	O	O
myeloma	O	O
25	O	O
June	O	O
2019	O	O

Randomized	B-study_type	B-study_type
phase	I-study_type	I-study_type
III	I-study_type	I-study_type
study	I-study_type	I-study_type
(	O	O
ADMYRE	O	O
)	O	O
of	O	O
plitidepsin	B-arm_description	B-arm_description
in	O	O
combination	O	O
with	O	O
dexamethasone	B-arm_description	B-arm_description
vs.	O	O
dexamethasone	B-arm_description	B-arm_description
alone	O	O
in	O	O
patients	O	O
with	O	O
relapsed	O	O
/	O	O
refractory	O	O
multiple	O	O
myeloma	O	O
IvanSpicka	B-authors	B-authors
Department	O	O
of	O	O
Medicine	O	O
Faculty	O	O
of	O	O
Medicine	O	O

The	O	O
prognosis	O	O
for	O	O
patients	O	O
with	O	O
multiple	O	O
myeloma	O	O
(	O	O
MM	O	O
)	O	O
who	O	O
are	O	O
refractory	O	O
to	O	O
both	O	O
proteasome	O	O
inhibitors	O	O
(	O	O
PIs	O	O
)	O	O
and	O	O
immunomodulatory	O	O
drugs	O	O
(	O	O
IMiDs	O	O
)	O	O
is	O	O
poor	O	O
:	O	O
with	O	O
further	O	O
treatment	O	O
,	O	O
the	O	O
median	O	O
survival	O	O
is	O	O
9	O	O
months	O	O
and	O	O
3	O	O
months	O	O
in	O	O
patients	O	O
without	O	O
further	O	O
treatment	O	O
[	O	O
1	O	O
]	O	O
.	O	O
Furthermore	O	O
,	O	O
treatment	O	O
options	O	O
for	O	O
MM	O	O
decrease	O	O
with	O	O
each	O	O
relapse	O	O
and	O	O
outcomes	O	O
with	O	O
subsequent	O	O
treatment	O	O
using	O	O
standard	O	O
therapies	O	O
are	O	O
characterized	O	O
by	O	O
short	O	O
duration	O	O
of	O	O
response	O	O
and	O	O
increasing	O	O
drug	O	O
resistance	O	O
[	O	O
2	O	O
]	O	O
.	O	O
Therefore	O	O
,	O	O
there	O	O
is	O	O
a	O	O
need	O	O
for	O	O
alternative	O	O
antimyeloma	O	O
treatments	O	O
for	O	O
patients	O	O
with	O	O
advanced	O	O
illness	O	O
following	O	O
refractory/	O	O
multiply	O	O
relapsed	O	O
disease	O	O
.	O	O

Safety	O	O
was	O	O
evaluated	O	O
in	O	O
all	O	O
patients	O	O
who	O	O
received	O	O
at	O	O
least	O	O
one	O	O
dose	O	O
of	O	O
the	O	O
study	O	O
treatment	O	O
by	O	O
assessment	O	O
of	O	O
adverse	O	O
events	O	O
(	O	O
AEs	O	O
)	O	O
,	O	O
clinical	O	O
laboratory	O	O
test	O	O
results	O	O
,	O	O
physical	O	O
examinations	O	O
,	O	O
and	O	O
vital	O	O
signs	O	O
.	O	O
AEs	O	O
were	O	O
recorded	O	O
and	O	O
coded	O	O
with	O	O
the	O	O
Medical	O	O
Dictionary	O	O
for	O	O
Regulatory	O	O
Activities	O	O
(	O	O
MedDRA	O	O
)	O	O
v.16.0	O	O
.	O	O
AEs	O	O
and	O	O
laboratory	O	O
values	O	O
were	O	O
graded	O	O
according	O	O
to	O	O
the	O	O
National	O	O
Cancer	O	O
Institute	O	O
-	O	O
Common	O	O
Toxicity	O	O
Criteria	O	O
for	O	O
Adverse	O	O
Events	O	O
(	O	O
NCI	O	O
-	O	O
CTCAE	O	O
)	O	O
v.4	O	O
.	O	O
All	O	O
patients	O	O
were	O	O
followed	O	O
until	O	O
recovery	O	O
from	O	O
any	O	O
treatment	O	O
-	O	O
related	O	O
AE	O	O
.	O	O
Follow	O	O
-	O	O
up	O	O
was	O	O
longer	O	O
in	O	O
arm	B-arm_description	B-arm_description
A	I-arm_description	O
partly	O	O
because	O	O
it	O	O
included	O	O
patients	O	O
that	O	O
had	O	O
crossed	O	O
over	O	O
from	O	O
arm	B-arm_description	B-arm_description
B.	I-arm_description	I-arm_description

All	O	O
treated	O	O
patients	O	O
were	O	O
evaluable	O	O
for	O	O
safety	O	O
.	O	O
The	O	O
median	O	O
(	O	O
range	O	O
)	O	O
of	O	O
cycles	O	O
received	O	O
was	O	O
3	O	O
(	O	O
1	O	O
-	O	O
33	O	O
)	O	O
in	O	O
arm	B-arm_description	B-arm_description
A	I-arm_description	I-arm_description
(	O	I-arm_description
plitidepsin	B-arm_description	B-arm_description
plus	B-arm_description	I-arm_description
DXM	I-arm_description	B-arm_description
;	O	O
total	O	O
cycles	O	O
=	O	O
842	O	O
)	O	O
and	O	O
2	O	O
(	O	O
1	O	O
-	O	O
21	O	O
)	O	O
in	O	O
arm	B-arm_description	B-arm_description
B	I-arm_description	I-arm_description
(	O	O
DXM	B-arm_description	B-arm_description
;	O	O
total	O	O
cycles	O	O
=	O	O
251	O	O
)	O	O
.	O	O
Median	O	O
time	O	O
on	O	O
treatment	O	O
was	O	O
12.3	O	O
weeks	O	O
(	O	O
1.3	O	O
-	O	O
137.1	O	O
weeks	O	O
)	O	O
in	O	O
arm	B-arm_description	B-arm_description
A	I-arm_description	I-arm_description
and	O	O
8.3	O	O
weeks	O	O
(	O	O
1.4	O	O
-	O	O
85.3	O	O
weeks	O	O
)	O	O
in	O	O
arm	B-arm_description	B-arm_description
B.	I-arm_description	I-arm_description
Fifteen	O	O
patients	O	O
(	O	O
9.0	O	O
%	O	O
)	O	O
discontinued	O	O
treatment	O	O
because	O	O
of	O	O
treatment	O	O
-	O	O
related	O	O
AEs	O	O
in	O	O
arm	B-arm_description	B-arm_description
A	I-arm_description	I-arm_description
and	O	O
eight	O	O
patients	O	O
(	O	O
9.6	O	O
%	O	O
)	O	O
in	O	O
arm	B-arm_description	B-arm_description
B.	I-arm_description	I-arm_description

In	O	O
arm	B-arm_description	B-arm_description
A	I-arm_description	I-arm_description
(	O	O
plitidepsin	B-arm_description	B-arm_description
plus	B-arm_description	I-arm_description
DXM	I-arm_description	B-arm_description
)	O	O
,	O	O
the	O	O
most	O	O
common	O	O
AEs	O	O
(	O	O
all	O	O
grades	O	O
)	O	O
related	O	O
to	O	O
the	O	O
study	O	O
treatment	O	O
(	O	O
or	O	O
with	O	O
unknown	O	O
causality	O	O
)	O	O
were	O	O
nausea	O	O
(	O	O
37.1	O	O
%	O	O
of	O	O
patients	O	O
)	O	O
,	O	O
fatigue	O	O
(	O	O
36.5	O	O
%	O	O
)	O	O
,	O	O
vomiting	O	O
(	O	O
16.8	O	O
%	O	O
)	O	O
,	O	O
diarrhea	O	O
(	O	O
14.4	O	O
%	O	O
)	O	O
,	O	O
myalgia	O	O
(	O	O
14.4	O	O
%	O	O
)	O	O
,	O	O
peripheral	O	O
edema	O	O
(	O	O
12.0	O	O
%	O	O
)	O	O
,	O	O
decreased	O	O
appetite	O	O
(	O	O
12.6	O	O
%	O	O
)	O	O
,	O	O
and	O	O
Table	O	O
2	O	O
)	O	O
.	O	O
Other	O	O
grade	O	O
3/4	O	O
AEs	O	O
of	O	O
specific	O	O
interest	O	O
were	O	O
as	O	O
follows	O	O
:	O	O
creatine	O	O
phosphokinase	O	O
(	O	O
CPK	O	O
)	O	O
increase	O	O
(	O	O
20.0	O	O
%	O	O
)	O	O
,	O	O
alanine	O	O
aminotransferase	O	O
(	O	O
ALT	O	O
)	O	O
increase	O	O
(	O	O
14.5	O	O
%	O	O
)	O	O
,	O	O
peripheral	O	O
sensory	O	O
neuropathy	O	O
(	O	O
0.6	O	O
%	O	O
)	O	O
,	O	O
and	O	O
infection	O	O
/	O	O
pneumonia	O	O
(	O	O
2.4	O	O
%	O	O
)	O	O
.	O	O
One	O	O
patient	O	O
died	O	O
following	O	O
a	O	O
treatment	O	O
-	O	O
related	O	O
AE	O	O
(	O	O
grade	O	O
4	O	O
myopathy	O	O
)	O	O
after	O	O
having	O	O
received	O	O
one	O	O
cycle	O	O
(	O	O
n	O	O
=	O	O
1/167	O	O
patients	O	O
;	O	O
0.6	O	O
%	O	O
)	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
long	O	O
-	O	O
term	O	O
data	O	O
from	O	O
the	O	O
trial	O	O
,	O	O
including	O	O
efficacy	O	O
outcomes	O	O
and	O	O
late	O	O
toxicity	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
the	O	O
role	O	O
of	O	O
early	O	O
marker	O	O
decline	O	O
for	O	O
predicting	O	O
long	O	O
-	O	O
term	O	O
outcomes	O	O
is	O	O
considered	O	O
.	O	O

Estimated	O	O
3-year	B-arm_efficacy_metric	O
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
higher	O	O
in	O	O
the	O	O
group	O	O
with	O	O
unfavourable	O	O
marker	O	O
decline	O	O
compared	O	O
with	O	O
those	O	O
with	O	O
favourable	O	O
decline	O	O
,	O	O
though	O	O
this	O	O
trend	O	O
was	O	O
non	O	O
-	O	O
significant	O	O
(	B-arm_efficacy_results	O
51.7	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
vs	I-arm_efficacy_results	O
41.0	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
HR	I-arm_efficacy_results	O
Z	I-arm_efficacy_results	O
0.82	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
p	I-arm_efficacy_results	O
Z	I-arm_efficacy_results	O
0.54	I-arm_efficacy_results	O
)	I-arm_efficacy_results	O
.	O	O
Results	O	O
were	O	O
similar	O	O
in	O	O
the	O	O
subgroup	O	O
who	O	O
did	O	O
not	O	O
receive	O	O
stabilising	O	O
chemotherapy	O	O
and	O	O
in	O	O
the	O	O
subgroup	O	O
of	O	O
BEP	B-arm_description	O
patients	O	O
.	O	O

Results	O	O
for	O	O
univariate	O	O
and	O	O
multivariable	O	O
models	O	O
for	O	O
OS	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
for	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
e	O	O
the	O	O
only	O	O
significant	O	O
associations	O	O
were	O	O
for	O	O
receipt	O	O
of	O	O
stabilising	O	O
chemotherapy	O	O
and	O	O
mediastinal	O	O
primary	O	O
tumours	O	O
(	O	O
appendix	O	O
C	O	O
)	O	O
.	O	O
Treatment	O	O
effect	O	O
remained	O	O
similar	O	O
after	O	O
adjustment	O	O
for	O	O
these	O	O
factors	O	O
.	O	O

Thirty	O	O
-	O	O
five	O	O
patients	O	O
relapsed	O	O
or	O	O
their	O	O
disease	O	O
progressed	O	O
during	O	O
the	O	O
trial	O	O
(	O	O
22	O	O
BEP	B-arm_description	B-arm_description
,	O	O
13	O	O
CBOP	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
BEP	I-arm_description	I-arm_description
)	O	O
,	O	O
including	O	O
all	O	O
patients	O	O
with	O	O
a	O	O
treatment	O	O
failure	O	O
.	O	O
Thirty	O	O
patients	O	O
(	O	O
20	O	O
BEP	B-arm_description	B-arm_description
,	O	O
10	O	O
CBOP	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
BEP	I-arm_description	I-arm_description
)	O	O
received	O	O
treatment	O	O
for	O	O
relapse	O	O
.	O	O
Of	O	O
the	O	O
remaining	O	O
five	O	O
,	O	O
three	O	O
died	O	O
around	O	O
the	O	O
time	O	O
of	O	O
diagnosis	O	O
of	O	O
relapse	O	O
/	O	O
progression	O	O
;	O	O
one	O	O
was	O	O
felt	O	O
not	O	O
to	O	O
be	O	O
fit	O	O
enough	O	O
for	O	O
salvage	O	O
treatment	O	O
and	O	O
died	O	O
two	O	O
months	O	O
later	O	O
;	O	O
and	O	O
the	O	O
remaining	O	O
patient	O	O
did	O	O
not	O	O
require	O	O
further	O	O
treatment	O	O
and	O	O
remained	O	O
alive	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
followup	O	O
.	O	O
Of	O	O
those	O	O
treated	O	O
,	O	O
all	O	O
but	O	O
5	O	O
received	O	O
combination	O	O
chemotherapy	O	O
(	O	O
sometimes	O	O
alongside	O	O
radiotherapy	O	O
or	O	O
surgery	O	O
)	O	O
,	O	O
most	O	O
commonly	O	O
paclitaxel	O	O
,	O	O
ifosfamide	O	O
and	O	O
cisplatin	O	O
(	O	O
TIP	O	O
)	O	O
(	O	O
13	O	O
patients	O	O
)	O	O
,	O	O
but	O	O
a	O	O
range	O	O
of	O	O
other	O	O
regimens	O	O
were	O	O
used	O	O
.	O	O
Only	O	O
1	O	O
patient	O	O
(	O	O
BEP	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
)	O	O
had	O	O
a	O	O
complete	O	O
response	O	O
and	O	O
9	O	O
(	O	O
7	O	O
BEP	B-arm_description	B-arm_description
,	O	O
2	O	O
CBOP	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
BEP	I-arm_description	I-arm_description
)	O	O
had	O	O
a	O	O
partial	O	O
response	O	O
with	O	O
negative	O	O
markers	O	O
.	O	O

Morphologic	O	O
response	O	O
to	O	O
chemotherapy	O	O
containing	O	O
bevacizumab	B-arm_description	B-arm_description
in	O	O
patients	O	O
with	O	O
colorectal	O	O
liver	O	O
metastases	O	O
A	O	O
post	B-study_type	B-study_type
hoc	I-study_type	I-study_type
analysis	I-study_type	I-study_type
of	O	O
the	O	O
WJOG4407	O	O
G	O	B-study_type
phase	B-study_type	I-study_type
III	I-study_type	I-study_type
study	I-study_type	I-study_type
Morphologic	O	O
response	O	O
to	O	O
chemotherapy	O	O
containing	O	O
bevacizumab	B-arm_description	B-arm_description
in	O	O
patients	O	O
with	O	O
colorectal	O	O
liver	O	O
metastases	O	O
A	O	O
post	B-study_type	B-study_type
hoc	I-study_type	I-study_type
analysis	I-study_type	I-study_type
of	O	O
the	O	O
WJOG4407	O	O
G	O	B-study_type
phase	B-study_type	I-study_type
III	I-study_type	I-study_type
study	I-study_type	I-study_type
MDAyumuHosokawa	B-authors	B-authors

morphologic	O	O
response	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
or	O	O
OS	O	O
,	O	O
whereas	O	O
RECIST	O	O
response	O	O
was	O	O
significantly	O	O
associated	O	O
with	O	O
both	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
and	O	O
OS	O	O
,	O	O
with	O	O
ETS	O	O
and	O	O
DpR	O	O
being	O	O
associated	O	O
with	O	O
significantly	O	O
longer	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
.	O	O

Länsi	O	O
-	O	O
Pohja	O	O
Central	O	O
Hospital	O	O
Kemi	O	O
Finland	O	O
AnuRäsänen	B-authors	B-authors
Department	O	O
of	O	O
Medicine	O	O
Kymenlaakso	O	O
Central	O	O
Hospital	O	O
Kotka	O	O
Finland	O	O
Department	O	O
of	O	O
Medicine	O	O
Kymenlaakso	O	O
Central	O	O
Hospital	O	O
Kotka	O	O
Finland	O	O
AnuSikiö	B-authors	B-authors
Department	O	O
of	O	O
Medicine	O	O

Helsinki	O	O
University	O	O
Hospital	O	O
and	O	O
University	O	O
of	O	O
Helsinki	O	O
Helsinki	O	O
Finland	O	O
TuomasSelander	B-authors	B-authors
Science	O	O
Service	O	O
Center	O	O
Kuopio	O	O
University	O	O
Hospital	O	O
Kuopio	O	O
Finland	O	O
Science	O	O
Service	O	O
Center	O	O
Kuopio	O	O
University	O	O
Hospital	O	O
Kuopio	O	O
Finland	O	O
Tarja	B-authors	B-authors
-	I-authors	I-authors
TerttuPelliniemi	I-authors	B-authors
Fimlab	O	O
Laboratories	O	O
Ltd	O	O
Tampere	O	O
Finland	O	O
Fimlab	O	O
Laboratories	O	O
Ltd	O	O
Tampere	O	O
Finland	O	O
SorellaIlveskero	B-authors	B-authors

RVD	O	O
induction	O	O
and	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
followed	O	O
by	O	O
lenalidomide	B-arm_description	B-arm_description
maintenance	I-arm_description	O
in	O	O
newly	O	O
diagnosed	O	O
multiple	O	O
myeloma	O	O
:	O	O
a	O	O
phase	B-study_type	B-study_type
2	I-study_type	I-study_type
study	I-study_type	I-study_type
of	O	O
the	O	O
Finnish	O	O
Myeloma	O	O
Group	O	O
SiniLuoma	B-authors	B-authors
Comprehensive	O	O
Cancer	O	O
Center	O	O
Department	O	O
of	O	O
Hematology	O	O

Lenalidomide	O	B-arm_description
maintenance	O	O
after	O	O
ASCT	O	O
prolongs	O	O
progression	O	B-arm_efficacy_metric
-	O	I-arm_efficacy_metric
free	O	I-arm_efficacy_metric
survival	O	I-arm_efficacy_metric
(	O	O
PFS	O	B-arm_efficacy_metric
)	O	O
[	O	O
2][3][4	O	O
]	O	O
and	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
[	O	O
3	O	O
]	O	O
and	O	O
is	O	O
approved	O	O
by	O	O
EMA	O	O
and	O	O
Food	O	O
and	O	O
Drug	O	O
Administration	O	O
(	O	O
FDA	O	O
)	O	O
for	O	O
NDMM	O	O
patients	O	O
after	O	O
ASCT	O	O
until	O	O
progression	O	O
.	O	O
The	O	O
three	O	O
randomized	O	O
controlled	O	O
trials	O	O
(	O	O
RCTs	O	O
)	O	O
evaluating	O	O
lenalidomide	O	O
maintenance	O	O
were	O	O
included	O	O
in	O	O
a	O	O
meta	O	O
-	O	O
analysis	O	O
[	O	O
5	O	O
]	O	O
which	O	O
demonstrated	O	O
a	O	O
significant	O	O
PFS	O	B-arm_efficacy_metric
and	O	O
OS	O	O
benefit	O	O
with	O	O
lenalidomide	O	O
maintenance	O	O
after	O	O
ASCT	O	O
when	O	O
compared	O	O
with	O	O
placebo	O	O
or	O	O
observation	O	O
.	O	O
The	O	O
optimal	O	O
duration	O	O
of	O	O
lenalidomide	O	O
maintenance	O	O
is	O	O
a	O	O
matter	O	O
of	O	O
debate	O	O
.	O	O
In	O	O
Cancer	O	O
and	O	O
Leukemia	O	O
Group	O	O
B	O	O
(	O	O
CALGB	O	O
)	O	O
[	O	O
3	O	O
]	O	O
and	O	O
Intergroupe	O	O
Francophone	O	O
du	O	O
Myelome	O	O
(	O	O
IFM	O	O
)	O	O
[	O	O
2	O	O
]	O	O
trials	O	O
,	O	O
patients	O	O
received	O	O
post	O	O
-	O	O
ASCT	O	O
placebo	O	O
or	O	O
continuous	O	O
lenalidomide	O	O
10	O	O
mg	O	O
for	O	O
3	O	O
months	O	O
escalated	O	O
then	O	O
to	O	O
15	O	O
mg	O	O
,	O	O
until	O	O
disease	O	O
progression	O	O
,	O	O
intolerable	O	O
side	O	O
effects	O	O
,	O	O
or	O	O
death	O	O
.	O	O
The	O	O
IFM	O	O
group	O	O
decided	O	O
to	O	O
stop	O	O
the	O	O
treatment	O	O
in	O	O
the	O	O
lenalidomide	O	O
arm	O	O
due	O	O
to	O	O
the	O	O
noticed	O	O
risk	O	O
of	O	O
secondary	O	O
primary	O	O
malignancies	O	O
(	O	O
SPMs	O	O
)	O	O
in	O	O
opposite	O	O
to	O	O
the	O	O
CALGB	O	O
trial	O	O
where	O	O
patients	O	O
continued	O	O
maintenance	O	O
until	O	O
progression	O	O
.	O	O
Based	O	O
on	O	O
the	O	O
meta	O	O
-	O	O
analysis	O	O
,	O	O
the	O	O
risk	O	O
of	O	O
death	O	O
due	O	O
to	O	O
SPM	O	O
was	O	O
similar	O	O
between	O	O
lenalidomide	O	O
and	O	O
placebo	O	O
or	O	O
observation	O	O
groups	O	O
but	O	O
there	O	O
was	O	O
a	O	O
34	O	O
%	O	O
reduction	O	O
in	O	O
risk	O	O
to	O	O
die	O	O
of	O	O
multiple	O	O
myeloma	O	O
(	O	O
MM	O	O
)	O	O
in	O	O
lenalidomide	O	O
maintenance	O	O
arm	O	O
[	O	O
5	O	O
]	O	O
.	O	O

Mian	O	O
et	O	O
al	O	O
.	O	O
showed	O	O
in	O	O
their	O	O
retrospective	O	O
analysis	O	O
a	O	O
positive	O	O
correlation	O	O
between	O	O
the	O	O
duration	O	O
of	O	O
lenalidomide	O	B-arm_description
maintenance	O	O
and	O	O
OS	O	O
[	O	O
6	O	O
]	O	O
.	O	O
In	O	O
the	O	O
study	O	O
by	O	O
Goldschmidt	O	O
et	O	O
al	O	O
.	O	O
,	O	O
the	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
lenalidomide	O	B-arm_description
maintenance	O	O
for	O	O
2	O	O
years	O	O
or	O	O
until	O	O
CR	O	O
.	O	O
In	O	O
patients	O	O
receiving	O	O
lenalidomide	O	B-arm_description
for	O	O
2	O	O
years	O	O
,	O	O
OS	O	O
was	O	O
higher	O	O
[	O	O
7	O	O
]	O	O
.	O	O

The	O	O
impact	O	O
of	O	O
minimal	O	O
residual	O	O
disease	O	O
(	O	O
MRD	O	O
)	O	O
negativity	O	O
for	O	O
PFS	O	B-arm_efficacy_metric
and	O	O
OS	O	O
has	O	O
been	O	O
demonstrated	O	O
in	O	O
several	O	O
trials	O	O
[	O	O
9][10][11][12][13][14	O	O
]	O	O
and	O	O
it	O	O
is	O	O
also	O	O
recommended	O	O
for	O	O
one	O	O
of	O	O
the	O	O
primary	O	O
endpoints	O	O
for	O	O
evaluating	O	O
the	O	O
approval	O	O
of	O	O
new	O	O
drugs	O	O
for	O	O
MM	O	O
[	O	O
9,15	O	O
]	O	O
.	O	O

Patients	O	O
were	O	O
initially	O	O
treated	O	O
with	O	O
RVD	B-arm_description	O
induction	O	O
comprising	O	O
three	B-arm_dosage	O
21-day	I-arm_dosage	B-arm_dosage
cycles	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	O
lenalidomide	B-arm_description	B-arm_description
25	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
14	I-arm_dosage	I-arm_dosage
;	I-arm_dosage	I-arm_dosage
bortezomib	B-arm_description	B-arm_description
1.3	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
4	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
8	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
and	I-arm_dosage	I-arm_dosage
11	I-arm_dosage	I-arm_dosage
subcutaneously	I-arm_dosage	I-arm_dosage
;	I-arm_dosage	O
and	I-arm_dosage	O
dexamethasone	B-arm_description	O
20	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
4	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
5	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
8	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
9	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	O
and	I-arm_dosage	O
11	I-arm_dosage	O
-	I-arm_dosage	O
12	I-arm_dosage	O
.	O	O
Acyclovir	O	O
and	O	O
enoxaparin	O	O
prophylaxis	O	O
were	O	O
given	O	O
during	O	O
induction	O	O
(	O	O
Online	O	O
Resources	O	O
4	O	O
-	O	O
5	O	O
)	O	O
.	O	O
The	O	O
mobilization	B-arm_description	O
in	O	O
arm	B-arm_description	B-arm_description
A	I-arm_description	I-arm_description
was	O	O
CY	B-arm_dosage	O
2	I-arm_dosage	B-arm_dosage
g	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
+	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
plus	I-arm_dosage	O
filgrastim	I-arm_dosage	O
5	I-arm_dosage	B-arm_dosage
μg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
kg	I-arm_dosage	I-arm_dosage
starting	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
+	I-arm_dosage	I-arm_dosage
4	I-arm_dosage	I-arm_dosage
,	O	O
and	O	O
in	O	O
arm	B-arm_description	B-arm_description
B	I-arm_description	I-arm_description
,	O	O
filgrastim	B-arm_dosage	O
10	I-arm_dosage	B-arm_dosage
μg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
kg	I-arm_dosage	I-arm_dosage
alone	I-arm_dosage	I-arm_dosage
starting	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
+	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
.	O	O
The	O	O
goal	O	O
was	O	O
to	O	O
collect	O	O
at	O	O
least	O	O
3	O	O
×	O	O
10	O	O
6	O	O
/kg	O	O
CD34	O	O
+	O	O
cells	O	O
for	O	O
one	O	O
transplant	O	O
and	O	O
6	O	O
×	O	O
10	O	O
6	O	O
/kg	O	O
if	O	O
the	O	O
second	O	O
transplant	O	O
was	O	O
an	O	O
option	O	O
.	O	O
The	O	O
details	O	O
of	O	O
the	O	O
apheresis	O	O
procedure	O	O
and	O	O
guidelines	O	O
for	O	O
use	O	O
of	O	O
plerixafor	O	O
as	O	O
well	O	O
as	O	O
the	O	O
results	O	O
of	O	O
the	O	O
randomized	O	O
mobilization	O	O
study	O	O
have	O	O
been	O	O
published	O	O
previously	O	O
[	O	O
18	O	O
]	O	O
.	O	O
Patients	O	O
received	O	O
a	O	O
single	O	O
ASCT	B-arm_description	O
after	I-arm_description	O
melphalan	I-arm_description	O
200	B-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
.	O	O

With	O	O
a	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
27	O	O
(	O	O
0	O	O
-	O	O
59	O	O
)	O	O
months	O	O
,	O	O
neither	O	O
median	O	B-arm_efficacy_metric
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
nor	O	O
OS	O	O
have	O	O
been	O	O
reached	O	O
.	O	O
The	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
at	O	O
1	B-arm_efficacy_results	O
,	I-arm_efficacy_results	O
2	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
and	I-arm_efficacy_results	O
3	I-arm_efficacy_results	O
years	I-arm_efficacy_results	O
after	I-arm_efficacy_results	O
inclusion	I-arm_efficacy_results	O
was	I-arm_efficacy_results	O
78	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
67	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
and	I-arm_efficacy_results	O
52	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
,	O	O
and	O	O
OS	O	O
96	O	O
%	O	O
,	O	O
90	O	O
%	O	O
,	O	O
and	O	O
83	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O
Median	O	B-arm_description
EFS	O	B-arm_efficacy_metric
was	O	O
24	O	O
months	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
9	O	O
-	O	O
39	O	O
months	O	O
)	O	O
(	O	O
Fig	O	O
.	O	O
1	O	O
)	O	O
.	O	O
The	O	O
median	B-arm_efficacy_metric	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
for	O	O
the	O	O
Revised	O	O
Multiple	O	O
Myeloma	O	O
International	O	O
Staging	O	O
System	O	O
(	O	O
R	O	O
-	O	O
ISS	O	O
)	O	O
stage	O	O
3	O	O
group	O	O
was	O	O
only	O	O
eight	B-arm_efficacy_results	O
(	I-arm_efficacy_results	O
95	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
CI	I-arm_efficacy_results	O
0	I-arm_efficacy_results	O
-	I-arm_efficacy_results	O
27	I-arm_efficacy_results	O
)	I-arm_efficacy_results	O
months	I-arm_efficacy_results	O
and	O	O
was	O	O
not	O	O
reached	O	O
for	O	O
the	O	O
other	O	O
groups	O	O
.	O	O
For	O	O
the	O	O
patients	O	O
who	O	O
started	O	O
maintenance	B-arm_description	O
(	O	O
N	O	O
=	O	O
54	O	O
)	O	O
,	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
at	O	O
1	B-arm_efficacy_results	O
,	I-arm_efficacy_results	O
2	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
and	I-arm_efficacy_results	O
3	I-arm_efficacy_results	O
years	I-arm_efficacy_results	O
after	I-arm_efficacy_results	O
inclusion	I-arm_efficacy_results	O
was	I-arm_efficacy_results	O
94	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
80	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
,	I-arm_efficacy_results	O
and	I-arm_efficacy_results	O
65	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
and	O	O
OS	O	O
100	O	O
%	O	O
,	O	O
96	O	O
%	O	O
,	O	O
and	O	O
87	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

To	O	O
test	O	O
the	O	O
predictive	O	O
impact	O	O
of	O	O
different	O	O
variables	O	O
on	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
gender	O	O
,	O	O
age	O	O
≤	O	O
or	O	O
>	O	O
65	O	O
years	O	O
,	O	O
study	O	O
arm	O	O
,	O	O
World	O	O
Health	O	O
Organization	O	O
(	O	O
WHO	O	O
)	O	O
performance	O	O
status	O	O
,	O	O
IMWG	O	O
group	O	O
,	O	O
R	O	O
-	O	O
ISS	O	O
,	O	O
ISS	O	O
,	O	O
HR	O	O
cytogenetics	O	O
,	O	O
best	O	O
serological	O	O
response	O	O
(	O	O
sCR	O	O
vs.	O	O
CR	O	O
/	O	O
VGPR	O	O
vs.	O	O
PR	O	O
/	O	O
worse	O	O
)	O	O
,	O	O
and	O	O
achievement	O	O
of	O	O
flow	O	O
-	O	O
MRD	O	O
-	O	O
negativity	O	O
or	O	O
PCR	O	O
-	O	O
negativity	O	O
were	O	O
tested	O	O
with	O	O
multivariate	O	O
analyses	O	O
.	O	O
In	O	O
correlation	O	O
analysis	O	O
,	O	O
there	O	O
proved	O	O
to	O	O
be	O	O
high	O	O
pairwise	O	O
correlations	O	O
,	O	O
between	O	O
0.677	O	O
and	O	O
0.773	O	O
between	O	O
flow	O	O
-	O	O
MRD	O	O
-	O	O
negativity	O	O
,	O	O
PCRnegativity	O	O
,	O	O
and	O	O
serological	O	O
responses	O	O
,	O	O
and	O	O
due	O	O
to	O	O
this	O	O
multicollinearity	O	O
,	O	O
these	O	O
three	O	O
factors	O	O
competed	O	O
for	O	O
the	O	O
same	O	O
predictive	O	O
power	O	O
.	O	O
In	O	O
multivariate	O	O
analysis	O	O
,	O	O
only	O	O
one	O	O
of	O	O
them	O	O
,	O	O
achievement	O	O
of	O	O
flow	O	O
-	O	O
MRD	O	O
-	O	O
negativity	O	O
,	O	O
provided	O	O

Adverse	O	O
events	O	O
(	O	O
AEs	O	O
)	O	O
were	O	O
assessed	O	O
from	O	O
all	O	O
the	O	O
patients	O	O
(	O	O
N	O	O
=	O	O
78	O	O
)	O	O
who	O	O
received	O	O
at	O	O
least	O	O
one	O	O
dose	O	O
of	O	O
trial	O	O
treatment	O	O
.	O	O
Lenalidomide	B-arm_description	B-arm_description
maintenance	I-arm_description	O
AEs	O	O
were	O	O
separately	O	O
assessed	O	O
from	O	O
the	O	O
patients	O	O
(	O	O
N	O	O
=	O	O
54	O	O
)	O	O
who	O	O
received	O	O
at	O	O
least	O	O
one	O	O
dose	O	O
on	O	O
maintenance	B-arm_description	B-arm_description
therapy	O	O
.	O	O

Canada	O	O
Division	O	O
of	O	O
Child	O	O
Neurology	O	O
Department	O	O
of	O	O
Pediatrics	O	O
CHU	O	O
Sainte	O	O
-	O	O
Justine	O	O
Université	O	O
de	O	O
Montréal	O	O
3175	O	O
Chemin	O	O
de	O	O
la	O	O
Côte	O	O
-	O	O
Sainte	O	O
-	O	O
Catherine	O	O
H3	O	O
T	O	O
1C5	O	O
Montreal	O	O
QC	O	O

Canada	O	O
Montreal	O	O
QC	O	O
Canada	O	O
A	O	O
phase	B-study_type	B-study_type
2	I-study_type	I-study_type
study	I-study_type	I-study_type
of	O	O
trametinib	O	O
for	O	O
patients	O	O
with	O	O
pediatric	O	O
glioma	O	O
or	O	O
plexiform	O	O
neurofibroma	O	O
with	O	O
refractory	O	O
tumor	O	O
and	O	O
activation	O	O
of	O	O
the	O	O
MAPK	O	O
/	O	O
ERK	O	O
pathway	O	O
:	O	O
TRAM-01	O	O
10.1186	O	O
/	O	O
s12885	O	O
-	O	O
019	O	O
-	O	O
6442	O	O
-	O	O
2	O	O
Received	O	O
:	O	O
10	O	O
October	O	O
2019	O	O
Accepted	O	O
:	O	O
8	O	O
December	O	O
2019	O	O

Discussion	O	O
:	O	O
Trametinib	O	O
will	O	O
allow	O	O
us	O	O
to	O	O
target	O	O
directly	O	O
and	O	O
specifically	O	O
the	O	O
MAPK	O	O
/	O	O
ERK	O	O
pathway	O	O
.	O	O
We	O	O
expect	O	O
to	O	O
observe	O	O
a	O	O
significant	O	O
response	O	O
in	O	O
most	O	O
patients	O	O
.	O	O
Following	O	O
our	O	O
study	O	O
,	O	O
trametinib	O	O
could	O	O
be	O	O
integrated	O	O
into	O	O
standard	O	O
treatment	O	O
of	O	O
PLGG	O	O
and	O	O
PN	O	O
.	O	O

Pediatric	O	O
low	O	O
-	O	O
grade	O	O
gliomas	O	O
Pediatric	O	O
low	O	O
grade	O	O
gliomas	O	O
(	O	O
PLGG	O	O
)	O	O
which	O	O
include	O	O
pilocytic	O	O
astrocytoma	O	O
(	O	O
PA	O	O
)	O	O
are	O	O
the	O	O
most	O	O
frequent	O	O
brain	O	O
tumors	O	O
and	O	O
represent	O	O
25	O	O
-	O	O
30	O	O
%	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
tumors	O	O
in	O	O
children	O	O
[	O	O
1	O	O
]	O	O
.	O	O
While	O	O
some	O	O
patients	O	O
can	O	O
be	O	O
cured	O	O
with	O	O
surgery	O	O
alone	O	O
,	O	O
more	O	O
than	O	O
70	O	O
%	O	O
need	O	O
complimentary	O	O
treatments	O	O
due	O	O
to	O	O
the	O	O
location	O	O
of	O	O
tumors	O	O
that	O	O
preclude	O	O
resection	O	O
[	O	O
2	O	O
]	O	O
.	O	O
Standard	O	O
therapy	O	O
for	O	O
PLGG	O	O
includes	O	O
chemotherapy	O	O
with	O	O
a	O	O
combination	O	O
of	O	O
intravenous	O	O
carboplatin	O	O
and	O	O
vincristine	O	O
,	O	O
or	O	O
weekly	O	O
vinblastine	O	O
for	O	O
70	O	O
weeks	O	O
.	O	O
Unfortunately	O	O
,	O	O
more	O	O
than	O	O
50	O	O
%	O	O
of	O	O
patients	O	O
will	O	O
have	O	O
progressive	O	O
disease	O	O
despite	O	O
conventional	O	O
treatment(s	O	O
)	O	O
[	O	O
3	O	O
]	O	O
[	O	O
4	O	O
]	O	O
.	O	O
Radiotherapy	O	O
remains	O	O
an	O	O
option	O	O
,	O	O
but	O	O
this	O	O
approach	O	O
has	O	O
significant	O	O
long	O	O
-	O	O
term	O	O
side	O	O
effects	O	O
including	O	O
cognitive	O	O
dysfunction	O	O
,	O	O
endocrinopathies	O	O
and	O	O
vasculopathies	O	O
[	O	O
5	O	O
]	O	O
.	O	O
Several	O	O
clinical	O	O
trials	O	O
have	O	O
focused	O	O
on	O	O
treatments	O	O
of	O	O
refractory	O	O
PLGG	O	O
but	O	O
have	O	O
failed	O	O
to	O	O
show	O	O
significant	O	O
efficacy	O	O
and	O	O
there	O	O
is	O	O
currently	O	O
no	O	O
standard	O	O
therapy	O	O
.	O	O

The	O	O
BRAF	O	O
V600E	O	O
mutation	O	O
lies	O	O
in	O	O
the	O	O
kinase	O	O
domain	O	O
and	O	O
results	O	O
in	O	O
a	O	O
constitutive	O	O
activation	O	O
of	O	O
the	O	O
MAPK	O	O
/	O	O
ERK	O	O
pathway	O	O
.	O	O
The	O	O
V600E	O	O
mutation	O	O
is	O	O
positive	O	O
in	O	O
5	O	O
-	O	O
10	O	O
%	O	O
of	O	O
PA	O	O
usually	O	O
involving	O	O
the	O	O
brainstem	O	O
and	O	O
deep	O	O
gray	O	O
nuclei	O	O
[	O	O
11	O	O
]	O	O
[	O	O
12	O	O
]	O	O
.	O	O

Recently	O	O
,	O	O
phase	O	B-study_type
I	O	I-study_type
and	O	I-study_type
II	O	I-study_type
study	O	I-study_type
with	O	O
selumetinib	O	B-arm_description
(	O	O
another	O	O
MEK	O	O
inhibitor	O	O
)	O	O
showed	O	O
promising	O	O
antitumor	O	O
activity	O	O
in	O	O
PLGG	O	O
[	O	O
22	O	O
]	O	O
[	O	O
23	O	O
]	O	O
and	O	O
Dombi	O	O
et	O	O
al	O	O
.	O	O
demonstrated	O	O
dramatic	O	O
responses	O	O
in	O	O
patients	O	O
with	O	O
PN	O	O
treated	O	O
with	O	O
selumetinib	O	O
[	O	O
24	O	O
]	O	O
.	O	O
However	O	O
,	O	O
this	O	O
agent	O	O
is	O	O
still	O	O
under	O	O
investigation	O	O
,	O	O
is	O	O
not	O	O
available	O	O
in	O	O
Canada	O	O
and	O	O
has	O	O
not	O	O
been	O	O
approved	O	O
yet	O	O
for	O	O
treatment	O	O
of	O	O
PN	O	O
or	O	O
PLGG	O	O
.	O	O

Total	O	O
leukocytes	O	O
≥3000	O	O
/	O	O
μL	O	O
Absolute	O	O
neutrophil	O	O
count	O	O
(	O	O
ANC	O	O
)	O	O
≥	O	O
1000	O	O
/	O	O
μL	O	O
Hemoglobin	O	O
>	O	O
80	O	O
g	O	O
/	O	O
l	O	O
(	O	O
transfusion	O	O
independent	O	O
within	O	O
last	O	O
2	O	O
weeks	O	O
)	O	O
Platelet	O	O
count	O	O
≥100,000	O	O
/	O	O
μL	O	O
(	O	O
transfusion	O	O
independent	O	O
within	O	O
last	O	O
2	O	O
weeks	O	O
)	O	O
Total	O	O
bilirubin	O	O
≤1	O	O
.	O	O
5	O	O

To	O	O
document	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
of	O	O
patients	O	O
,	O	O
the	O	O
PedsQL	O	O
Generic	O	O
scale	O	O
and	O	O
Brain	O	O
Tumor	O	O
module	O	O
[	O	O
32][33][34	O	O
]	O	O
.	O	O
The	O	O
measures	O	O
are	O	O
available	O	O
over	O	O
the	O	O
age	O	O
span	O	O
with	O	O
an	O	O
infant	O	O
scale	O	O
for	O	O
patients	O	O
under	O	O
2	O	O
years	O	O
will	O	O
be	O	O
used	O	O
to	O	O
assess	O	O
the	O	O
physical	O	O
,	O	O
mental	O	O
,	O	O
social	O	O
health	O	O
dimensions	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
cognitive	O	O
development	O	O
of	O	O
children	O	O
[	O	O
35	O	O
]	O	O
.	O	O
The	O	O
PedsQL	O	O
integrates	O	O
the	O	O
generic	O	O
and	O	O
disease	O	O
-	O	O
specific	O	O
approaches	O	O
with	O	O
child	O	O
selfreports	O	O
and	O	O
parent	O	O
proxy	O	O
-	O	O
reports	O	O
[	O	O
36	O	O
]	O	O
.	O	O
Thus	O	O
,	O	O
both	O	O
questionnaires	O	O
will	O	O
be	O	O
completed	O	O
by	O	O
the	O	O
patient	O	O
and	O	O
one	O	O
caregiver	O	O
.	O	O

An	O	O
independent	O	O
and	O	O
outside	O	O
ARO	O	O
(	O	O
academic	O	O
research	O	O
organization	O	O
)	O	O
,	O	O
Exactis	O	O
Innovation	O	O
,	O	O
has	O	O
been	O	O
assigned	O	O
for	O	O
the	O	O
management	O	O
of	O	O
this	O	O
study	O	O
.	O	O
Exactis	O	O
will	O	O
be	O	O
responsible	O	O
for	O	O
overseeing	O	O
the	O	O
regulatory	O	O
aspects	O	O
and	O	O
,	O	O
monitoring	O	O
of	O	O
sites	O	O
,	O	O
verify	O	O
compliance	O	O
and	O	O
conduct	O	O
site	O	O
visits	O	O
.	O	O

A	O	O
Data	O	O
Monitoring	O	O
Committee	O	O
(	O	O
DMC	O	O
)	O	O
will	O	O
receive	O	O
and	O	O
review	O	O
the	O	O
progress	O	O
and	O	O
accrual	O	O
data	O	O
of	O	O
this	O	O
trial	O	O
and	O	O
will	O	O
safeguard	O	O
the	O	O
interests	O	O
of	O	O
trial	O	O
participants	O	O
,	O	O
periodically	O	O
review	O	O
and	O	O
evaluate	O	O
the	O	O
accumulated	O	O
study	O	O
data	O	O
for	O	O
participant	O	O
safety	O	O
and	O	O
efficacy	O	O
and	O	O
monitor	O	O
the	O	O
progress	O	O
and	O	O
overall	O	O
conduct	O	O
of	O	O
the	O	O
clinical	O	O
trial	O	O
.	O	O
The	O	O
DMC	O	O
has	O	O
access	O	O
to	O	O
quarterly	O	O
study	O	O
reports	O	O
,	O	O
raw	O	O
study	O	O
data	O	O
so	O	O
that	O	O
they	O	O
can	O	O
see	O	O
any	O	O
emerging	O	O
risks	O	O
such	O	O
as	O	O
frequent	O	O
or	O	O
severe	O	O
adverse	O	O
events	O	O
.	O	O

Trifluridine	O	B-arm_description
/	O	O
tipiracil	O	O
(	O	O
TAS-102	O	O
)	O	O
is	O	O
a	O	O
novel	O	O
,	O	O
oral	O	O
combination	O	O
comprising	O	O
the	O	O
thymidine	O	O
-	O	O
based	O	O
nucleoside	O	O
analog	O	O
trifluridine	O	O
and	O	O
tipiracil	O	O
hydrochloride	O	O
at	O	O
a	O	O
molar	O	O
ratio	O	O
of	O	O
1:0.5	O	O
.	O	O
Trifluridine	O	O
is	O	O
incorporated	O	O
into	O	O
DNA	O	O
after	O	O
phosphorylation	O	O
by	O	O
thymidine	O	O
kinase	O	O
1	O	O
(	O	O
TK1	O	O
)	O	O
.	O	O
We	O	O
previously	O	O
reported	O	O
results	O	O
from	O	O
a	O	O
randomized	O	B-study_type
phase	O	B-study_type
2	O	I-study_type
study	O	I-study_type
of	O	O
trifluridine	O	O
/	O	O
tipiracil	O	O
(	O	O
J003	O	O
-	O	O
10040030	O	O
)	O	O
,	O	O
and	O	O
this	O	O
therapy	O	O
was	O	O
first	O	O
approved	O	O
in	O	O
Japan	O	O
in	O	O
2014	O	O
[	O	O
8	O	O
]	O	O
.	O	O
More	O	O
recently	O	O
,	O	O
the	O	O
international	O	O
phase	O	B-study_type
3	O	I-study_type
RECOURSE	O	O
trial	O	O
has	O	O
demonstrated	O	O
a	O	O
more	O	O
significant	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
benefit	O	O
of	O	O
trifluridine/	O	O
tipiracil	O	O
compared	O	O
with	O	O
placebo	O	O
,	O	O
with	O	O
acceptable	O	O
toxicity	O	O
,	O	O
in	O	O
patients	O	O
with	O	O
refractory	O	O
mCRC	O	O
[	O	O
7	O	O
]	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
the	O	O
Asian	O	O
phase	O	B-study_type
3	O	I-study_type
TERRA	O	O
trial	O	O
has	O	O
reported	O	O
the	O	O
survival	O	O
benefit	O	O
and	O	O
safety	O	O
of	O	O
trifluridine	O	O
/	O	O
tipiracil	O	O
in	O	O
Asian	O	O
population	O	O
[	O	O
9	O	O
]	O	O
.	O	O
Based	O	O
on	O	O
these	O	O
findings	O	O
,	O	O
trifluridine	O	O
/	O	O
tipiracil	O	O
has	O	O
been	O	O
approved	O	O
by	O	O
many	O	O
countries	O	O
and	O	O
regions	O	O
including	O	O
the	O	O
US	O	O
Food	O	O
and	O	O
Drug	O	O
Administration	O	O
and	O	O
European	O	O
Medicines	O	O
Agency	O	O
.	O	O

Clinical	O	O
data	O	O
of	O	O
patients	O	O
with	O	O
mCRC	O	O
who	O	O
received	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
plus	O	I-arm_description
bevacizumab	B-arm_description	B-arm_description
or	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
monotherapy	O	I-arm_description
at	O	O
the	O	O
National	O	O
Cancer	O	O
Center	O	O
Hospital	O	O
East	O	O
was	O	O
retrospectively	B-study_type	O
collected	O	O
.	O	O
Study	O	O
protocol	O	O
was	O	O
approved	O	O
by	O	O
the	O	O
institutional	O	O
review	O	O
board	O	O
.	O	O
Informed	O	O
consent	O	O
requirement	O	O
was	O	O
waived	O	O
due	O	O
to	O	O
the	O	O
study	O	O
's	O	O
observational	B-study_type	O
retrospective	I-study_type	O
design	I-study_type	O
,	O	O
with	O	O
an	O	O
opt	O	O
-	O	O
out	O	O
opportunity	O	O
provided	O	O
at	O	O
the	O	O
institution	O	O
's	O	O
website	O	O
.	O	O
Patient	O	O
follow	O	O
-	O	O
up	O	O
was	O	O
performed	O	O
until	O	O
December	O	O
2018	O	O
.	O	O

Trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
plus	O	I-arm_description
bevacizumab	O	B-arm_description
regimen	O	O
consisted	O	O
of	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
35	B-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	I-arm_dosage
body	I-arm_dosage	O
surface	I-arm_dosage	O
area	I-arm_dosage	O
,	I-arm_dosage	O
given	I-arm_dosage	B-arm_dosage
orally	I-arm_dosage	I-arm_dosage
twice	I-arm_dosage	I-arm_dosage
a	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
5	I-arm_dosage	I-arm_dosage
and	I-arm_dosage	I-arm_dosage
8	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
12	I-arm_dosage	I-arm_dosage
in	I-arm_dosage	I-arm_dosage
a	I-arm_dosage	I-arm_dosage
28-day	I-arm_dosage	I-arm_dosage
cycle	I-arm_dosage	I-arm_dosage
,	O	O
and	O	O
bevacizumab	B-arm_description	B-arm_description
5	B-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
kg	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	I-arm_dosage
bodyweight	I-arm_dosage	O
,	O	O
administered	O	O
by	O	O
intravenous	O	O
infusion	O	O
every	B-arm_dosage	B-arm_dosage
2	I-arm_dosage	I-arm_dosage
weeks	I-arm_dosage	I-arm_dosage
.	O	O
Trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
monotherapy	O	O
consisted	O	O
of	O	O
trifluridine/	B-arm_description	B-arm_description
tipiracil	I-arm_description	I-arm_description
35	B-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	I-arm_dosage
body	I-arm_dosage	O
surface	I-arm_dosage	O
area	I-arm_dosage	O
,	O	O
given	O	B-arm_dosage
orally	O	I-arm_dosage
twice	B-arm_dosage	I-arm_dosage
a	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
5	I-arm_dosage	I-arm_dosage
and	I-arm_dosage	I-arm_dosage
8	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
12	I-arm_dosage	I-arm_dosage
in	I-arm_dosage	I-arm_dosage
a	I-arm_dosage	I-arm_dosage
28-day	I-arm_dosage	I-arm_dosage
cycle	I-arm_dosage	I-arm_dosage
.	O	O

Median	O	B-arm_description
OS	O	O
was	O	O
8.6	O	B-arm_efficacy_results
months	O	I-arm_efficacy_results
(	O	I-arm_efficacy_results
95	O	I-arm_efficacy_results
%	O	I-arm_efficacy_results
CI	O	I-arm_efficacy_results
6.9	O	I-arm_efficacy_results
-	O	I-arm_efficacy_results
10.3	O	I-arm_efficacy_results
months	O	I-arm_efficacy_results
)	O	O
for	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
plus	O	I-arm_description
bevacizumab	B-arm_description	B-arm_description
and	O	O
8.0	O	O
months	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
6.6	O	O
-	O	O
9.4	O	O
months	O	O
)	O	O
for	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
monotherapy	O	O
(	O	O
Fig	O	O
.	O	O
1b	O	O
)	O	O
.	O	O
In	O	O
multivariate	O	O
analysis	O	O
,	O	O
an	O	O
OS	O	O
benefit	O	O
was	O	O
also	O	O
observed	O	O
for	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
plus	O	I-arm_description
bevacizumab	B-arm_description	B-arm_description
compared	O	O
with	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
monotherapy	O	O
,	O	O
but	O	O
without	O	O
statistical	O	O
significance	O	O
(	O	O
HR	O	O
0.74	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
0.48	O	O
-	O	O
1.14	O	O
;	O	O
log	O	O
-	O	O
rank	O	O
p	O	O
=	O	O
0.164	O	O
)	O	O
.	O	O
Similarly	O	O
to	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
longer	O	O
OS	O	O
was	O	O
observed	O	O
for	O	O
all	O	O
subgroups	O	O
,	O	O
except	O	O
ECOG	O	O
PS	O	O
.	O	O

Three	O	O
patients	O	O
in	O	O
the	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
plus	O	I-arm_description
bevacizumab	B-arm_description	B-arm_description
group	I-arm_description	I-arm_description
and	O	O
one	O	O
patient	O	O
in	O	O
the	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
monotherapy	O	I-arm_description
group	O	I-arm_description
had	O	O
partial	O	O
response	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
5.0	O	O
and	O	O
1.5	O	O
%	O	O
ORR	O	O
for	O	O
each	O	O
group	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
=	O	O
0.35	O	O
)	O	O
.	O	O
Disease	O	O
control	O	O
was	O	O
achieved	O	O
in	O	O
32	O	O
patients	O	O
(	O	O
53.3	O	O
%	O	O
)	O	O
in	O	O
the	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
plus	O	I-arm_description
bevacizumab	B-arm_description	B-arm_description
group	I-arm_description	I-arm_description
and	O	O
in	O	O
30	O	O
patients	O	O
(	O	O
45.5	O	O
%	O	O
)	O	O
in	O	O
the	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	B-arm_description	I-arm_description
monotherapy	O	I-arm_description
group	O	I-arm_description
(	O	O
p	O	O
=	O	O
0.48	O	O
)	O	O
(	O	O
Table	O	O
3	O	O
)	O	O
.	O	O
Additionally	O	O
,	O	O
proportion	O	O
of	O	O
patients	O	O
with	O	O
6	O	O
months	O	O
or	O	O
longer	O	O
of	O	O
disease	O	O
control	O	O
were	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
plus	O	I-arm_description
bevacizumab	B-arm_description	I-arm_description
group	I-arm_description	I-arm_description
than	O	O
the	O	O
trifluridine	B-arm_description	B-arm_description
/	I-arm_description	I-arm_description
tipiracil	I-arm_description	I-arm_description
monotherapy	O	I-arm_description
group	O	I-arm_description
(	O	O
26.7	O	O
%	O	O
vs.	O	O
12.1	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.04	O	O
)	O	O
.	O	O

Multicenter	B-study_type	B-study_type
,	I-study_type	I-study_type
randomised	I-study_type	I-study_type
,	I-study_type	I-study_type
open	I-study_type	I-study_type
-	I-study_type	I-study_type
label	I-study_type	I-study_type
,	I-study_type	I-study_type
non	I-study_type	I-study_type
-	I-study_type	I-study_type
comparative	I-study_type	I-study_type
phase	I-study_type	I-study_type
2	I-study_type	I-study_type
trial	I-study_type	I-study_type
on	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
the	O	O
combination	O	O
of	O	O
bevacizumab	B-arm_description	B-arm_description
and	I-arm_description	O
trabectedin	I-arm_description	O
with	O	O
or	O	O
without	O	O
carboplatin	B-arm_efficacy_metric	O
in	O	O
women	O	O
with	O	O
partially	O	O
platinum	O	O
-	O	O
sensitive	O	O
recurrent	O	O
ovarian	O	O
cancer	O	O
20	O	O
September	O	O
2019	O	O

Secondary	O	O
objectives	O	O
of	O	O
the	O	O
study	O	O
were	O	O
progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
(	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
)	O	O
,	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
,	O	O
and	O	O
the	O	O
toxicity	O	O
profile	O	O
.	O	O
The	O	O
secondary	O	O
efficacy	O	O
endpoints	O	O
were	O	O
evaluated	O	O
in	O	O
the	O	O
PP	O	O
population	O	O
.	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
defined	O	O
as	O	O
the	O	O
time	O	O
between	O	O
study	O	O
entry	O	O
and	O	O
progression	O	O
or	O	O
death	O	O
for	O	O
any	O	O
cause	O	O
.	O	O
Subjects	O	O
with	O	O
no	O	O
recurrence	O	O
or	O	O
who	O	O
died	O	O
while	O	O
on	O	O
study	O	O
were	O	O
censored	O	O
at	O	O
the	O	O
last	O	O
disease	O	O
assessment	O	O
date	O	O
.	O	O
OS	O	O
was	O	O
defined	O	O
as	O	O
the	O	O
time	O	O
between	O	O
the	O	O
study	O	O
entry	O	O
and	O	O
death	O	O
,	O	O
regardless	O	O
of	O	O
the	O	O
cause	O	O
of	O	O
death	O	O
.	O	O
Subjects	O	O
who	O	O
were	O	O
not	O	O
reported	O	O
as	O	O
having	O	O
died	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
analysis	O	O
were	O	O
censored	O	O
at	O	O
the	O	O
date	O	O
they	O	O
were	O	O
last	O	O
known	O	O
to	O	O
be	O	O
alive	O	O
.	O	O
Survival	O	O
curves	O	O
were	O	O
estimated	O	O
by	O	O
the	O	O
Kaplan	O	O
-	O	O
Meier	O	O
(	O	O
KM	O	O
)	O	O
method	O	O
.	O	O

From	O	O
July	O	O
2013	O	O
through	O	O
March	O	O
2016	O	O
,	O	O
21	O	O
patients	O	O
were	O	O
randomised	O	O
to	O	O
the	O	O
BT+C	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
.	O	O
Figure	O	O
2	O	O
shows	O	O
the	O	O
flow	O	O
-	O	O
chart	O	O
and	O	O
the	O	O
populations	O	O
for	O	O
primary	O	O
and	O	O
secondary	O	O
analyses	O	O
.	O	O
Table	O	O
1	O	O
lists	O	O
the	O	O
clinical	O	O
characteristics	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
no	O	O
major	O	O
violations	O	O
of	O	O
eligibility	O	O
criteria	O	O
.	O	O
Median	O	O
age	O	O
was	O	O
59.4	O	O
years	O	O
(	O	O
range	O	O
54.0	O	O
-	O	O
66.1	O	O
)	O	O
at	O	O
study	O	O
entry	O	O
;	O	O
17	O	O
(	O	O
85	O	O
%	O	O
)	O	O
patients	O	O
were	O	O
facing	O	O
their	O	O
first	O	O
progression	O	O
of	O	O
disease	O	O
and	O	O
the	O	O
other	O	O
3	O	O
(	O	O
15	O	O
%	O	O
)	O	O
the	O	O
second	O	O
.	O	O
The	O	O
median	O	O
platinumfree	O	O
interval	O	O
from	O	O
the	O	O
previous	O	O
platinum	O	O
-	O	O
based	O	O
therapy	O	O
was	O	O
8.2	O	O
months	O	O
(	O	O
IQR	O	O
:	O	O
6.6	O	O
-	O	O
10.7	O	O
;	O	O
range	O	O
6.1	O	O
-	O	O
12.8	O	O
)	O	O
.	O	O

In	O	O
the	O	O
PP	O	O
population	O	O
,	O	O
CR	O	O
was	O	O
observed	O	O
in	O	O
9	O	O
(	O	O
45	O	O
%	O	O
)	O	O
and	O	O
PR	O	O
in	O	O
8	O	O
(	O	O
40	O	O
%	O	O
)	O	O
patients	O	O
.	O	O
Three	O	O
patients	O	O
(	O	O
15	O	O
%	O	O
)	O	O
reached	O	O
SD	O	O
and	O	O
none	O	O
progressed	O	O
at	O	O
the	O	O
first	O	O
disease	O	O
assessment	O	O
.	O	O

Efficacy	O	O
and	O	O
safety	O	O
for	O	O
the	O	O
first	O	O
stage	O	O
are	O	O
illustrated	O	O
in	O	O
Table	O	O
2	O	O
.	O	O
The	O	O
BT+C	B-arm_description	B-arm_description
arm	I-arm_description	O
was	O	O
not	O	O
expanded	O	O
to	O	O
second	O	O
stage	O	O
on	O	O
account	O	O
of	O	O
excessive	O	O
toxicity	O	O
.	O	O

Epithelial	O	O
tubo	O	O
-	O	O
ovarian	O	O
cancer	O	O
(	O	O
ETOC	O	O
)	O	O
is	O	O
the	O	O
deadliest	O	O
cancer	O	O
among	O	O
women	O	O
,	O	O
placing	O	O
with	O	O
fourth	O	O
place	O	O
of	O	O
all	O	O
the	O	O
fetal	O	O
diseases	O	O
among	O	O
women	O	O
and	O	O
ranking	O	O
seventh	O	O
of	O	O
most	O	O
common	O	O
cancers	O	O
in	O	O
women	O	O
's	O	O
cancer	O	O
and	O	O
women	O	O
's	O	O
cancer	O	O
-	O	O
related	O	O
deaths	O	O
in	O	O
Taiwan	O	O
and	O	O
globally	O	O
in	O	O
2018	O	O
[	O	O
1][2][3][4][5][6	O	O
]	O	O
.	O	O
Serous	O	O
-	O	O
type	O	O
is	O	O
the	O	O
most	O	O
common	O	O
subtype	O	O
among	O	O
EOCs	O	O
in	O	O
general	O	O
;	O	O
however	O	O
,	O	O
endometriosis	O	O
-	O	O
associated	O	O
EOCs	O	O
,	O	O
such	O	O
as	O	O
clear	O	O
cell	O	O
type	O	O
or	O	O
endometrioid	O	O
type	O	O
are	O	O
relatively	O	O
common	O	O
in	O	O
certain	O	O
populations	O	O
,	O	O
including	O	O
Taiwan	O	O
and	O	O
Japan	O	O
[	O	O
7][8][9][10][11	O	O
]	O	O
.	O	O
Clinically	O	O
,	O	O
the	O	O
serous	O	O
-	O	O
type	O	O
EOC	O	O
and	O	O
primary	O	O
peritoneal	O	O
serous	O	O
carcinoma	O	O
(	O	O
PPSC	O	O
)	O	O
and	O	O
primary	O	O
Fallopian	O	O
tube	O	O
cancer	O	O
(	O	O
PFTC	O	O
)	O	O
are	O	O
often	O	O
considered	O	O
the	O	O
same	O	O
group	O	O
disease	O	O
,	O	O
based	O	O
on	O	O
the	O	O
similar	O	O
clinical	O	O
behavior	O	O
and	O	O
possibly	O	O
sharing	O	O
the	O	O
similar	O	O
pathogenesis	O	O
[	O	O
12][13][14][15][16][17][18	O	O
]	O	O
.	O	O
In	O	O
1996	O	O
,	O	O
McGuire	O	O
and	O	O
colleagues	O	O
conducted	O	O
a	O	O
clinical	O	O
trial	O	O
to	O	O
set	O	O
up	O	O
the	O	O
standard	O	O
therapy	O	O
for	O	O
patients	O	O
with	O	O
ETOC	O	O
,	O	O
including	O	O
primary	O	O
debulking	O	O
surgery	O	O
(	O	O
PDS	O	O
)	O	O
,	O	O
also	O	O
called	O	O
primary	O	O
cytoreductive	O	O
surgery	O	O
(	O	O
PCS	O	O
)	O	O
plus	O	O
adjuvant	O	O
triweekly	O	O
paclitaxel	O	O
and	O	O
cisplatin	O	O
therapy	O	O
[	O	O
19	O	O
]	O	O
.	O	O
The	O	O
following	O	O
studies	O	O
have	O	O
confirmed	O	O
the	O	O
superiority	O	O
of	O	O
survival	O	O
benefits	O	O
using	O	O
paclitaxel	O	O
into	O	O
cisplatin	O	O
-	O	O
based	O	O
regimens	O	O
in	O	O
place	O	O
of	O	O
cyclophosphamide	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
ETOC	O	O
and	O	O
PPSC	O	O
[	O	O
20,21	O	O
]	O	O
.	O	O
Additionally	O	O
,	O	O
carboplatin	O	O
in	O	O
place	O	O
of	O	O
cisplatin	O	O
in	O	O
this	O	O
combination	O	O
has	O	O
statistically	O	O
significantly	O	O
reduced	O	O
the	O	O
cisplatin	O	O
-	O	O
related	O	O
potential	O	O
toxicity	O	O
of	O	O
neural	O	O
and	O	O
renal	O	O
systems	O	O
and	O	O
ameliorated	O	O
the	O	O
cisplatin	O	O
-	O	O
related	O	O
high	O	O
emetic	O	O
effects	O	O
[	O	O
22][23][24][25	O	O
]	O	O
.	O	O

Based	O	O
on	O	O
the	O	O
relative	O	O
worse	O	O
prognosis	O	O
of	O	O
advanced	O	O
-	O	O
stage	O	O
ETOC	O	O
and	O	O
PPSC	O	O
,	O	O
many	O	O
new	O	O
modalities	O	O
and	O	O
strategies	O	O
have	O	O
been	O	O
recently	O	O
developed	O	O
[	O	O
56][57][58][59	O	O
]	O	O
.	O	O
Although	O	O
some	O	O
of	O	O
them	O	O
have	O	O
been	O	O
already	O	O
recommended	O	O
by	O	O
updated	O	O
NCCN	O	O
guidelines	O	O
for	O	O
ETOC	O	O
and	O	O
PPSC	O	O
treatment	O	O
[	O	O
4,26	O	O
]	O	O
,	O	O
they	O	O
are	O	O
not	O	O
widely	O	O
used	O	O
in	O	O
the	O	O
routine	O	O
clinical	O	O
practice	O	O
[	O	O
60	O	O
]	O	O
.	O	O
Among	O	O
these	O	O
,	O	O
induction	O	O
chemotherapy	O	O
(	O	O
neoadjuvant	O	O
chemotherapy	O	O
-	O	O
NACT	O	O
)	O	O
using	O	O
either	O	O
standard	O	O
form	O	O
of	O	O
paclitaxel	O	O
and	O	O
carboplatin	O	O
or	O	O
its	O	O
modification	O	O
form	O	O
,	O	O
including	O	O
dose	O	O
-	O	O
dense	O	O
or	O	O
high	O	O
-	O	O
dose	O	O
chemotherapy	O	O
,	O	O
and	O	O
in	O	O
additional	O	O
adding	O	O
bevacizumab	O	O
,	O	O
has	O	O
become	O	O
more	O	O
and	O	O
more	O	O
popular	O	O
,	O	O
especially	O	O
for	O	O
those	O	O
patients	O	O
who	O	O
are	O	O
not	O	O
candidates	O	O
for	O	O
immediate	O	O
PCS	O	O
[	O	O
61][62][63][64][65][66][67][68][69	O	O
]	O	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
application	O	O
of	O	O
a	O	O
combination	O	O
of	O	O
taxane	O	O
and	O	O
platinum	O	O
in	O	O
ETOC	O	O
has	O	O
been	O	O
conducted	O	O
.	O	O
In	O	O
the	O	O
management	O	O
of	O	O
all	O	O
chemosensitive	O	O
epithelial	O	O
cancers	O	O
,	O	O
combination	O	O
chemotherapy	O	O
treatment	O	O
has	O	O
provided	O	O
significant	O	O
survival	O	O
benefits	O	O
compared	O	O
to	O	O
single	O	O
agent	O	O
chemotherapy	O	O
when	O	O
applied	O	O
as	O	O
initial	O	O
therapy	O	O
,	O	O
and	O	O
there	O	O
is	O	O
no	O	O
doubt	O	O
that	O	O
the	O	O
treatment	O	O
of	O	O
ETOC	O	O
is	O	O
similar	O	O
in	O	O
this	O	O
regard	O	O
[	O	O
121	O	O
]	O	O
.	O	O
Studies	O	O
showed	O	O
that	O	O
combination	O	O
of	O	O
taxane	O	O
and	O	O
platinum	O	O
compound	O	O
appears	O	O
both	O	O
to	O	O
attenuate	O	O
the	O	O
toxicity	O	O
of	O	O
the	O	O
platinum	O	O
compound	O	O
and	O	O
to	O	O
facilitate	O	O
the	O	O
delivery	O	O
of	O	O
full	O	O
dose	O	O
on	O	O
schedule	O	O
and	O	O
this	O	O
full	O	O
dose	O	O
on	O	O
schedule	O	O
showed	O	O
the	O	O
strong	O	O
correlation	O	O
with	O	O
patient	O	O
outcomes	O	O
[	O	O
110	O	O
]	O	O
.	O	O
Since	O	O
both	O	O
platinum	O	O
and	O	O
paclitaxel	O	O
are	O	O
the	O	O
essential	O	O
cytotoxic	O	O
agents	O	O
in	O	O
ETOC	O	O
patients	O	O
after	O	O
PCS	O	O
,	O	O
either	O	O
any	O	O
one	O	O
or	O	O
both	O	O
can	O	O
be	O	O
administered	O	O
as	O	O
dose	O	O
-	O	O
dense	O	O
protocol	O	O
.	O	O
Furthermore	O	O
,	O	O
dose	O	O
-	O	O
dense	O	O
can	O	O
be	O	O
classified	O	O
according	O	O
to	O	O
the	O	O
types	O	O
,	O	O
including	O	O
semiweekly	O	O
dose	O	O
-	O	O
dense	O	O
,	O	O
in	O	O
which	O	O
paclitaxel	O	O
was	O	O
given	O	O
weekly	O	O
and	O	O
carboplatin	O	O
was	O	O
given	O	O
triweekly	O	O
,	O	O
and	O	O
weekly	O	O
dose	O	O
dense	O	O
,	O	O
in	O	O
which	O	O
both	O	O
paclitaxel	O	O
and	O	O
carboplatin	O	O
were	O	O
given	O	O
weekly	O	O
[	O	O
47	O	O
]	O	O
.	O	O
An	O	O
accumulation	O	O
dose	O	O
of	O	O
paclitaxel	O	O
is	O	O
240	O	O
-	O	O
270	O	O
mg	O	O
/	O	O
m	O	O
2	O	O
with	O	O
separating	O	O
into	O	O
80	O	O
-	O	O
90	O	O
mg	O	O
/	O	O
m	O	O
2	O	O
per	O	O
week	O	O
compared	O	O
to	O	O
a	O	O
single	O	O
use	O	O
of	O	O
175	O	O
-	O	O
180	O	O
mg	O	O
/	O	O
m	O	O
2	O	O
every	O	O
three	O	O
weeks	O	O
.	O	O
By	O	O
contrast	O	O
,	O	O
the	O	O
dosage	O	O
of	O	O
carboplatin	O	O
seems	O	O
to	O	O
be	O	O
consistent	O	O
with	O	O
accumulation	O	O
dose	O	O
as	O	O
AUC	O	O
5	O	O
-	O	O
7	O	O
,	O	O
regardless	O	O
of	O	O
administration	O	O
triweekly	O	O
(	O	O
a	O	O
single	O	O
use	O	O
of	O	O
AUC	O	O
5	O	O
-	O	O
7	O	O
)	O	O
or	O	O
weekly	O	O
(	O	O
AUC	O	O
2	O	O
)	O	O
.	O	O

In	O	O
order	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
and	O	O
safety	O	O
of	O	O
dose	O	O
-	O	O
dense	O	O
of	O	O
paclitaxel	B-arm_description	O
combining	B-arm_description	O
with	O	O
either	O	O
cisplatin	O	B-arm_description
or	O	O
carboplatin	B-arm_description	O
,	O	O
the	O	O
following	O	O
retrospective	B-study_type	O
study	I-study_type	O
was	O	O
conducted	O	O
.	O	O
Patients	O	O
with	O	O
FIGO	O	O
IIIC	O	O
serous	O	O
-	O	O
type	O	O
ETOC	O	O
and	O	O
PPSC	O	O
treated	O	O
either	O	O
with	O	O
triweekly	B-arm_dosage	O
cisplatin	B-arm_description	O
(	I-arm_dosage	O
20	I-arm_dosage	O
mg	I-arm_dosage	O
/	I-arm_dosage	O
m	I-arm_dosage	O
2	I-arm_dosage	O
)	I-arm_dosage	O
plus	B-arm_description	O
dose	I-arm_dosage	O
-	I-arm_dosage	O
dense	I-arm_dosage	O
weekly	I-arm_dosage	O
paclitaxel	B-arm_description	O
(	I-arm_dosage	O
80	I-arm_dosage	O
mg	I-arm_dosage	O
/	I-arm_dosage	O
m	I-arm_dosage	O
2	I-arm_dosage	O
)	I-arm_dosage	O
or	O	O
triweekly	B-arm_dosage	O
carboplatin	I-arm_dosage	O
(	I-arm_dosage	O
AUC	I-arm_dosage	O
5	I-arm_dosage	O
)	I-arm_dosage	O
plus	I-arm_dosage	O
dose	I-arm_dosage	O
-	I-arm_dosage	O
dense	I-arm_dosage	O
weekly	I-arm_dosage	O
paclitaxel	I-arm_dosage	O
(	I-arm_dosage	O
80	I-arm_dosage	O
mg	I-arm_dosage	O
/	I-arm_dosage	O
m	I-arm_dosage	O
2	I-arm_dosage	O
)	I-arm_dosage	O
as	O	O
postoperative	O	O
adjuvant	O	O
chemotherapy	O	O
after	O	O
PCS	O	O
were	O	O
retrospectively	O	O
reviewed	O	O
.	O	O
However	O	O
,	O	O
nearly	O	O
all	O	O
dose	O	O
-	O	O
dense	O	O
paclitaxel	B-arm_description	O
-	O	O
platinum	O	O
combination	O	O
chemotherapy	O	O
regimens	O	O
used	O	O
as	O	O
the	O	O
front	O	O
-	O	O
line	O	O
postoperative	O	O
adjuvant	O	O
therapy	O	O
are	O	O
focused	O	O
on	O	O
the	O	O
dose	O	O
-	O	O
dense	O	O
paclitaxel	B-arm_description	O
,	O	O
without	O	O
consideration	O	O
of	O	O
either	O	O
the	O	O
platinum	O	O
compounds	O	O
or	O	O
the	O	O
dose	O	O
-	O	O
dense	O	O
agents	O	O
.	O	O

All	O	O
patients	O	O
underwent	O	O
PCS	O	O
initially	O	O
and	O	O
then	O	O
were	O	O
treated	O	O
with	O	O
weekly	O	O
paclitaxel	B-arm_description	B-arm_description
(	I-arm_dosage	O
80	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
)	I-arm_dosage	I-arm_dosage
plus	B-arm_description	O
either	I-arm_dosage	O
triweekly	I-arm_dosage	O
cisplatin	B-arm_description	B-arm_description
(	I-arm_dosage	O
20	I-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
)	I-arm_dosage	O
or	O	O
triweekly	B-arm_dosage	B-arm_description
carboplatin	B-arm_description	O
(	I-arm_dosage	O
AUC	I-arm_dosage	O
5	I-arm_dosage	O
)	I-arm_dosage	O
.	O	O
Paclitaxel	B-arm_description	B-arm_description
was	I-arm_dosage	O
administered	I-arm_dosage	O
over	I-arm_dosage	O
2	I-arm_dosage	B-arm_dosage
h	I-arm_dosage	I-arm_dosage
intravenously	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
8	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
and	I-arm_dosage	I-arm_dosage
15	I-arm_dosage	I-arm_dosage
,	O	O
and	B-arm_dosage	O
either	O	O
cisplatin	B-arm_description	B-arm_description
for	I-arm_dosage	O
1	I-arm_dosage	B-arm_dosage
h	I-arm_dosage	I-arm_dosage
or	O	O
carboplatin	B-arm_description	B-arm_description
for	I-arm_dosage	O
1	I-arm_dosage	B-arm_dosage
h	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
was	I-arm_dosage	O
infused	I-arm_dosage	O
intravenously	I-arm_dosage	O
.	O	O
Premedication	O	O
including	O	O
dexamethasone	O	O
(	O	O
20	O	O
mg	O	O
)	O	O
,	O	O
2000	O	O
ml	O	O
of	O	O
normal	O	O
saline	O	O
,	O	O
and	O	O
palonosetron	O	O
(	O	O
250	O	O
ug	O	O
)	O	O
was	O	O
prescribed	O	O
intravenously	O	O
during	O	O
the	O	O
chemotherapy	O	O
therapy	O	O
day	O	O
.	O	O
When	O	O
grade	O	O
3/4	O	O
neutropenia	O	O
occurred	O	O
,	O	O
the	O	O
patients	O	O
were	O	O
treated	O	O
with	O	O
granulocyte	O	O
colony	O	O
-	O	O
stimulating	O	O
factor	O	O
(	O	O
GCSF	O	O
)	O	O
for	O	O
three	O	O
days	O	O
before	O	O
chemotherapy	O	O
.	O	O
However	O	O
,	O	O
treatment	O	O
was	O	O
delayed	O	O
if	O	O
febrile	O	O
neutropenia	O	O
or	O	O
grade	O	O
3/4	O	O
neutropenia	O	O
without	O	O
correction	O	O
was	O	O
noted	O	O
.	O	O
If	O	O
a	O	O
three	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
liver	O	O
enzymes	O	O
of	O	O
patients	O	O
was	O	O
detected	O	O
,	O	O
paclitaxel	B-arm_description	O
(	I-arm_dosage	O
60	I-arm_dosage	O
mg	I-arm_dosage	O
/	I-arm_dosage	O
m	I-arm_dosage	O
2	I-arm_dosage	O
)	I-arm_dosage	O
was	O	O
used	O	O
.	O	O
The	O	O
cisplatin	B-arm_description	O
dose	O	O
was	O	O
decreased	O	O
to	O	O
half	O	O
dosage	O	O
if	O	O
the	O	O
estimated	O	O
glomerular	O	O
filtration	O	O
rate	O	O
(	O	O
eGFR	O	O
)	O	O
was	O	O
decreased	O	O
to	O	O
45	O	O
-	O	O
60	O	O
ml	O	O
/	O	O
min	O	O
,	O	O
which	O	O
was	O	O
calculated	O	O
using	O	O
the	O	O
Cockcroft	O	O
-	O	O
Gault	O	O
formula	O	O
[	O	O
122][123][124	O	O
]	O	O
.	O	O

During	O	O
the	O	O
whole	O	O
study	O	O
period	O	O
with	O	O
a	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
time	O	O
of	O	O
55	O	O
months	O	O
(	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
data	O	O
cutoff	O	O
on	O	O
30	O	O
June	O	O
2019	O	O
)	O	O
,	O	O
disease	O	O
progression	O	O
and/or	O	O
disease	O	O
-	O	O
related	O	O
death	O	O
occurred	O	O
in	O	O
23	O	O
patients	O	O
(	O	O
57.5	O	O
%	O	O
)	O	O
.	O	O
As	O	O
was	O	O
presented	O	O
in	O	O
Figure	O	O
1	O	O
,	O	O
the	O	O
median	B-arm_efficacy_metric	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
25.0	B-arm_efficacy_results	O
months	I-arm_efficacy_results	O
in	O	O
patients	O	O
treated	O	O
with	O	O
the	O	O
paclitaxel	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
carboplatin	I-arm_description	I-arm_description
regimen	O	O
,	O	O
and	O	O
30.0	B-arm_efficacy_results	O
months	I-arm_efficacy_results	O
in	O	O
patients	O	O
treated	O	O
with	O	O
the	O	O
paclitaxel	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
cisplatin	I-arm_description	I-arm_description
regimen	O	O
,	O	O
without	O	O
a	O	O
statistically	O	O
significant	O	O
difference	O	O
.	O	O
The	O	O
median	O	O
OS	O	O
was	O	O
55.0	O	O
months	O	O
and	O	O
58.5	O	O
months	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
paclitaxel	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
carboplatin	I-arm_description	I-arm_description
and	O	O
paclitaxel	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
cisplatin	I-arm_description	I-arm_description
regimens	O	O
,	O	O
respectively	O	O
(	O	O
Figure	O	O
2	O	O
)	O	O
.	O	O
There	O	O
was	O	O
also	O	O
no	O	O
statistically	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O
Table	O	O
2	O	O
.	O	O
Adverse	O	O
events	O	O
the	O	O
patients	O	O
with	O	O
FIGO	O	O
IIIC	O	O
serous	O	O
type	O	O
epithelial	O	O
tubo	O	O
-	O	O
ovarian	O	O
cancer	O	O
,	O	O
or	O	O
primary	O	O
peritoneal	O	O
carcinoma	O	O
treated	O	O
with	O	O
weekly	O	O
paclitaxel	B-arm_description	O
(	I-arm_dosage	O
80	I-arm_dosage	O
mg	I-arm_dosage	O
/	I-arm_dosage	O
m	I-arm_dosage	O
2	I-arm_dosage	O
)	I-arm_dosage	O
plus	O	O
either	O	O
carboplatin	B-arm_description	B-arm_description
(	I-arm_dosage	O
AUC	I-arm_dosage	O
5	I-arm_dosage	O
)	I-arm_dosage	O
or	O	O
cisplatin	B-arm_description	O
(	I-arm_dosage	O
20mg	I-arm_dosage	O
/	I-arm_dosage	O
m	I-arm_dosage	O
2	I-arm_dosage	O
)	I-arm_dosage	O
combination	O	O
chemotherapy	O	O
triweekly	B-arm_dosage	O
.	O	O

Addressing	O	O
Dose	O	O
-	O	O
Dense	O	O
therapy	O	O
:	O	O
Survival	O	O
Outcome	O	O
(	O	O
Table	O	O
5	O	O
)	O	O
Some	O	O
early	O	O
phase	O	O
studies	O	O
have	O	O
also	O	O
been	O	O
conducted	O	O
to	O	O
test	O	O
the	O	O
tolerability	O	O
and	O	O
efficacy	O	O
of	O	O
dose	O	O
-	O	O
dense	O	O
weekly	O	O
paclitaxel	B-arm_description	O
(	I-arm_dosage	O
80	I-arm_dosage	O
mg	I-arm_dosage	O
/	I-arm_dosage	O
m	I-arm_dosage	O
2	I-arm_dosage	O
)	I-arm_dosage	O
and	O	O
triweekly	O	O
carboplatin	B-arm_description	O
(	I-arm_dosage	O
AUC	I-arm_dosage	O
5	O	O
)	O	O
with	O	O
other	O	O
agents	O	O
[	O	O
132,133	O	O
]	O	O
.	O	O
For	O	O
example	O	O
,	O	O
one	O	O
phase	O	O
II	O	O
study	O	O
modified	O	O
a	O	O
dose	O	O
-	O	O
dense	O	O
paclitaxel	O	O
(	O	O
80	O	O
mg	O	O
/	O	O
m	O	O
2	O	O
)	O	O
and	O	O
carboplatin	O	O
(	O	O
AUC	O	O
5	O	O
)	O	O
every	O	O
four	O	O
weeks	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
advanced	O	O
-	O	O
stage	O	O
ETOC	O	O
patients	O	O
,	O	O
and	O	O
found	O	O
that	O	O
the	O	O
median	O	B-arm_efficacy_metric
PFS	O	B-arm_efficacy_metric
and	O	O
OS	O	O
were	O	O
22.5	O	O
and	O	O
31.5	O	O
months	O	O
,	O	O
respectively	O	O
[	O	O
132	O	O
]	O	O
.	O	O
Another	O	O
phase	O	O
II	O	O
study	O	O
adding	O	O
bevacizumab	O	B-arm_description
in	O	O
dose	O	O
-	O	O
dense	O	O
chemotherapy	O	O
(	O	O
weekly	O	O
paclitaxel	O	O
80	O	O
mg	O	O
/	O	O
m	O	O
2	O	O
and	O	O
triweekly	O	O
carboplatin	O	O
AUC	O	O
5	O	O
)	O	O
showed	O	O
that	O	O
the	O	O
median	O	B-arm_efficacy_metric
PFS	O	B-arm_efficacy_metric
was	O	O
16.9	O	O
-	O	O
22.4	O	O
months	O	O
in	O	O
advanced	O	O
-	O	O
stage	O	O
ETOC	O	O
patients	O	O
[	O	O
133	O	O
]	O	O
.	O	O

Consistent	O	O
with	O	O
the	O	O
increased	O	O
toxicity	O	O
of	O	O
the	O	O
use	O	O
of	O	O
carboplatin	O	O
in	O	O
previous	O	O
studies	O	O
[	O	O
136	O	O
]	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
grade	O	O
3/4	O	O
neutropenia	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
cisplatin	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
paclitaxel	I-arm_description	I-arm_description
arm	O	I-arm_description
than	O	O
in	O	O
that	O	O
of	O	O
the	O	O
carboplatin	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
paclitaxel	I-arm_description	I-arm_description
arm	O	I-arm_description
(	O	O
27.8	O	O
%	O	O
versus	O	O
77.3	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.002	O	O
)	O	O
in	O	O
our	O	O
study	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
other	O	O
parameters	O	O
of	O	O
hematological	O	O
examination	O	O
,	O	O
including	O	O
grade	O	O
3/4	O	O
anemia	O	O
and	O	O
grade	O	O
3/4	O	O
thrombocytopenia	O	O
also	O	O
favored	O	O
the	O	O
cisplatin	B-arm_description	O
-	I-arm_description	O
paclitaxel	I-arm_description	O
regimen	O	O
with	O	O
incidence	O	O
of	O	O
5.6	O	O
%	O	O
and	O	O
none	O	O
,	O	O
respectively	O	O
,	O	O
compared	O	O
to	O	O
22.7	O	O
%	O	O
and	O	O
13.6	O	O
%	O	O
in	O	O
the	O	O
carboplatin	B-arm_description	O
-	I-arm_description	O
paclitaxel	I-arm_description	O
regimen	O	O
in	O	O
the	O	O
current	O	O
study	O	O
.	O	O
We	O	O
believe	O	O
that	O	O
this	O	O
carboplatin	B-arm_description	O
-	I-arm_description	O
paclitaxel	I-arm_description	O
combination	O	O
therapy	O	O
-	O	O
related	O	O
hematotoxicity	O	O
might	O	O
explain	O	O
why	O	O
more	O	O
patients	O	O
in	O	O
the	O	O
carboplatin	B-arm_description	O
-	I-arm_description	O
paclitaxel	I-arm_description	O
arm	O	O
had	O	O
a	O	O
prolongation	O	O
of	O	O
the	O	O
period	O	O
between	O	O
the	O	O
initial	O	O
first	O	O
dose	O	O
of	O	O
chemotherapy	O	O
and	O	O
the	O	O
final	O	O
dose	O	O
of	O	O
chemotherapy	O	O
(	O	O
six	O	O
cycles	O	O
of	O	O
chemotherapy	O	O
)	O	O
than	O	O
those	O	O
in	O	O
the	O	O
cisplatin	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
paclitaxel	I-arm_description	I-arm_description
arm	O	I-arm_description
(	O	O
45	O	O
%	O	O
versus	O	O
11.1	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0.018	O	O
)	O	O
.	O	O
Further	O	O
survival	O	O
analysis	O	O
showed	O	O
that	O	O
this	O	O
prolongation	O	O
of	O	O
the	O	O
therapeutic	O	O
period	O	O
might	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
worse	O	O
outcome	O	O
in	O	O
FIGO	O	O
IIIC	O	O
ETOC	O	O
and	O	O
PPSC	O	O
patients	O	O
.	O	O

The	O	O
current	O	O
study	O	O
has	O	O
the	O	O
following	O	O
strengths	O	O
:	O	O
All	O	O
patients	O	O
were	O	O
serous	O	O
-	O	O
type	O	O
ETOC	O	O
and	O	O
PPSC	O	O
with	O	O
FIGO	O	O
stage	O	O
IIIC	O	O
.	O	O
The	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
was	O	O
long	O	O
enough	O	O
,	O	O
of	O	O
nearly	O	O
5	O	O
years	O	O
(	O	O
a	O	O
mean	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
of	O	O
55	O	O
months	O	O
)	O	O
.	O	O
All	O	O
patients	O	O
were	O	O
treated	O	O
with	O	O
by	O	O
one	O	O
senior	O	O
doctor	O	O
(	O	O
P.-H.W	O	O
)	O	O
.	O	O
All	O	O
the	O	O
suggested	O	O
study	O	O
population	O	O
was	O	O
homogeneous	O	O
.	O	O

Squamous	O	O
cell	O	O
lung	O	O
cancer	O	O
(	O	O
SCC	O	O
)	O	O
accounts	O	O
for	O	O
approximately	O	O
20%-30	O	O
%	O	O
of	O	O
all	O	O
lung	O	O
cancers	O	O
.	O	O
However	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
notable	O	O
advances	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
metastatic	O	O
non	O	O
-	O	O
SCC	O	O
due	O	O
to	O	O
genetic	O	O
alterations	O	O
,	O	O
the	O	O
first	O	O
-	O	O
line	O	O
treatment	O	O
of	O	O
SCC	O	O
has	O	O
not	O	O
necessarily	O	O
been	O	O
established	O	O
.	O	O
Although	O	O
the	O	O
efficacy	O	O
of	O	O
immune	O	O
checkpoint	O	O
inhibitors	O	O
has	O	O
been	O	O
previously	O	O
demonstrated	O	O
,	O	O
platinum	O	O
-	O	O
based	O	O
cytotoxic	O	O
therapy	O	O
is	O	O
still	O	O
considered	O	O
a	O	O
cornerstone	O	O
of	O	O
the	O	O
treatment	O	O
of	O	O
SCC	O	O
.	O	O
1	O	O
In	O	O
clinical	O	O
practice	O	O
,	O	O
the	O	O
conventional	O	O
regimens	O	O
for	O	O
SCC	O	O
include	O	O
a	O	O
combination	O	O
of	O	O
cisplatin	O	O
or	O	O
carboplatin	O	O
with	O	O
taxanes	O	O
,	O	O
gemcitabine	O	O
,	O	O
and	O	O
S-1	O	O
based	O	O
chemotherapy	O	O
.	O	O
However	O	O
,	O	O
the	O	O
median	O	O
overall	O	O
survival	O	O
remains	O	O
approximately	O	O
12	O	O
-	O	O
17	O	O
months	O	O
,	O	O
regardless	O	O
of	O	O
the	O	O
occurrence	O	O
of	O	O
severe	O	O
adverse	O	O
events	O	O
.	O	O
[	O	O
2][3][4][5][6][7	O	O
]	O	O
Therefore	O	O
,	O	O
a	O	O
novel	O	O
combination	O	O
of	O	O
anticancer	O	O
agents	O	O
leading	O	O
to	O	O
fewer	O	O
severe	O	O
adverse	O	O
events	O	O
is	O	O
required	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
SCC	O	O
patients	O	O
.	O	O

This	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
accordance	O	O
with	O	O
the	O	O
Declaration	O	O
of	O	O
Helsinki	O	O
.	O	O
The	O	O
study	O	O
protocol	O	O
was	O	O
reviewed	O	O
and	O	O
approved	O	O
by	O	O
the	O	O
institutional	O	O
review	O	O
boards	O	O
of	O	O
the	O	O
participating	O	O
institutions	O	O
,	O	O
and	O	O
a	O	O
written	O	O
informed	O	O
consent	O	O
was	O	O
obtained	O	O
from	O	O
all	O	O
patients	O	O
.	O	O
This	O	O
trial	O	O
was	O	O
registered	O	O
with	O	O
University	O	O
Hospital	O	O
Medical	O	O
Information	O	O
Network	O	O
(	O	O
UMIN000003282	O	O
)	O	O
.	O	O

All	O	O
patients	O	O
received	O	O
nedaplatin	B-arm_description	B-arm_description
(	O	O
100	B-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
)	O	I-arm_dosage
intravenously	B-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
and	O	O
amrubicin	B-arm_description	B-arm_description
(	O	O
25	B-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
)	O	I-arm_dosage
on	B-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
3	I-arm_dosage	I-arm_dosage
every	I-arm_dosage	I-arm_dosage
4	I-arm_dosage	I-arm_dosage
weeks	I-arm_dosage	I-arm_dosage
.	O	O
Each	O	O
patient	O	O
received	O	O
a	O	O
minimum	B-arm_dosage	O
of	I-arm_dosage	O
three	I-arm_dosage	O
cycles	I-arm_dosage	O
until	O	O
the	O	O
onset	O	O
of	O	O
a	O	O
progressive	O	O
disease	O	O
or	O	O
unacceptable	O	O
toxicity	O	O
.	O	O
The	O	O
maximal	O	O
number	O	O
of	O	O
chemotherapy	O	O
cycles	O	O
was	O	O
six	O	O
;	O	O
however	O	O
,	O	O
the	O	O
patients	O	O
underwent	O	O
more	O	O
cycles	O	O
,	O	O
if	O	O
necessary	O	O
.	O	O

The	O	O
response	O	O
was	O	O
investigator	O	O
-	O	O
determined	O	O
according	O	O
to	O	O
RECIST	O	O
version	O	O
1.1	O	O
.	O	O
All	O	O
adverse	O	O
events	O	O
were	O	O
recorded	O	O
and	O	O
classified	O	O
by	O	O
grade	O	O
according	O	O
to	O	O
the	O	O
Common	O	O
Terminology	O	O
Criteria	O	O
for	O	O
Adverse	O	O
Events	O	O
(	O	O
CTCAE	O	O
)	O	O
version	O	O
4.0	O	O
.	O	O

PRISM	O	O
protocol	O	O
:	O	O
a	O	O
randomised	B-study_type	B-study_type
phase	I-study_type	B-study_type
II	I-study_type	I-study_type
trial	I-study_type	I-study_type
of	O	O
nivolumab	B-arm_description	B-arm_description
in	O	O
combination	O	O
with	O	O
alternatively	O	O
scheduled	O	O
ipilimumab	B-arm_description	B-arm_description
in	O	O
firstline	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
advanced	O	O
or	O	O
metastatic	O	O
renal	O	O
cell	O	O
carcinoma	O	O

Leeds	O	O
Institute	O	O
of	O	O
Medical	O	O
Research	O	O
at	O	O
St	O	O
James	O	O
's	O	O
,	O	O
St.	O	O
James	O	O
's	O	O
University	O	O
Hospital	O	O
Beckett	O	O
Street	O	O
LS9	O	O
7TF	O	O
Leeds	O	O
UK	O	O
GalinaVelikova	B-authors	B-authors
University	O	O
of	O	O
Leeds	O	O
LS9	O	O
7TF	O	O
Leeds	O	O
UK	O	O
TomWaddell	B-authors	B-authors

UK	O	O
RosamondeEBanks	B-authors	B-authors
Rosamonde	B-authors	B-authors
E	I-authors	B-authors
Banks	I-authors	B-authors
Leeds	O	O
Institute	O	O
of	O	O
Medical	O	O
Research	O	O
at	O	O
St	O	O
James	O	O
's	O	O
,	O	O
St.	O	O
James	O	O
's	O	O
University	O	O
Hospital	O	O
Beckett	O	O
Street	O	O
LS9	O	O
7TF	O	O
Leeds	O	O

UK	O	O
Beckett	O	O
Street	O	O
LS9	O	O
7TF	O	O
Leeds	O	O
UK	O	O
Leeds	O	O
Institute	O	O
of	O	O
Medical	O	O
Research	O	O
at	O	O
St	O	O
James	O	O
's	O	O
,	O	O
St.	O	O
James	O	O
's	O	O
University	O	O
Hospital	O	O
Beckett	O	O
Street	O	O
LS9	O	O
7TF	O	O
Leeds	O	O

Kidney	O	O
cancer	O	O
is	O	O
the	O	O
14th	O	O
most	O	O
common	O	O
cancer	O	O
worldwide	O	O
with	O	O
an	O	O
estimated	O	O
400,000	O	O
new	O	O
cases	O	O
,	O	O
and	O	O
175,000	O	O
attributable	O	O
deaths	O	O
,	O	O
in	O	O
2018	O	O
[	O	O
1	O	O
]	O	O
.	O	O
The	O	O
majority	O	O
of	O	O
kidney	O	O
cancers	O	O
(	O	O
90	O	O
%	O	O
)	O	O
are	O	O
renal	O	O
cell	O	O
carcinomas	O	O
(	O	O
RCC	O	O
)	O	O
,	O	O
most	O	O
of	O	O
which	O	O
(	O	O
75	O	O
%	O	O
)	O	O
are	O	O
of	O	O
the	O	O
clear	O	O
cell	O	O
subtype	O	O
[	O	O
2	O	O
]	O	O
.	O	O

Studies	O	O
in	O	O
other	O	O
cancer	O	O
types	O	O
demonstrate	O	O
ipilimumab	O	B-arm_description
dose	O	O
and	O	O
/	O	O
or	O	O
frequency	O	O
can	O	O
affect	O	O
the	O	O
toxicity	O	O
and	O	O
efficacy	O	O
of	O	O
treatment	O	O
.	O	O
In	O	O
advanced	O	O
melanoma	O	O
,	O	O
for	O	O
example	O	O
,	O	O
10	O	B-arm_dosage
mg/	O	I-arm_dosage
kg	O	I-arm_dosage
ipilimumab	O	B-arm_description
every	O	O
3	O	B-arm_dosage
weeks	O	I-arm_dosage
for	O	I-arm_dosage
4	O	I-arm_dosage
doses	O	I-arm_dosage
was	O	O
associated	O	O
with	O	O
longer	O	O
median	O	O
OS	O	O
but	O	O
higher	O	O
rates	O	O
of	O	O
grade	O	O
3	O	O
or	O	O
4	O	O
toxicity	O	O
,	O	O
in	O	O
comparison	O	O
to	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
dosing	O	O
[	O	O
10	O	O
]	O	O
.	O	O
A	O	O
recently	O	O
reported	O	O
melanoma	O	O
trial	O	O
comparing	O	O
I3	O	O
+	O	O
N1	O	O
versus	O	O
I1	O	O
+	O	O
N3	O	O
again	O	O
showed	O	O
a	O	O
favourable	O	O
toxicity	O	O
profile	O	O
associated	O	O
with	O	O
a	O	O
lower	O	O
dose	O	O
of	O	O
ipilimumab	O	B-arm_description
,	O	O
with	O	O
no	O	O
apparent	O	O
difference	O	O
in	O	O
efficacy	O	O
at	O	O
a	O	O
minimum	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
12	O	O
months	O	O
[	O	O
11	O	O
]	O	O
.	O	O
Varying	O	O
doses	O	O
and	O	O
schedules	O	O
of	O	O
ipilimumab	O	B-arm_description
plus	O	O
nivolumab	O	B-arm_description
have	O	O
also	O	O
been	O	O
examined	O	O
amongst	O	O
8	O	O
cohorts	O	O
within	O	O
the	O	O
phase	O	B-study_type
Ib	O	I-study_type
CM012	O	I-study_type
study	O	I-study_type
in	O	O
patients	O	O
with	O	O
nonsmall	O	O
cell	O	O
lung	O	O
cancer	O	O
,	O	O
including	O	O
nivolumab	O	B-arm_description
3	O	B-arm_dosage
mg	O	I-arm_dosage
/	O	I-arm_dosage
kg	O	I-arm_dosage
q2W	O	I-arm_dosage
plus	O	O
ipilimumab	O	B-arm_description
1	O	B-arm_dosage
mg	O	I-arm_dosage
/	O	I-arm_dosage
kg	O	I-arm_dosage
given	O	O
either	O	O
6-(n	O	O
=	O	O
39	O	O
)	O	O
or	O	O
12-(n	O	O
=	O	O
38	O	O
)	O	O
weekly	O	O
[	O	O
12	O	O
]	O	O
.	O	O
The	O	O
schedule	O	O
N3	O	O
(	O	O
2-weekly	O	O
)	O	O
+	O	O
I1	O	O
(	O	O
6weekly	O	O
)	O	O
was	O	O
selected	O	O
for	O	O
phase	O	O
III	O	O
evaluation	O	O
based	O	O
on	O	O
its	O	O
safety	O	O
and	O	O
efficacy	O	O
profile	O	O
[	O	O
13	O	O
]	O	O
.	O	O
Thus	O	O
,	O	O
formal	O	O
investigation	O	O
of	O	O
the	O	O
scheduling	O	O
of	O	O
ipilimumab	O	B-arm_description
when	O	O
given	O	O
in	O	O
combination	O	O
with	O	O
nivolumab	O	B-arm_description
in	O	O
patients	O	O
with	O	O
mRCC	O	O
is	O	O
warranted	O	O
.	O	O

The	O	O
primary	O	O
aim	O	O
of	O	O
the	O	O
PRISM	O	O
trial	O	O
is	O	O
to	O	O
assess	O	O
whether	O	O
the	O	O
proposed	O	O
alternative	O	O
scheduling	O	O
of	O	O
ipilimumab	B-arm_description	B-arm_description
(	O	O
12-weekly	O	O
)	O	O
,	O	O
when	O	O
given	O	O
in	O	O
combination	O	O
with	O	O
nivolumab	B-arm_description	B-arm_description
,	O	O
warrants	O	O
further	O	O
consideration	O	O
based	O	O
on	O	O
safety	O	O
and	O	O
efficacy	O	O
,	O	O
as	O	O
defined	O	O
by	O	O
the	O	O
proportion	O	O
of	O	O
participants	O	O
experiencing	O	O
a	O	O
grade	O	O
3	O	O
or	O	O
4	O	O
adverse	O	O
reaction	O	O
(	O	O
AR	O	O
)	O	O
within	O	O
12	O	O
months	O	O
and	O	O
12-month	O	O
progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
(	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
)	O	O
.	O	O

We	O	O
expect	O	O
approximately	O	O
40	O	O
%	O	O
of	O	O
participants	O	O
to	O	O
experience	O	O
a	O	O
grade	O	O
3	O	O
or	O	O
4	O	O
AR	O	O
within	O	O
the	O	O
initial	O	O
12	O	O
months	O	O
of	O	O
treatment	O	O
when	O	O
treated	O	O
with	O	O
the	O	O
standard	O	O
schedule	O	O
(	O	O
Arm	B-arm_description	B-arm_description
B	I-arm_description	I-arm_description
)	O	O
[	O	O
18	O	O
]	O	O
.	O	O
To	O	O
detect	O	O
a	O	O
clinically	O	O
relevant	O	O
reduction	O	O
to	O	O
22	O	O
%	O	O
with	O	O
the	O	O
modified	O	O
schedule	O	O
(	O	O
Arm	B-arm_description	B-arm_description
A	I-arm_description	I-arm_description
)	O	O
(	O	O
equivalent	O	O
to	O	O
a	O	O
45	O	O
%	O	O
relative	O	O
reduction	O	O
;	O	O
odds	O	O
ratio	O	O
(	O	O
OR	O	O
)	O	O
=	O	O
0.423	O	O
)	O	O
,	O	O
with	O	O
80	O	O
%	O	O
power	O	O
at	O	O
the	O	O
two	O	O
-	O	O
sided	O	O
10	O	O
%	O	O
significance	O	O
level	O	O
,	O	O
would	O	O
require	O	O
178	O	O
participants	O	O
,	O	O
allowing	O	O
for	O	O
5	O	O
%	O	O
attrition	O	O
.	O	O

Randomisation	O	O
will	O	O
be	O	O
performed	O	O
following	O	O
confirmation	O	O
of	O	O
eligibility	O	O
(	O	O
and	O	O
prior	O	O
to	O	O
any	O	O
trial	O	O
treatment	O	O
)	O	O
via	O	O
a	O	O
central	O	O
automated	O	O
24-h	O	O
system	O	O
(	O	O
provided	O	O
by	O	O
University	O	O
of	O	O
Leeds	O	O
)	O	O
to	O	O
either	O	O
the	O	O
modified	O	O
schedule	O	O
or	O	O
the	O	O
standard	O	O
schedule	O	O
on	O	O
a	O	O
2:1	O	O
allocation	O	O
ratio	O	O
in	O	O
favour	O	O
of	O	O
the	O	O
modified	O	O
schedule	O	O
.	O	O
A	O	O
computer	O	O
-	O	O
generated	O	O
minimisation	O	O
programme	O	O
incorporating	O	O
a	O	O
random	O	O
element	O	O
generated	O	O
by	O	O
the	O	O
independent	O	O
CTRU	O	O
Statisticians	O	O
will	O	O
be	O	O
used	O	O
to	O	O
ensure	O	O
treatment	O	O
groups	O	O
are	O	O
well	O	O
balanced	O	O
proportionately	O	O
with	O	O
respect	O	O
to	O	O
:	O	O
IMDC	O	O
prognostic	O	O
group	O	O
(	O	O
favourable	O	O
/	O	O
intermediate	O	O
/	O	O
poor	O	O
risk	O	O
)	O	O
;	O	O
nephrectomy	O	O
status	O	O
(	O	O
nephrectomy	O	O
/	O	O
no	O	O
nephrectomy	O	O
)	O	O
;	O	O
and	O	O
disease	O	O
type	O	O
(	O	O
metastatic	O	O
/	O	O
locally	O	O
advanced	O	O
)	O	O
.	O	O
Irrespective	O	O
of	O	O
their	O	O
randomised	O	O
allocation	O	O
,	O	O
participants	O	O
should	O	O
commence	O	O
therapy	O	O
within	O	O
14	O	O
days	O	O
of	O	O
randomisation	O	O
.	O	O

Participants	O	O
who	O	O
have	O	O
undergone	O	O
any	O	O
prior	O	O
systemic	O	O
anti	O	O
-	O	O
cancer	O	O
treatment	O	O
,	O	O
including	O	O
with	O	O
an	O	O
anti	O	O
-	O	O
PD-1	O	O
,	O	O
anti	O	O
-	O	O
PD	O	O
-	O	O
L1	O	O
,	O	O
anti	O	O
-	O	O
PD	O	O
-	O	O
L2	O	O
,	O	O
anti	O	O
-	O	O
CTLA-4	O	O
antibody	O	O
,	O	O
or	O	O
any	O	O
other	O	O
antibody	O	O
or	O	O
drug	O	O
specifically	O	O
targeting	O	O
T	O	O
-	O	O
cell	O	O
co	O	O
-	O	O
stimulation	O	O
or	O	O
immune	O	O
checkpoint	O	O
pathways	O	O
(	O	O
previous	O	O
participation	O	O
in	O	O
adjuvant	O	O
studies	O	O
allowed	O	O
,	O	O
providing	O	O
the	O	O
patient	O	O
was	O	O
on	O	O
the	O	O
observation	O	O
/	O	O
placebo	O	B-arm_description
armthis	O	O
may	O	O
require	O	O
unblinding	O	O
of	O	O
the	O	O
patient	O	O
)	O	O
Patients	O	O
should	O	O
be	O	O
excluded	O	O
if	O	O
they	O	O
have	O	O
a	O	O
condition	O	O
requiring	O	O
systemic	O	O
treatment	O	O
with	O	O
either	O	O
corticosteroids	O	O
(	O	O
>	O	O
10	O	O
mg	O	O
daily	O	O
prednisone	O	O
or	O	O
equivalent	O	O
)	O	O
or	O	O
other	O	O
immunosuppressive	O	O
medications	O	O
within	O	O
14	O	O
days	O	O
of	O	O
study	O	O
drug	O	O
administration	O	O
.	O	O
(	O	O
Inhaled	O	O
or	O	O
topical	O	O
steroids	O	O
and	O	O
adrenal	O	O
replacement	O	O
doses	O	O
>	O	O
10	O	O
mg	O	O
daily	O	O
prednisone	O	O
equivalents	O	O
are	O	O
permitted	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
active	O	O
autoimmune	O	O
disease	O	O
)	O	O
.	O	O

Analyses	O	O
will	O	O
be	O	O
conducted	O	O
following	O	O
modified	O	O
intention	O	O
-	O	O
to	O	O
-	O	O
treat	O	O
principles	O	O
(	O	O
unless	O	O
otherwise	O	O
stated	O	O
a	O	O
priori	O	O
)	O	O
meaning	O	O
participants	O	O
will	O	O
be	O	O
analysed	O	O
in	O	O
the	O	O
group	O	O
to	O	O
which	O	O
they	O	O
were	O	O
randomised	O	O
regardless	O	O
of	O	O
compliance	O	O
or	O	O
cross	O	O
-	O	O
over	O	O
.	O	O
Participants	O	O
will	O	O
be	O	O
included	O	O
in	O	O
the	O	O
primary	O	O
and	O	O
key	O	O
secondary	O	O
analyses	O	O
provided	O	O
they	O	O
have	O	O
received	O	O
at	O	O
least	O	O
one	O	O
dose	O	O
of	O	O
trial	O	O
treatment	O	O
and	O	O
have	O	O
provided	O	O
the	O	O
relevant	O	O
outcome	O	O
data	O	O
.	O	O

Concordance	O	O
of	O	O
real	O	O
-	O	O
world	O	O
versus	O	O
conventional	O	O
progression	O	B-arm_efficacy_metric
-	O	I-arm_efficacy_metric
free	O	I-arm_efficacy_metric
survival	O	I-arm_efficacy_metric
from	O	O
a	O	O
phase	B-study_type	B-study_type
3	I-study_type	I-study_type
trial	I-study_type	I-study_type
of	O	O
endocrine	O	O
therapy	O	O
as	O	O
first	O	O
-	O	O
line	O	O
treatment	O	O
for	O	O
metastatic	O	O
breast	O	O
cancer	O	O
CynthiaHuang	B-authors	B-authors

cynthia.huang@pfizer.com	O	O
CynthiaHuang	B-authors	B-authors
Cynthia	B-authors	B-authors
Huang	I-authors	I-authors
cynthia.huang@pfizer.com	O	B-authors
Bartlett1	B-authors	B-authors
☯	O	B-authors
Bartlett1	B-authors	B-authors
☯	O	B-authors
Bartlett	B-authors	B-authors
1	O	B-authors
☯	O	B-authors
JackMardekian1	B-authors	B-authors
☯	O	B-authors
JackMardekian1	B-authors	B-authors
☯	O	B-authors
Jack	B-authors	B-authors
Mardekian	I-authors	I-authors
1	O	B-authors
☯	O	B-authors
MatthewJamesCotter	B-authors	B-authors
MatthewJamesCotter	B-authors	B-authors
Matthew	B-authors	B-authors
James	I-authors	B-authors
Cotter	I-authors	I-authors
XinHuang	B-authors	B-authors
XinHuang	B-authors	B-authors
Xin	B-authors	I-authors
Huang	I-authors	I-authors
ZheZhang1	B-authors	B-authors
☯	O	B-authors
ZheZhang1	B-authors	B-authors
☯	O	B-authors
Zhe	B-authors	B-authors
Zhang	I-authors	I-authors
1	O	O
☯	O	O
ChristinaMParrinello	B-authors	B-authors
Flatiron	O	O
Health	O	O
New	O	O
York	O	O
NY	O	O

0000	O	O
-	O	O
0002	O	O
-	O	O
9838	O	O
-	O	O
0544	O	O
ArielBulua	B-authors	B-authors
Ariel	B-authors	B-authors
Bulua	I-authors	O
0000	O	O
-	O	O
0002	O	O
-	O	O
9838	O	O
-	O	O
0544	O	O
2	O	O
☯	O	O
1	O	O
Pfizer	O	O
Inc	O	O
New	O	O
York	O	O
NY	O	O

Funding	O	O
:	O	O
These	O	O
analyses	O	O
and	O	O
the	O	O
studies	O	O
included	O	O
in	O	O
these	O	O
analyses	O	O
(	O	O
NCT01740427	O	O
)	O	O
were	O	O
sponsored	O	O
by	O	O
Pfizer	O	O
Inc.	O	O
The	O	O
real	B-arm_description	O
-	I-arm_description	O
world	I-arm_description	O
data	O	O
used	O	O
are	O	O
derived	O	O
from	O	O
the	O	O
Flatiron	O	O
Health	O	O
Analytic	O	O
electronic	O	O
health	O	O
record	O	O
database	O	O
as	O	O
reported	O	O
in	O	O
the	O	O
manuscript	O	O
and	O	O
were	O	O
purchased	O	O
by	O	O
Pfizer	O	O
from	O	O
Flatiron	O	O
Health	O	O
Inc.	O	O
,	O	O
an	O	O
independent	O	O
subsidiary	O	O
of	O	O
the	O	O
Roche	O	O
Group	O	O
.	O	O
Editorial	O	O
and	O	O
medical	O	O
writing	O	O
support	O	O
was	O	O
provided	O	O
by	O	O
Catherine	O	O
Grillo	O	O
,	O	O
of	O	O
Complete	O	O
Healthcare	O	O
Communications	O	O
,	O	O
LLC	O	O
(	O	O
North	O	O
Wales	O	O
,	O	O
PA	O	O
)	O	O
,	O	O
a	O	O
CHC	O	O
Group	O	O
company	O	O
,	O	O
and	O	O
was	O	O
funded	O	O
by	O	O
Pfizer	O	O
.	O	O
The	O	O
authors	O	O
also	O	O
wish	O	O
to	O	O
thank	O	O
Amy	O	O
P.	O	O
Abernethy	O	O
,	O	O
MD	O	O
,	O	O
PhD	O	O
,	O	O
for	O	O
her	O	O
work	O	O
on	O	O
developing	O	O
this	O	O
manuscript	O	O
while	O	O
at	O	O
Flatiron	O	O
Health	O	O
Inc.	O	O
;	O	O
Dr.	O	O
Abernethy	O	O
's	O	O
participation	O	O
in	O	O
the	O	O
development	O	O
of	O	O
this	O	O
manuscript	O	O
occurred	O	O
prior	O	O
to	O	O
her	O	O
appointment	O	O
as	O	O
Principal	O	O
Deputy	O	O
Commissioner	O	O
of	O	O
the	O	O
U.S.	O	O
Food	O	O
and	O	O
Drug	O	O
Administration	O	O
.	O	O
Cynthia	B-authors	B-authors
Huang	I-authors	I-authors
Bartlett	I-authors	O
is	O	O
a	O	O
former	O	O
employee	O	O
of	O	O
Pfizer	O	O
Inc.	O	O
Jack	B-authors	B-authors
Mardekian	I-authors	I-authors
,	O	O
Matthew	B-authors	B-authors
James	I-authors	I-authors
Cotter	I-authors	O
,	O	O
Xin	B-authors	B-authors
Huang	I-authors	I-authors
and	O	O
Zhe	B-authors	B-authors
Zhang	I-authors	O
are	O	O
employed	O	O
by	O	O
Pfizer	O	O
Inc.	O	O
Pfizer	O	O
Inc	O	O
provided	O	O
support	O	O
in	O	O
the	O	O
form	O	O
of	O	O
salaries	O	O
for	O	O
authors	O	O
CHB	O	O
,	O	O
JM	O	O
,	O	O
MJC	O	O
,	O	O
XH	O	O
and	O	O
ZZ	O	O
,	O	O
study	O	O
design	O	O
,	O	O
data	O	O
collection	O	O
,	O	O
and	O	O
data	O	O
analysis	O	O
.	O	O
The	O	O
interpretation	O	O
of	O	O
the	O	O
data	O	O
,	O	O
the	O	O
content	O	O
of	O	O
the	O	O
manuscript	O	O
,	O	O
and	O	O
the	O	O
decision	O	O
to	O	O
publish	O	O
were	O	O
at	O	O
the	O	O
discretion	O	O
of	O	O
the	O	O
authors	O	O
.	O	O
Christina	B-authors	O
M.	I-authors	O
Parrinello	I-authors	O
and	O	O
Ariel	B-authors	O
Bulua	I-authors	O
Bourla	I-authors	O
are	O	O
employed	O	O
by	O	O
Flatiron	O	O
Health	O	O
.	O	O
Flatiron	O	O
Health	O	O
provided	O	O
support	O	O
in	O	O
the	O	O
form	O	O
of	O	O
study	O	O
design	O	O
,	O	O
data	O	O
collection	O	O
and	O	O
management	O	O
,	O	O
and	O	O
salaries	O	O
for	O	O
authors	O	O
CMP	O	O
and	O	O
ABB	O	O
,	O	O
but	O	O
did	O	O
not	O	O
have	O	O
any	O	O
additional	O	O
role	O	O
in	O	O
the	O	O
data	O	O
analysis	O	O
,	O	O
decision	O	O
to	O	O
publish	O	O
,	O	O
or	O	O
preparation	O	O
of	O	O
the	O	O
manuscript	O	O
.	O	O

The	O	O
Flatiron	O	O
real	O	O
-	O	O
world	O	O
dataset	O	O
is	O	O
covered	O	O
under	O	O
the	O	O
Health	O	O
Insurance	O	O
Portability	O	O
and	O	O
Accountability	O	O
Act	O	O
of	O	O
1996	O	O
(	O	O
HIPAA	O	O
)	O	O
through	O	O
Business	O	O
Associate	O	O
Agreements	O	O
with	O	O
every	O	O
provider	O	O
in	O	O
the	O	O
Flatiron	O	O
network	O	O
.	O	O
These	O	O
agreements	O	O
authorize	O	O
Flatiron	O	O
to	O	O
collect	O	O
and	O	O
de	O	O
-	O	O
identify	O	O
patient	O	O
-	O	O
level	O	O
structured	O	O
and	O	O
unstructured	O	O
data	O	O
to	O	O
create	O	O
de	O	O
-	O	O
identified	O	O
data	O	O
sets	O	O
for	O	O
research	O	O
purposes	O	O
.	O	O
Processed	O	O
data	O	O
are	O	O
de	O	O
-	O	O
identified	O	O
according	O	O
to	O	O
either	O	O
the	O	O
Safe	O	O
Harbor	O	O
or	O	O
Expert	O	O
Determination	O	O
method	O	O
as	O	O
outlined	O	O
in	O	O
HIPAA	O	O
Section	O	O
164.514(b	O	O
)	O	O
.	O	O
When	O	O
using	O	O
the	O	O
Expert	O	O
Determination	O	O
method	O	O
,	O	O
Flatiron	O	O
employs	O	O
a	O	O
third	O	O
-	O	O
party	O	O
expert	O	O
to	O	O
design	O	O
the	O	O
de	O	O
-	O	O
identification	O	O
methodology	O	O
and	O	O
certify	O	O
that	O	O
the	O	O
dataset	O	O
is	O	O
de	O	O
-	O	O
identified	O	O
.	O	O
Only	O	O
de	O	O
-	O	O
identified	O	O
data	O	O
is	O	O
delivered	O	O
to	O	O
clients	O	O
.	O	O
Institutional	O	O
Review	O	O
Board	O	O
(	O	O
IRB	O	O
)	O	O
approval	O	O
was	O	O
obtained	O	O
for	O	O
this	O	O
study	O	O
;	O	O
informed	O	O
consent	O	O
was	O	O
waived	O	O
by	O	O
the	O	O
IRB	O	O
as	O	O
the	O	O
study	O	O
was	O	O
retrospective	O	O
and	O	O
non	O	O
-	O	O
interventional	O	O
,	O	O
using	O	O
routinely	O	O
collected	O	O
data	O	O
.	O	O
Details	O	O
on	O	O
the	O	O
IRB	O	O
are	O	O
available	O	O
in	O	O
S1	O	O
Appendix	O	O
.	O	O

Propensity	O	O
scores	O	O
were	O	O
generated	O	O
using	O	O
a	O	O
multivariable	O	O
logistic	O	O
model	O	O
executed	O	O
on	O	O
data	O	O
from	O	O
107	O	O
real	O	B-arm_description
-	O	O
world	O	O
patients	O	O
and	O	O
222	O	O
PALOMA-2	O	B-arm_description
patients	O	O
.	O	O
Study	O	O
origin	O	O
(	O	O
real	B-arm_description	B-arm_description
-	I-arm_description	O
world	I-arm_description	O
or	O	O
PALOMA-2	O	B-arm_description
)	O	O
was	O	O
used	O	O
as	O	O
an	O	O
outcome	O	O
and	O	O
potential	O	O
baseline	O	O
confounders	O	O
were	O	O
included	O	O
as	O	O
covariates	O	O
,	O	O
having	O	O
been	O	O
selected	O	O
based	O	O
on	O	O
the	O	O
authors	O	O
'	O	O
clinical	O	O
judgment	O	O
.	O	O
Covariates	O	O
included	O	O
were	O	O
age	O	O
,	O	O
race	O	O
,	O	O
disease	O	O
stage	O	O
at	O	O
diagnosis	O	O
(	O	O
I	O	O
-	O	O
IV	O	O
or	O	O
unrecorded	O	O
/	O	O
unknown	O	O
)	O	O
,	O	O
ECOG	O	O
PS	O	O
score	O	O
,	O	O
number	O	O
of	O	O
disease	O	O
sites	O	O
at	O	O
diagnosis	O	O
(	O	O
1	O	O
,	O	O
2	O	O
,	O	O
�	O	O
3	O	O
)	O	O
,	O	O
and	O	O
bone	O	O
-	O	O
only	O	O
metastases	O	O
.	O	O
In	O	O
order	O	O
to	O	O
balance	O	O
the	O	O
2	O	O
study	O	O
cohorts	O	O
for	O	O
duration	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
the	O	O
propensity	O	O
score	O	O
model	O	O
also	O	O
included	O	O
potential	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
a	O	O
baseline	O	O
measure	O	O
defined	O	O
as	O	O
the	O	O
number	O	O
of	O	O
months	O	O
from	O	O
a	O	O
patient	O	O
's	O	O
start	O	O
of	O	O
treatment	O	O
date	O	O
to	O	O
the	O	O
study	O	O
cutoff	O	O
:	O	O
September	O	O
30	O	O
,	O	O
2016	O	O
for	O	O
the	O	B-arm_description
real	B-arm_description	I-arm_description
-	I-arm_description	I-arm_description
world	I-arm_description	O
cohort	O	O
and	O	O
February	O	O
26	O	O
,	O	O
2016	O	O
for	O	B-arm_description
PALOMA-2	O	O

odds	O	O
ratio	O	O
:	O	O
0.92	O	O
[	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
0.56	O	O
-	O	O
1.53	O	O
]	O	O
;	O	O
2-sided	O	O
P	O	O
=	O	O
.83	O	O
)	O	O
.	O	O
No	O	O
significant	O	O
difference	O	O
was	O	O
observed	O	O
between	O	O
rwRR	O	O
and	O	O
ORR	O	O
in	O	O
IPTW	O	O
adjusted	O	O
comparisons	O	O
:	O	O
41.8	O	O
%	O	O
and	O	O
39.4	O	O
%	O	O
,	O	O
respectively	O	O
(	O	O
odds	O	O
https://doi.org/10.1371/journal.pone.0227256.g002	O	O

In	O	O
addition	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
global	O	O
PALOMA-2	B-arm_description	O
study	O	O
,	O	O
patients	O	O
in	O	O
the	O	O
real	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
world	I-arm_description	I-arm_description
cohort	O	I-arm_description
are	O	O
all	O	O
from	O	O
the	O	O
US	O	O
and	O	O
receive	O	O
care	O	O
in	O	O
routine	O	O
clinical	O	O
settings	O	O
,	O	O
which	O	O
may	O	O
have	O	O
contributed	O	O
to	O	O
the	O	O
observed	O	O
differences	O	O
in	O	O
the	O	O
frequency	O	O
of	O	O
tumor	O	O
assessments	O	O
.	O	O
The	O	O
PALOMA-2	B-arm_description	O
protocol	O	O
specified	O	O
that	O	O
tumor	O	O
assessments	O	O
be	O	O
conducted	O	O
every	O	O
12	O	O
weeks	O	O
,	O	O
while	O	O
in	O	O
the	O	O
real	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
world	I-arm_description	I-arm_description
cohort	O	I-arm_description
scans	O	O
were	O	O
ordered	O	O
at	O	O
the	O	O
discretion	O	O
of	O	O
the	O	O
treating	O	O
physician	O	O
.	O	O
It	O	O
is	O	O
noteworthy	O	O
that	O	O
12	O	O
of	O	O
the	O	O
patients	O	O
without	O	O
tumor	O	O
assessments	O	O
had	O	O
durations	O	O
of	O	O
treatment	O	O
longer	O	O
than	O	O
12	O	O
weeks	O	O
.	O	O

Survival	O	O
benefits	O	O
of	O	O
dose	O	O
-	O	O
dense	O	O
early	O	O
postoperative	O	O
intraperitoneal	O	O
chemotherapy	O	O
in	O	O
front	O	O
-	O	O
line	O	O
therapy	O	O
for	O	O
advanced	O	O
ovarian	O	O
cancer	O	O
:	O	O
a	O	O
randomised	B-study_type	B-study_type
controlled	I-study_type	I-study_type
study	I-study_type	I-study_type
6	O	O
August	O	O
2019	O	O

The	O	O
comparisons	O	O
and	O	O
distributions	O	O
of	O	O
characteristics	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
and	O	O
subgroups	O	O
were	O	O
conducted	O	O
with	O	O
the	O	O
Chisquare	O	O
or	O	O
Student	O	O
's	O	O
or	O	O
Mann	O	O
-	O	O
Whitney	O	O
U	O	O
tests	O	O
.	O	O
Median	O	O
survival	O	O
was	O	O
evaluated	O	O
using	O	O
the	O	O
Kaplan	O	O
-	O	O
Meier	O	O
method	O	O
,	O	O
and	O	O
a	O	O
log	O	O
-	O	O
rank	O	O
test	O	O
was	O	O
used	O	O
to	O	O
compare	O	O
survival	O	O
between	O	O
two	O	O
randomised	O	O
groups	O	O
.	O	O
Treatment	O	O
effects	O	O
were	O	O
estimated	O	O
by	O	O
using	O	O
the	O	O
Cox	O	O
regression	O	O
model	O	O
when	O	O
proportional	O	O
hazards	O	O
could	O	O
be	O	O
assumed	O	O
.	O	O
Because	O	O
there	O	O
was	O	O
no	O	O
prespecified	O	O
plan	O	O
to	O	O
stratify	O	O
or	O	O
adjust	O	O
for	O	O
multiple	O	O
comparisons	O	O
,	O	O
a	O	O
multivariable	O	O
analysis	O	O
was	O	O
performed	O	O
to	O	O
evaluate	O	O
efficacy	O	O
outcomes	O	O
with	O	O
the	O	O
adjustment	O	O
for	O	O
the	O	O
important	O	O
baseline	O	O
confounders	O	O
,	O	O
such	O	O
as	O	O
FIGO	O	O
stage	O	O
,	O	O
neoadjuvant	O	O
chemotherapy	O	O
and	O	O
residual	O	O
diseases	O	O
.	O	O
The	O	O
previous	O	O
analysis	O	O
of	O	O
12-month	O	O
nonprogression	O	O
rate	O	O
has	O	O
been	O	O
conducted	O	O
(	O	O
two	O	O
-	O	O
sided	O	O
α	O	O
=	O	O
0.05	O	O
)	O	O
.	O	O
5	O	O
Here	O	O
,	O	O
prespecified	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
and	O	O
OS	O	O
analyses	O	O
were	O	O
performed	O	O
after	O	O
sufficient	O	O
follow	O	O
-	O	O
up	O	O
for	O	O
the	O	O
observation	O	O
of	O	O
160	O	O
(	O	O
80	O	O
%	O	O
)	O	O
events	O	O
of	O	O
disease	O	O
progression	O	O
,	O	O
or	O	O
death	O	O
from	O	O
ovarian	O	O
cancer	O	O
,	O	O
using	O	O
a	O	O
two	O	O
-	O	O
sided	O	O
α	O	O
of	O	O
0.05	O	O
.	O	O

Censored	O	O
on	O	O
September	O	O
10	O	O
,	O	O
2018	O	O
(	O	O
3	O	O
years	O	O
after	O	O
the	O	O
last	O	O
patient	O	O
enrolled	O	O
)	O	O
,	O	O
the	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
time	O	O
was	O	O
69.1	O	O
months	O	O
(	O	O
interquartile	O	O
range	O	O
,	O	O
53.1	O	O
-	O	O
83.9	O	O
)	O	O
.	O	O
The	O	O
median	O	O
time	O	O
to	O	O
the	O	O
first	O	O
cycle	O	O
of	O	O
standard	O	O
IV	O	O
chemotherapy	O	O
since	O	O
primary	O	O
surgery	O	O
were	O	O
49	O	O
days	O	O
and	O	O
15	O	O
days	O	O
in	O	O
the	O	O
DD	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EPIC	I-arm_description	I-arm_description
and	O	I-arm_description
IV	B-arm_description	I-arm_description
group	I-arm_description	I-arm_description
,	O	O
respectively	O	O
(	O	O
Student	O	O
's	O	O
t	O	O
test	O	O
,	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
but	O	O
the	O	O
period	O	O
of	O	O
front	O	O
-	O	O
line	O	O
chemotherapy	O	O
was	O	O
similar	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
,	O	O
with	O	O
only	O	O
a	O	O
0.2-month	O	O
increase	O	O
in	O	O
the	O	O
DD	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EPIC	I-arm_description	I-arm_description
group	O	I-arm_description
.	O	O

Assessment	O	O
of	O	O
precision	O	O
irradiation	O	O
in	O	O
early	O	O
non	O	O
-	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
and	O	O
interstitial	O	O
lung	O	O
disease	O	O
(	O	O
ASPIRE	O	O
-	O	O
ILD	O	O
)	O	O
:	O	O
study	B-study_type	B-study_type
protocol	I-study_type	I-study_type
for	I-study_type	O
a	I-study_type	O
phase	I-study_type	B-study_type
II	I-study_type	I-study_type
trial	I-study_type	I-study_type
Assessment	O	O
of	O	O
precision	O	O
irradiation	O	O
in	O	O
early	O	O
non	O	O
-	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
and	O	O
interstitial	O	O
lung	O	O
disease	O	O
(	O	O
ASPIRE	O	O
-	O	O
ILD	O	O
)	O	O
:	O	O
study	B-study_type	B-study_type
protocol	I-study_type	I-study_type
for	I-study_type	O
a	I-study_type	O
phase	I-study_type	B-study_type
II	I-study_type	I-study_type
trial	I-study_type	I-study_type
DavidAPalma	B-authors	B-authors

Department	O	O
of	O	O
Radiation	O	O
Oncology	O	O
,	O	O
Centre	O	O
Hospitalier	O	O
de	O	O
l'Université	O	O
de	O	O
Montréal	O	O
1051	O	O
Sanguinet	O	O
Street	O	O
H2X	O	O
3E4	O	O
Montreal	O	O
Quebec	O	O
Canada	O	O
StewartGaede	O	B-authors
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
StephenHarrow	B-authors	B-authors

1053	O	O
Great	O	O
Western	O	O
Road	O	O
G12	O	O
0YN	O	O
Glasgow	O	O
UK	O	O
JoannaMLaba	B-authors	B-authors
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
XMelody	B-authors	B-authors
Qu	I-authors	O
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
GeorgeBRodrigues	B-authors	B-authors
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
BrianPYaremko	B-authors	B-authors
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
EdwardYu	B-authors	B-authors
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
Department	O	O
of	O	O
Oncology	O	O
Western	O	O
University	O	O
1151	O	O
Richmond	O	O
Street	O	O
N6A	O	O
3K7	O	O
London	O	O
Ontario	O	O
Canada	O	O
AlexanderVLouie	B-authors	B-authors

Therefore	O	O
,	O	O
the	O	O
true	O	O
rates	O	O
of	O	O
toxicity	O	O
of	O	O
SABR	O	O
in	O	O
fibrotic	O	O
ILD	O	O
patients	O	O
are	O	O
likely	O	O
higher	O	O
than	O	O
in	O	O
the	O	O
general	O	O
population	O	O
,	O	O
but	O	O
the	O	O
precise	O	O
extent	O	O
of	O	O
toxicity	O	O
remains	O	O
unknown	O	O
.	O	O

For	O	O
patients	O	O
with	O	O
ILD	O	O
and	O	O
concurrent	O	O
early	O	O
-	O	O
stage	O	O
lung	O	O
cancer	O	O
who	O	O
are	O	O
not	O	O
candidates	O	O
for	O	O
surgery	O	O
,	O	O
these	O	O
data	O	O
showing	O	O
high	O	O
rates	O	O
of	O	O
toxicity	O	O
have	O	O
led	O	O
to	O	O
a	O	O
difficult	O	O
clinical	O	O
dilemma	O	O
,	O	O
since	O	O
there	O	O
are	O	O
few	O	O
alternate	O	O
treatment	O	O
options	O	O
.	O	O
The	O	O
option	O	O
of	O	O
delivering	O	O
no	O	O
treatment	O	O
whatsoever	O	O
,	O	O
which	O	O
avoids	O	O
any	O	O
risk	O	O
of	O	O
treatment	O	O
-	O	O
related	O	O
toxicity	O	O
,	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
high	O	O
risk	O	O
of	O	O
death	O	O
due	O	O
to	O	O
the	O	O
lung	O	O
cancer	O	O
itself	O	O
.	O	O
The	O	O
median	O	O
survival	O	O
for	O	O
untreated	O	O
stage	O	O
I	O	O
NSCLC	O	O
is	O	O
only	O	O
6	O	O
-	O	O
8	O	O
months	O	O
,	O	O
with	O	O
1-year	O	O
mortality	O	O
of	O	O
60	O	O
-	O	O
70	O	O
%	O	O
[	O	O
12	O	O
]	O	O
,	O	O
much	O	O
higher	O	O
than	O	O
the	O	O
risks	O	O
associated	O	O
with	O	O
SABR	O	O
treatment	O	O
.	O	O
For	O	O
example	O	O
,	O	O
in	O	O
one	O	O
study	O	O
of	O	O
untreated	O	O
patients	O	O
with	O	O
NSCLC	O	O
in	O	O
the	O	O
U.S.	O	O
National	O	O
Cancer	O	O
Database	O	O
,	O	O
the	O	O
median	O	O
survival	O	O
for	O	O
patients	O	O
with	O	O
stage	O	O
I	O	O
NSCLC	O	O
who	O	O
were	O	O
unfit	O	O
for	O	O
an	O	O
operation	O	O
was	O	O
7.6	O	O
months	O	O
[	O	O
13	O	O
]	O	O
.	O	O
This	O	O
suggests	O	O
that	O	O
even	O	O
in	O	O
patients	O	O
with	O	O
an	O	O
ILD	O	O
-	O	O
GAP	O	O
score	O	O
>	O	O
5	O	O
,	O	O
the	O	O
risk	O	O
of	O	O
death	O	O
due	O	O
to	O	O
lung	O	O
cancer	O	O
within	O	O
1	O	O
year	O	O
exceeds	O	O
the	O	O
risk	O	O
of	O	O
death	O	O
due	O	O
to	O	O
ILD	O	O
or	O	O
complications	O	O
of	O	O
SABR	O	O
.	O	O

Alternatively	O	O
,	O	O
it	O	O
may	O	O
be	O	O
necessary	O	O
to	O	O
reduce	O	O
the	O	O
dose	O	O
of	O	O
SABR	O	O
,	O	O
at	O	O
the	O	O
risk	O	O
of	O	O
compromising	O	O
tumor	O	O
control	O	O
.	O	O
Adjustments	O	O
to	O	O
the	O	O
SABR	O	O
fractionation	O	O
schedule	O	O
may	O	O
reduce	O	O
the	O	O
risk	O	O
of	O	O
toxicity	O	O
,	O	O
while	O	O
still	O	O
maintaining	O	O
some	O	O
benefit	O	O
.	O	O
Radiation	O	O
dose	O	O
is	O	O
expressed	O	O
in	O	O
Gray	O	O
(	O	O
Gy	O	O
)	O	O
,	O	O
with	O	O
most	O	O
SABR	O	O
treatments	O	O
delivering	O	O
approximately	O	O
a	O	O
total	O	O
dose	O	O
50	O	O
-	O	O
60	O	O
Gy	O	O
.	O	O
This	O	O
total	O	O
dose	O	O
is	O	O
divided	O	O
up	O	O
into	O	O
smaller	O	O
individual	O	O
fractions	O	O
of	O	O
radiation	O	O
.	O	O
Conventional	O	O
radiotherapy	O	O
employs	O	O
fraction	O	O
sizes	O	O
of	O	O
approximately	O	O
2	O	O
Gy	O	O
per	O	O
day	O	O
,	O	O
5	O	O
days	O	O
per	O	O
week	O	O
,	O	O
and	O	O
would	O	O
require	O	O
30	O	O
fractions	O	O
to	O	O
deliver	O	O
60	O	O
Gy	O	O
.	O	O
This	O	O
prolonged	O	O
treatment	O	O
time	O	O
(	O	O
i.e.	O	O
6	O	O
weeks	O	O
of	O	O
treatment	O	O
)	O	O
may	O	O
allow	O	O
for	O	O
tumor	O	O
repopulation	O	O
,	O	O
compromising	O	O
treatment	O	O
outcomes	O	O
.	O	O
With	O	O
SABR	O	O
,	O	O
common	O	O
fractionations	O	O
include	O	O
54	O	O
Gy	O	O
in	O	O
3	O	O
fractions	O	O
(	O	O
i.e.	O	O
18	O	O
Gy	O	O
per	O	O
fraction	O	O
)	O	O
,	O	O
48	O	O
Gy	O	O
in	O	O
4	O	O
fractions	O	O
(	O	O
i.e.	O	O
12	O	B-arm_dosage
Gy	O	I-arm_dosage
per	O	I-arm_dosage
fraction	O	I-arm_dosage
)	O	O
and	O	O
60	O	O
Gy	O	O
in	O	O
8	O	O
fractions	O	O
(	O	O
i.e.	O	O
7.5	O	O
Gy	O	O
per	O	O
day	O	O
)	O	O
.	O	O
SABR	O	O
fractions	O	O
are	O	O
often	O	O
given	O	O
every	O	O
second	O	O
day	O	O
(	O	O
or	O	O
even	O	O
more	O	O
widely	O	O
spaced	O	O
)	O	O
to	O	O
maximize	O	O
the	O	O
time	O	O
for	O	O
normal	O	O
tissue	O	O
repair	O	O
between	O	O
fractions	O	O
.	O	O

To	O	O
compare	O	O
the	O	O
potency	O	O
of	O	O
these	O	O
different	O	O
radiation	O	O
dose	O	O
fractionations	O	O
,	O	O
a	O	O
formula	O	O
called	O	O
the	O	O
biologically	O	O
effective	O	O
dose	O	O
(	O	O
BED	O	O
)	O	O
is	O	O
used	O	O
.	O	O
BED	O	O
takes	O	O
into	O	O
account	O	O
the	O	O
total	O	O
number	O	O
of	O	O
fractions	O	O
,	O	O
the	O	O
dose	O	O
per	O	O
fraction	O	O
,	O	O
and	O	O
the	O	O
intrinsic	O	O
radiation	O	O
response	O	O
curve	O	O
of	O	O
the	O	O
individual	O	O
tissues	O	O
treated	O	O
.	O	O
BED	O	O
is	O	O
calculated	O	O
according	O	O
to	O	O
the	O	O
formula	O	O

During	O	O
the	O	O
design	O	O
of	O	O
this	O	O
trial	B-study_type	O
in	O	O
2016	O	O
-	O	O
17	O	O
,	O	O
several	O	O
options	O	O
were	O	O
considered	O	O
and	O	O
ultimately	O	O
discussed	O	O
at	O	O
a	O	O
meeting	O	O
of	O	O
the	O	O
Canadian	O	O
Pulmonary	O	O
Radiotherapy	O	O
Investigators	O	O
'	O	O
(	O	O
CAPRI	O	O
)	O	O
Group	O	O
at	O	O
the	O	O
September	O	O
2017	O	O
Canadian	O	O
Association	O	O
of	O	O
Radiation	O	O
Oncology	O	O
Annual	O	O
Meeting	O	O
.	O	O
Two	O	O
main	O	O
alternative	O	O
approaches	O	O
were	O	O
considered	O	O
:	O	O

There	O	O
is	O	O
precedent	O	O
for	O	O
this	O	O
approach	O	O
,	O	O
as	O	O
two	O	O
other	O	O
phase	O	B-study_type
I	O	I-study_type
trials	O	I-study_type
of	O	O
SABR	O	O
have	O	O
started	O	O
at	O	O
therapeutic	O	O
doses	O	O
:	O	O
RTOG	O	O
0813	O	O
for	O	O
central	O	O
tumors	O	O
(	O	O
started	O	O
at	O	O
50	O	O
Gy	O	O
in	O	O
5	O	O
fractions	O	O
before	O	O
escalating	O	O
to	O	O
60	O	O
Gy	O	O
in	O	O
5	O	O
fractions	O	O
)	O	O
and	O	O
SUNSET	O	O
for	O	O
ultra	O	O
-	O	O
central	O	O
tumors	O	O
(	O	O
starting	O	O
at	O	O
60	O	O
Gy	O	O
in	O	O
8	O	O
fractions	O	O
,	O	O
currently	O	O
underway	O	O
)	O	O
[	O	O
15	O	O
]	O	O
.	O	O

The	O	O
Study	O	O
Schema	O	O
can	O	O
be	O	O
found	O	O
in	O	O
Fig	O	O
.	O	O
1	O	O
.	O	O
The	O	O
required	O	O
sample	O	O
size	O	O
is	O	O
39	O	O
.	O	O
Patients	O	O
who	O	O
meet	O	O
eligibility	O	O
criteria	O	O
but	O	O
decline	O	O
to	O	O
pursue	O	O
radiation	O	O
and	O	O
patients	O	O
for	O	O
whom	O	O
SABR	O	O
can	O	O
not	O	O
be	O	O
delivered	O	O
at	O	O
the	O	O
recommended	O	O
doses	O	O
due	O	O
to	O	O
inacceptable	O	O
doses	O	O
to	O	O
normal	O	O
tissues	O	O
at	O	O
risk	O	O
will	O	O
be	O	O
asked	O	O
to	O	O
consent	O	O
to	O	O
limited	O	O
ongoing	O	O
follow	O	O
-	O	O
up	O	O
only	O	O
.	O	O

Overall	O	O
survival	O	O
:	O	O
defined	O	O
as	O	O
time	O	O
from	O	O
enrollment	O	O
to	O	O
death	O	O
from	O	O
any	O	O
cause	O	O
Changes	O	O
in	O	O
pulmonary	O	O
function	O	O
tests	O	O
,	O	O
including	O	O
diffusing	O	O
capacity	O	O
of	O	O
the	O	O
lungs	O	O
for	O	O
carbon	O	O
monoxide	O	O
(	O	O
DLCO	O	O
)	O	O
,	O	O
forced	O	O
expiratory	O	O
volume	O	O
in	O	O
1	O	O
s	O	O
(	O	O
FEV	O	O
1	O	O
)	O	O
,	O	O
and	O	O
forced	O	O
vital	O	O
capacity	O	O
(	O	O
FVC	O	O
)	O	O
.	O	O
Exploratory	O	O
quantitative	O	O
analysis	O	O
of	O	O
HRCT	O	O
features	O	O
(	O	O
i.e.	O	O
radiomics	O	O
)	O	O
Analysis	O	O
of	O	O
outcomes	O	O
for	O	O
patients	O	O
who	O	O
otherwise	O	O
meet	O	O
the	O	O
study	O	O
enrollment	O	O
criteria	O	O
but	O	O
decline	O	O
radiotherapy	O	O
.	O	O

History	O	O
/	O	O
physical	O	O
examination	O	O
within	O	O
4	O	O
weeks	O	O
prior	O	O
to	O	O
registration	O	O
,	O	O
including	O	O
documentation	O	O
of	O	O
current	O	O
medications	O	O
and	O	O
home	O	O
oxygen	O	O
use	O	O
.	O	O
HRCT	O	O
scan	O	O
of	O	O
the	O	O
thorax	O	O
(	O	O
with	O	O
contrast	O	O
unless	O	O
medically	O	O
contraindicated	O	O
)	O	O
within	O	O
12	O	O
weeks	O	O
of	O	O
registration	O	O
.	O	O
Slice	O	O
thickness	O	O
must	O	O
be	O	O
1.5	O	O
mm	O	O
or	O	O
less	O	O
with	O	O
continuous	O	O
(	O	O
i.e.	O	O
non	O	O
-	O	O
gapped	O	O
)	O	O
images	O	O
.	O	O
Each	O	O
centre	O	O
must	O	O
communicate	O	O
with	O	O
their	O	O
radiologists	O	O
to	O	O
ensure	O	O
that	O	O
CT	O	O
scans	O	O
are	O	O
done	O	O
using	O	O
protocols	O	O
adequate	O	O
for	O	O
ILD	O	O
.	O	O
The	O	O
primary	O	O
tumor	O	O
dimensions	O	O
will	O	O
be	O	O
measured	O	O
on	O	O
CT	O	O
.	O	O

Positron	O	O
emission	O	O
tomography	O	O
(	O	O
PET	O	O
)	O	O
scan	O	O
of	O	O
the	O	O
entire	O	O
body	O	O
within	O	O
8	O	O
weeks	O	O
of	O	O
registration	O	O
,	O	O
using	O	O
FDG	O	O
.	O	O
Pre	O	O
-	O	O
bronchodilator	O	O
spirometry	O	O
,	O	O
lung	O	O
volumes	O	O
and	O	O
diffusion	O	O
capacity	O	O
within	O	O
8	O	O
weeks	O	O
prior	O	O
to	O	O
treatment	O	O
.	O	O
Assessment	O	O
by	O	O
a	O	O
respirologist	O	O
/	O	O
pulmonologist	O	O
within	O	O
4	O	O
weeks	O	O
of	O	O
enrollment	O	O
,	O	O
for	O	O
the	O	O
following	O	O
purposes	O	O
:	O	O
To	O	O
optimize	O	O
pulmonary	O	O
function	O	O
and	O	O
treatment	O	O
of	O	O
ILD	O	O
,	O	O
if	O	O
possible	O	O
.	O	O

Clinical	O	O
/	O	O
Laboratory	O	O
Data	O	O
:	O	O
Including	O	O
clinical	O	O
history	O	O
,	O	O
symptoms	O	O
with	O	O
date	O	O
of	O	O
onset	O	O
,	O	O
smoking	O	O
history	O	O
(	O	O
including	O	O
pack	O	O
years	O	O
and	O	O
quit	O	O
date	O	O
)	O	O
,	O	O
exposures	O	O
,	O	O
CTD	O	O
features	O	O
,	O	O
serology	O	O
(	O	O
normal	O	O
and	O	O
abnormal	O	O
)	O	O
,	O	O
pulmonary	O	O
function	O	O
tests	O	O
,	O	O
and	O	O
the	O	O
subtype	O	O
of	O	O
ILD	O	O
as	O	O
determined	O	O
by	O	O
the	O	O
treating	O	O
respirologist	O	O
.	O	O
Pathology	O	O
:	O	O
slides	O	O
(	O	O
to	O	O
be	O	O
returned	O	O
)	O	O
and	O	O
pathology	O	O
reports	O	O
Radiology	O	O
:	O	O
Digital	O	O
Imaging	O	O
and	O	O
Communications	O	O
in	O	O
Medicine	O	O
(	O	O
DICOM	O	O
)	O	O
images	O	O
of	O	O
thoracic	O	O
CT	O	O
scans	O	O
(	O	O
through	O	O
Quantitative	O	O
Imaging	O	O
for	O	O
Personalized	O	O
Cancer	O	O
Medicine	O	O
(	O	O
QIPCM	O	O
)	O	O
)	O	O
and	O	O
radiology	O	O
reports	O	O

The	O	O
total	O	O
dose	O	O
will	O	O
be	O	O
50	B-arm_dosage	B-arm_dosage
Gy	I-arm_dosage	I-arm_dosage
in	I-arm_dosage	I-arm_dosage
5	I-arm_dosage	I-arm_dosage
fractions	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
given	I-arm_dosage	I-arm_dosage
every	I-arm_dosage	I-arm_dosage
second	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
.	O	O
In	O	O
the	O	O
event	O	O
that	O	O
the	O	O
dose	O	O
is	O	O
de	O	O
-	O	O
escalated	O	O
to	O	O
50	O	B-arm_dosage
Gy	O	I-arm_dosage
in	O	I-arm_dosage
10	O	I-arm_dosage
fractions	O	I-arm_dosage
or	O	I-arm_dosage
45	O	I-arm_dosage
Gy	O	I-arm_dosage
in	O	I-arm_dosage
15	O	I-arm_dosage
fractions	O	I-arm_dosage
,	O	O
then	O	O
the	O	O
same	O	O
prescribing	O	O
principles	O	O
apply	O	O
(	O	O
i.e.	O	O
using	O	O
a	O	O
SABR	O	O
-	O	O
like	O	O
technique	O	O
)	O	O
but	O	O
these	O	O
latter	O	O
two	O	O
fractionations	O	O
are	O	O
given	O	O
daily	O	O
.	O	O

The	O	O
lung	O	O
constraints	O	O
are	O	O
critically	O	O
important	O	O
for	O	O
this	O	O
study	O	O
.	O	O
If	O	O
one	O	O
or	O	O
more	O	O
of	O	O
the	O	O
lung	O	O
constraints	O	O
can	O	O
not	O	O
be	O	O
met	O	O
,	O	O
even	O	O
after	O	O
varying	O	O
the	O	O
prescription	O	O
isodose	O	O
surface	O	O
percentage	O	O
between	O	O
60	O	O
and	O	O
90	O	O
%	O	O
,	O	O
PTV	O	O
coverage	O	O
must	O	O
then	O	O
be	O	O
compromised	O	O
.	O	O
Target	O	O
coverage	O	O
may	O	O
be	O	O
reduced	O	O
until	O	O
95	O	O
%	O	O
of	O	O
the	O	O
IGTV	O	O
is	O	O
receiving	O	O
the	O	O
95	O	O
%	O	O
of	O	O
the	O	O
prescription	O	O
dose	O	O
,	O	O
and	O	O
90	O	O
%	O	O
of	O	O
the	O	O
IGTV	O	O
is	O	O
receiving	O	O
99	O	O
%	O	O
of	O	O
the	O	O
prescription	O	O
dose	O	O
,	O	O
with	O	O
the	O	O
PTV	O	O
covered	O	O
as	O	O
well	O	O
as	O	O
possible	O	O
while	O	O
respecting	O	O
lung	O	O
constraints	O	O
.	O	O

If	O	O
the	O	O
lung	O	O
dose	O	O
constraints	O	O
still	O	O
can	O	O
not	O	O
be	O	O
met	O	O
,	O	O
the	O	O
patient	O	O
should	O	O
be	O	O
treated	O	O
with	O	O
a	O	O
10	O	O
or	O	O
15-fraction	O	O
regimen	O	O
.	O	O
Such	O	O
patients	O	O
treated	O	O
with	O	O
protracted	O	O
regimens	O	O
due	O	O
to	O	O
inability	O	O
to	O	O
meet	O	O
dose	O	O
constraints	O	O
will	O	O
not	O	O
count	O	O
toward	O	O
the	O	O
primary	O	O
analysis	O	O
,	O	O
but	O	O
should	O	O
still	O	O
be	O	O
followed	O	O
for	O	O
toxicity	O	O
and	O	O
outcomes	O	O
.	O	O
Such	O	O
patients	O	O
will	O	O
be	O	O
reported	O	O
as	O	O
a	O	O
separate	O	O
cohort	O	O
.	O	O

In	O	O
order	O	O
to	O	O
ensure	O	O
patient	O	O
safety	O	O
and	O	O
effective	O	O
treatment	O	O
delivery	O	O
,	O	O
a	O	O
robust	O	O
quality	O	O
assurance	O	O
protocol	O	O
is	O	O
incorporated	O	O
.	O	O
The	O	O
following	O	O
requirements	O	O
must	O	O
be	O	O
completed	O	O
for	O	O
each	O	O
patient	O	O
:	O	O

Definitions	O	O
Adverse	O	O
Event	O	O
(	O	O
AE	O	O
)	O	O
or	O	O
reaction	O	O
,	O	O
as	O	O
per	O	O
definitions	O	O
by	O	O
the	O	O
Common	O	O
Terminology	O	O
Criteria	O	O
for	O	O
Adverse	O	O
Events	O	O
[	O	O
21	O	O
]	O	O
,	O	O
is	O	O
any	O	O
unfavorable	O	O
and	O	O
unintended	O	O
sign	O	O
(	O	O
including	O	O
an	O	O
abnormal	O	O
laboratory	O	O
finding	O	O
)	O	O
,	O	O
symptom	O	O
,	O	O
or	O	O
disease	O	O
temporally	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
a	O	O
medical	O	O
treatment	O	O
or	O	O
procedure	O	O
that	O	O
may	O	O
or	O	O
may	O	O
not	O	O
be	O	O
considered	O	O
related	O	O
to	O	O
the	O	O
medical	O	O
treatment	O	O
or	O	O
procedure	O	O
.	O	O
Serious	O	O
Adverse	O	O
Event	O	O
(	O	O
SAE	O	O
)	O	O
or	O	O
reaction	O	O
as	O	O
defined	O	O
in	O	O
the	O	O
International	O	O
Council	O	O
for	O	O
Harmonisation	O	O
(	O	O
ICH	O	O
)	O	O
Guideline	O	O
:	O	O
Clinical	O	O
Safety	O	O
Data	O	O
Management	O	O
:	O	O
Definitions	O	O
and	O	O
Standards	O	O
for	O	O
Expedited	O	O
Reporting	O	O
,	O	O
Section	O	O
2B	O	O
[	O	O
22	O	O
]	O	O
includes	O	O
any	O	O
untoward	O	O
medical	O	O
occurrence	O	O
at	O	O
any	O	O
dose	O	O
that	O	O
:	O	O

RT	O	O
delivered	O	O
in	O	O
this	O	O
protocol	O	O
can	O	O
adversely	O	O
affect	O	O
organs	O	O
at	O	O
risk	O	O
,	O	O
most	O	O
notably	O	O
lungs	O	O
,	O	O
airway	O	O
,	O	O
esophagus	O	O
,	O	O
pulmonary	O	O
vessels	O	O
,	O	O
and	O	O
heart	O	O
/	O	O
pericardium	O	O
,	O	O
as	O	O
these	O	O
organs	O	O
may	O	O
be	O	O
in	O	O
close	O	O
proximity	O	O
to	O	O
the	O	O
intended	O	O
target	O	O
(	O	O
PTV	O	O
)	O	O
of	O	O
RT	O	O
.	O	O

Any	O	O
Grade	O	O
3	O	O
-	O	O
5	O	O
toxicity	O	O
listed	O	O
in	O	O
Table	O	O
4	O	O
will	O	O
automatically	O	O
be	O	O
considered	O	O
to	O	O
be	O	O
possibly	O	O
,	O	O
probably	O	O
or	O	O
definitely	O	O
related	O	O
to	O	O
treatment	O	O
,	O	O
unless	O	O
there	O	O
is	O	O
clear	O	O
evidence	O	O
that	O	O
the	O	O
adverse	O	O
event	O	O
is	O	O
unrelated	O	O
or	O	O
unlikely	O	O
to	O	O
be	O	O
related	O	O
.	O	O
The	O	O
latter	O	O
instance	O	O
may	O	O
occur	O	O
,	O	O
for	O	O
example	O	O
,	O	O
in	O	O
the	O	O
case	O	O
of	O	O
a	O	O
cardiac	O	O
event	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
an	O	O
upper	O	O
lobe	O	O
tumor	O	O
and	O	O
negligible	O	O
heart	O	O
dose	O	O
,	O	O
or	O	O
esophageal	O	O
issues	O	O
in	O	O
a	O	O
patient	O	O
who	O	O
received	O	O
negligible	O	O
esophageal	O	O
dose	O	O
.	O	O
The	O	O
final	O	O
decision	O	O
will	O	O
be	O	O
made	O	O
by	O	O
the	O	O
members	O	O
of	O	O
the	O	O
data	O	O
safety	O	O
monitoring	O	O
committee	O	O
(	O	O
DSMC	O	O
)	O	O
.	O	O
See	O	O
below	O	O
for	O	O
causality	O	O
definitions	O	O
.	O	O

Note	O	O
:	O	O
The	O	O
term	O	O
"	O	O
severe	O	O
"	O	O
is	O	O
a	O	O
measure	O	O
of	O	O
intensity	O	O
:	O	O
thus	O	O
a	O	O
severe	O	O
adverse	O	O
event	O	O
is	O	O
not	O	O
necessarily	O	O
serious	O	O
.	O	O
For	O	O
example	O	O
,	O	O
nausea	O	O
of	O	O
several	O	O
hours	O	O
'	O	O
duration	O	O
may	O	O
be	O	O
rated	O	O
as	O	O
severe	O	O
,	O	O
but	O	O
may	O	O
not	O	O
be	O	O
clinically	O	O
serious	O	O
.	O	O

Any	O	O
grade	O	O
4	O	O
or	O	O
5	O	O
adverse	O	O
reaction	O	O
that	O	O
is	O	O
definitely	O	O
,	O	O
probably	O	O
,	O	O
or	O	O
possibly	O	O
the	O	O
result	O	O
of	O	O
experimental	O	O
treatment	O	O
(	O	O
i.e.	O	O
radiotherapy	O	O
)	O	O
must	O	O
be	O	O
verbally	O	O
reported	O	O
to	O	O
the	O	O
Principal	O	O
Investigator	O	O
and	O	O
Coordinating	O	O
Centre	O	O
within	O	O
24	O	O
h	O	O
of	O	O
discovery	O	O
,	O	O
and	O	O
to	O	O
the	O	O
approving	O	O
REB	O	O
if	O	O
necessary	O	O
as	O	O
per	O	O
their	O	O
reporting	O	O
guidelines	O	O
.	O	O

Local	O	O
and	O	O
non	O	O
-	O	O
local	O	O
SAEs	O	O
will	O	O
be	O	O
reported	O	O
to	O	O
the	O	O
applicable	O	O
REB	O	O
as	O	O
per	O	O
their	O	O
reporting	O	O
guidelines	O	O
.	O	O
All	O	O
serious	O	O
,	O	O
unexpected	O	O
adverse	O	O
events	O	O
or	O	O
reactions	O	O
regardless	O	O
of	O	O
causality	O	O
will	O	O
be	O	O
reported	O	O
within	O	O
7	O	O
days	O	O
of	O	O
discovery	O	O
to	O	O
the	O	O
pertinent	O	O
REB	O	O
,	O	O
or	O	O
as	O	O
required	O	O
as	O	O
per	O	O
the	O	O
REB	O	O
guidelines	O	O
.	O	O

A	O	O
sample	O	O
size	O	O
of	O	O
39	O	O
patients	O	O
provides	O	O
>	O	O
80	O	O
%	O	O
power	O	O
to	O	O
detect	O	O
an	O	O
OS	O	O
improvement	O	O
of	O	O
>	O	O
20	O	O
%	O	O
at	O	O
1	O	O
year	O	O
,	O	O
compared	O	O
to	O	O
a	O	O
historical	O	O
control	O	O
of	O	O
<	O	O
50	O	O
%	O	O
(	O	O
i.e.	O	O
70	O	O
%	O	O
vs.	O	O
49	O	O
%	O	O
)	O	O
,	O	O
using	O	O
a	O	O
one	O	O
-	O	O
sample	O	O
,	O	O
one	O	O
sided	O	O
binomial	O	O
test	O	O
at	O	O
the	O	O
0.05	O	O
significance	O	O
level	O	O
,	O	O
assuming	O	O
10	O	O
%	O	O
dropout	O	O
or	O	O
loss	O	O
to	O	O
follow	O	O
-	O	O
up	O	O
before	O	O
one	O	O
year	O	O
.	O	O
All	O	O
cohorts	O	O
will	O	O
be	O	O
combined	O	O
for	O	O
this	O	O
primary	O	O
analysis	O	O
.	O	O

The	O	O
names	O	O
and	O	O
personal	O	O
information	O	O
of	O	O
study	O	O
participants	O	O
will	O	O
be	O	O
held	O	O
in	O	O
strict	O	O
confidence	O	O
.	O	O
All	O	O
study	O	O
records	O	O
(	O	O
case	O	O
report	O	O
forms	O	O
,	O	O
safety	O	O
reports	O	O
,	O	O
correspondence	O	O
,	O	O
etc	O	O
.	O	O
)	O	O
will	O	O
only	O	O
identify	O	O
the	O	O
subject	O	O
by	O	O
initials	O	O
,	O	O
month	O	O
and	O	O
year	O	O
of	O	O
birth	O	O
,	O	O
and	O	O
the	O	O
assigned	O	O
study	O	O
identification	O	O
number	O	O
.	O	O
The	O	O
investigator	O	O
will	O	O
maintain	O	O
a	O	O
confidential	O	O
subject	O	O
identification	O	O
list	O	O
(	O	O
Master	O	O
List	O	O
)	O	O
during	O	O
the	O	O
course	O	O
of	O	O
the	O	O
study	O	O
.	O	O
Access	O	O
to	O	O
confidential	O	O
information	O	O
(	O	O
i.e.	O	O
,	O	O
source	O	O
documents	O	O
and	O	O
patient	O	O
records	O	O
)	O	O
is	O	O
only	O	O
permitted	O	O
for	O	O
direct	O	O
subject	O	O
management	O	O
and	O	O
for	O	O
those	O	O
involved	O	O
in	O	O
monitoring	O	O
the	O	O
conduct	O	O
of	O	O
the	O	O
study	O	O
(	O	O
i.e.	O	O
,	O	O
Sponsors	O	O
,	O	O
contract	O	O
research	O	O
organizations	O	O
,	O	O
representatives	O	O
of	O	O
the	O	O
IRB/	O	O
REB	O	O
,	O	O
and	O	O
regulatory	O	O
agencies	O	O
)	O	O
.	O	O
The	O	O
subject	O	O
's	O	O
name	O	O
will	O	O
not	O	O
be	O	O
used	O	O
in	O	O
any	O	O
public	O	O
report	O	O
of	O	O
the	O	O
study	O	O
.	O	O

Anonymized	O	O
imaging	O	O
data	O	O
will	O	O
be	O	O
collected	O	O
through	O	O
the	O	O
Quantitative	O	O
Imaging	O	O
for	O	O
Personalized	O	O
Cancer	O	O
Medicine	O	O
(	O	O
QIPCM	O	O
)	O	O
platform	O	O
(	O	O
qipcm.technainstitute.com	O	O
)	O	O
.	O	O
QIPCM	O	O
provides	O	O
centralized	O	O
storage	O	O
and	O	O
data	O	O
analysis	O	O
tools	O	O
for	O	O
medical	O	O
imaging	O	O
,	O	O
and	O	O
is	O	O
compliant	O	O
with	O	O
national	O	O
and	O	O
international	O	O
privacy	O	O
regulations	O	O
.	O	O
A	O	O
flowchart	O	O
of	O	O
enrollment	O	O
and	O	O
central	O	O
review	O	O
can	O	O
be	O	O
found	O	O
in	O	O
Additional	O	O
file	O	O
5	O	O
.	O	O

6	O	O
-	O	O
5	O	O
-	O	O
1	O	O
Kashiwanoha	O	O
277	O	O
-	O	O
8577	O	O
Kashiwa	O	O
Chiba	O	O
Japan	O	O
•HirokiHara	B-authors	O
Department	O	O
of	O	O
Gastroenterology	O	O
Saitama	O	O
Cancer	O	O
Center	O	O
780	O	O
Komuro	O	O
362	O	O
-	O	O
0806	O	O
Ina	O	O
Saitama	O	O
Japan	O	O
•TakakiYoshikawa	B-authors	O

Pertuzumab	B-arm_description	B-arm_description
plus	I-arm_description	I-arm_description
trastuzumab	I-arm_description	I-arm_description
and	I-arm_description	I-arm_description
chemotherapy	I-arm_description	I-arm_description
for	O	O
Japanese	O	O
patients	O	O
with	O	O
HER2-positive	O	O
metastatic	O	O
gastric	O	O
or	O	O
gastroesophageal	O	O
junction	O	O
cancer	O	O
:	O	O
a	O	O
subgroup	B-study_type	B-study_type
analysis	I-study_type	I-study_type
of	O	O
the	O	O
JACOB	O	O
trial	O	B-study_type
KoheiShitara	B-authors	B-authors
kshitara@east.ncc.go.jp	O	O

The	O	O
primary	O	O
objective	O	O
of	O	O
the	O	O
JACOB	O	O
trial	O	O
was	O	O
to	O	O
compare	O	O
OS	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
pertuzumab	B-arm_description	B-arm_description
plus	I-arm_description	I-arm_description
trastuzumab	I-arm_description	I-arm_description
and	I-arm_description	I-arm_description
chemotherapy	I-arm_description	I-arm_description
with	O	O
those	O	O
treated	O	O
with	O	O
placebo	B-arm_description	B-arm_description
plus	I-arm_description	I-arm_description
trastuzumab	I-arm_description	I-arm_description
and	I-arm_description	I-arm_description
chemotherapy	I-arm_description	I-arm_description
.	O	O
Key	O	O
secondary	O	O
objectives	O	O
included	O	O
comparison	O	O
of	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
ORR	O	O
,	O	O
duration	O	O
of	O	O
response	O	O
,	O	O
patient	O	O
-	O	O
reported	O	O
outcomes	O	O
(	O	O
PROs	O	O
)	O	O
,	O	O
and	O	O
safety	O	O
between	O	O
the	O	O
two	O	O
arms	O	O
.	O	O

The	O	O
Kaplan	O	O
-	O	O
Meier	O	O
method	O	O
was	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
distributions	O	O
of	O	O
OS	O	O
,	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
and	O	O
duration	O	O
of	O	O
response	O	O
,	O	O
including	O	O
estimates	O	O
of	O	O
the	O	O
medians	O	O
,	O	O
with	O	O
95	O	O
%	O	O
CIs	O	O
calculated	O	O
using	O	O
the	O	O
Brookmeyer	O	O
and	O	O
Crowley	O	O
method	O	O
.	O	O
Cox	O	O
proportional	O	O
hazards	O	O
regression	O	O
models	O	O
were	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
HR	O	O
for	O	O
OS	O	O
and	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
with	O	O
95	O	O
%	O	O
CIs	O	O
between	O	O
treatment	O	O
arms	O	O
.	O	O
For	O	O
ORR	O	O
and	O	O
clinical	O	O
benefit	O	O
rate	O	O
,	O	O
the	O	O
proportion	O	O
of	O	O
patients	O	O
achieving	O	O
an	O	O
overall	O	O
response	O	O
per	O	O
the	O	O
Response	O	O
Evaluation	O	O
Criteria	O	O
In	O	O
Solid	O	O
Tumors	O	O
(	O	O
RECIST	O	O
)	O	O
version	O	O
1.1	O	O
was	O	O
summarized	O	O
and	O	O
95	O	O
%	O	O
CIs	O	O
were	O	O
calculated	O	O
using	O	O
the	O	O
Clopper	O	O
-	O	O
Pearson	O	O
method	O	O
.	O	O
Adverse	O	O
events	O	O
(	O	O
AEs	O	O
)	O	O
were	O	O
graded	O	O
per	O	O
the	O	O
National	O	O
Cancer	O	O
Institute	O	O
-Common	O	O
Terminology	O	O
Criteria	O	O
for	O	O
Adverse	O	O
Events	O	O
(	O	O
NCI	O	O
-	O	O
CTCAE	O	O
)	O	O
,	O	O
version	O	O
4.03	O	O
.	O	O
PRO	O	O
assessments	O	O
included	O	O
health	O	O
-	O	O
related	O	O
quality	O	O
of	O	O
life	O	O
and	O	O
time	O	O
to	O	O
deterioration	O	O
(	O	O
TTD	O	O
)	O	O
in	O	O
gastric	O	O
cancer	O	O
-	O	O
related	O	O
symptoms	O	O
,	O	O
which	O	O
were	O	O
assessed	O	O
using	O	O
the	O	O
European	O	O
Organisation	O	O
for	O	O
Research	O	O
and	O	O
Treatment	O	O
of	O	O
Cancer	O	O
(	O	O
EORTC	O	O
)	O	O
Quality	O	O
of	O	O
Life	O	O
Questionnaire	O	O
of	O	O
cancer	O	O
patients	O	O
(	O	O
QLQ	O	O
-	O	O
C30	O	O
v3.0	O	O
)	O	O
,	O	O
gastric	O	O
cancer	O	O
module	O	O
(	O	O
QLQ	O	O
-	O	O
STO22	O	O
)	O	O
,	O	O
and	O	O
EuroQol	O	O
five	O	O
-	O	O
dimensional	O	O
questionnaire	O	O
(	O	O
EQ-5D-3L	O	O
)	O	O
.	O	O
TTD	O	O
assessments	O	O
included	O	O
the	O	O
time	O	O
from	O	O
baseline	O	O
to	O	O
≥	O	O
10-point	O	O
increase	O	O
in	O	O
abdominal	O	O
pain	O	O
,	O	O
eating	O	O
restriction	O	O
,	O	O
appetite	O	O
loss	O	O
,	O	O
and	O	O
fatigue	O	O
(	O	O
TTD1	O	O
)	O	O
,	O	O
and	O	O
the	O	O
TTD	O	O
from	O	O
initiation	O	O
of	O	O
therapy	O	O
with	O	O
pertuzumab	B-arm_description	B-arm_description
/	O	I-arm_description
placebo	B-arm_description	I-arm_description
plus	I-arm_description	I-arm_description
trastuzumab	I-arm_description	B-arm_description
alone	O	O
following	O	O
cessation	O	O
of	O	O
chemotherapy	O	O
(	O	O
TTD2	O	O
)	O	O
.	O	O
The	O	O
distribution	O	O
of	O	O
TTD	O	O
,	O	O
including	O	O
an	O	O
estimate	O	O
of	O	O
the	O	O
median	O	O
,	O	O
was	O	O
assessed	O	O
using	O	O
the	O	O
Kaplan	O	O
-	O	O
Meier	O	O
method	O	O
.	O	O

All	O	O
patients	O	O
included	O	O
in	O	O
the	O	O
study	O	O
experienced	O	O
AEs	O	O
.	O	O
AEs	O	O
were	O	O
decreased	O	O
ejection	O	O
fraction	O	O
and	O	O
muscle	O	O
weakness	O	O
(	O	O
n	O	O
=	O	O
1	O	O
each	O	O
)	O	O
in	O	O
the	O	O
pertuzumab	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
and	O	O
decreased	O	O
ejection	O	O
fraction	O	O
,	O	O
multiple	O	O
organ	O	O
dysfunction	O	O
syndrome	O	O
,	O	O
gastrointestinal	O	O
anastomotic	O	O
leak	O	O
,	O	O
and	O	O
renal	O	O
dysfunction	O	O
(	O	O
n	O	O
=	O	O
1	O	O
each	O	O
)	O	O
in	O	O
the	O	O
placebo	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
.	O	O
The	O	O
total	O	O
number	O	O
of	O	O
deaths	O	O
was	O	O
24	O	O
(	O	O
60.0	O	O
%	O	O
)	O	O
in	O	O
the	O	O
pertuzumab	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
and	O	O
30	O	O
(	O	O
75.0	O	O
%	O	O
)	O	O
in	O	O
the	O	O
placebo	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
,	O	O
of	O	O
which	O	O
one	O	O
in	O	O
each	O	O
arm	O	O
was	O	O
AE	O	O
-	O	O
related	O	O
.	O	O
Fatal	O	O
AEs	O	O
were	O	O
myocardial	O	O
infarction	O	O
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
in	O	O
the	O	O
pertuzumab	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
and	O	O
multiple	O	O
organ	O	O
dysfunction	O	O
syndrome	O	O
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
in	O	O
the	O	O
placebo	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
.	O	O
A	O	O
summary	O	O
of	O	O
cardiac	O	O
AEs	O	O
is	O	O
provided	O	O
in	O	O
Table	O	O
4	O	O
.	O	O

Overall	O	O
health	O	O
-	O	O
related	O	O
quality	O	O
of	O	O
life	O	O
was	O	O
similar	O	O
between	O	O
arms	O	O
for	O	O
the	O	O
greater	O	O
part	O	O
of	O	O
the	O	O
study	O	O
,	O	O
with	O	O
no	O	O
clinically	O	O
meaningful	O	O
differences	O	O
detected	O	O
(	O	O
Fig	O	O
.	O	O
5	O	O
)	O	O
.	O	O
The	O	O
TTD1	O	O
and	O	O
TTD2	O	O
for	O	O
abdominal	O	O
pain	O	O
,	O	O
appetite	O	O
loss	O	O
,	O	O
eating	O	O
restrictions	O	O
,	O	O
and	O	O
fatigue	O	O
are	O	O
summarized	O	O
in	O	O
Table	O	O
5	O	O
.	O	O
A	O	O
consistent	O	O
trend	O	O
of	O	O
improved	O	O
TTD	O	O
was	O	O
observed	O	O
for	O	O
each	O	O
symptom	O	O
in	O	O
the	O	O
pertuzumab	O	B-arm_description
arm	O	O
compared	O	O
with	O	O
the	O	O
placebo	B-arm_description	B-arm_description
arm	I-arm_description	O
.	O	O

The	O	O
conflicting	O	O
effects	O	O
of	O	O
quality	O	O
of	O	O
life	O	O
and	O	O
survival	O	O
benefits	O	O
disrupt	O	O
proper	O	O
assessment	O	O
of	O	O
the	O	O
added	O	O
value	O	O
of	O	O
acalabrutinib	O	B-arm_description
,	O	O
which	O	O
might	O	O
lead	O	O
to	O	O
delays	O	O
in	O	O
patient	O	O
access	O	O
.	O	O

To	O	O
get	O	O
novel	O	O
haematological	O	O
agents	O	O
to	O	O
patients	O	O
effectively	O	O
and	O	O
in	O	O
a	O	O
timely	O	O
manner	O	O
,	O	O
development	O	O
should	O	O
include	O	O
an	O	O
early	O	O
assessment	O	O
of	O	O
added	O	O
value	O	O
such	O	O
as	O	O
that	O	O
presented	O	O
here	O	O
.	O	O
makers	O	O
and	O	O
manufacturers	O	O
to	O	O
streamline	O	O
clinical	O	O
development	O	O
and	O	O
reimbursement	O	O
processes	O	O
[	O	O
15][16][17][18	O	O
]	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
construct	O	O
,	O	O
based	O	O
on	O	O
published	O	O
phase	B-study_type	B-study_type
I	I-study_type	I-study_type
/	I-study_type	I-study_type
II	I-study_type	I-study_type
data	I-study_type	O
,	I-study_type	O
an	I-study_type	O
early	I-study_type	O
cost	I-study_type	O
-	I-study_type	O
utility	I-study_type	O
analysis	I-study_type	O
comparing	O	O
acalabrutinib	B-arm_description	B-arm_description
and	O	O
ibrutinib	B-arm_description	B-arm_description
for	O	O
chronic	O	O
lymphocytic	O	O
leukaemia	O	O
to	O	O
assist	O	O
early	O	O
reimbursement	O	O
decision	O	O
making	O	O
.	O	O
Sensitivity	O	O
analyses	O	O
were	O	O
performed	O	O
,	O	O
and	O	O
possible	O	O
development	O	O
scenarios	O	O
were	O	O
assessed	O	O
,	O	O
identifying	O	O
critical	O	O
parameters	O	O
and	O	O
quantifying	O	O
their	O	O
relative	O	O
impact	O	O
on	O	O
incremental	O	O
costs	O	O
and	O	O
QALYs	O	O
.	O	O

Costs	O	O
of	O	O
grade	O	O
3	O	O
and	O	O
4	O	O
adverse	O	O
events	O	O
(	O	O
AEs	O	O
)	O	O
were	O	O
included	O	O
according	O	O
to	O	O
the	O	O
UK	O	O
national	O	O
schedule	O	O
of	O	O
reference	O	O
costs	O	O
2015	O	O
-	O	O
2016	O	O
[	O	O
26	O	O
]	O	O
.	O	O
Incidences	O	O
were	O	O
implemented	O	O
from	O	O
clinical	O	O
trials	O	O
for	O	O
acalabrutinib	B-arm_description	B-arm_description
and	O	O
from	O	O
the	O	O
NICE	O	O
ibrutinib	B-arm_description	B-arm_description
assessment	O	O
[	O	O
13,14	O	O
]	O	O
.	O	O
AE	O	O
costs	O	O
were	O	O
inflicted	O	O
once	O	O
,	O	O
in	O	O
the	O	O
first	O	O
cycle	O	O
.	O	O
This	O	O
matched	O	O
the	O	O
approach	O	O
used	O	O
in	O	O
the	O	O
NICE	O	O
ibrutinib	B-arm_description	B-arm_description
submission	O	O
and	O	O
is	O	O
supported	O	O
by	O	O
the	O	O
fact	O	O
that	O	O
onset	O	O
of	O	O
side	O	O
effects	O	O
was	O	O
generally	O	O
within	O	O
the	O	O
first	O	O
half	O	O
year	O	O
and	O	O
the	O	O
duration	O	O
of	O	O
side	O	O
effects	O	O
was	O	O
short	O	O
[	O	O
2,14	O	O
]	O	O
.	O	O

Annual	O	O
healthcare	O	O
resource	O	O
use	O	O
such	O	O
as	O	O
hospital	O	O
visits	O	O
or	O	O
blood	O	O
tests	O	O
associated	O	O
with	O	O
routine	O	O
follow	O	O
-	O	O
up	O	O
care	O	O
was	O	O
included	O	O
.	O	O
Resource	O	O
use	O	O
is	O	O
based	O	O
on	O	O
expert	O	O
elicitation	O	O
reported	O	O
by	O	O
the	O	O
manufacturer	O	O
in	O	O
the	O	O
ibrutinib	B-arm_description	B-arm_description
submission	O	O
and	O	O
differs	O	O
per	O	O
model	O	O
state	O	O
(	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
PPS	O	O
-	O	O
ST	O	O
,	O	O
PPS	O	O
-	O	O
BSC	O	O
)	O	O
and	O	O
whether	O	O
the	O	O
patient	O	O
in	O	O
the	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
state	O	O
was	O	O
a	O	O
complete	O	O
responder	O	O
(	O	O
CR	O	O
)	O	O
,	O	O
partial	O	O
responder	O	O
(	O	O
PR	O	O
)	O	O
or	O	O
non	O	O
-	O	O
responder	O	O
(	O	O
NR	O	O
,	O	O
including	O	O
stable	O	O
disease	O	O
and	O	O
progressive	O	O
disease	O	O
)	O	O
.	O	O
Treatment	O	O
responses	O	O
for	O	O
ibrutinib	B-arm_description	B-arm_description
were	O	O
reported	O	O
to	O	O
be	O	O
84	O	O
%	O	O
PR	O	O
,	O	O
6	O	O
%	O	O
CR	O	O
and	O	O
10	O	O
%	O	O
NR	O	O
.	O	O
For	O	O
acalabrutinib	B-arm_description	B-arm_description
,	O	O
95	O	O
%	O	O
were	O	O
PR	O	O
and	O	O
5	O	O
%	O	O
were	O	O
NR	O	O
[	O	O
13,14	O	O
]	O	O
.	O	O
Full	O	O
calculations	O	O
of	O	O
AE	O	O
costs	O	O
and	O	O
resource	O	O
use	O	O
per	O	O
treatment	O	O
are	O	O
provided	O	O
in	O	O
ESM	O	O
3	O	O
.	O	O

Baseline	O	O
characteristics	O	O
of	O	O
all	O	O
30	O	O
patients	O	O
are	O	O
listed	O	O
in	O	O
Table	O	O
1	O	O
.	O	O
The	O	O
median	O	O
age	O	O
was	O	O
68.5	O	O
years	O	O
.	O	O
80	O	O
%	O	O
of	O	O
patients	O	O
were	O	O
male	O	O
.	O	O
All	O	O
treated	O	O
patients	O	O
had	O	O
an	O	O
ECOG	O	O
of	O	O
0	O	O
or	O	O
1	O	O
.	O	O
Median	O	O
tumor	O	O
length	O	O
was	O	O
5.0	O	O
cm	O	O
(	O	O
range	O	O
,	O	O
1	O	O
-	O	O
11	O	O
cm	O	O
)	O	O
.	O	O
29	O	O
patients	O	O
completed	O	O
the	O	O
radiotherapy	B-arm_description	B-arm_description
with	O	O
median	B-arm_dosage	O
dose	I-arm_dosage	O
was	I-arm_dosage	O
60	I-arm_dosage	B-arm_dosage
Gy	I-arm_dosage	I-arm_dosage
,	O	O
1	O	O
patients	O	O
had	O	O
interruption	O	O
of	O	O
treatment	O	O
when	O	O
received	O	O
36	O	O
Gy	O	O
due	O	O
to	O	O
esophageal	O	O
fistula	O	O
.	O	O
26	O	O
patients	O	O
completed	O	O
the	O	O
chemotherapy	O	O
as	O	O
planned	O	O
.	O	O
The	O	O
second	O	O
nedaplatin	B-arm_description	O
dose	O	O
was	O	O
reduced	O	O
by	O	O
25	O	O
%	O	O
in	O	O
two	O	O
patient	O	O
due	O	O
to	O	O
grade	O	O
4	O	O
myelotoxicity	O	O
occurred	O	O
.	O	O
2	O	O
patients	O	O
received	O	O
1	O	O
cycle	O	O
of	O	O

All	O	O
patients	O	O
were	O	O
evaluated	O	O
for	O	O
treatment	O	O
response	O	O
6	O	O
weeks	O	O
after	O	O
completion	O	O
of	O	O
treatment	O	O
.	O	O
Notable	O	O
,	O	O
ORR	O	O
was	O	O
up	O	O
to	O	O
90	O	O
%	O	O
.	O	O
For	O	O
surviving	O	O
patients	O	O
,	O	O
the	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
time	O	O
was	O	O
24	O	O
months	O	O
(	O	O
range	O	O
,	O	O
19	O	O
-	O	O
29.5	O	O
m	O	O
)	O	O
.	O	O
Total	O	O
median	O	B-arm_description
OS	O	O
was	O	O
30	O	O
months	O	O
and	O	O
the	O	O
1and	O	O
2-year	O	O
OS	O	O
rates	O	O
in	O	O
all	O	O
patients	O	O
were	O	O
70.4	O	O
%	O	O
and	O	O
55.7	O	O
%	O	O
.	O	O
The	O	O
median	O	B-arm_efficacy_metric
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
20	B-arm_efficacy_results	O
months	I-arm_efficacy_results	O
,	O	O
with	O	O
the	O	O
1-and	O	O
2-year	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
rates	I-arm_efficacy_metric	O
were	O	O
74.8	B-arm_efficacy_results	O
%	I-arm_efficacy_results	O
and	I-arm_efficacy_results	O
43.3	I-arm_efficacy_results	O
%	O	O
(	O	O
Fig	O	O
.	O	O
1	O	O
)	O	O
.	O	O

The	O	O
major	O	O
toxicities	O	O
were	O	O
leukopenia	O	O
and	O	O
thrombopenia	O	O
.	O	O
At	O	O
least	O	O
III	O	O
°	O	O
leukopenia	O	O
and	O	O
thrombopenia	O	O
were	O	O
seen	O	O
in	O	O
50	O	O
%	O	O
and	O	O
30	O	O
%	O	O
of	O	O
patients	O	O
.	O	O
Other	O	O
toxicities	O	O
of	O	O
grade	O	O
≥3	O	O
included	O	O
oesophagitis	O	O
(	O	O
one	O	O
patient	O	O
)	O	O
and	O	O
pain	O	O
in	O	O
upper	O	O
limb	O	O
(	O	O
one	O	O
patient	O	O
)	O	O
.	O	O
No	O	O
grade	O	O
≥3	O	O
anaemia	O	O
and	O	O
cardiotoxicity	O	O
were	O	O
observed	O	O
.	O	O
One	O	O
patients	O	O
developed	O	O
esophageal	O	O
fistula	O	O
at	O	O
a	O	O
radiation	B-arm_description	O
dose	O	O
of	O	O
36	O	O
Gy	O	O
with	O	O
1	O	O
cycle	O	O
concurrent	O	O
raltitrexed	B-arm_description	O
/	O	O
nedaplatin	B-arm_description	O
chemotherapy	O	O
.	O	O
There	O	O
was	O	O
no	O	O
treatment	O	O
-	O	O
related	O	O
death	O	O
and	O	O
radiation	O	O
-	O	O
induced	O	O
lung	O	O
injury	O	O
.	O	O

Male	O	O
/	O	O
female	O	O
24	O	O
(	O	O
80%)/6(20	O	O
%	O	O
)	O	O
Age	O	O
(	O	O
mean	O	O
±	O	O
SD	O	O
)	O	O
68.5	O	O
(	O	O
68.5	O	O
±	O	O
8.4	O	O
)	O	O
Tumor	O	O
locations	O	O
:	O	O
Cervical	O	O
/	O	O
Ut	O	O
/	O	O
Mt	O	O
/	O	O
Lt	O	O
6	O	O
(	O	O
20%)/6(20%)/9(30%)/9(30	O	O
%	O	O
)	O	O
chemotherapy	O	O
(	O	O
27	O	O
patients	O	O
with	O	O
NDP	O	B-arm_description
/	O	I-arm_description
S-1	O	I-arm_description
regimen	O	O
,	O	O
30	O	O
patients	O	O
with	O	O
NDP	O	B-arm_description
/	O	O
docetaxel	O	B-arm_description
regimen	O	O
,	O	O
and	O	O
13	O	O
patients	O	O
with	O	O
NDP	O	O
alone	O	O
regimen	O	O
)	O	O
.	O	O
The	O	O
overall	O	O
response	O	O
rate	O	O
was	O	O
81.4	O	O
%	O	O
.	O	O
The	O	O
1-year	O	O
and	O	O
2-year	O	O
OS	O	O
rate	O	O
was	O	O
82.9	O	O
%	O	O
and	O	O
53.9	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
with	O	O
a	O	O
median	O	O
survival	O	O
time	O	O
of	O	O
25	O	O
months	O	O
.	O	O
Compared	O	O
with	O	O
this	O	O
result	O	O
,	O	O
the	O	O
overall	O	O
response	O	O
rate	O	O
and	O	O
median	O	O
survival	O	O
time	O	O
in	O	O
our	O	O
study	O	O
was	O	O
better	O	O
,	O	O
while	O	O
the	O	O
1-year	O	O
OS	O	O
was	O	O
much	O	O
lower	O	O
(	O	O
70.4	O	O
%	O	O
vs	O	O
82.9	O	O
%	O	O
)	O	O
.	O	O
A	O	O
possible	O	O
explanation	O	O
was	O	O
the	O	O
differences	O	O
in	O	O
radiation	B-arm_description	O
dose	O	O
,	O	O
radiation	O	O
volume	O	O
and	O	O
chemotherapy	O	O
regimens	O	O
.	O	O
The	O	O
radiation	B-arm_description	O
dose	O	O
of	O	O
our	O	O
study	O	O
was	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
Zhu	O	O
's	O	O
study	O	O
,	O	O
with	O	O
a	O	O
median	B-arm_dosage	O
dose	I-arm_dosage	O
of	I-arm_dosage	O
60	I-arm_dosage	B-arm_dosage
Gy	I-arm_dosage	I-arm_dosage
vs	I-arm_dosage	O
64	I-arm_dosage	O
Gy	I-arm_dosage	O
(	O	O
range	O	O
,	O	O
60	O	O
-	O	O
66	O	O
Gy	O	O
)	O	O
.	O	O

Phase	B-study_type	B-study_type
II	I-study_type	I-study_type
study	I-study_type	I-study_type
of	O	O
R	O	O
-	O	O
CVP	O	O
followed	O	O
by	O	O
rituximab	B-arm_description	B-arm_description
maintenance	I-arm_description	O
therapy	I-arm_description	O
for	O	O
patients	O	O
with	O	O
advanced	O	O
marginal	O	O
zone	O	O
lymphoma	O	O
:	O	O
consortium	O	O
for	O	O
improving	O	O
survival	O	O
of	O	O
lymphoma	O	O
(	O	O
CISL	O	O
)	O	O
study	O	O

In	O	O
B	O	O
-	O	O
cell	O	O
malignancies	O	O
,	O	O
rituximab	O	O
(	O	O
Mabthera	O	O
®	O	O
;	O	O
Roche	O	O
,	O	O
Basel	O	O
,	O	O
Switzerland	O	O
)	O	O
was	O	O
the	O	O
first	O	O
targeted	O	O
therapy	O	O
drug	O	O
which	O	O
caused	O	O
a	O	O
paradigm	O	O
shift	O	O
in	O	O
disease	O	O
treatment	O	O
[	O	O
11	O	O
]	O	O
.	O	O
Rituximab	O	O
is	O	O
a	O	O
chimeric	O	O
,	O	O
monoclonal	O	O
antibody	O	O
targeting	O	O
CD20	O	O
,	O	O
a	O	O
cell	O	O
surface	O	O
antigen	O	O
expressed	O	O
during	O	O
most	O	O
stages	O	O
of	O	O
B	O	O
-	O	O
cell	O	O
development	O	O
[	O	O
12	O	O
]	O	O
,	O	O
and	O	O
is	O	O
found	O	O
on	O	O
95	O	O
%	O	O
of	O	O
B	O	O
-	O	O
cell	O	O
lymphoma	O	O
cells	O	O
[	O	O
13	O	O
]	O	O
.	O	O
The	O	O
clinical	O	O
efficacy	O	O
of	O	O
rituximab	O	O
was	O	O
first	O	O
demonstrated	O	O
in	O	O
follicular	O	O
lymphoma	O	O
(	O	O
FL	O	O
)	O	O
[	O	O
14,15	O	O
]	O	O
and	O	O
it	O	O
has	O	O
since	O	O
been	O	O
prescribed	O	O
for	O	O
other	O	O
subtypes	O	O
of	O	O
NHL	O	O
,	O	O
including	O	O
MZL	O	O
,	O	O
with	O	O
promising	O	O
results	O	O
[	O	O
16][17][18][19][20][21][22][23][24	O	O
]	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
evaluated	O	O
rituximab	B-arm_description	O
as	O	O
a	O	O
candidate	O	O
maintenance	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
MZL	O	O
.	O	O

Patients	O	O
who	O	O
had	O	O
received	O	O
prior	O	O
chemotherapy	O	O
or	O	O
radiotherapy	O	O
for	O	O
MZL	O	O
were	O	O
excluded	O	O
from	O	O
the	O	O
study	O	O
,	O	O
as	O	O
were	O	O
those	O	O
with	O	O
a	O	O
large	O	O
cell	O	O
component	O	O
>	O	O
10	O	O
%	O	O
,	O	O
central	O	O
nervous	O	O
system	O	O
involvement	O	O
,	O	O
or	O	O
previous	O	O
malignancy	O	O
in	O	O
the	O	O
past	O	O
5	O	O
years	O	O
with	O	O
the	O	O
exceptions	O	O
of	O	O
curatively	O	O
treated	O	O
non	O	O
-	O	O
melanoma	O	O
skin	O	O
cancer	O	O
,	O	O
in	O	O
situ	O	O
carcinoma	O	O
of	O	O
the	O	O
cervix	O	O
uteri	O	O
,	O	O
or	O	O
thyroid	O	O
cancer	O	O
with	O	O
completed	O	O
active	O	O
treatment	O	O
and	O	O
no	O	O
evidence	O	O
of	O	O
recurrence	O	O
over	O	O
a	O	O
period	O	O
of	O	O
1	O	O
year	O	O
.	O	O
Informed	O	O
consent	O	O
was	O	O
obtained	O	O
from	O	O
all	O	O
patients	O	O
for	O	O
their	O	O
participation	O	O
in	O	O
the	O	O
study	O	O
.	O	O
Informed	O	O
consent	O	O
and	O	O
patients	O	O
'	O	O
enrolment	O	O
were	O	O
acquired	O	O
after	O	O
the	O	O
first	O	O
line	O	O
R	O	O
-	O	O
CVP	O	O
treatment	O	O
.	O	O
Investigators	O	O
clearly	O	O
discussed	O	O
with	O	O
the	O	O
patients	O	O
for	O	O
their	O	O
treatment	O	O
option	O	O
including	O	O
"	O	O
watchful	O	O
wait	O	O
"	O	O
.	O	O
This	O	O
clinical	O	O
trial	O	O
obtained	O	O
informed	O	O
consents	O	O
for	O	O
R	O	O
-	O	O
maintenance	O	O
treatment	O	O
.	O	O
This	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
accordance	O	O
with	O	O
the	O	O
Declaration	O	O
of	O	O
Helsinki	O	O
and	O	O
International	O	O
Conference	O	O
on	O	O
Harmonisation	O	O
Good	O	O
Clinical	O	O
Practice	O	O
guidelines	O	O
.	O	O
The	O	O
study	O	O
design	O	O
was	O	O
reviewed	O	O
and	O	O
approved	O	O
by	O	O
the	O	O
relevant	O	O
independent	O	O
ethics	O	O
committees	O	O
for	O	O
each	O	O
investigational	O	O
site	O	O
.	O	O
All	O	O
authors	O	O
had	O	O
access	O	O
to	O	O
primary	O	O
clinical	O	O
trial	O	O
data	O	O
.	O	O

This	O	O
trial	O	O
was	O	O
designed	O	O
according	O	O
to	O	O
the	O	O
Simon	O	O
"	O	O
optimal	O	O
"	O	O
design	O	O
for	O	O
phase	O	O
II	O	O
trials	O	O
and	O	O
aimed	O	O
to	O	O
determine	O	O
whether	O	O
rituximab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
maintenance	I-arm_description	I-arm_description
following	O	O
R	O	O
-	O	O
CVP	O	O
could	O	O
improve	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
[	O	O
33	O	O
]	O	O
.	O	O
Based	O	O
on	O	O
literature	O	O
analyses	O	O
[	O	O
7,24	O	O
]	O	O
,	O	O
the	O	O
baseline	O	O
3-year	B-arm_efficacy_metric	O
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
rate	I-arm_efficacy_metric	O
was	O	O
expected	O	O
to	O	O
be	O	O
50	O	O
%	O	O
,	O	O
with	O	O
an	O	O
anticipated	O	O
treatment	O	O
difference	O	O
of	O	O
20	O	O
%	O	O
.	O	O
Assuming	O	O
a	O	O
drop	O	O
-	O	O
out	O	O
rate	O	O
of	O	O
10	O	O
%	O	O
,	O	O
a	O	O
total	O	O
of	O	O
47	O	O
patients	O	O
were	O	O
required	O	O
to	O	O
achieve	O	O
a	O	O
power	O	O
of	O	O
80	O	O
%	O	O
to	O	O
detect	O	O
a	O	O
20	O	O
%	O	O
treatment	O	O
difference	O	O
with	O	O
an	O	O
alpha	O	O
of	O	O
0.05	O	O
.	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
defined	O	O
as	O	O
the	O	O
time	O	O
R	O	O
-	O	O
CVP	O	O
treatment	O	O
started	O	O
to	O	O
the	O	O
first	O	O
recorded	O	O
incidence	O	O
of	O	O
relapse	O	O
,	O	O
disease	O	O
progression	O	O
,	O	O
death	O	O
due	O	O
to	O	O
any	O	O
cause	O	O
,	O	O
or	O	O
last	O	O
date	O	O
of	O	O
follow	O	O
up	O	O
for	O	O
the	O	O
enrolled	O	O
patients	O	O
who	O	O
did	O	O
not	O	O
progress	O	O
.	O	O

Portal	O	O
vein	O	O
invasion	O	O
(	O	O
PVI	O	O
)	O	O
frequently	O	O
develops	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
hepatocellular	O	O
carcinoma	O	O
(	O	O
HCC	O	O
)	O	O
,	O	O
and	O	O
has	O	O
an	O	O
estimated	O	O
incidence	O	O
rate	O	O
of	O	O
34	O	O
to	O	O
80	O	O
%	O	O
[	O	O
1,2	O	O
]	O	O
.	O	O
Without	O	O
treatment	O	O
,	O	O
PVI	O	O
prognosticates	O	O
extremely	O	O
poor	O	O
prognosis	O	O
with	O	O
a	O	O
median	O	O
survival	O	O
of	O	O
only	O	O
2.7	O	O
months	O	O
[	O	O
3	O	O
]	O	O
.	O	O
Sorafenib	O	O
is	O	O
currently	O	O
regarded	O	O
as	O	O
the	O	O
standard	O	O
systemic	O	O
therapy	O	O
for	O	O
HCC	O	O
with	O	O
PVI	O	O
,	O	O
but	O	O
the	O	O
survival	O	O
gain	O	O
is	O	O
only	O	O
2	O	O
-	O	O
3	O	O
months	O	O
[	O	O
4][5][6][7	O	O
]	O	O
.	O	O

Stereotactic	O	O
ablative	O	O
radiotherapy	O	O
(	O	O
SABR	O	O
)	O	O
is	O	O
an	O	O
emerging	O	O
technique	O	O
,	O	O
and	O	O
can	O	O
achieve	O	O
tumorcidal	O	O
doses	O	O
in	O	O
limited	O	O
fractions	O	O
,	O	O
with	O	O
significant	O	O
normal	O	O
tissue	O	O
sparing	O	O
.	O	O
Several	O	O
studies	O	O
have	O	O
reported	O	O
favorable	O	O
results	O	O
with	O	O
SABR	O	O
for	O	O
treating	O	O
different	O	O
cancers	O	O
[	O	O
13,14	O	O
]	O	O
.	O	O
We	O	O
hypothesized	O	O
that	O	O
SABR	O	O
would	O	O
provide	O	O
more	O	O
benefit	O	O
than	O	O
would	O	O
CFRT	O	O
in	O	O
HCC	O	O
patients	O	O
with	O	O
PVI	O	O
.	O	O

Univariable	O	O
analysis	O	O
revealed	O	O
that	O	O
the	O	O
presence	O	O
of	O	O
SABR	B-arm_description	O
,	O	O
ECOG	O	O
0	O	O
-	O	O
1	O	O
,	O	O
CP	O	O
class	O	O
A	O	O
,	O	O
single	O	O
tumor	O	O
,	O	O
tumor	O	O
size	O	O
≤8	O	O
cm	O	O
,	O	O
Vp3	O	O
,	O	O
AFP	O	O
≤200	O	O
ng	O	O
/	O	O
ml	O	O
,	O	O
prior	O	O
treatment	O	O
,	O	O
and	O	O
BED	O	O
≥65	O	O
Gy	O	O
were	O	O
predictors	O	O
of	O	O
superior	O	O
OS	O	O
.	O	O
No	O	O
survival	O	O
difference	O	O
was	O	O
noted	O	O
between	O	O
patients	O	O
treated	O	O
before	O	O
December	O	O
31	O	O
,	O	O
2011	O	O
versus	O	O
after	O	O
December	O	O
31	O	O
,	O	O
2011	O	O
.	O	O
Given	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
high	O	O
correlation	O	O
between	O	O
BED	O	O
and	O	O
the	O	O
RT	O	O
Fig	O	O
.	O	O
3	O	O
Overall	O	O
survival	O	O
(	O	O
a	O	O
)	O	O
and	O	O
in	B-arm_efficacy_metric	O
-	I-arm_efficacy_metric	O
field	I-arm_efficacy_metric	O
progression	I-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
(	O	O
b	O	O
)	O	O
in	O	O
the	O	O
entire	O	O
cohort	O	O
using	O	O
Kaplan	O	O
Meier	O	O
method	O	O
technique	O	O
(	O	O
p	O	O
<	O	O
0.001	O	O
)	O	O
,	O	O
these	O	O
variables	O	O
were	O	O
analyzed	O	O
by	O	O
two	O	O
different	O	O
Cox	O	O
models	O	O
to	O	O
avoid	O	O
collinearity	O	O
.	O	O
The	O	O
presence	O	O
of	O	O
SABR	B-arm_description	B-arm_description
and	O	O
BED	O	O
≥65	O	O
Gy	O	O
correlated	O	O
significantly	O	O
with	O	O
superior	O	O
OS	O	O
in	O	O
separate	O	O
multivariable	O	O
analysis	O	O
models	O	O
(	O	O
Table	O	O
3	O	O
)	O	O
.	O	O
Furthermore	O	O
,	O	O
we	O	O
identified	O	O
that	O	O
the	O	O
SABR	B-arm_description	B-arm_description
group	O	O
with	O	O
BED	O	B-arm_description
≥65Gy	O	O
showed	O	O
a	O	O
higher	O	O
survival	O	O
rate	O	O
than	O	O
the	O	O
CFRT	B-arm_description	B-arm_description
group	O	O
with	O	O
BED	O	B-arm_description
<	O	O
65Gy	O	O
(	O	O
p	O	O
=	O	O
0.005	O	O
)	O	O
(	O	O
Fig	O	O
.	O	O
5	O	O
)	O	O
.	O	O

Faculty	O	O
of	O	O
Medicine	O	O
and	O	O
Health	O	O
Technology	O	O
Tays	O	O
Cancer	O	O
Centre	O	O
Tampere	O	O
University	O	O
P.O.	O	O
Box	O	O
100	O	O
FI-33014	O	O
Tampere	O	O
Finland	O	O
Department	O	O
of	O	O
Oncology	O	O
Tampere	O	O
University	O	O
Hospital	O	O
P.O.	O	O
Box	O	O
2000	O	O
FI-33521	O	O
Tampere	O	O
Finland	O	O
OutiLahdenperä	B-authors	B-authors
PiaVihinen	B-authors	B-authors
ArjaJukkola	B-authors	B-authors
PeeterKarihtala	B-authors	B-authors
SonjaAho	O	B-authors
Department	O	O
of	O	O
Oncology	O	O

Faculty	O	O
of	O	O
Medicine	O	O
and	O	O
Health	O	O
Technology	O	O
Tays	O	O
Cancer	O	O
Centre	O	O
Tampere	O	O
University	O	O
P.O.	O	O
Box	O	O
100	O	O
FI-33014	O	O
Tampere	O	O
Finland	O	O
Department	O	O
of	O	O
Oncology	O	O
Tampere	O	O
University	O	O
Hospital	O	O
P.O.	O	O
Box	O	O
2000	O	O
FI-33521	O	O
Tampere	O	O
Finland	O	O

Faculty	O	O
of	O	O
Medicine	O	O
and	O	O
Health	O	O
Technology	O	O
Tays	O	O
Cancer	O	O
Centre	O	O
Tampere	O	O
University	O	O
P.O.	O	O
Box	O	O
100	O	O
FI-33014	O	O
Tampere	O	O
Finland	O	O
Department	O	O
of	O	O
Oncology	O	O
Tampere	O	O
University	O	O
Hospital	O	O
P.O.	O	O
Box	O	O
2000	O	O
FI-33521	O	O
Tampere	O	O
Finland	O	O
EmiliaAKorhonen	B-authors	B-authors

Faculty	O	O
of	O	O
Medicine	O	O
and	O	O
Health	O	O
Technology	O	O
Tays	O	O
Cancer	O	O
Centre	O	O
Tampere	O	O
University	O	O
P.O.	O	O
Box	O	O
100	O	O
FI-33014	O	O
Tampere	O	O
Finland	O	O
Department	O	O
of	O	O
Oncology	O	O
Tampere	O	O
University	O	O
Hospital	O	O
P.O.	O	O
Box	O	O
2000	O	O
FI-33521	O	O
Tampere	O	O

Faculty	O	O
of	O	O
Medicine	O	O
and	O	O
Health	O	O
Technology	O	O
Tays	O	O
Cancer	O	O
Centre	O	O
Tampere	O	O
University	O	O
P.O.	O	O
Box	O	O
100	O	O
FI-33014	O	O
Tampere	O	O
Finland	O	O
Department	O	O
of	O	O
Oncology	O	O
Tampere	O	O
University	O	O
Hospital	O	O
P.O.	O	O
Box	O	O
2000	O	O
FI-33521	O	O
Tampere	O	O

Blood	O	O
samples	O	O
were	O	O
obtained	O	O
from	O	O
the	O	O
patients	O	O
during	O	O
treatment	O	O
.	O	O
EDTA	O	O
samples	O	O
for	O	O
plasma	O	O
analysis	O	O
were	O	O
obtained	O	O
at	O	O
the	O	O
baseline	O	O
,	O	O
every	O	O
6	O	O
weeks	O	O
during	O	O
the	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
taxane	I-arm_description	I-arm_description
combination	I-arm_description	I-arm_description
,	O	O
at	O	O
the	O	O
discontinuation	O	O
of	O	O
taxane	B-arm_description	O
treatment	O	O
,	O	O
during	O	O
the	O	O
bevacizumab	B-arm_description	B-arm_description
maintenance	O	O
therapy	O	O
,	O	O
first	O	O
every	O	O
three	O	O
weeks	O	O
for	O	O
the	O	O
first	O	O
two	O	O
months	O	O
and	O	O
thereafter	O	O
every	O	O
12	O	O
weeks	O	O
,	O	O
and	O	O
at	O	O
the	O	O
final	O	O
study	O	O
visit	O	O
.	O	O

The	O	O
patient	O	O
population	O	O
and	O	O
the	O	O
analyzed	O	O
plasma	O	O
samples	O	O
were	O	O
identical	O	O
to	O	O
our	O	O
previous	O	O
paper	O	O
focusing	O	O
on	O	O
plasma	O	O
interleukin-8	O	O
levels	O	O
as	O	O
a	O	O
prognostic	O	O
marker	O	O
[	O	O
27	O	O
]	O	O
.	O	O
At	O	O
the	O	O
baseline	O	O
,	O	O
plasma	O	O
samples	O	O
were	O	O
available	O	O
from	O	O
53	O	O
patients	O	O
(	O	O
82	O	O
%	O	O
)	O	O
.	O	O
Overall	O	O
,	O	O
plasma	O	O
samples	O	O
were	O	O
available	O	O
from	O	O
58	O	O
(	O	O
89	O	O
%	O	O
)	O	O
of	O	O
the	O	O
65	O	O
patients	O	O
treated	O	O
in	O	O
the	O	O
study	O	O
.	O	O
Key	O	O
characteristics	O	O
of	O	O
the	O	O
study	O	O
population	O	O
and	O	O
the	O	O
main	O	O
efficacy	O	O
outcomes	O	O
are	O	O
presented	O	O
in	O	O
Table	O	O
1	O	O
.	O	O
Plasma	O	O
samples	O	O
for	O	O
Tie1	B-arm_description	B-arm_description
and	O	O
Ang2	B-arm_description	B-arm_description
were	O	O
analyzed	O	O
at	O	O
four	O	O
time	O	O
points	O	O
:	O	O
at	O	O
the	O	O
baseline	O	O
,	O	O
six	O	O
weeks	O	O
after	O	O
the	O	O
treatment	O	O
initiation	O	O
,	O	O
six	O	O
months	O	O
after	O	O
the	O	O
treatment	O	O
initiation	O	O
and	O	O
at	O	O
the	O	O
final	O	O
visit	O	O
.	O	O
The	O	O
number	O	O
of	O	O
patients	O	O
that	O	O
had	O	O
plasma	O	O
samples	O	O
analyzed	O	O
and	O	O
the	O	O
reasons	O	O
for	O	O
exclusions	O	O
are	O	O
presented	O	O
in	O	O
a	O	O
flow	O	O
chart	O	O
(	O	O
Fig	O	O
.	O	O
1	O	O
)	O	O
.	O	O
Six	O	O
weeks	O	O
'	O	O
and	O	O
six	O	O
months	O	O
'	O	O
samples	O	O
were	O	O
available	O	O
only	O	O
for	O	O
those	O	O
patients	O	O
that	O	O
were	O	O
still	O	O
on	O	O
study	O	O
treatment	O	O
at	O	O
that	O	O
time	O	O
point	O	O
.	O	O

The	O	O
statistical	O	O
plan	O	O
for	O	O
the	O	O
biomarker	O	O
analysis	O	O
was	O	O
exploratory	O	O
.	O	O
Tie1	B-arm_description	B-arm_description
and	O	O
Ang2	B-arm_description	B-arm_description
were	O	O
dichotomized	O	O
as	O	O
low	O	O
or	O	O
high	O	O
for	O	O
each	O	O
patient	O	O
using	O	O
the	O	O
median	O	O
value	O	O
as	O	O
the	O	O
cutoff	O	O
.	O	O
Sensitivity	O	O
,	O	O
specificity	O	O
and	O	O
area	O	O
under	O	O
curve	O	O
(	O	O
AUC	O	O
)	O	O
for	O	O
plasma	O	O
Tie1	O	B-arm_description
concentration	O	O
were	O	O
determined	O	O
using	O	O
receiver	O	O
operator	O	O
characteristic	O	O
(	O	O
ROC	O	O
)	O	O
analysis	O	O
.	O	O
Baseline	O	O
Tie1	B-arm_description	B-arm_description
or	O	O
Ang2	B-arm_description	B-arm_description
levels	O	O
as	O	O
independent	O	O
prognostic	O	O
factors	O	O
(	O	O
below	O	O
/	O	O
above	O	O
median	O	O
)	O	O
were	O	O
evaluated	O	O
using	O	O
Cox	O	O
proportional	O	O
hazard	O	O
regression	O	O
analysis	O	O
.	O	O
Multivariate	O	O
analysis	O	O
was	O	O
performed	O	O
using	O	O
the	O	O
Cox	O	O
model	O	O
,	O	O
and	O	O
it	O	O
was	O	O
adjusted	O	O
by	O	O
age	O	O
(	O	O
continuous	O	O
)	O	O
,	O	O
menopausal	O	O
status	O	O
(	O	O
yes	O	O
/	O	O
no	O	O
)	O	O
,	O	O
hormone	O	O
receptor	O	O
status	O	O
(	O	O
negative	O	O
/	O	O
positive	O	O
)	O	O
,	O	O
presence	O	O
of	O	O
visceral	O	O
metastasis	O	O
(	O	O
yes	O	O
/	O	O
no	O	O
)	O	O
,	O	O
number	O	O
of	O	O
metastatic	O	O
lesions	O	O
(	O	O
cut	O	O
-	O	O
off	O	O
of	O	O
three	O	O
metastatic	O	O
lesions	O	O
)	O	O
and	O	O
extent	O	O
of	O	O
the	O	O
disease	O	O
(	O	O
cutoff	O	O
of	O	O
three	O	O
metastatic	O	O
sites	O	O
)	O	O
.	O	O
The	O	O
Mann	O	O
-	O	O
Whitney	O	O
U	O	O
test	O	O

Median	O	O
progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
was	O	O
longer	O	O
for	O	O
patients	O	O
in	O	O
the	O	O
low	O	O
baseline	O	O
Tie1	O	B-arm_description
level	O	I-arm_description
group	O	I-arm_description
than	O	O
for	O	O
the	O	O
patients	O	O
in	O	O
the	O	O
high	O	O
baseline	O	O
Tie1	B-arm_description	B-arm_description
group	O	I-arm_description
(	O	O
Fig	O	O
.	O	O
3a	O	O
,	O	O
Table	O	O
2	O	O
)	O	O
.	O	O
No	O	O
difference	O	O
was	O	O
observed	O	O
in	O	O
progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
in	O	O
relation	O	O
to	O	O
baseline	O	O
Ang2	B-arm_description	B-arm_description
levels	O	O
(	O	O
Fig	O	O
.	O	O
3b	O	O
,	O	O
Table	O	O
2	O	O
)	O	O
.	O	O

Japan	O	O
Department	O	O
of	O	O
Medical	O	O
Oncology	O	O
Faculty	O	O
of	O	O
Medicine	O	O
,	O	O
Osakasayam	O	O
Kindai	O	O
University	O	O
Japan	O	O
Japan	O	O
Multicentre	B-study_type	O
,	I-study_type	O
phase	I-study_type	B-study_type
II	I-study_type	I-study_type
study	I-study_type	I-study_type
of	O	O
eribulin	B-arm_description	B-arm_description
in	O	O
combination	O	O
with	O	O
S-1	B-arm_description	B-arm_description
in	O	O
patients	O	O
with	O	O
advanced	O	O
breast	O	O
cancer	O	O
10.1186	O	O
/	O	O
s12885	O	O
-	O	O
019	O	O
-	O	O
6200	O	O
-	O	O
5	O	O
Received	O	O
:	O	O
25	O	O
January	O	O
2019	O	O
Accepted	O	O
:	O	O
24	O	O
September	O	O
2019	O	O

We	O	O
previously	O	O
reported	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
synergistic	O	O
effect	O	O
ofS-1	O	O
and	O	O
eribulin	O	B-arm_description
in	O	O
preclinical	O	O
models	O	O
[	O	O
17	O	O
]	O	O
,	O	O
and	O	O
recommended	O	O
using	O	O
the	O	O
phase	O	B-study_type
II	O	I-study_type
dose	O	O
of	O	O
the	O	O
combination	O	O
in	O	O
the	O	O
patients	O	O
with	O	O
ABC	O	O
who	O	O
had	O	O
been	O	O
previously	O	O
treated	O	O
with	O	O
anthracycline	O	O
and	O	O
taxane	O	O
[	O	O
18	O	O
]	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
report	O	O
results	O	O
of	O	O
this	O	O
phase	B-study_type	B-study_type
II	I-study_type	I-study_type
study	I-study_type	I-study_type
of	O	O
the	O	O
administration	O	O
of	O	O
eribulin	B-arm_description	B-arm_description
in	O	O
combination	O	O
with	O	O
S-1	B-arm_description	O
in	O	O
patients	O	O
with	O	O
ABC	O	O
and	O	O
poor	O	O
prognosis	O	O
.	O	O

Patients	O	O
were	O	O
intravenously	O	O
administered	O	O
eribulin	B-arm_description	B-arm_description
mesylate	O	O
at	O	B-arm_dosage
a	O	I-arm_dosage
dose	O	I-arm_dosage
of	O	I-arm_dosage
1.4	B-arm_dosage	I-arm_dosage
mg	I-arm_dosage	I-arm_dosage
per	I-arm_dosage	I-arm_dosage
square	I-arm_dosage	I-arm_dosage
meter	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	I-arm_dosage
body	I-arm_dosage	I-arm_dosage
surface	I-arm_dosage	I-arm_dosage
area	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
and	I-arm_dosage	I-arm_dosage
8	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
with	I-arm_dosage	I-arm_dosage
administrations	I-arm_dosage	I-arm_dosage
repeated	I-arm_dosage	I-arm_dosage
every	I-arm_dosage	I-arm_dosage
21	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
.	O	O
S-1	B-arm_description	B-arm_description
was	O	O
administered	O	O
orally	B-arm_dosage	B-arm_dosage
on	I-arm_dosage	I-arm_dosage
a	I-arm_dosage	I-arm_dosage
daily	I-arm_dosage	I-arm_dosage
basis	I-arm_dosage	I-arm_dosage
at	I-arm_dosage	I-arm_dosage
a	I-arm_dosage	I-arm_dosage
dose	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	I-arm_dosage
65	I-arm_dosage	I-arm_dosage
mg	I-arm_dosage	I-arm_dosage
per	I-arm_dosage	I-arm_dosage
square	I-arm_dosage	I-arm_dosage
meter	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	I-arm_dosage
body	I-arm_dosage	O
surface	I-arm_dosage	O
area	I-arm_dosage	O
(	I-arm_dosage	O
divided	I-arm_dosage	O
into	I-arm_dosage	O
two	I-arm_dosage	B-arm_dosage
doses	I-arm_dosage	I-arm_dosage
)	I-arm_dosage	I-arm_dosage
for	I-arm_dosage	I-arm_dosage
14	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
and	I-arm_dosage	I-arm_dosage
repeated	I-arm_dosage	I-arm_dosage
every	I-arm_dosage	I-arm_dosage
21	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
.	O	I-arm_dosage
The	O	O
assigned	O	O
treatment	O	O
was	O	O
continued	O	O
until	O	O
disease	O	O
progression	O	O
or	O	O
unacceptable	O	O
toxic	O	O
effects	O	O
occurred	O	O
.	O	O

The	O	O
median	O	O
OS	O	O
was	O	O
not	O	O
reached	O	O
as	O	O
of	O	O
May	O	O
2017	O	O
(	O	O
Fig	O	O
.	O	O
4	O	O
)	O	O
.	O	O
The	O	O
DOR	O	O
was	O	O
7.8	O	O
months	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
1.9	O	O
to	O	O
−	O	O
22.5	O	O
)	O	O
(	O	O
data	O	O
not	O	O
shown	O	O
)	O	O
.	O	O
Disease	O	O
progression	O	O
due	O	O
to	O	O
new	O	O
metastases	O	O
occurred	O	O
in	O	O
nine	O	O
patients	O	O
(	O	O
27.2	O	O
%	O	O
)	O	O
.	O	O
An	O	O
increase	O	O
in	O	O
the	O	O
size	O	O
of	O	O
the	O	O
pre	O	O
-	O	O
existing	O	O
lesions	O	O
occurred	O	O
in	O	O
five	O	O
(	O	O
15.2	O	O
%	O	O
)	O	O
patients	O	O
.	O	O
The	O	O
new	O	O
metastasis	O	O
-	O	O
free	O	O
survival	O	O
after	O	O
eribulin	B-arm_description	B-arm_description
and	O	O
S-1	B-arm_description	B-arm_description
combination	O	O
therapy	O	O
was	O	O
9.2	O	O
months	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
5.1	O	O
to	O	O
14.8	O	O
)	O	O
(	O	O
Fig	O	O
.	O	O
5	O	O
)	O	O
.	O	O

Prognostic	O	O
impact	O	O
of	O	O
pathological	O	O
complete	O	O
remission	O	O
after	O	O
preoperative	O	O
irradiation	O	O
in	O	O
patients	O	O
with	O	O
locally	O	O
advanced	O	O
head	O	O
and	O	O
neck	O	O
squamous	O	O
cell	O	O
carcinoma	O	O
:	O	O
re	O	O
-	O	O
analysis	O	O
of	O	O
a	O	O
phase	B-study_type	B-study_type
3	I-study_type	I-study_type
clinical	I-study_type	I-study_type
study	I-study_type	I-study_type
Prognostic	O	O
impact	O	O
of	O	O
pathological	O	O
complete	O	O
remission	O	O
after	O	O
preoperative	O	O
irradiation	O	O
in	O	O
patients	O	O
with	O	O
locally	O	O
advanced	O	O
head	O	O
and	O	O
neck	O	O
squamous	O	O
cell	O	O
carcinoma	O	O
:	O	O
re	O	O
-	O	O
analysis	O	O
of	O	O
a	O	O
phase	B-study_type	B-study_type
3	I-study_type	I-study_type
clinical	I-study_type	I-study_type
study	I-study_type	I-study_type
05	O	O
Mar	O	O
,	O	O
2014	O	O
05	O	O
Mar	O	O
,	O	O
2014	O	O
KaiWang	B-authors	B-authors

Department	O	O
of	O	O
Radiation	O	O
Oncology	O	O
,	O	O
National	O	O
Cancer	O	O
Center	O	O
/	O	O
Cancer	O	O
Hospital	O	O
,	O	O
Chinese	O	O
Academy	O	O
of	O	O
Medical	O	O
Sciences	O	O
and	O	O
Peking	O	O
Union	O	O
Medical	O	O
College	O	O
Beijing	O	O
China	O	O
JingweiLuo	B-authors	B-authors

Department	O	O
of	O	O
Radiation	O	O
Oncology	O	O
,	O	O
National	O	O
Cancer	O	O
Center	O	O
/	O	O
Cancer	O	O
Hospital	O	O
,	O	O
Chinese	O	O
Academy	O	O
of	O	O
Medical	O	O
Sciences	O	O
and	O	O
Peking	O	O
Union	O	O
Medical	O	O
College	O	O
Beijing	O	O
China	O	O
LiGao	B-authors	B-authors

Department	O	O
of	O	O
Radiation	O	O
Oncology	O	O
,	O	O
National	O	O
Cancer	O	O
Center	O	O
/	O	O
Cancer	O	O
Hospital	O	O
,	O	O
Chinese	O	O
Academy	O	O
of	O	O
Medical	O	O
Sciences	O	O
and	O	O
Peking	O	O
Union	O	O
Medical	O	O
College	O	O
Beijing	O	O
China	O	O
JunlinYi	B-authors	B-authors
yijunlin1969@163.com	O	B-authors

Department	O	O
of	O	O
Radiation	O	O
Oncology	O	O
,	O	O
National	O	O
Cancer	O	O
Center	O	O
/	O	O
Cancer	O	O
Hospital	O	O
,	O	O
Chinese	O	O
Academy	O	O
of	O	O
Medical	O	O
Sciences	O	O
and	O	O
Peking	O	O
Union	O	O
Medical	O	O
College	O	O
Beijing	O	O
China	O	O
YuanQu	B-authors	B-authors

Department	O	O
of	O	O
Radiation	O	O
Oncology	O	O
,	O	O
National	O	O
Cancer	O	O
Center	O	O
/	O	O
Cancer	O	O
Hospital	O	O
,	O	O
Chinese	O	O
Academy	O	O
of	O	O
Medical	O	O
Sciences	O	O
and	O	O
Peking	O	O
Union	O	O
Medical	O	O
College	O	O
Beijing	O	O
China	O	O
YuanTang	B-authors	B-authors

Department	O	O
of	O	O
Radiation	O	O
Oncology	O	O
,	O	O
National	O	O
Cancer	O	O
Center	O	O
/	O	O
Cancer	O	O
Hospital	O	O
,	O	O
Chinese	O	O
Academy	O	O
of	O	O
Medical	O	O
Sciences	O	O
and	O	O
Peking	O	O
Union	O	O
Medical	O	O
College	O	O
Beijing	O	O
China	O	O
WeixinLiu	B-authors	B-authors

China	O	O
Beijing	O	O
China	O	O
Department	O	O
of	O	O
Radiation	O	O
Oncology	O	O
,	O	O
National	O	O
Cancer	O	O
Center	O	O
/	O	O
Cancer	O	O
Hospital	O	O
,	O	O
Chinese	O	O
Academy	O	O
of	O	O
Medical	O	O
Sciences	O	O
and	O	O
Peking	O	O
Union	O	O
Medical	O	O
College	O	O
Beijing	O	O

China	O	O
Beijing	O	O
China	O	O
Department	O	O
of	O	O
Radiation	O	O
Oncology	O	O
,	O	O
National	O	O
Cancer	O	O
Center	O	O
/	O	O
Cancer	O	O
Hospital	O	O
,	O	O
Chinese	O	O
Academy	O	O
of	O	O
Medical	O	O
Sciences	O	O
and	O	O
Peking	O	O
Union	O	O
Medical	O	O
College	O	O
Beijing	O	O

China	O	O
Beijing	O	O
China	O	O
Department	O	O
of	O	O
Radiation	O	O
Oncology	O	O
,	O	O
National	O	O
Cancer	O	O
Center	O	O
/	O	O
Cancer	O	O
Hospital	O	O
,	O	O
Chinese	O	O
Academy	O	O
of	O	O
Medical	O	O
Sciences	O	O
and	O	O
Peking	O	O
Union	O	O
Medical	O	O
College	O	O
Beijing	O	O

China	O	O
Beijing	O	O
China	O	O
Prognostic	O	O
impact	O	O
of	O	O
pathological	O	O
complete	O	O
remission	O	O
after	O	O
preoperative	O	O
irradiation	O	O
in	O	O
patients	O	O
with	O	O
locally	O	O
advanced	O	O
head	O	O
and	O	O
neck	O	O
squamous	O	O
cell	O	O
carcinoma	O	O
:	O	O
re	O	O
-	O	O
analysis	O	O
of	O	O
a	O	O
phase	B-study_type	B-study_type
3	I-study_type	I-study_type
clinical	I-study_type	I-study_type
study	I-study_type	I-study_type
05	O	O
Mar	O	O
,	O	O
2014	O	O
05	O	O
Mar	O	O
,	O	O
2014	O	O
05	O	O
Mar	O	O
,	O	O
2014	O	O
10.1186	O	O
/	O	O
s13014	O	O
-	O	O
019	O	O
-	O	O
1428	O	O
-	O	O
4	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
analyzed	O	O
the	O	O
relationships	O	O
between	O	O
pathological	O	O
complete	O	O
remission	O	O
(	O	O
pCR	O	O
)	O	O
and	O	O
clinical	O	O
outcomes	O	O
in	O	O
these	O	O
72	O	O
non	O	O
-	O	O
responder	O	O
patients	O	O
.	O	O

Effects	O	O
of	O	O
the	O	O
MAML2	O	O
genetic	O	O
variants	O	O
in	O	O
glioma	O	O
susceptibility	O	O
and	O	O
prognosis	O	O
Effects	O	O
of	O	O
the	O	O
MAML2	O	O
genetic	O	O
variants	O	O
in	O	O
glioma	O	O
susceptibility	O	O
and	O	O
prognosis	O	O
29	O	O
September	O	O
2020	O	O
29	O	O
September	O	O
2020	O	O
MingZhang	B-authors	B-authors

Mastermind	O	O
-	O	O
like	O	O
transcriptional	O	O
co	O	O
-	O	O
activator	O	O
2	O	O
(	O	O
MAML2	O	O
)	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
mastermind	O	O
-	O	O
like	O	O
family	O	O
of	O	O
proteins	O	O
,	O	O
which	O	O
is	O	O
a	O	O
co	O	O
-	O	O
activator	O	O
of	O	O
the	O	O
oncogenic	O	O
NOTCH	O	O
signaling	O	O
pathway	O	O
[	O	O
8	O	O
]	O	O
.	O	O
NOTCH	O	O
signaling	O	O
activation	O	O
has	O	O
been	O	O
demonstrated	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
carcinogenesis	O	O
,	O	O
which	O	O
plays	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
cell	O	O
proliferation	O	O
,	O	O
metastasis	O	O
and	O	O
epithelial	O	O
-	O	O
mesenchymal	O	O
transition	O	O
in	O	O
many	O	O
diverse	O	O
solid	O	O
tumors	O	O
including	O	O
glioma	O	O
[	O	O
9,10	O	O
]	O	O
.	O	O
Several	O	O
studies	O	O
have	O	O
demonstrated	O	O
MAML2	O	O
abnormal	O	O
expression	O	O
in	O	O
various	O	O
cancers	O	O
,	O	O
such	O	O
as	O	O
mucoepidermoid	O	O
carcinoma	O	O
,	O	O
hidradenoma	O	O
and	O	O
breast	O	O
cancer	O	O
[	O	O
11][12][13	O	O
]	O	O
.	O	O
These	O	O
studies	O	O
have	O	O
suggested	O	O
that	O	O
MAML2	O	O
might	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
tumorigenesis	O	O
and	O	O
progression	O	O
of	O	O
cancers	O	O
.	O	O
Based	O	O
on	O	O
microarray	O	O
data	O	O
of	O	O
glioma	O	O
,	O	O
MAML2	O	O
as	O	O
a	O	O
novel	O	O
gene	O	O
related	O	O
to	O	O
glioma	O	O
was	O	O
identified	O	O
[	O	O
14	O	O
]	O	O
.	O	O
Additionally	O	O
,	O	O
epidemiological	O	O
studies	O	O
have	O	O
confirmed	O	O
that	O	O
polymorphisms	O	O
in	O	O
MAML2	O	O
,	O	O
a	O	O
NOTCH	O	O
pathway	O	O
gene	O	O
,	O	O
were	O	O
related	O	O
to	O	O
cancer	O	O
susceptibility	O	O
and	O	O
prognosis	O	O
[	O	O
15,16	O	O
]	O	O
.	O	O
However	O	O
,	O	O
no	O	O
previous	O	O
study	O	O
has	O	O
investigated	O	O
the	O	O
contribution	O	O
of	O	O
MAML2	O	O
variants	O	O
to	O	O
glioma	O	O
risk	O	O
and	O	O
prognosis	O	O
.	O	O

Genomic	O	O
DNA	O	O
was	O	O
extracted	O	O
from	O	O
EDTA	O	O
anticoagulated	O	O
peripheral	O	O
blood	O	O
samples	O	O
from	O	O
each	O	O
subject	O	O
using	O	O
a	O	O
Qiagen	O	O
DNA	O	O
Isolation	O	O
Kit	O	O
(	O	O
Qiagen	O	O
,	O	O
Valencia	O	O
,	O	O
CA	O	O
,	O	O
U.S.A.	O	O
)	O	O
according	O	O
to	O	O
the	O	O
manufacturer	O	O
's	O	O
instructions	O	O
,	O	O
and	O	O
stored	O	O
at	O	O
−20	O	O
•	O	O
C	O	O
until	O	O
additional	O	O
analysis	O	O
.	O	O
MAML2	O	O
mRNA	O	O
expression	O	O
analysis	O	O
in	O	O
glioma	O	O
was	O	O
performed	O	O
using	O	O
GEPIA	O	O
(	O	O
http	O	O
:	O	O
//gepia.cancer	O	O
-	O	O
pku.cn/	O	O
)	O	O
datasets	O	O
.	O	O
Seven	O	O
MAML2	O	O
SNPs	O	O
(	O	O
rs7107785	O	O
,	O	O
rs479825	O	O
,	O	O
rs7938889	O	O
,	O	O
rs11021499	O	O
,	O	O
rs7115578	O	O
,	O	O
rs4598633	O	O
and	O	O
rs485842	O	O
)	O	O
were	O	O
selected	O	O
as	O	O
candidate	O	O
SNPs	O	O
for	O	O
genotyping	O	O
in	O	O
the	O	O
current	O	O
study	O	O
.	O	O
These	O	O
SNPs	O	O
were	O	O
selected	O	O
based	O	O
on	O	O
a	O	O
minor	O	O
allele	O	O
frequency	O	O
(	O	O
MAF	O	O
)	O	O
of	O	O
>	O	O
5	O	O
%	O	O
in	O	O
Chinese	O	O
populations	O	O
and	O	O
with	O	O
a	O	O
pairwise	O	O
r	O	O
2	O	O
≥	O	O
0.80	O	O
,	O	O
from	O	O
the	O	O
NCBI	O	O
dbSNP	O	O
database	O	O
(	O	O
http://www.ncbi.nlm.nih.gov/projects/SNP	O	O
)	O	O
and	O	O
the	O	O
1000	O	O
Genomes	O	O
Project	O	O
data	O	O
(	O	O
http://www.internationalgenome.org/	O	O
)	O	O
.	O	O
To	O	O
evaluate	O	O
the	O	O
potential	O	O
function	O	O
of	O	O
the	O	O
selected	O	O
SNPs	O	O
,	O	O
we	O	O
conducted	O	O
in	O	O
silico	O	O
analysis	O	O
using	O	O
HaploReg	O	O
v4.1	O	O
(	O	O
https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php	O	O
)	O	O
and	O	O
SNPinfo	O	O
Web	O	O
Server	O	O
(	O	O
https://snpinfo.niehs.nih.gov/	O	O
)	O	O
.	O	O
MAML2	O	O
SNPs	O	O
genotyping	O	O
was	O	O
performed	O	O
Agena	O	O
MassARRAY	O	O
system	O	O
(	O	O
Agena	O	O
,	O	O
San	O	O
Diego	O	O
,	O	O
CA	O	O
,	O	O
U.S.A.	O	O
)	O	O
in	O	O
double	O	O
-	O	O
blinded	O	O
[	O	O
17,18	O	O
]	O	O
.	O	O
The	O	O
primers	O	O
used	O	O
in	O	O
amplification	O	O
and	O	O
single	O	O
base	O	O
extension	O	O
were	O	O
shown	O	O
in	O	O
Supplementary	O	O
Table	O	O
S1	O	O
,	O	O
which	O	O
was	O	O
designed	O	O
by	O	O
the	O	O
MassARRAY	O	O
Assay	O	O
Design	O	O
3.0	O	O
software	O	O
.	O	O
For	O	O
quality	O	O
control	O	O
,	O	O
the	O	O
call	O	O
rate	O	O
of	O	O
genotyping	O	O
>	O	O
95	O	O
%	O	O
,	O	O
and	O	O
approximately	O	O
10	O	O
%	O	O
of	O	O
the	O	O
samples	O	O
were	O	O
randomly	O	O
selected	O	O
for	O	O
repeated	O	O
analysis	O	O
,	O	O
of	O	O
which	O	O
the	O	O
reproducibility	O	O
was	O	O
100	O	O
%	O	O
.	O	O

Detailed	O	O
information	O	O
about	O	O
the	O	O
seven	O	O
selected	O	O
SNPs	O	O
is	O	O
displayed	O	O
in	O	O
Supplementary	O	O
Table	O	O
S2	O	O
.	O	O
Genotype	O	O
distribution	O	O
of	O	O
all	O	O
SNPs	O	O
among	O	O
controls	B-arm_description	O
was	O	O
in	O	O
agreement	O	O
with	O	O
HWE	O	O
(	O	O
P>0.05	O	O
)	O	O
.	O	O
In	O	O
silico	O	O
analysis	O	O
using	O	O
HaploReg	O	O
v4.1	O	O
and	O	O
SNPinfo	O	O
Web	O	O
Server	O	O
,	O	O
the	O	O
function	O	O
of	O	O
the	O	O
selected	O	O
SNPs	O	O
was	O	O
successfully	O	O
predicted	O	O
to	O	O
have	O	O
biological	O	O
functions	O	O
(	O	O
Supplementary	O	O
Table	O	O
S2	O	O
)	O	O
.	O	O
Furthermore	O	O
,	O	O
we	O	O
extracted	O	O
MAML2	O	O
expression	O	O
data	O	O
between	O	O
glioma	B-arm_description	O
patients	I-arm_description	O
and	O	O
healthy	B-arm_description	O
controls	I-arm_description	O
from	O	O
GEPIA	O	O
database	O	O
.	O	O
Supplementary	O	O
Figure	O	O
S1	O	O
showed	O	O
that	O	O
there	O	O
were	O	O
significant	O	O
differences	O	O
of	O	O
MAML2	O	O
expression	O	O
in	O	O
glioblastoma	O	O
multiforme	O	O
and	O	O
brain	O	O
lower	O	O
grade	O	O
glioma	O	O
compared	O	O
with	O	O
normal	O	O
tissue	O	O
(	O	O
P<0.01	O	O
)	O	O
.	O	O
Moreover	O	O
,	O	O
the	O	O
expression	O	O
of	O	O
MAMAL2	O	O
was	O	O
particularly	O	O
associated	O	O
with	O	O
the	O	O
prognosis	O	O
of	O	O
lower	O	O
grade	O	O
glioma	O	O
(	O	O
log	O	O
-	O	O
rank	O	O
P=0.0094	O	O
,	O	O
Supplementary	O	O
Figure	O	O
S2	O	O
)	O	O
.	O	O

Germany	O	O
Darmstadt	O	O
Germany	O	O
Survival	O	O
Analysis	B-study_type	O
in	O	O
Patients	O	O
with	O	O
Metastatic	O	O
Merkel	O	O
Cell	O	O
Carcinoma	O	O
Treated	O	O
with	O	O
Avelumab	B-arm_description	B-arm_description
July	O	O
26	O	O
,	O	O
2019	O	O
July	O	O
26	O	O
,	O	O
2019	O	O
July	O	O
26	O	O
,	O	O
2019	O	O
10.1007	O	O
/	O	O
s12325	O	O
-	O	O
019	O	O
-	O	O
01034	O	O
-	O	O
0	O	O
Received	O	O
:	O	O
May	O	O
20	O	O
,	O	O
2019	O	O

In	O	O
recent	O	O
years	O	O
this	O	O
trend	O	O
appears	O	O
to	O	O
be	O	O
shifting	O	O
[	O	O
7][8][9	O	O
]	O	O
,	O	O
likely	O	O
because	O	O
of	O	O
an	O	O
increasing	O	O
number	O	O
of	O	O
oncology	O	O
therapies	O	O
with	O	O
novel	O	O
mechanisms	O	O
of	O	O
action	O	O
receiving	O	O
regulatory	O	O
approvals	O	O
based	O	O
on	O	O
short	O	O
-	O	O
term	O	O
data	O	O
and/or	O	O
surrogate	O	O
endpoints	O	O
[	O	O
10,11	O	O
]	O	O
.	O	O
Specifically	O	O
,	O	O
the	O	O
novel	O	O
patterns	O	O
of	O	O
response	O	O
observed	O	O
with	O	O
immunooncology	O	O
(	O	O
IO	O	O
)	O	O
treatments	O	O
,	O	O
including	O	O
durable	O	O
response	O	O
for	O	O
a	O	O
fraction	O	O
of	O	O
patients	O	O
and	O	O
a	O	O
plateau	O	O
in	O	O
survival	O	O
curves	O	O
[	O	O
12][13][14	O	O
]	O	O
,	O	O
have	O	O
led	O	O
to	O	O
'	O	O
'	O	O
unconventional	O	O
'	O	O
'	O	O
survival	O	O
curves	O	O
,	O	O
inadequately	O	O
captured	O	O
with	O	O
standard	O	O
parametric	O	O
approaches	O	O
[	O	O
7][8][9][15][16][17][18	O	O
]	O	O
.	O	O

The	O	O
estimated	O	O
mean	O	O
OS	O	O
(	O	O
beyond	O	O
the	O	O
landmark	O	O
point	O	O
)	O	O
from	O	O
the	O	O
log	O	O
-	O	O
normal	O	O
model	O	O
for	O	O
patients	O	O
who	O	O
did	O	O
not	O	O
achieve	O	O
response	O	O
was	O	O
1.2	O	O
years	O	O
(	O	O
Fig	O	O
.	O	O
2a	O	O
)	O	O
(	O	O
see	O	O
ESM	O	O
Table	O	O
2	O	O
)	O	O
.	O	O

The	O	O
Efficacy	O	O
and	O	O
Safety	O	O
of	O	O
Modified	O	O
Docetaxel	B-arm_description	B-arm_description
,	O	O
Cisplatin	B-arm_description	B-arm_description
,	O	O
and	O	O
5-Fluorouracil	B-arm_description	O
Vs	O	O
.	O	O
Epirubicin	B-arm_description	B-arm_description
,	O	O
Oxaliplatin	B-arm_description	B-arm_description
,	O	O
and	O	O
Capecitabine	B-arm_description	B-arm_description
Regimen	O	O
in	O	O
the	O	O
Advanced	O	O
Gastric	O	O
Cancer	O	O
:	O	O
A	O	O
Randomized	B-study_type	B-study_type
Controlled	I-study_type	I-study_type
Clinical	I-study_type	I-study_type
Trial	I-study_type	I-study_type

Although	O	O
different	O	O
studies	O	O
have	O	O
been	O	O
conducted	O	O
on	O	O
the	O	O
efficacy	O	O
,	O	O
safety	O	O
,	O	O
and	O	O
tolerability	O	O
of	O	O
m	O	B-arm_description
-	O	I-arm_description
DCF	O	I-arm_description
and	O	O
EOX	O	O
regimens	O	O
,	O	O
few	O	O
studies	O	O
have	O	O
compared	O	O
these	O	O
two	O	O
regimens	O	O
.	O	O
Therefore	O	O
,	O	O
we	O	O
designed	O	O
and	O	O
performed	O	O
this	O	O
trial	O	O
to	O	O
determine	O	O
the	O	O
optimal	O	O
chemotherapy	O	O
regimen	O	O
for	O	O
patients	O	O
with	O	O
stage	O	O
IV	O	O
gastric	O	O
cancer	O	O
.	O	O

The	O	O
treatment	O	O
cycle	O	O
for	O	O
both	O	O
m	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
DCF	I-arm_description	I-arm_description
and	O	O
EOX	B-arm_description	B-arm_description
treatment	I-arm_description	O
regimens	O	O
was	O	O
repeated	O	O
every	O	O
three	O	O
weeks	O	O
for	O	O
a	O	O
maximum	O	O
of	O	O
eight	O	O
cycles	O	O
,	O	O
except	O	O
for	O	O
samples	O	O
with	O	O
disease	O	O
progression	O	O
,	O	O
unacceptable	O	O
toxicity	O	O
,	O	O
withdrawal	O	O
from	O	O
the	O	O
study	O	O
,	O	O
or	O	O
death	O	O
.	O	O
Researchers	O	O
graded	O	O
all	O	O
side	O	O
effects	O	O
and	O	O
toxic	O	O
effects	O	O
in	O	O
patients	O	O
according	O	O
to	O	O
the	O	O
criteria	O	O
of	O	O
the	O	O
National	O	O
Cancer	O	O
Institute	O	O
(	O	O
version	O	O
2.0	O	O
)	O	O
in	O	O
each	O	O
visit	O	O
.	O	O

Effects	O	O
of	O	O
dose	O	O
modifications	O	O
on	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
dacomitinib	O	O
for	O	O
EGFR	O	O
mutation	O	O
-	O	O
positive	O	O
non	O	O
-	O	O
small	O	O
-	O	O
cell	O	O
lung	O	O
cancer	O	O
17	O	O
July	O	O
2019	O	O

For	O	O
patients	O	O
with	O	O
dacomitinib	B-arm_description	B-arm_description
DRs	O	O
,	O	O
frequency	O	O
and	O	O
severity	O	O
of	O	O
AEs	O	O
of	O	O
interest	O	O
(	O	O
diarrhea	O	O
,	O	O
dermatitis	O	O
acneiform	O	O
,	O	O
stomatitis	O	O
and	O	O
paronychia	O	O
)	O	O
before	O	O
and	O	O
after	O	O
DR	B-arm_dosage	O
from	I-arm_dosage	O
45	I-arm_dosage	O
mg	I-arm_dosage	O
QD	I-arm_dosage	O
were	O	O
analyzed	O	O
by	O	O
NCI	O	O
-	O	O
CTCAE	O	O
grade	O	O
.	O	O
Plasma	O	O
steady	O	O
-	O	O
state	O	O
trough	O	O
concentrations	O	O
(	O	O
C	O	O
trough	O	O
,	O	O
ss	O	O
)	O	O
of	O	O
dacomitinib	B-arm_description	B-arm_description
were	O	O
collected	O	O
at	O	O
day	O	O
1	O	O
of	O	O
cycle	O	O
2	O	O
,	O	O
after	O	O
at	O	O
least	O	O
14	O	O
days	O	O
of	O	O
consecutive	O	O
dacomitinib	O	B-arm_description
45	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
dosing	O	O
.	O	O
These	O	O
measurements	O	O
were	O	O
used	O	O
to	O	O
compare	O	O
the	O	O
initial	O	O
plasma	O	O
exposure	O	O
in	O	O
patients	O	O
who	O	O
remained	O	O
at	O	O
45	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
for	O	O
the	O	O
duration	O	O
of	O	O
treatment	O	O
,	O	O
patients	O	O
whose	O	O
dose	O	O
was	O	O
reduced	O	O
to	O	O
30	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
as	O	O
the	O	O
lowest	O	O
dose	O	O
and	O	O
patients	O	O
whose	O	O
dose	O	O
was	O	O
reduced	O	O
to	O	O
15	O	O
mg	O	O
QD	O	O
as	O	O
the	O	O
lowest	O	O
dose	O	O
.	O	O
Kaplan	O	O
-	O	O
Meier	O	O
estimates	O	O
were	O	O
used	O	O
to	O	O
construct	O	O
survival	O	O
curves	O	O
and	O	O
calculate	O	O
median	O	O
(	O	O
with	O	O
95	O	O
%	O	O
CIs	O	O
)	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
and	O	O
OS	O	O
for	O	O
all	O	O
patients	O	O
in	O	O
the	O	O
dacomitinib	B-arm_description	B-arm_description
arm	I-arm_description	O
,	O	O
all	O	O
patients	O	O
in	O	O
the	O	O
dacomitinib	B-arm_description	B-arm_description
arm	I-arm_description	O
who	O	O
underwent	O	O
DR	O	O
(	O	O
to	O	O
either	O	O
30	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
or	O	O
15	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
as	O	O
lowest	O	O
dose	O	O
)	O	O
,	O	O
patients	O	O
in	O	O
the	O	O
dacomitinib	B-arm_description	B-arm_description
arm	I-arm_description	O
who	O	O
remained	O	O
at	O	O
45	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
for	O	O
the	O	O
duration	O	O
of	O	O
treatment	O	O
,	O	O
patients	O	O
in	O	O
the	O	O
dacomitinib	B-arm_description	B-arm_description
arm	I-arm_description	O
who	O	O
dose	O	O
reduced	O	O
to	O	O
30	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
as	O	O
lowest	O	O
dose	O	O
and	O	O
patients	O	O
who	O	O
dose	O	O
reduced	O	O
to	O	O
15	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
as	O	O
lowest	O	O
dose	O	O
.	O	O

Among	O	O
all	O	O
patients	O	O
starting	O	O
on	O	O
the	O	O
45-mg	B-arm_dosage	B-arm_dosage
QD	I-arm_dosage	I-arm_dosage
dose	I-arm_dosage	O
of	O	O
dacomitinib	B-arm_description	B-arm_description
(	O	O
n	O	O
=	O	O
227	O	O
)	O	O
,	O	O
DRs	O	O
due	O	O
to	O	O
AEs	O	B-arm_description
occurred	O	O
in	O	O
150	O	O
(	O	O
66.1	O	O
%	O	O
)	O	O
patients	O	O
,	O	O
while	O	O
77	O	O
(	O	O
33.9	O	O
%	O	O
)	O	O
patients	O	O
stayed	O	O
at	O	O
45	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
for	O	O
the	O	O
duration	O	O
of	O	O
treatment	O	O
.	O	O
In	O	O
total	O	O
87	O	O
patients	O	O
(	O	O
38.3	O	O
%	O	O
of	O	O
all	O	O
patients	O	O
randomized	O	O
to	O	O
the	O	O
dacomitinib	B-arm_description	B-arm_description
arm	I-arm_description	I-arm_description
)	O	O
reduced	O	O
to	O	O
30	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
as	O	O
the	O	O
lowest	O	O
dose	O	O
and	O	O
63	O	O
patients	O	O
(	O	O
27.8	O	O
%	O	O
of	O	O
all	O	O
patients	O	O
randomized	O	O
to	O	O
the	O	O
dacomitinib	O	B-arm_description
arm	O	I-arm_description
)	O	O
further	O	O
dose	O	O
reduced	O	O
to	O	O
15	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
as	O	O
the	O	O
lowest	O	O
dose	O	O
.	O	O
Median	O	O
time	O	O
to	O	O
DR	O	O
was	O	O
12.9	O	O
weeks	O	O
for	O	O
the	O	O
87	O	O
patients	O	O
with	O	O
30	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
as	O	O
the	O	O
lowest	O	O
dose	O	O
received	O	O
.	O	O
For	O	O
the	O	O
63	O	O
patients	O	O
who	O	O
received	O	O
15	O	O
mg	O	O
as	O	O
the	O	O
lowest	O	O
dose	O	O
,	O	O
median	O	O
time	O	O
to	O	O
the	O	O
first	O	O
DR	O	O
(	O	O
to	O	O
30	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
)	O	O
was	O	O
8.4	O	O
weeks	O	O
and	O	O
median	O	O
time	O	O
to	O	O
subsequent	O	O
DR	O	O
to	O	O
15	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
(	O	O
from	O	O
30	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
)	O	O
was	O	O
12.4	O	O
weeks	O	O
.	O	O
There	O	O
were	O	O
no	O	O
baseline	O	O
clinical	O	O
characteristics	O	O
that	O	O
were	O	O
predictive	O	O
of	O	O
which	O	O
patients	O	O
received	O	O
DRs	O	O
.	O	O
However	O	O
,	O	O
DRs	O	O
generally	O	O
occurred	O	O
more	O	O
frequently	O	O
in	O	O
females	O	O
.	O	O
Additionally	O	O
,	O	O
median	O	O
weights	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
lower	O	O
-	O	O
and	O	O
upper	O	O
-	O	O
range	O	O
bounds	O	O
for	O	O
weight	O	O
,	O	O
were	O	O
lower	O	O
in	O	O
patients	O	O
in	O	O
both	O	O
DR	O	B-arm_description
groups	O	O
than	O	O
in	O	O
those	O	O
remaining	O	O
at	O	O
45	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
for	O	O
the	O	O
duration	O	O
of	O	O
treatment	O	O
(	O	O
Supplementary	O	O
Table	O	O
1	O	O
)	O	O
.	O	O

Median	B-arm_efficacy_metric	B-arm_description
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
similar	O	O
in	O	O
all	O	O
dacomitinib	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
treated	I-arm_description	I-arm_description
patients	I-arm_description	O
(	O	O
n	O	O
=	O	O
227	O	O
)	O	O
and	O	O
those	B-arm_description	O
with	I-arm_description	O
DR	I-arm_description	B-arm_description
(	O	O
n	O	O
=	O	O
150	O	O
)	O	O
:	O	O
14.7	B-arm_efficacy_results	O
(	I-arm_efficacy_results	O
95	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
CI	I-arm_efficacy_results	O
:	I-arm_efficacy_results	O
11.1	I-arm_efficacy_results	O
-	I-arm_efficacy_results	O
16.6	I-arm_efficacy_results	O
)	I-arm_efficacy_results	O
months	I-arm_efficacy_results	O
and	O	O
16.6	B-arm_efficacy_results	O
(	I-arm_efficacy_results	O
95	I-arm_efficacy_results	O
%	I-arm_efficacy_results	O
CI	I-arm_efficacy_results	O
:	I-arm_efficacy_results	O
14.6	I-arm_efficacy_results	O
-	I-arm_efficacy_results	O
18.6	I-arm_efficacy_results	O
)	I-arm_efficacy_results	O
months	I-arm_efficacy_results	O
,	O	O
respectively	O	O
(	O	O
Figure	O	O
1A	O	O
)	O	O
.	O	O
Median	B-arm_efficacy_metric	B-arm_description
(	I-arm_efficacy_metric	O
95	I-arm_efficacy_metric	O
%	I-arm_efficacy_metric	O
CI	I-arm_efficacy_metric	O
)	I-arm_efficacy_metric	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
by	O	O
the	O	O
lowest	O	O
dose	O	O
received	O	O
was	O	O
as	O	O
follows	O	O
:	O	O
9.1	B-arm_efficacy_results	O
(	I-arm_efficacy_results	O
5.6	I-arm_efficacy_results	O
-	I-arm_efficacy_results	O
12.8	I-arm_efficacy_results	O
)	I-arm_efficacy_results	O
months	I-arm_efficacy_results	O
for	O	O
patients	B-arm_description	O
(	I-arm_description	O
n	I-arm_description	O
=	I-arm_description	O
77	I-arm_description	O
)	I-arm_description	O
who	I-arm_description	O
remained	I-arm_description	O
on	I-arm_description	O
45	I-arm_description	B-arm_dosage
mg	I-arm_description	I-arm_dosage
QD	I-arm_description	I-arm_dosage
and	O	O
12.9	B-arm_efficacy_results	O
(	I-arm_efficacy_results	O
10.8	I-arm_efficacy_results	O
-	I-arm_efficacy_results	O
16.7	I-arm_efficacy_results	O
)	I-arm_efficacy_results	O
months	I-arm_efficacy_results	O
for	O	O
patients	B-arm_description	O
(	I-arm_description	O
n	I-arm_description	O
=	I-arm_description	O
87	I-arm_description	O
)	I-arm_description	O
who	I-arm_description	O
received	I-arm_description	O
30	I-arm_description	B-arm_dosage
mg	I-arm_description	I-arm_dosage
QD	I-arm_description	I-arm_dosage
as	I-arm_description	O
the	I-arm_description	O
lowest	I-arm_description	O
dose	I-arm_description	O
and	O	O
31.2	B-arm_efficacy_results	O
(	I-arm_efficacy_results	O
16.5	I-arm_efficacy_results	O
-	I-arm_efficacy_results	O
35.1	I-arm_efficacy_results	O
)	I-arm_efficacy_results	O
months	I-arm_efficacy_results	O
for	O	O
patients	B-arm_description	O
(	I-arm_description	O
n	I-arm_description	O
=	I-arm_description	O
63	I-arm_description	O
)	I-arm_description	O
who	I-arm_description	O
received	I-arm_description	O
15	I-arm_description	B-arm_dosage
mg	I-arm_description	I-arm_dosage
QD	I-arm_description	I-arm_dosage
as	I-arm_description	O
the	I-arm_description	O
lowest	I-arm_description	O
dose	I-arm_description	O
(	O	O
Figure	O	O
1B	O	O
)	O	O
.	O	O
Median	O	B-arm_description
(	O	O
95	O	O
%	O	O
CI	O	O
)	O	O
OS	O	O
was	O	O
also	O	O
similar	O	O
in	O	O
all	O	O
dacomitinib	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
treated	I-arm_description	I-arm_description
patients	I-arm_description	O
(	O	O
n	O	O
=	O	O
227	O	O
)	O	O
and	O	O
those	O	O
with	O	O
DR	B-arm_description	B-arm_description
(	O	O
n	O	O
=	O	O
151	O	O
)	O	O
:	O	O
34.1	O	O
(	O	O
29.5	O	O
-	O	O
37.7	O	O
)	O	O
months	O	O
and	O	O
36.7	O	O
(	O	O
32.6	O	O
-not	O	O
reached	O	O
[	O	O
NR	O	O
]	O	O
)	O	O
months	O	O
,	O	O
respectively	O	O
(	O	O
Figure	O	O
2A	O	O
)	O	O
.	O	O
Median	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
)	O	O
OS	O	O
for	O	O
each	O	O
of	O	O
the	O	O
lowest	O	O
dose	O	O
groups	O	O
was	O	O
as	O	O
follows	O	O
:	O	O
22.0	O	O
(	O	O
15.6	O	O
-	O	O
26.4	O	O
)	O	O
months	O	O
for	O	O
patients	B-arm_description	O
(	I-arm_description	O
n	I-arm_description	O
=	I-arm_description	O
76	I-arm_description	O
)	I-arm_description	O
who	I-arm_description	O
remained	I-arm_description	O
on	I-arm_description	O
45	I-arm_description	B-arm_dosage
mg	I-arm_description	I-arm_dosage
QD	I-arm_description	I-arm_dosage
and	O	O
32.6	O	O
(	O	O
28.8	O	O
-	O	O
37.7	O	O
)	O	O
months	O	O
for	O	O
patients	B-arm_description	O
(	I-arm_description	O
n	I-arm_description	O
=	I-arm_description	O
88	I-arm_description	O
)	I-arm_description	O
who	I-arm_description	O
received	I-arm_description	O
30	I-arm_description	B-arm_dosage
mg	I-arm_description	I-arm_dosage
QD	I-arm_description	I-arm_dosage
as	I-arm_description	O
the	I-arm_description	O
lowest	I-arm_description	O
dose	I-arm_description	O
and	O	O
NR	O	O
(	O	O
34.7-NR	O	O
)	O	O
months	O	O
for	O	O
patients	B-arm_description	O
(	I-arm_description	O
n	I-arm_description	O
=	I-arm_description	O
63	I-arm_description	O
)	I-arm_description	O
who	I-arm_description	O
received	I-arm_description	O
15	I-arm_description	B-arm_dosage
mg	I-arm_description	I-arm_dosage
QD	I-arm_description	I-arm_dosage
as	I-arm_description	O
the	I-arm_description	O
lowest	I-arm_description	O
dose	I-arm_description	O
(	O	O
Figure	O	O
2B	O	O
)	O	O
.	O	O

•	O	O
Initial	O	O
plasma	O	O
dacomitinib	B-arm_description	B-arm_description
exposure	O	O
at	O	O
45	O	B-arm_dosage
mg	O	I-arm_dosage
QD	O	I-arm_dosage
was	O	O
generally	O	O
lower	O	O
in	O	O
patients	B-arm_description	O
remaining	I-arm_description	O
at	I-arm_description	O
45	I-arm_description	B-arm_dosage
mg	I-arm_description	I-arm_dosage
QD	I-arm_description	I-arm_dosage
compared	O	O
with	O	O
dose	B-arm_description	O
-	I-arm_description	O
reducing	I-arm_description	O
patients	I-arm_description	O
.	O	O

•	O	O
Tolerability	O	O
-	O	O
guided	O	O
dose	O	O
modifications	O	O
enabled	O	O
patients	O	O
to	O	O
manage	O	O
AEs	O	O
and	O	O
continue	O	O
with	O	O
dacomitinib	B-arm_description	B-arm_description
treatment	O	O
and	O	O
benefit	O	O
from	O	O
improvement	O	O
in	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
and	O	O
OS	O	O
.	O	O

Novartis	O	O
,	O	O
Zimmer	O	O
Becton	O	O
Dickinson	O	O
Baxter	O	O
,	O	O
Merck	O	O
,	O	O
Pfizer	O	O
,	O	O
Stryker	O	O
,	O	O
Procter	O	O
&	O	O
Gamble	O	O
,	O	O
Walgreens	O	O
Novartis	O	O
,	O	O
Zimmer	O	O
Cardinal	O	O
Health	O	O
,	O	O
Express	O	O
Scripts	O	O
Becton	O	O
Dickinson	O	O

Clinical	O	O
response	O	O
to	O	O
CRT	O	O
was	O	O
evaluated	O	O
10	O	O
to	O	O
16	O	O
weeks	O	O
after	O	O
CRT	O	O
with	O	O
a	O	O
PET	O	O
/	O	O
CT	O	O
and	O	O
clinical	O	O
examinations	O	O
by	O	O
the	O	O
treating	O	O
radiation	O	O
oncologist	O	O
and	O	O
head	O	O
and	O	O
neck	O	O
surgeon	O	O
.	O	O
Decisions	O	O
for	O	O
surgical	O	O
intervention	O	O
(	O	O
ie	O	O
,	O	O
biopsy	O	O
,	O	O
neck	O	O
dissection	O	O
)	O	O
were	O	O
based	O	O
on	O	O
the	O	O
PET	O	O
/	O	O
CT	O	O
and	O	O
clinical	O	O
evaluations	O	O
demonstrating	O	O
suspicion	O	O
of	O	O
residual	O	O
tumor	O	O
.	O	O

Clinician	O	O
assessments	O	O
of	O	O
toxicity	O	O
(	O	O
National	O	O
Cancer	O	O
Institute	O	O
's	O	O
Common	O	O
Terminology	O	O
Criteria	O	O
for	O	O
Adverse	O	O
Events	O	O
[	O	O
CTCAE	O	O
]	O	O
version	O	O
4.03	O	O
)	O	O
and	O	O
patient	O	O
self	O	O
-	O	O
reported	O	O
symptoms	O	O
(	O	O
patient	O	O
-	O	O
reported	O	O
outcomes	O	O
version	O	O
of	O	O
the	O	O
CTCAE	O	O
[	O	O
PRO	O	O
-	O	O
CTCAE	O	O
]	O	O
)	O	O
were	O	O
collected	O	O
before	O	O
treatment	O	O
,	O	O
weekly	O	O
during	O	O
treatment	O	O
,	O	O
and	O	O
during	O	O
subsequent	O	O
follow	O	O
-	O	O
up	O	O
visits	O	O
.	O	O
16,17	O	O
Thirty	O	O
head	O	O
and	O	O
neck	O	O
-	O	O
specific	O	O
items	O	O
were	O	O
selected	O	O
from	O	O
the	O	O
PRO	O	O
-	O	O
CTCAE	O	O
.	O	O
18	O	O
Patients	O	O
also	O	O
completed	O	O
European	O	O
Organisation	O	O
for	O	O
Research	O	O
and	O	O
Treatment	O	O
of	O	O
Cancer	O	O
Quality	O	O
of	O	O
Life	O	O
Questionnaire	O	O
(	O	O
EORTC	O	O
QLQ	O	O
)	O	O
C30	O	O
,	O	O
EORTC	O	O
QLQ	O	O
H&N35	O	O
,	O	O
and	O	O
Eating	O	O
Assessment	O	O
Tool	O	O
10	O	O
questionnaires	O	O
before	O	O
treatment	O	O
,	O	O
weekly	O	O
during	O	O
treatment	O	O
,	O	O
and	O	O
during	O	O
subsequent	O	O
follow	O	O
-	O	O
up	O	O
visits	O	O
.	O	O
[	O	O
19][20][21	O	O
]	O	O
Modified	O	O
barium	O	O
swallow	O	O
studies	O	O
were	O	O
performed	O	O
before	O	O
treatment	O	O
,	O	O
6	O	O
to	O	O
8	O	O
weeks	O	O
after	O	O
treatment	O	O
,	O	O
and	O	O
6	O	O
months	O	O
after	O	O
treatment	O	O
.	O	O
The	O	O
Rosenbek	O	O
Penetration	O	O
Aspiration	O	O
Scale	O	O
was	O	O
used	O	O
to	O	O
quantify	O	O
dysphagia	O	O
.	O	O
22	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
of	O	O
this	O	O
study	O	O
was	O	O
2-year	B-arm_efficacy_metric	O
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
.	O	O
The	O	O
reported	O	O
PFS	O	B-arm_efficacy_metric
for	O	O
patients	O	O
with	O	O
HPV	O	O
-	O	O
associated	O	O
OPSCC	O	O
treated	O	O
with	O	O
standard	O	O
-	O	O
intensity	O	O
70	O	O
Gy	O	O
and	O	O
cisplatin	O	O
in	O	O
RTOG	O	O
0129	O	O
was	O	O
74	O	O
%	O	O
(	O	O
3	O	O
year	O	O
)	O	O
and	O	O
in	O	O
RTOG	O	O
1016	O	O
was	O	O
78	O	O
%	O	O
(	O	O
5	O	O
year	O	O
)	O	O
.	O	O
1	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
was	O	O
defined	O	O
as	O	O
the	O	O
time	O	O
from	O	O
the	O	O
beginning	O	O
of	O	O
treatment	O	O
to	O	O
cancer	O	O
progression	O	O
or	O	O
death	O	O
.	O	O
Power	O	O
calculations	O	O
were	O	O
based	O	O
on	O	O
the	O	O
null	O	O
hypothesis	O	O
that	O	O
the	O	O
true	O	O
2-year	B-arm_efficacy_metric	O
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
rate	I-arm_efficacy_metric	O
was	O	O
87	B-arm_efficacy_results	O
%	I-arm_efficacy_results	O
,	O	O
with	O	O
the	O	O
alternative	O	O
hypothesis	O	O
being	O	O
that	O	O
the	O	O
2-year	B-arm_efficacy_metric	O
PFS	I-arm_efficacy_metric	B-arm_efficacy_metric
rate	I-arm_efficacy_metric	O
was	O	O
0.80	B-arm_efficacy_results	O
(	O	O
or	O	O
less	O	O
)	O	O
.	O	O
For	O	O
a	O	O
planned	O	O
total	O	O
sample	O	O
size	O	O
of	O	O
90	O	O
,	O	O
the	O	O
null	O	O
hypothesis	O	O
would	O	O
have	O	O
been	O	O
rejected	O	O
if	O	O
18	O	O
or	O	O
more	O	O
patients	O	O
had	O	O
a	O	O
tumor	O	O
recurrence	O	O
or	O	O
death	O	O
,	O	O
with	O	O
a	O	O
type	O	O
1	O	O
error	O	O
of	O	O
less	O	O
than	O	O
0.05	O	O
.	O	O
A	O	O
pathologically	O	O
positive	O	O
lymph	O	O
node	O	O
that	O	O
was	O	O
found	O	O
on	O	O
a	O	O
neck	O	O
dissection	O	O
that	O	O
was	O	O
performed	O	O
because	O	O
of	O	O
the	O	O
results	O	O
of	O	O
the	O	O
3-month	O	O
post	O	O
-	O	O
treatment	O	O
PET	O	O
/	O	O
CT	O	O
was	O	O
not	O	O
classified	O	O
as	O	O
a	O	O
regional	O	O
failure	O	O
.	O	O
This	O	O
neck	O	O
dissection	O	O
was	O	O
prespecified	O	O
in	O	O
the	O	O
protocol	O	O
design	O	O
,	O	O
outside	O	O
of	O	O
the	O	O
trial	O	O
is	O	O
standard	O	O
of	O	O
care	O	O
,	O	O
and	O	O
was	O	O
considered	O	O
a	O	O
planned	O	O
part	O	O
of	O	O
the	O	O
treatment	O	O
.	O	O
Kaplan	O	O
Meier	O	O
estimates	O	O
of	O	O
local	O	O
control	O	O
,	O	O
regional	O	O
control	O	O
,	O	O
local	O	O
-	O	O
regional	O	O
control	O	O
(	O	O
LRC	O	O
)	O	O
,	O	O
distant	O	O
metastasis	O	O
-	O	O
free	O	O
survival	O	O
(	O	O
DMFS	O	O
)	O	O
,	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
causespecific	O	O
survival	O	O
,	O	O
and	O	O
OS	O	O
were	O	O
calculated	O	O
.	O	O

Pertinent	O	O
patient	O	O
-	O	O
reported	O	O
acute	O	O
nonhematologic	O	O
toxicity	O	O
is	O	O
listed	O	O
in	O	O
Table	O	O
3	O	O
.	O	O
Complete	O	O
EORTC	O	O
QLQ	O	O
C30	O	O
and	O	O
EORTC	O	O
QLQ	O	O
H&N-35	O	O
and	O	O
Eating	O	O
Assessment	O	O
Tool	O	O
10	O	O
results	O	O
are	O	O
listed	O	O
in	O	O
Appendix	O	O
Table	O	O
A1	O	O
(	O	O
online	O	O
only	O	O
)	O	O
.	O	O
Selected	O	O
domains	O	O
and	O	O
symptoms	O	O
from	O	O
these	O	O
QLQs	O	O
are	O	O
shown	O	O
in	O	O
Fig	O	O
2	O	O
.	O	O
As	O	O
expected	O	O
,	O	O
we	O	O
observed	O	O
declines	O	O
in	O	O
global	O	O
QOL	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
symptom	O	O
scores	O	O
soon	O	O
after	O	O
the	O	O
completion	O	O
of	O	O
treatment	O	O
.	O	O
All	O	O
QOL	O	O
items	O	O
,	O	O
domains	O	O
,	O	O
and	O	O
symptom	O	O
scores	O	O
had	O	O
returned	O	O
to	O	O
baseline	O	O
by	O	O
6	O	O
months	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
dry	O	O
mouth	O	O
and	O	O
sticky	O	O
saliva	O	O
.	O	O
There	O	O
was	O	O
continued	O	O
improvement	O	O
in	O	O
these	O	O
symptoms	O	O
beyond	O	O
1	O	O
year	O	O
.	O	O
Notably	O	O
,	O	O
patients	O	O
reported	O	O
that	O	O
their	O	O
swallowing	O	O
function	O	O
returned	O	O
to	O	O
baseline	O	O
.	O	O

First	O	O
draft	O	O
submitted	O	O
:	O	O
9	O	O
October	O	O
2019	O	O
;	O	O
Accepted	O	O
for	O	O
publication	O	O
:	O	O
1	O	O
November	O	O
2019	O	O
;	O	O
2618	O	O
•	O	O
gastrointestinal	O	O
stromal	O	O
tumor	O	O
•	O	O
KIT	O	O
•	O	O
PDGFRA	O	O
•	O	O
Phase	B-study_type	B-study_type
III	I-study_type	I-study_type
trial	I-study_type	I-study_type
•	O	O
receptor	O	O
tyrosine	O	O
kinase	O	O
•	O	O
ripretinib	B-arm_description	B-arm_description
•	O	O
sarcoma	O	O
•	O	O
targeted	O	O
therapy	O	O
•	O	O
tyrosine	O	O
kinase	O	O
inhibitor	O	O
JohnNemunaitis	B-authors	B-authors
john.nemunaitis@utoledo.edu	O	O

Despite	O	O
significant	O	O
improvement	O	O
in	O	O
outcomes	O	O
compared	O	O
with	O	O
those	O	O
in	O	O
the	O	O
pre	O	O
-	O	O
TKI	O	O
therapy	O	O
era	O	O
,	O	O
response	O	O
to	O	O
imatinib	O	O
is	O	O
not	O	O
experienced	O	O
by	O	O
all	O	O
patients	O	O
,	O	O
and	O	O
most	O	O
patients	O	O
with	O	O
GIST	O	O
will	O	O
ultimately	O	O
develop	O	O
resistance	O	O
to	O	O
imatinib	O	O
,	O	O
most	O	O
commonly	O	O
due	O	O
to	O	O
the	O	O
development	O	O
of	O	O
secondary	O	O
mutations	O	O
in	O	O
KIT	O	O
[	O	O
33,[39][40][41][42][43	O	O
]	O	O
.	O	O
Secondary	O	O
resistance	O	O
mutations	O	O
usually	O	O
arise	O	O
in	O	O
the	O	O
catalytic	O	O
domain	O	O
of	O	O
the	O	O
kinase	O	O
:	O	O
at	O	O
the	O	O
switch	O	O
pocket	O	O
,	O	O
which	O	O
typically	O	O
occur	O	O
in	O	O
KIT	O	O
exons	O	O
13	O	O
and	O	O
14	O	O
or	O	O
PDGFRA	O	O
exons	O	O
14	O	O
and	O	O
15	O	O
and	O	O
sterically	O	O
disrupt	O	O
drug	O	O
binding	O	O
or	O	O
conformationally	O	O
activate	O	O
KIT	O	O
and	O	O
in	O	O
the	O	O
activation	O	O
loop	O	O
switch	O	O
encoded	O	O
by	O	O
KIT	O	O
exons	O	O
17	O	O
and	O	O
18	O	O
and	O	O
PDGFRA	O	O
exon	O	O
18	O	O
[	O	O
29,44,45	O	O
]	O	O
.	O	O
Activation	O	O
loop	O	O
mutations	O	O
act	O	O
by	O	O
shifting	O	O
the	O	O
kinase	O	O
into	O	O
an	O	O
activated	O	O
Type	O	O
I	O	O
or	O	O
on	O	O
-	O	O
state	O	O
conformation	O	O
that	O	O
is	O	O
less	O	O
amenable	O	O
to	O	O
drug	O	O
binding	O	O
by	O	O
any	O	O
of	O	O
the	O	O
approved	O	O
Type	O	O
II	O	O
TKIs	O	O
[	O	O
46	O	O
]	O	O
.	O	O
Although	O	O
uncommon	O	O
in	O	O
primary	O	O
GIST	O	O
(	O	O
1	O	O
-	O	O
2	O	O
%	O	O
of	O	O
newly	O	O
diagnosed	O	O
cases	O	O
)	O	O
,	O	O
mutations	O	O
in	O	O
exons	O	O
13	O	O
,	O	O
14	O	O
and	O	O
17	O	O
are	O	O
often	O	O
responsible	O	O
for	O	O
acquired	O	O
imatinib	O	O
resistance	O	O
[	O	O
38	O	O
]	O	O
,	O	O
with	O	O
exon	O	O
17	O	O
mutations	O	O
alone	O	O
accounting	O	O
for	O	O
as	O	O
many	O	O
as	O	O
50	O	O
%	O	O
of	O	O
the	O	O
acquired	O	O
resistance	O	O
cases	O	O
to	O	O
imatinib	O	O
;	O	O
exon	O	O
17	O	O
mutations	O	O
also	O	O
result	O	O
in	O	O
resistance	O	O
to	O	O
sunitinib	O	O
[	O	O
38,47	O	O
]	O	O
.	O	O
Figure	O	O
3	O	O
depicts	O	O
the	O	O
secondary	O	O
KIT	O	O
mutations	O	O
in	O	O
patients	O	O
with	O	O
GIST	O	O
across	O	O
exons	O	O
13	O	O
,	O	O
14	O	O
,	O	O
17	O	O
and	O	O
18	O	O
.	O	O

PF-06439535	B-arm_description	O
(	O	O
a	O	O
Bevacizumab	O	B-arm_description
Biosimilar	O	O
)	O	O
Compared	O	O
with	O	O
Reference	O	O
Bevacizumab	O	B-arm_description
(	O	O
Avastin	O	B-arm_description
®	O	O
)	O	O
,	O	O
Both	O	O
Plus	O	O
Paclitaxel	B-arm_description	B-arm_description
and	I-arm_description	O
Carboplatin	I-arm_description	B-arm_description
,	O	O
as	O	O
First	O	O
-	O	O
Line	O	O
Treatment	O	O
for	O	O
Advanced	O	O
Non	O	O
-	O	O
Squamous	O	O
Non	O	O
-	O	O
Small	O	O
-	O	O
Cell	O	O
Lung	O	O
Cancer	O	O
:	O	O
A	O	O
Randomized	B-study_type	B-study_type
,	I-study_type	I-study_type
Double	I-study_type	I-study_type
-	I-study_type	I-study_type
Blind	I-study_type	I-study_type
Study	I-study_type	I-study_type
23	O	O
July	O	O
2019	O	O

National	O	O
and	O	O
Kapodistrian	O	O
University	O	O
of	O	O
Athens	O	O
Sotiria	O	O
General	O	O
Hospital	O	O
Athens	O	O
Greece	O	O
VladimirVladimirov	B-authors	B-authors
Outpatient	O	O
Department	O	O
Pyatigorsk	O	O
Oncology	O	O
Dispensary	O	O
Stavropol	O	O
Region	O	O
Pyatigorsk	O	O
Russian	O	O
Federation	O	O
Outpatient	O	O
Department	O	O
Pyatigorsk	O	O
Oncology	O	O
Dispensary	O	O
Stavropol	O	O
Region	O	O
Pyatigorsk	O	O
Russian	O	O
Federation	O	O
ManuelaZereu	B-authors	B-authors
Nucleo	O	O
de	O	O
Oncologia	O	O
Santa	O	O
Casa	O	O
Hospital	O	O

PF-06439535	B-arm_description	O
(	O	O
a	O	O
Bevacizumab	O	B-arm_description
Biosimilar	O	O
)	O	O
Compared	O	O
with	O	O
Reference	O	O
Bevacizumab	B-arm_description	B-arm_description
(	I-arm_description	O
Avastin	I-arm_description	B-arm_description
®	I-arm_description	O
)	I-arm_description	O
,	O	O
Both	O	O
Plus	O	B-arm_description
Paclitaxel	B-arm_description	B-arm_description
and	B-arm_description	O
Carboplatin	B-arm_description	B-arm_description
,	O	O
as	O	O
First	O	O
-	O	O
Line	O	O
Treatment	O	O
for	O	O
Advanced	O	O
Non	O	O
-	O	O
Squamous	O	O
Non	O	O
-	O	O
Small	O	O
-	O	O
Cell	O	O
Lung	O	O
Cancer	O	O
:	O	O
A	O	O
Randomized	B-study_type	B-study_type
,	I-study_type	I-study_type
Double	I-study_type	I-study_type
-	I-study_type	I-study_type
Blind	I-study_type	I-study_type
Study	I-study_type	I-study_type
NielsReinmuth	B-authors	B-authors
n.reinmuth@asklepios.com	O	O

When	O	O
PF-06439535	B-arm_description	B-arm_description
or	O	O
bevacizumab	B-arm_description	B-arm_description
-	O	O
EU	O	O
was	O	O
combined	O	O
with	O	O
paclitaxel	B-arm_description	O
and	I-arm_description	O
carboplatin	B-arm_description	O
in	O	O
the	O	O
first	O	O
-	O	O
line	O	O
treatment	O	O
of	O	O
advanced	O	O
non	O	O
-	O	O
squamous	O	O
non	O	O
-	O	O
small	O	O
-	O	O
cell	O	O
lung	O	O
cancer	O	O
,	O	O
we	O	O
identified	O	O
no	O	O
notable	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
treatment	O	O
groups	O	O
with	O	O
respect	O	O
to	O	O
efficacy	O	O
,	O	O
safety	O	O
,	O	O
pharmacokinetics	O	O
,	O	O
or	O	O
immunogenicity	O	O
.	O	O

After	O	O
chemotherapy	O	O
had	O	O
been	O	O
discontinued	O	O
,	O	O
PF-06439535	B-arm_description	B-arm_description
or	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
monotherapy	O	O
could	O	O
be	O	O
administered	O	O
until	O	O
disease	O	O
progression	O	O
(	O	O
defined	O	O
per	O	O
RECIST	O	O
1.1	O	O
)	O	O
,	O	O
unacceptable	O	O
toxicity	O	O
,	O	O
discretion	O	O
of	O	O
the	O	O
investigator	O	O
,	O	O
death	O	O
,	O	O
withdrawal	O	O
of	O	O
consent	O	O
,	O	O
or	O	O
the	O	O
end	O	O
of	O	O
the	O	O
study	O	O
,	O	O
whichever	O	O
came	O	O
first	O	O
.	O	O
The	O	O
dose	O	O
and	O	O
regimen	O	O
for	O	O
PF-06439535	B-arm_description	B-arm_description
and	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
were	O	O
chosen	O	O
to	O	O
be	O	O
consistent	O	O
with	O	O
the	O	O
product	O	O
labeling	O	O
of	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
.	O	O
The	O	O
chemotherapy	O	O
given	O	O
and	O	O
the	O	O
regimens	O	O
used	O	O
were	O	O
considered	O	O
standard	O	O
of	O	O
care	O	O
.	O	O

Tumor	O	O
assessments	O	O
included	O	O
computed	O	O
tomography	O	O
(	O	O
CT	O	O
)	O	O
or	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
scans	O	O
of	O	O
the	O	O
head	O	O
,	O	O
chest	O	O
,	O	O
abdomen	O	O
(	O	O
including	O	O
adrenals	O	O
)	O	O
,	O	O
and	O	O
other	O	O
disease	O	O
sites	O	O
such	O	O
as	O	O
the	O	O
pelvis	O	O
if	O	O
clinically	O	O
indicated	O	O
.	O	O
CT	O	O
scans	O	O
were	O	O
performed	O	O
with	O	O
contrast	O	O
media	O	O
unless	O	O
contraindicated	O	O
for	O	O
medical	O	O
reasons	O	O
.	O	O
MRI	O	O
was	O	O
only	O	O
used	O	O
when	O	O
considered	O	O
more	O	O
appropriate	O	O
than	O	O
CT	O	O
or	O	O
when	O	O
there	O	O
was	O	O
a	O	O
contraindication	O	O
for	O	O
use	O	O
of	O	O
CT	O	O
with	O	O
contrast	O	O
.	O	O
For	O	O
a	O	O
given	O	O
patient	O	O
,	O	O
the	O	O
same	O	O
method	O	O
of	O	O
tumor	O	O
assessment	O	O
was	O	O
used	O	O
throughout	O	O
the	O	O
trial	O	O
.	O	O
CT	O	O
or	O	O
MRI	O	O
assessments	O	O
were	O	O
performed	O	O
every	O	O
6	O	O
weeks	O	O
(	O	O
±	O	O
7	O	O
days	O	O
)	O	O
until	O	O
week	O	O
25	O	O
(	O	O
based	O	O
on	O	O
date	O	O
of	O	O
randomization	O	O
)	O	O
.	O	O
After	O	O
week	O	O
25	O	O
,	O	O
assessments	O	O
were	O	O
performed	O	O
every	O	O
9	O	O
weeks	O	O
(	O	O
±	O	O
7	O	O
days	O	O
)	O	O
until	O	O
1	O	O
year	O	O
from	O	O
randomization	O	O
.	O	O
Responses	O	O
were	O	O
required	O	O
to	O	O
be	O	O
confirmed	O	O
by	O	O
a	O	O
second	O	O
set	O	O
of	O	O
scans	O	O
obtained	O	O
6	O	O
weeks	O	O
(	O	O
±	O	O
7	O	O
days	O	O
)	O	O
later	O	O
in	O	O
accordance	O	O
with	O	O
RECIST	O	O
1.1	O	O
.	O	O
Additionally	O	O
,	O	O
brain	O	O
scans	O	O
were	O	O
performed	O	O
as	O	O
clinically	O	O
indicated	O	O
and	O	O
at	O	O
the	O	O
time	O	O
of	O	O
a	O	O
confirmatory	O	O
scan	O	O
for	O	O
CR	O	O
/	O	O
PR	O	O
.	O	O
Patients	O	O
who	O	O
continued	O	O
to	O	O
receive	O	O
study	O	O
treatment	O	O
after	O	O
1	O	O
year	O	O
had	O	O
tumor	O	O
assessments	O	O
performed	O	O
according	O	O
to	O	O
local	O	O
standard	O	O
of	O	O
care	O	O
.	O	O

Blood	O	O
samples	O	O
for	O	O
assessment	O	O
of	O	O
immunogenicity	O	O
were	O	O
collected	O	O
pre	O	O
-	O	O
dose	O	O
at	O	O
specified	O	O
study	O	O
cycles	O	O
and	O	O
analyzed	O	O
for	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
ADAs	O	O
(	O	O
anti	O	O
-	O	O
bevacizumab	O	O
or	O	O
anti	O	O
-	O	O
PF-06439535	O	O
antibodies	O	O
)	O	O
.	O	O
A	O	O
single	O	O
,	O	O
sensitive	O	O
,	O	O
specific	O	O
,	O	O
and	O	O
semi	O	O
-	O	O
quantitative	O	O
electrochemiluminescent	O	O
immunoassay	O	O
was	O	O
used	O	O
.	O	O
The	O	O
ADA	O	O
assay	O	O
had	O	O
been	O	O
validated	O	O
and	O	O
used	O	O
biotinylated	O	O
and	O	O
ruthenium	O	O
-	O	O
labeled	O	O
PF-06439535	O	B-arm_description
as	O	O
reagents	O	O
.	O	O
Analysis	O	O
of	O	O
ADA	O	O
samples	O	O
followed	O	O
a	O	O
tiered	O	O
approach	O	O
of	O	O
screening	O	O
,	O	O
confirmation	O	O
,	O	O
and	O	O
titer	O	O
determination	O	O
.	O	O
Only	O	O
those	O	O
samples	O	O
confirmed	O	O
positive	O	O
for	O	O
ADAs	O	O
were	O	O
further	O	O
tested	O	O
for	O	O
NAbs	O	O
.	O	O
The	O	O
NAb	O	O
analysis	O	O
was	O	O
conducted	O	O
using	O	O
a	O	O
single	O	O
,	O	O
validated	O	O
,	O	O
quasi	O	O
-	O	O
quantitative	O	O
enzyme	O	O
-	O	O
linked	O	O
immunosorbent	O	O
assay	O	O
(	O	O
ELISA	O	O
)	O	O
that	O	O
utilized	O	O
PF-06439535	O	O
as	O	O
a	O	O
reagent	O	O
.	O	O
Analysis	O	O
of	O	O
NAb	O	O
samples	O	O
followed	O	O
a	O	O
tiered	O	O
approach	O	O
of	O	O
screening	O	O
and	O	O
titer	O	O
determination	O	O
.	O	O

The	O	O
primary	O	O
efficacy	O	O
analysis	O	O
for	O	O
statistical	O	O
equivalence	O	O
was	O	O
performed	O	O
when	O	O
all	O	O
patients	O	O
had	O	O
completed	O	O
the	O	O
week	O	O
25	O	O
visit	O	O
to	O	O
support	O	O
the	O	O
primary	O	O
endpoint	O	O
analysis	O	O
or	O	O
had	O	O
discontinued	O	O
from	O	O
the	O	O
disease	O	O
evaluation	O	O
period	O	O
earlier	O	O
.	O	O
All	O	O
other	O	O
analyses	O	O
presented	O	O
herein	O	O
are	O	O
based	O	O
on	O	O
final	O	O
data	O	O
after	O	O
study	O	O
completion	O	O
.	O	O
All	O	O
statistical	O	O
analyses	O	O
were	O	O
conducted	O	O
as	O	O
specified	O	O
in	O	O
the	O	O
statistical	O	O
analysis	O	O
plan	O	O
,	O	O
which	O	O
can	O	O
be	O	O
accessed	O	O
at	O	O
ClinicalTrials.gov	O	O
.	O	O

Overall	O	O
,	O	O
the	O	O
disposition	O	O
of	O	O
patients	O	O
between	O	O
treatment	O	O
groups	O	O
was	O	O
comparable	O	O
.	O	O
Among	O	O
the	O	O
714	O	O
patients	O	O
in	O	O
the	O	O
safety	O	O
population	O	O
,	O	O
the	O	O
primary	O	O
reason	O	O
for	O	O
discontinuation	O	O
of	O	O
PF-06439535	B-arm_description	B-arm_description
or	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
was	O	O
objective	O	O
disease	O	O
progression	O	O
or	O	O
relapse	O	O
(	O	O
176	O	O
[	O	O
49.4	O	O
%	O	O
]	O	O
patients	O	O
in	O	O
the	O	O
PF-06439535	B-arm_description	B-arm_description
group	I-arm_description	I-arm_description
and	O	O
207	O	O
[	O	O
57.8	O	O
%	O	O
]	O	O
patients	O	O
in	O	O
the	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
group	I-arm_description	I-arm_description
)	O	O
(	O	O
ESM	O	O
,	O	O
Table	O	O
S2	O	O
)	O	O
.	O	O
Including	O	O
the	O	O
survival	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
,	O	O
the	O	O
most	O	O
frequent	O	O
reason	O	O
for	O	O
discontinuation	O	O
from	O	O
the	O	O
study	O	O
was	O	O
death	O	O
(	O	O
136	O	O
[	O	O
38.2	O	O
%	O	O
]	O	O
patients	O	O
in	O	O
the	O	O
PF-06439535	B-arm_description	B-arm_description
group	I-arm_description	I-arm_description
and	O	O
138	O	O
[	O	O
38.5	O	O
%	O	O
]	O	O
patients	O	O
in	O	O
the	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
group	I-arm_description	I-arm_description
)	O	O
.	O	O

As	O	O
of	O	O
study	O	O
completion	O	O
(	O	O
22	O	O
December	O	O
2017	O	O
)	O	O
,	O	O
the	O	O
extent	O	O
of	O	O
exposure	O	O
was	O	O
similar	O	O
between	O	O
treatment	O	O
groups	O	O
in	O	O
the	O	O
safety	O	O
population	O	O
.	O	O
The	O	O
mean	O	O
(	O	O
standard	O	O
deviation	O	O
)	O	O
duration	O	O
of	O	O
treatment	O	O
was	O	O
35.2	O	O
(	O	O
27.19	O	O
)	O	O
weeks	O	O
in	O	O
the	O	O
PF-06439535	B-arm_description	B-arm_description
group	I-arm_description	O
and	O	O
34.9	O	O
(	O	O
25.96	O	O
)	O	O
weeks	O	O
in	O	O
the	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
group	I-arm_description	I-arm_description
.	O	O
In	O	O
the	O	O
PF-06439535	B-arm_description	B-arm_description
group	I-arm_description	O
,	O	O
the	O	O
median	O	O
number	O	O
of	O	O
cycles	O	O
of	O	O
PF-06439535	B-arm_description	B-arm_description
treatment	I-arm_description	O
was	O	O
11.0	O	O
(	O	O
range	O	O
1	O	O
-	O	O
41	O	O
)	O	O
,	O	O
with	O	O
6.0	O	O
cycles	O	O
(	O	O
range	O	O
1	O	O
-	O	O
6	O	O
cycles	O	O
)	O	O
of	O	O
paclitaxel	O	O
treatment	O	O
and	O	O
6.0	O	O
cycles	O	O
(	O	O
range	O	O
1	O	O
-	O	O
6	O	O
cycles	O	O
)	O	O
of	O	O
carboplatin	O	O
treatment	O	O
.	O	O
In	O	O
the	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
group	I-arm_description	I-arm_description
,	O	O
the	O	O
median	O	O
number	O	O
of	O	O
cycles	O	O
of	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
treatment	O	O
was	O	O
11.0	O	O
(	O	O
range	O	O
1	O	O
-	O	O
38	O	O
)	O	O
,	O	O
with	O	O
6.0	O	O
cycles	O	O
(	O	O
range	O	O
1	O	O
-	O	O
6	O	O
cycles	O	O
)	O	O
of	O	O
paclitaxel	O	O
treatment	O	O
and	O	O
6.0	O	O
cycles	O	O
(	O	O
range	O	O
1	O	O
-	O	O
6	O	O
cycles	O	O
)	O	O
of	O	O
carboplatin	O	O
treatment	O	O
.	O	O
Table	O	O
2	O	O
)	O	O
.	O	O
The	O	O
unstratified	O	O
ORR	O	O
risk	O	O
ratio	O	O
was	O	O
1.015	O	O
,	O	O
with	O	O
a	O	O
95	O	O
%	O	O
CI	O	O
of	O	O
0.863	O	O
-	O	O
1.193	O	O
and	O	O
a	O	O
90	O	O
%	O	O
CI	O	O
of	O	O
0.886	O	O
-	O	O
1.163	O	O
.	O	O
The	O	O
unstratified	O	O
ORR	O	O
risk	O	O
difference	O	O
was	O	O
0.653	O	O
%	O	O
,	O	O
with	O	O
a	O	O
95	O	O
%	O	O
CI	O	O
of	O	O
−	O	O
6.608	O	O
%	O	O
to	O	O
7.908	O	O
%	O	O
.	O	O
All	O	O
three	O	O
CIs	O	O
fell	O	O
entirely	O	O
within	O	O
the	O	O
equivalence	O	O
margins	O	O
described	O	O
earlier	O	O
(	O	O
Fig	O	O
.	O	O
2	O	O
)	O	O
.	O	O
Thus	O	O
,	O	O
similarity	O	O
between	O	O
PF-06439535	B-arm_description	B-arm_description
and	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
was	O	O
demonstrated	O	O
for	O	O
ORR	O	O
,	O	O
based	O	O
on	O	O
the	O	O
pre	O	O
-	O	O
specified	O	O
criteria	O	O
for	O	O
each	O	O
of	O	O
the	O	O
three	O	O
health	O	O
authorities	O	O
.	O	O

Analyses	O	O
of	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
OS	O	O
,	O	O
and	O	O
DOR	O	O
were	O	O
based	O	O
on	O	O
final	O	O
data	O	O
after	O	O
study	O	O
completion	O	O
on	O	O
22	O	O
Fig	O	O
.	O	O
1	O	O
Participant	O	O
flow	O	O
diagram	O	O
.	O	O
a	O	O
One	O	O
patient	O	O
received	O	O
paclitaxel	O	O
and	O	O
carboplatin	O	O
but	O	O
withdrew	O	O
before	O	O
receiving	O	O
PF-06439535	B-arm_description	B-arm_description
.	O	O
b	O	O
Patient	O	O
was	O	O
indicated	O	O
as	O	O
"	O	O
study	O	O
terminated	O	O
by	O	O
sponsor	O	O
"	O	O
by	O	O
the	O	O
investigator	O	O
;	O	O
however	O	O
,	O	O
this	O	O
patient	O	O
was	O	O
considered	O	O
to	O	O
have	O	O
met	O	O
the	O	O
definition	O	O
of	O	O
study	O	O
completion	O	O
(	O	O
i.e.	O	O
patient	O	O
was	O	O
alive	O	O
and	O	O
had	O	O
completed	O	O
survival	O	O
followup	O	O
as	O	O
defined	O	O
by	O	O
the	O	O
protocol	O	O
)	O	O
.	O	O
c	O	O
The	O	O
most	O	O
frequently	O	O
reported	O	O
reason	O	O
for	O	O
patients	O	O
not	O	O
being	O	O
included	O	O
in	O	O
the	O	O
PP	O	O
population	O	O
was	O	O
due	O	O
to	O	O
being	O	O
randomized	O	O
but	O	O
never	O	O
dosed	O	O
with	O	O
PF-06439535	B-arm_description	B-arm_description
or	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
(	O	O
3	O	O
[	O	O
0.8	O	O
%	O	O
]	O	O
patients	O	O
in	O	O
the	O	O
PF-06439535	B-arm_description	B-arm_description
group	I-arm_description	I-arm_description
and	O	O
3	O	O
[	O	O
0.8	O	O
%	O	O
]	O	O
patients	O	O
in	O	O
the	O	O
bevacizumab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
EU	I-arm_description	I-arm_description
group	I-arm_description	I-arm_description
)	O	O
.	O	O
Bevacizumab	B-arm_description	O
-	I-arm_description	O
EU	I-arm_description	O
reference	I-arm_description	O
bevacizumab	B-arm_description	O
sourced	O	O
from	O	O
the	O	O
European	O	O
Union	O	O
,	O	O
COPD	O	O
chronic	O	O
obstructive	O	O
pulmonary	O	O
disease	O	O
,	O	O
ITT	O	O
intent	O	O
-	O	O
to	O	O
-	O	O
treat	O	O
,	O	O
ORR	O	O
objective	O	O
response	O	O
rate	O	O
,	O	O
PK	O	O
pharmacokinetics	O	O
,	O	O
PP	O	O
per	O	O
-	O	O
protocol	O	O

Enhanced	O	O
antitumor	O	O
effect	O	O
of	O	O
binimetinib	B-arm_description	B-arm_description
in	O	O
combination	B-arm_description	O
with	I-arm_description	O
capecitabine	I-arm_description	B-arm_description
for	O	O
biliary	O	O
tract	O	O
cancer	O	O
patients	O	O
with	O	O
mutations	O	O
in	O	O
the	O	O
RAS	O	O
/	O	O
RAF	O	O
/	O	O
MEK	O	O
/	O	O
ERK	O	O
pathway	O	O
:	O	O
phase	B-study_type	B-study_type
Ib	I-study_type	I-study_type
study	I-study_type	I-study_type
Enhanced	O	O
antitumor	O	O
effect	O	O
of	O	O
binimetinib	B-arm_description	B-arm_description
in	O	O
combination	B-arm_description	O
with	I-arm_description	O
capecitabine	I-arm_description	B-arm_description
for	O	O
biliary	O	O
tract	O	O
cancer	O	O
patients	O	O
with	O	O
mutations	O	O
in	O	O
the	O	O
RAS	O	O
/	O	O
RAF	O	O
/	O	O
MEK	O	O
/	O	O
ERK	O	O
pathway	O	O
:	O	O
phase	B-study_type	B-study_type
Ib	I-study_type	I-study_type
study	I-study_type	I-study_type
17	O	O
July	O	O
2019	O	O
17	O	O
July	O	O
2019	O	O
JinWonKim	B-authors	B-authors

Biliary	O	O
tract	O	O
cancer	O	O
(	O	O
BTC	O	O
)	O	O
arises	O	O
from	O	O
bile	O	O
duct	O	O
epithelial	O	O
cells	O	O
,	O	O
and	O	O
is	O	O
a	O	O
heterogeneous	O	O
family	O	O
of	O	O
malignant	O	O
diseases	O	O
that	O	O
includes	O	O
intrahepatic	O	O
cholangiocarcinoma	O	O
,	O	O
extrahepatic	O	O
cholangiocarcinoma	O	O
,	O	O
gallbladder	O	O
cancer	O	O
and	O	O
ampulla	O	O
of	O	O
Vater	O	O
cancer	O	O
.	O	O
The	O	O
incidence	O	O
of	O	O
BTC	O	O
is	O	O
higher	O	O
in	O	O
Korea	O	O
,	O	O
China	O	O
and	O	O
Thailand	O	O
than	O	O
the	O	O
rest	O	O
of	O	O
the	O	O
world	O	O
.	O	O
1	O	O
Currently	O	O
,	O	O
gemcitabine	O	O
-	O	O
based	O	O
chemotherapy	O	O
is	O	O
globally	O	O
considered	O	O
the	O	O
first	O	O
-	O	O
line	O	O
treatment	O	O
for	O	O
recurrent	O	O
or	O	O
metastatic	O	O
BTC	O	O
.	O	O
2	O	O
However	O	O
,	O	O
even	O	O
with	O	O
chemotherapy	O	O
,	O	O
the	O	O
median	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
of	O	O
recurrent	O	O
or	O	O
metastatic	O	O
BTC	O	O
is~1	O	O
year	O	O
.	O	O
2	O	O
There	O	O
is	O	O
no	O	O
solid	O	O
evidence	O	O
for	O	O
the	O	O
role	O	O
of	O	O
second	O	O
-	O	O
line	O	O
chemotherapy	O	O
,	O	O
although	O	O
fluoropyrimidine	O	O
-	O	O
based	O	O
chemotherapy	O	O
is	O	O
widely	O	O
used	O	O
in	O	O
practice	O	O
.	O	O
3	O	O
ABC-06	O	O
trial	O	O
has	O	O
been	O	O
evaluating	O	O
the	O	O
clinical	O	O
efficacy	O	O
of	O	O
second	O	O
-	O	O
line	O	O
mFOLFOX	O	O
with	O	O
active	O	O
symptom	O	O
control	O	O
compared	O	O
with	O	O
active	O	O
symptom	O	O
control	O	O
alone	O	O
in	O	O
BTC	O	O
.	O	O
Furthermore	O	O
,	O	O
no	O	O
targeted	O	O
therapy	O	O
has	O	O
been	O	O
approved	O	O
for	O	O
BTC	O	O
,	O	O
although	O	O
many	O	O
interesting	O	O
genetic	O	O
alterations	O	O
in	O	O
BTC	O	O
have	O	O
been	O	O
identified	O	O
.	O	O
4	O	O
There	O	O
is	O	O
,	O	O
therefore	O	O
,	O	O
a	O	O
significant	O	O
unmet	O	O
need	O	O
for	O	O
new	O	O
and	O	O
effective	O	O
BTC	O	O
treatment	O	O
strategies	O	O
.	O	O

In	O	O
BTC	O	O
,	O	O
the	O	O
RAS	O	O
/	O	O
RAF	O	O
/	O	O
MEK	O	O
/	O	O
ERK	O	O
pathway	O	O
is	O	O
known	O	O
to	O	O
be	O	O
activated	O	O
in	O	O
up	O	O
to	O	O
20	O	O
-	O	O
40	O	O
%	O	O
of	O	O
cases	O	O
,	O	O
which	O	O
is	O	O
mediated	O	O
by	O	O
mutations	O	O
in	O	O
KRAS	O	O
,	O	O
NRAS	O	O
,	O	O
BRAF	O	O
and	O	O
so	O	O
on	O	O
.	O	O
4,5	O	O
The	O	O
RAS	O	O
/	O	O
RAF	O	O
/	O	O
MEK	O	O
/	O	O
ERK	O	O
pathway	O	O
is	O	O
a	O	O
series	O	O
of	O	O
proteins	O	O
that	O	O
mediates	O	O
communication	O	O
between	O	O
the	O	O
cell	O	O
surface	O	O
and	O	O
nucleus	O	O
,	O	O
which	O	O
has	O	O
been	O	O
linked	O	O
to	O	O
several	O	O
vital	O	O
cellular	O	O
functions	O	O
,	O	O
such	O	O
as	O	O
proliferation	O	O
,	O	O
apoptosis	O	O
and	O	O
metabolism	O	O
.	O	O
6,7	O	O
Therefore	O	O
,	O	O
this	O	O
pathway	O	O
could	O	O
have	O	O
a	O	O
potential	O	O
to	O	O
be	O	O
a	O	O
good	O	O
therapeutic	O	O
target	O	O
in	O	O
BTC	O	O
.	O	O
Furthermore	O	O
,	O	O
mutations	O	O
in	O	O
RAS	O	O
or	O	O
BRAF	O	O
have	O	O
been	O	O
suggested	O	O
as	O	O
predictive	O	O
biomarkers	O	O
for	O	O
MEK	O	O
inhibition	O	O
.	O	O
8,9	O	O
In	O	O
previous	O	O
clinical	O	O
trials	O	O
,	O	O
selumetinib	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
MEK1/	O	O
2	O	O
,	O	O
demonstrated	O	O
interesting	O	O
activity	O	O
and	O	O
acceptable	O	O
tolerability	O	O
in	O	O
patients	O	O
with	O	O
metastatic	O	O
BTC	O	O
.	O	O
10,11	O	O
Similarly	O	O
,	O	O
binimetinib	O	B-arm_description
is	O	O
a	O	O
potent	O	O
,	O	O
adenosine	O	O
triphosphate	O	O
-	O	O
uncompetitive	O	O
,	O	O
highly	O	O
selective	O	O
allosteric	O	O
inhibitor	O	O
of	O	O
MEK1/2	O	O
with	O	O
on	O	O
-	O	O
target	O	O
activity	O	O
that	O	O
has	O	O
been	O	O
demonstrated	O	O
both	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O
12	O	O
Moreover	O	O
,	O	O
phase	O	O
I	O	O
study	O	O
of	O	O
binimetinib	O	B-arm_description
showed	O	O
a	O	O
manageable	O	O
safety	O	O
profile	O	O
,	O	O
target	O	O
inhibition	O	O
and	O	O
dose	O	O
-	O	O
proportional	O	O
exposure	O	O
.	O	O
13	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
evaluated	O	O
the	O	O
preclinical	O	O
synergistic	O	O
activity	O	O
of	O	O
binimetinib	B-arm_description	B-arm_description
and	O	O
fluoropyrimidine	O	O
against	O	O
BTC	O	O
cell	O	O
lines	O	O
.	O	O
Supported	O	O
by	O	O
the	O	O
preclinical	O	O
results	O	O
,	O	O
we	O	O
then	O	O
conducted	O	O
a	O	O
phase	B-study_type	B-study_type
Ib	I-study_type	I-study_type
study	I-study_type	I-study_type
of	O	O
binimetinib	B-arm_description	B-arm_description
and	O	O
capecitabine	B-arm_description	B-arm_description
in	O	O
gemcitabinepretreated	O	O
BTC	O	O
patients	O	O
to	O	O
assess	O	O
the	O	O
safety	O	O
and	O	O
early	O	O
antitumor	O	O
activity	O	O
.	O	O
Furthermore	O	O
,	O	O
we	O	O
identified	O	O
genetic	O	O
alterations	O	O
to	O	O
the	O	O
RAS	O	O
/	O	O
RAF	O	O
/	O	O
MEK	O	O
/	O	O
ERK	O	O
pathway	O	O
and	O	O
determined	O	O
plasma	O	O
biomarker	O	O
concentrations	O	O
.	O	O

Nine	O	O
patients	O	O
were	O	O
recruited	O	O
for	O	O
the	O	O
dose	O	O
-	O	O
escalation	O	O
part	O	O
.	O	O
None	O	O
of	O	O
the	O	O
patients	O	O
experienced	O	O
DLT	O	B-arm_description
up	O	O
to	O	O
DL3	O	B-arm_description
;	O	O
therefore	O	O
,	O	O
the	O	O
RP2D	O	O
was	O	O
determined	O	O
as	O	O
DL3	O	B-arm_description
(	O	O
binimetinib	B-arm_description	B-arm_description
30	B-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
,	O	I-arm_dosage
capecitabine	B-arm_description	B-arm_description
1250	B-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
,	O	I-arm_dosage
twice	B-arm_dosage	I-arm_dosage
daily	I-arm_dosage	I-arm_dosage
on	I-arm_dosage	I-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
-	I-arm_dosage	I-arm_dosage
14	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
in	I-arm_dosage	I-arm_dosage
3-week	I-arm_dosage	I-arm_dosage
cycles	I-arm_dosage	I-arm_dosage
)	O	O
.	O	O
For	O	O
the	O	O
expansion	O	O
part	O	O
,	O	O
25	O	O
patients	O	O
were	O	O
enrolled	O	O
(	O	O
Supplementary	O	O
Fig	O	O
.	O	O
S1	O	O
)	O	O
.	O	O
At	O	O
the	O	O
data	O	O
cutoff	O	O
time	O	O
,	O	O
22	O	O
patients	O	O
had	O	O
died	O	O
,	O	O
and	O	O
treatment	O	O
was	O	O
ongoing	O	O
in	O	O
three	O	O
patients	O	O
.	O	O
The	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
duration	O	O
was	O	O
6.8	O	O
months	O	O
(	O	O
range	O	O
,	O	O
2.0	O	O
-	O	O
17.8	O	O
)	O	O
and	O	O
patients	O	O
received	O	O
a	O	O
median	O	O
of	O	O
five	O	O
cycles	O	O
(	O	O
range	O	O
,	O	O
1	O	O
-	O	O
16	O	O
)	O	O
.	O	O

In	O	O
terms	O	O
of	O	O
IL-6	O	O
plasma	O	O
concentrations	O	O
,	O	O
the	O	O
mean	O	O
value	O	O
(	O	O
±	O	O
standard	O	O
deviation	O	O
)	O	O
of	O	O
baseline	O	O
plasma	O	O
IL-6	O	O
was	O	O
11.5	O	O
pg	O	O
/	O	O
ml	O	O
(	O	O
±	O	O
12.6	O	O
)	O	O
.	O	O
Patients	O	O
with	O	O
higher	O	O
baseline	O	O
IL-6	O	O
showed	O	O
significantly	O	O
shorter	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
and	O	O
OS	O	O
(	O	O
p	B-arm_efficacy_results	O
=	I-arm_efficacy_results	O
0.025	I-arm_efficacy_results	O
,	O	O
p	O	O
=	O	O
0.033	O	O
,	O	O
respectively	O	O
;	O	O
Fig	O	O
.	O	O
3a	O	O
,	O	O
b	O	O
)	O	O
.	O	O
Similarly	O	O
,	O	O
the	O	O
baseline	O	O
value	O	O
of	O	O
IL-6	O	O
was	O	O
associated	O	O
with	O	O
tumour	O	O
response	O	O
,	O	O
that	O	O
is	O	O
,	O	O
IL-6	O	O
was	O	O
higher	O	O
in	O	O
PD	O	O
than	O	O
PR	O	O
patients	O	O
.	O	O
The	O	O
mean	O	O
concentrations	O	O
were	O	O
19.9	O	O
,	O	O
9.2	O	O
and	O	O
7.7	O	O
pg	O	O
/	O	O
ml	O	O
for	O	O
PD	O	O
,	O	O
SD	O	O
and	O	O
PR	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
=	O	O
0.085	O	O
)	O	O
.	O	O
With	O	O
regard	O	O
to	O	O
changes	O	O
between	O	O
baseline	O	O
and	O	O
after	O	O
the	O	O
second	O	O
cycle	O	O
,	O	O
a	O	O
greater	O	O
increase	O	O
in	O	O
the	O	O
IL-6	O	O
concentration	O	O
(	O	O
Δ	O	O
>	O	O
14.8	O	O
pg	O	O
/	O	O
ml	O	O
)	O	O
was	O	O
associated	O	O
with	O	O
shorter	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
and	O	O
OS	O	O
(	O	O
Fig	O	O
.	O	O
3c	O	O
,	O	O
d	O	O
)	O	O
.	O	O
Furthermore	O	O
,	O	O
the	O	O
plasma	O	O
concentrations	O	O
of	O	O
IL-6	O	O
when	O	O
PD	O	O
was	O	O
confirmed	O	O
were	O	O
also	O	O
significantly	O	O
increased	O	O
relative	O	O
to	O	O
baseline	O	O
(	O	O
mean	O	O
±	O	O
standard	O	O
deviation	O	O
:	O	O
32.0	O	O
±	O	O
29.8	O	O
vs.	O	O
9.0	O	O
±	O	O
5.9	O	O
pg	O	O
/	O	O
ml	O	O
,	O	O
respectively	O	O
;	O	O
paired	O	O
t	O	O
test	O	O
,	O	O
p	O	O
=	O	O
0.008	O	O
)	O	O
.	O	O

Radiotherapy	O	O
Oncology	O	O
Department	O	O
,	O	O
IRCCS	O	O
CROB	O	O
,	O	O
Rionero	O	O
In	O	O
Vulture	O	O
,	O	O
Italy	O	O
.	O	O
16	O	O
Radiotherapy	O	O
Unit	O	O
,	O	O
Ospedale	O	O
San	O	O
Camillo	O	O
de	O	O
Lellis	O	O
,	O	O
Rieti	O	O
,	O	O
Italy	O	O
.	O	O
17	O	O
Università	O	O
Cattolica	O	O
del	O	O
Sacro	O	O
Cuore	O	O
,	O	O
Istituto	O	O
di	O	O
Radiologia	O	O
,	O	O
Roma	O	O
,	O	O
Italy	O	O
.	O	O
18	O	O
Radiation	O	O
Oncology	O	O
Department	O	O
,	O	O
University	O	O
of	O	O
Genoa	O	O
(	O	O
DISSAL	O	O
)	O	O
and	O	O
IRCCS	O	O
Ospedale	O	O
Policlinico	O	O
San	O	O
Martino	O	O
,	O	O
Genoa	O	O
Italy	O	O
MarioSantarelli	B-authors	B-authors
MariaAntoniettaGambacorta	B-authors	B-authors

Participants	O	O
entering	O	O
the	O	O
PREST	O	O
trial	O	O
are	O	O
affected	O	O
by	O	O
a	O	O
solid	O	O
tumor	O	O
with	O	O
histologically	O	O
confirmed	O	O
diagnosis	O	O
and	O	O
associated	O	O
bone	O	O
metastases	O	O
.	O	O
The	O	O
estimated	O	O
prognosis	O	O
is	O	O
intermediate	O	O
or	O	O
high	O	O
(	O	O
i.e.	O	O
,	O	O
>	O	O
6	O	O
months	O	O
)	O	O
according	O	O
to	O	O
the	O	O
Mizumoto	O	O
prognostic	O	O
score	O	O
.	O	O
Eligibility	O	O
criteria	O	O
are	O	O
summarized	O	O
in	O	O
Table	O	O
1	O	O
.	O	O

The	O	O
PREST	O	O
trial	O	O
is	O	O
promoted	O	O
by	O	O
Fondazione	O	O
Policlinico	O	O
Gemelli	O	O
-	O	O
IRCCS	O	O
in	O	O
Rome	O	O
(	O	O
Italy	O	O
)	O	O
.	O	O
The	O	O
local	O	O
Ethics	O	O
Committee	O	O
has	O	O
approved	O	O
the	O	O
protocol	O	O
.	O	O
Each	O	O
interested	O	O
center	O	O
will	O	O
submit	O	O
the	O	O
protocol	O	O
to	O	O
its	O	O
ethics	O	O
committee	O	O
for	O	O
approval	O	O
before	O	O
accrual	O	O
.	O	O
After	O	O
approval	O	O
,	O	O
the	O	O
center	O	O
will	O	O
receive	O	O
a	O	O
dedicated	O	O
electronic	O	O
case	O	O
report	O	O
form	O	O
(	O	O
CRF	O	O
)	O	O
.	O	O
Eligible	O	O
participants	O	O
who	O	O
have	O	O
provided	O	O
consent	O	O
and	O	O
meet	O	O
the	O	O
inclusion	O	O
criteria	O	O
are	O	O
anonymously	O	O
registered	O	O
on	O	O
the	O	O
CRF	O	O
by	O	O
assigning	O	O
a	O	O
numerical	O	O
code	O	O
.	O	O

Following	O	O
the	O	O
assessment	O	O
for	O	O
eligibility	O	O
and	O	O
after	O	O
informed	O	O
consent	O	O
is	O	O
signed	O	O
,	O	O
eligible	O	O
participants	O	O
are	O	O
randomized	O	O
by	O	O
phone	O	O
to	O	O
the	O	O
promoting	O	O
centre	O	O
.	O	O
Participants	O	O
undergo	O	O
a	O	O
blind	B-study_type	O
randomization	I-study_type	O
using	O	O
minimization	O	O
algorithms	O	O
based	O	O
on	O	O
key	O	O
prognostic	O	O
factors	O	O
,	O	O
incorporating	O	O
a	O	O
random	O	O
element	O	O
.	O	O
Patients	O	O
are	O	O
allocated	O	O
in	O	O
a	O	O
1:1	O	O
ratio	O	O
to	O	O
either	O	O
gold	O	O
standard	O	O
radiotherapy	B-arm_description	O
treatment	I-arm_description	O
or	O	O
interventional	O	O
SIB	O	O
radiotherapy	O	O
treatment	O	O
.	O	O

CT	O	O
simulation	O	O
will	O	O
be	O	O
carried	O	O
out	O	O
with	O	O
custom	O	O
immobilization	O	O
support	O	O
for	O	O
each	O	O
patient	O	O
(	O	O
Aquaplast	O	O
®	O	O
head	O	O
mask	O	O
and/or	O	O
vacuum	O	O
mattresses	O	O
)	O	O
.	O	O
For	O	O
target	O	O
delineation	O	O
,	O	O
co	O	O
-	O	O
registration	O	O
with	O	O
MRI	O	O
will	O	O
be	O	O
performed	O	O
using	O	O
the	O	O
Velocity	O	O
®	O	O
application	O	O
.	O	O
The	O	O
GTV	O	O
is	O	O
defined	O	O
as	O	O
the	O	O
visible	O	O
lesion	O	O
on	O	O
MRI	O	O
imaging	O	O
.	O	O
In	O	O
the	O	O
experimental	O	O
arm	O	O
,	O	O
two	O	O
volumes	O	O
will	O	O
be	O	O
defined	O	O
:	O	O
PTV1	O	B-arm_description
,	O	O
including	O	O
GTV	O	B-arm_description
plus	O	O
a	O	O
2-mm	O	O
isotropic	O	O
margin	O	O
;	O	O
and	O	O
PTV2	O	B-arm_description
,	O	O
including	O	O
total	O	O
vertebra	O	O
plus	O	O
a	O	O
2-mm	O	O
isotropic	O	O
margin	O	O
.	O	O
In	O	O
the	O	O
standard	O	O
arm	O	O
,	O	O
a	O	O
single	O	O
volume	O	O
will	O	O
be	O	O
contoured	O	O
:	O	O
PTV1	O	B-arm_description
(	O	O
total	O	O
vertebra	O	O
plus	O	O
a	O	O
1	O	O
cm	O	O
isotropic	O	O
margin	O	O
)	O	O
.	O	O

The	O	O
PREST	O	O
trial	O	O
will	O	O
provide	O	O
insight	O	O
on	O	O
efficacy	O	O
of	O	O
a	O	O
hypofractionated	O	O
SBRT	O	O
IMRT	O	O
-	O	O
SIB	O	O
in	O	O
pain	O	O
control	O	O
with	O	O
respect	O	O
to	O	O
gold	O	O
standard	O	O
fractionation	O	O
.	O	O
Highlights	O	O
of	O	O
this	O	O
study	O	O
include	O	O
personalization	O	O
by	O	O
prognostic	O	O
score	O	O
stratification	O	O
,	O	O
selection	O	O
based	O	O
on	O	O
imaging	O	O
-	O	O
driven	O	O
stability	O	O
scores	O	O
,	O	O
ultra	O	O
-	O	O
conformed	O	O
RT	O	O
planning	O	O
,	O	O
and	O	O
lower	O	O
number	O	O
of	O	O
RT	O	O
sessions	O	O
.	O	O
To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
study	O	O
design	O	O
of	O	O
its	O	O
kind	O	O
.	O	O
The	O	O
results	O	O
will	O	O
clarify	O	O
if	O	O
this	O	O
highly	O	O

Myers	O	O
Squibb	O	O
,	O	O
Clovis	O	O
Oncology	O	O
,	O	O
Incyte	O	O
,	O	O
Janssen	O	O
Pharmaceuticals	O	O
,	O	O
Pharmacyclics	O	O
,	O	O
Seattle	O	O
Genetics	O	O
,	O	O
Urogen	O	O
Pharma	O	O
Research	O	O
Funding	O	O
:	O	O
Progenics	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
Sanofi	O	O
(	O	O
Inst	O	O
)	O	O

Bristol	O	O
-	O	O
Myers	O	O
Squibb	O	O
(	O	O
Inst	O	O
)	O	O
Myers	O	O
Squibb	O	O
,	O	O
Clovis	O	O
Oncology	O	O
,	O	O
Incyte	O	O
,	O	O
Janssen	O	O
Pharmaceuticals	O	O
,	O	O
Pharmacyclics	O	O
,	O	O
Seattle	O	O
Genetics	O	O
,	O	O
Urogen	O	O
Pharma	O	O
Research	O	O
Funding	O	O
:	O	O
Progenics	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
Sanofi	O	O
(	O	O
Inst	O	O
)	O	O
Seattle	O	O
Genetics	O	O
(	O	O
Inst	O	O
)	O	O
Clovis	O	O
Oncology	O	O
(	O	O
Inst	O	O
)	O	O
Ada	O	O
Cap	O	O
(	O	O
Inst	O	O
)	O	O
Endocyte	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
Genentech	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
Merck	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
Astellas	O	O
Medivation	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
Novartis	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
AstraZeneca	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
Bayer	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
Eli	O	O
Lilly	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
Innocrin	O	O
Pharma	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
MedImmune	O	O
(	O	O
Inst	O	O
)	O	O
,	O	O
Pfizer	O	O
(	O	O
Inst	O	O
)	O	O
Roche	O	O
(	O	O
Inst	O	O
)	O	O

The	O	O
phase	O	B-study_type
I	O	I-study_type
dose	O	I-study_type
escalation	O	I-study_type
and	O	I-study_type
expansion	O	I-study_type
study	O	I-study_type
EV-101	O	O
(	O	O
ClinicalTrials.gov	O	O
identifier	O	O
:	O	O
NCT02091999	O	O
)	O	O
demonstrated	O	O
that	O	O
enfortumab	O	B-arm_description
vedotin	O	O
,	O	O
administered	O	O
on	O	B-arm_dosage
days	O	I-arm_dosage
1	O	I-arm_dosage
,	O	I-arm_dosage
8	O	I-arm_dosage
,	O	I-arm_dosage
and	O	I-arm_dosage
15	O	I-arm_dosage
of	O	I-arm_dosage
every	O	I-arm_dosage
28-day	O	I-arm_dosage
cycle	O	I-arm_dosage
,	O	O
has	O	O
antitumor	O	O
activity	O	O
in	O	O
previously	O	O
treated	O	O
patients	O	O
with	O	O
metastatic	O	O
urothelial	O	O
carcinoma	O	O
,	O	O
including	O	O
those	O	O
who	O	O
received	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
and	O	O
anti	O	O
-	O	O
PD-1	O	O
/	O	O
L1	O	O
therapy	O	O
.	O	O
17	O	O
Pharmacokinetic	O	O
data	O	O
from	O	O
this	O	O
study	O	O
demonstrate	O	O
a	O	O
half	O	O
-	O	O
life	O	O
of	O	O
approximately	O	O
2	O	O
days	O	O
,	O	O
which	O	O
supports	O	O
this	O	O
dosing	O	O
schedule	O	O
.	O	O
18	O	O
EV-201	O	O
,	O	O
a	O	O
two	B-study_type	B-study_type
-	I-study_type	I-study_type
cohort	I-study_type	I-study_type
,	I-study_type	I-study_type
single	I-study_type	I-study_type
-	I-study_type	I-study_type
arm	I-study_type	I-study_type
,	I-study_type	I-study_type
phase	I-study_type	I-study_type
II	I-study_type	I-study_type
study	I-study_type	I-study_type
,	O	O
was	O	O
designed	O	O
to	O	O
establish	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
enfortumab	B-arm_description	B-arm_description
vedotin	I-arm_description	O
in	O	O
patients	O	O
with	O	O
locally	O	O
advanced	O	O
or	O	O
metastatic	O	O
urothelial	O	O
carcinoma	O	O
who	O	O
were	O	O
previously	O	O
treated	O	O
with	O	O
anti	O	O
-	O	O
PD-1	O	O
/	O	O
L1	O	O
therapy	O	O
.	O	O
Cohort	O	O
1	O	O
enrolled	O	O
patients	O	O
who	O	O
were	O	O
previously	O	O
treated	O	O
with	O	O
both	O	O
platinum	O	O
chemotherapy	O	O
and	O	O
an	O	O
anti	O	O
-	O	O
PD-1	O	O
/	O	O
L1	O	O
therapy	O	O
,	O	O
whereas	O	O
Cohort	O	O
2	O	O
continues	O	O
to	O	O
enroll	O	O
patients	O	O
who	O	O
were	O	O
previously	O	O
treated	O	O
only	O	O
with	O	O
an	O	O
anti	O	O
-	O	O
PD-1	O	O
/	O	O
L1	O	O
therapy	O	O
.	O	O
Here	O	O
,	O	O
we	O	O
report	O	O
results	O	O
from	O	O
EV-201	O	O
Cohort	O	O
1	O	O
.	O	O

Patients	O	O
with	O	O
locally	O	O
advanced	O	O
or	O	O
metastatic	O	O
urothelial	O	O
carcinoma	O	O
who	O	O
were	O	O
previously	O	O
treated	O	O
with	O	O
anti	O	O
-	O	O
PD-1/	O	O
L1	O	O
therapy	O	O
and	O	O
age	O	O
18	O	O
years	O	O
or	O	O
older	O	O
were	O	O
eligible	O	O
to	O	O
enroll	O	O
if	O	O
they	O	O
experienced	O	O
progression	O	O
during	O	O
or	O	O
after	O	O
their	O	O
most	O	O
recent	O	O
therapy	O	O
,	O	O
had	O	O
an	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
performance	O	O
status	O	O
score	O	O
of	O	O
1	O	O
or	O	O
less	O	O
,	O	O
and	O	O
had	O	O
adequate	O	O
baseline	O	O
organ	O	O
function	O	O
.	O	O
Patients	O	O
with	O	O
ongoing	O	O
sensory	O	O
or	O	O
motor	O	O
neuropathy	O	O
grade	O	O
2	O	O
or	O	O
greater	O	O
,	O	O
active	O	O
CNS	O	O
metastases	O	O
,	O	O
or	O	O
uncontrolled	O	O
diabetes	O	O
were	O	O
excluded	O	O
.	O	O
Uncontrolled	O	O
diabetes	O	O
was	O	O
defined	O	O
as	O	O
hemoglobin	O	O
A1C	O	O
of	O	O
8	O	O
%	O	O
or	O	O
greater	O	O
or	O	O
hemoglobin	O	O
A1C	O	O
of	O	O
7	O	O
%	O	O
to	O	O
less	O	O
than	O	O
8	O	O
%	O	O
with	O	O
associated	O	O
diabetes	O	O
symptomspolyuria	O	O
or	O	O
polydipsia	O	O
-	O	O
that	O	O
were	O	O
not	O	O
otherwise	O	O
explained	O	O
.	O	O
There	O	O
were	O	O
no	O	O
limits	O	O
for	O	O
prior	O	O
lines	O	O
of	O	O
therapy	O	O
,	O	O
including	O	O
taxanes	O	O
.	O	O
Full	O	O
eligibility	O	O
criteria	O	O
are	O	O
available	O	O
in	O	O
the	O	O
protocol	O	O
(	O	O
Data	O	O
Supplement	O	O
)	O	O
.	O	O
patients	O	O
were	O	O
discontinued	O	O
from	O	O
the	O	O
study	O	O
before	O	O
receiving	O	O
study	O	O
treatment	O	O
;	O	O
1	O	O
due	O	O
to	O	O
clinical	O	O
deterioration	O	O
,	O	O
1	O	O
per	O	O
patient	O	O
decision	O	O
,	O	O
and	O	O
1	O	O
due	O	O
to	O	O
low	O	O
hemoglobin	O	O
levels	O	O
after	O	O
screening	O	O
and	O	O
enrollment	O	O
.	O	O
This	O	O
latter	O	O
patient	O	O
met	O	O
all	O	O
eligibility	O	O
criteria	O	O
,	O	O
including	O	O
adequate	O	O
hemoglobin	O	O
level	O	O
and	O	O
was	O	O
enrolled	O	O
in	O	O
the	O	O
study	O	O
;	O	O
however	O	O
,	O	O
the	O	O
patient	O	O
's	O	O
hemoglobin	O	O
levels	O	O
were	O	O
subsequently	O	O
found	O	O
to	O	O
be	O	O
low	O	O
and	O	O
the	O	O
investigator	O	O
withdrew	O	O
the	O	O
patient	O	O
from	O	O
the	O	O
study	O	O
as	O	O
a	O	O
result	O	O
.	O	O

EV-201	O	O
is	O	O
a	O	O
global	B-study_type	B-study_type
,	I-study_type	I-study_type
single	I-study_type	I-study_type
-	I-study_type	I-study_type
arm	I-study_type	I-study_type
,	I-study_type	I-study_type
two	I-study_type	I-study_type
-	I-study_type	I-study_type
cohort	I-study_type	I-study_type
,	I-study_type	I-study_type
phase	I-study_type	I-study_type
II	I-study_type	I-study_type
multicenter	I-study_type	I-study_type
study	I-study_type	I-study_type
that	O	O
was	O	O
designed	O	O
to	O	O
assess	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
enfortumab	B-arm_description	B-arm_description
vedotin	I-arm_description	O
(	O	O
Fig	O	O
1	O	O
)	O	O
.	O	O
Cohort	O	O
1	O	O
enrolled	O	O
platinum	O	O
-	O	O
and	O	O
anti	O	O
-	O	O
PD-1	O	O
/	O	O
L1-treated	O	O
patients	O	O
with	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
performance	O	O
status	O	O
scores	O	O
of	O	O
1	O	O
or	O	O
less	O	O
.	O	O
Platinum	O	O
treatment	O	O
was	O	O
defined	O	O
as	O	O
platinum	O	O
-	O	O
containing	O	O
chemotherapy	O	O
in	O	O
the	O	O
neoadjuvant	O	O
and/or	O	O
adjuvant	O	O
setting	O	O
with	O	O
recurrent	O	O
or	O	O
progressive	O	O
disease	O	O
within	O	O
12	O	O
months	O	O
of	O	O
completion	O	O
,	O	O
or	O	O
platinum	O	O
in	O	O
the	O	O
locally	O	O
advanced	O	O
or	O	O
metastatic	O	O
setting	O	O
.	O	O

Long	O	O
-	O	O
Term	O	O
Results	O	O
from	O	O
the	O	O
IDEAL	O	O
-	O	O
CRT	O	O
Phase	B-study_type	B-study_type
1/2	I-study_type	I-study_type
Trial	I-study_type	I-study_type
of	O	O
Isotoxically	O	O
Dose	O	O
-	O	O
Escalated	O	O
Radiation	O	O
Therapy	O	O
and	O	O
Concurrent	O	O
Chemotherapy	O	O
for	O	O
Stage	O	O
II	O	O
/	O	O
III	O	O
Non	O	O
-	O	O
small	O	O
Cell	O	O
Lung	O	O
Cancer	O	O
10.1016	O	O
/	O	O
j.ijrobp.2019.11.397	O	O

Time	O	O
-	O	O
to	O	O
-	O	O
event	O	O
endpoints	O	O
were	O	O
measured	O	O
from	O	O
the	O	O
start	O	O
of	O	O
treatment	O	O
,	O	O
censored	O	O
at	O	O
the	O	O
date	O	O
last	O	O
seen	O	O
,	O	O
and	O	O
estimated	O	O
using	O	O
the	O	O
Kaplan	O	O
-	O	O
Meier	O	O
method	O	O
to	O	O
allow	O	O
for	O	O
each	O	O
patient	O	O
's	O	O
length	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
.	O	O
Exploratory	O	O
univariable	O	O
and	O	O
multivariable	O	O
analyses	O	O
of	O	O
associations	O	O
between	O	O
these	O	O
endpoints	O	O
and	O	O
patient	O	O
-	O	O
and	O	O
treatment	O	O
-	O	O
related	O	O
factors	O	O
were	O	O
performed	O	O
using	O	O
Cox	O	O
proportional	O	O
hazards	O	O
regression	O	O
.	O	O
Stepwise	O	O
bidirectional	O	O
elimination	O	O
,	O	O
including	O	O
all	O	O
factors	O	O
with	O	O
P	O	O
<	O	O
.20	O	O
,	O	O
was	O	O
used	O	O
to	O	O
find	O	O
the	O	O
model	O	O
with	O	O
the	O	O
lowest	O	O
Akaike	O	O
Information	O	O
Criterion	O	O
score	O	O
.	O	O
Reported	O	O
confidence	O	O
intervals	O	O
(	O	O
CIs	O	O
)	O	O
and	O	O
significance	O	O
levels	O	O
are	O	O
2-sided	O	O
except	O	O
where	O	O
otherwise	O	O
indicated	O	O
.	O	O

Pancreatic	O	O
cancer	O	O
is	O	O
a	O	O
devastating	O	O
disease	O	O
with	O	O
an	O	O
overall	O	O
5year	O	O
survival	O	O
of	O	O
less	O	O
than	O	O
5	O	O
%	O	O
.	O	O
1,2	O	O
The	O	O
mortality	O	O
trend	O	O
is	O	O
increasing	O	O
in	O	O
both	O	O
genders	O	O
,	O	O
3,4	O	O
and	O	O
pancreatic	O	O
cancer	O	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
common	O	O
causes	O	O
of	O	O
death	O	O
from	O	O
cancer	O	O
.	O	O
5	O	O
Over	O	O
the	O	O
past	O	O
two	O	O
decades	O	O
,	O	O
gemcitabine	O	O
monotherapy	O	O
has	O	O
been	O	O
a	O	O
standard	O	O
treatment	O	O
for	O	O
metastatic	O	O
pancreatic	O	O
cancer	O	O
.	O	O
6	O	O
In	O	O
2011	O	O
,	O	O
the	O	O
FOLFIRINOX	O	O
regimen	O	O
(	O	O
fluorouracil	O	O
,	O	O
leucovorin	O	O
,	O	O
irinotecan	O	O
,	O	O
and	O	O
oxaliplatin	O	O
)	O	O
7,8	O	O
and	O	O
the	O	O
combination	O	O
of	O	O
gemcitabine	O	O
with	O	O
nab	O	O
-	O	O
paclitaxel	O	O
9,10	O	O
demonstrated	O	O
an	O	O
improvement	O	O
in	O	O
progression	O	O
-	O	O
free	O	O
survival	O	O
and	O	O
overall	O	O
survival	O	O
compared	O	O
with	O	O
gemcitabine	O	O
alone	O	O
.	O	O
These	O	O
regimens	O	O
are	O	O
thus	O	O
now	O	O
considered	O	O
as	O	O
the	O	O
standard	O	O
first	O	O
-	O	O
line	O	O
treatment	O	O
options	O	O
in	O	O
patients	O	O
with	O	O
metastatic	O	O
pancreatic	O	O
cancer	O	O
and	O	O
good	O	O
general	O	O
status	O	O
without	O	O
marked	O	O
cholestasis	O	O
.	O	O

Using	O	O
a	O	O
minimization	O	O
technique	O	O
stratified	O	O
by	O	O
center	O	O
and	O	O
ECOG	O	O
performance	O	O
status	O	O
,	O	O
patients	O	O
were	O	O
randomly	O	O
assigned	O	O
(	O	O
1:2	O	O
ratio	O	O
)	O	O
to	O	O
receive	O	O
nab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
paclitaxel	I-arm_description	I-arm_description
plus	I-arm_description	I-arm_description
gemcitabine	I-arm_description	I-arm_description
(	O	I-arm_description
control	B-arm_description	I-arm_description
arm	I-arm_description	I-arm_description
)	O	O
or	O	O
nab	B-arm_description	B-arm_description
-	I-arm_description	I-arm_description
paclitaxel	I-arm_description	I-arm_description
plus	I-arm_description	I-arm_description
sLV5FU2	I-arm_description	B-arm_description
(	I-arm_description	O
experimental	I-arm_description	O
arm	I-arm_description	O
)	I-arm_description	O
.	O	O
Both	O	O
regimens	O	O
were	O	O
administered	O	O
every	B-arm_dosage	O
28	I-arm_dosage	O
days	I-arm_dosage	O
and	O	O
details	O	O
of	O	O
the	O	O
regimens	O	O
have	O	O
previously	O	O
been	O	O
published	O	O
.	O	O
12	O	O
The	O	O
primary	O	O
endpoint	O	O
was	O	O
progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
at	O	O
4	O	O
months	O	O
in	O	O
the	O	O
first	O	O
72	O	O
patients	O	O
in	O	O
the	O	O
sLV5FU2	O	B-arm_description
group	O	I-arm_description
.	O	O
Secondary	O	O
endpoints	O	O
were	O	O
objective	O	O
response	O	O
,	O	O
progressionfree	B-arm_efficacy_metric	B-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
,	O	O
overall	O	O
survival	O	O
,	O	O
tolerance	O	O
and	O	O
HRQoL.	O	O

HRQoL	O	O
deterioration	O	O
-	O	B-arm_efficacy_metric
free	O	I-arm_efficacy_metric
survival	O	I-arm_efficacy_metric
(	O	O
QFS	O	O
)	O	O
was	O	O
used	O	O
as	O	O
a	O	O
modality	O	O
of	O	O
longitudinal	O	O
analysis	O	O
.	O	O
QFS	O	O
was	O	O
defined	O	O
as	O	O
the	O	O
time	O	O
between	O	O
randomization	O	O
and	O	O
the	O	O
first	O	O
HRQoL	O	O
score	O	O
deterioration	O	O
of	O	O
at	O	O
least	O	O
5	O	O
points	O	O
,	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
baseline	O	O
score	O	O
,	O	O
with	O	O
no	O	O
further	O	O
improvement	O	O
of	O	O
at	O	O
least	O	O
5	O	O
points	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
baseline	O	O
score	O	O
,	O	O
or	O	O
death	O	O
,	O	O
whichever	O	O
occurred	O	O
first	O	O
.	O	O
17,18	O	O
QFS	O	O
curves	O	O
were	O	O
estimated	O	O
using	O	O
the	O	O
Kaplan	O	O
-	O	O
Meier	O	O
estimation	O	O
method	O	O
.	O	O
Univariate	O	O
Cox	O	O
models	O	O
were	O	O
used	O	O
to	O	O
calculate	O	O
HRs	O	O
and	O	O
90	O	O
%	O	O
CIs	O	O
of	O	O
the	O	O
treatment	O	O
effect	O	O
.	O	O
All	O	O
variables	O	O
collected	O	O
at	O	O
baseline	O	O
were	O	O
tested	O	O
by	O	O
univariate	O	O
Cox	O	O
analysis	O	O
.	O	O
The	O	O
impact	O	O
of	O	O
time	O	O
to	O	O
toxicity	O	O
grade	O	O
3	O	O
-	O	O
4	O	O
was	O	O
also	O	O
tested	O	O
by	O	O
univariate	O	O
analysis	O	O
as	O	O
a	O	O
timedependent	O	O
variable	O	O
.	O	O

Between	O	O
December	O	O
2013	O	O
and	O	O
October	O	O
2014	O	O
,	O	O
114	O	O
patients	O	O
were	O	O
randomized	O	O
:	O	O
39	O	O
in	O	O
the	O	O
gemcitabine	B-arm_description	B-arm_description
group	I-arm_description	I-arm_description
and	O	O
75	O	O
in	O	O
the	O	O
sLV5FU2	B-arm_description	B-arm_description
group	I-arm_description	I-arm_description
.	O	O
Sixty	O	O
-	O	O
four	O	O
patients	O	O
(	O	O
56.1	O	O
%	O	O
)	O	O
completed	O	O
the	O	O
QLQ	O	O
-	O	O
C30	O	O
questionnaire	O	O
at	O	O
baseline	O	O
,	O	O
22	O	O
patients	O	O
(	O	O
56.4	O	O
%	O	O
)	O	O
in	O	O
the	O	O
gemcitabine	B-arm_description	B-arm_description
group	I-arm_description	I-arm_description
,	O	O
and	O	O
42	O	O
(	O	O
56.0	O	O
%	O	O
)	O	O
in	O	O
the	O	O
sLV5FU2	B-arm_description	B-arm_description
group	I-arm_description	I-arm_description
(	O	O
Figure	O	O
1	O	O
)	O	O
.	O	O
Patients	O	O
in	O	O
the	O	O
sLV5FU2	B-arm_description	B-arm_description
group	I-arm_description	I-arm_description
completed	O	O
the	O	O
questionnaire	O	O
longer	O	O
after	O	O
compared	O	O
to	O	O
the	O	O
gemcitabine	B-arm_description	B-arm_description
group	I-arm_description	I-arm_description
.	O	O
Indeed	O	O
,	O	O
there	O	O
were	O	O
more	O	O
patients	O	O
included	O	O
in	O	O
this	O	O
treatment	O	O
arm	O	O
due	O	O
to	O	O
the	O	O
ratio	O	O
1:2	O	O
and	O	O
the	O	O
median	O	O
overall	O	O
survival	O	O
was	O	O
significantly	O	O
longer	O	O
in	O	O
this	O	O
treatment	O	O
arm	O	O
.	O	O
The	O	O
median	O	O
age	O	O
was	O	O
66	O	O
years	O	O
(	O	O
range	O	O
45	O	O
-	O	O
86	O	O
)	O	O
and	O	O
70	O	O
patients	O	O
(	O	O
61.4	O	O
%	O	O
)	O	O
were	O	O
men	O	O
.	O	O
The	O	O
baseline	O	O
characteristics	O	O
of	O	O
the	O	O
patients	O	O
are	O	O
described	O	O
according	O	O
to	O	O
baseline	O	O
HRQoL	O	O
availability	O	O
in	O	O
Table	O	O
1	O	O
.	O	O
Baseline	O	O
HRQoL	O	O
level	O	O
was	O	O
similar	O	O
between	O	O
treatment	O	O
arms	O	O
(	O	O
Table	O	O
S1	O	O
)	O	O
.	O	O

The	O	O
main	O	O
limitation	O	O
of	O	O
this	O	O
study	O	O
was	O	O
the	O	O
relatively	O	O
low	O	O
proportion	O	O
(	O	O
56.1	O	O
%	O	O
)	O	O
of	O	O
questionnaires	O	O
completed	O	O
at	O	O
baseline	O	O
.	O	O
However	O	O
,	O	O
the	O	O
completion	O	O
rate	O	O
was	O	O
similar	O	O
in	O	O
both	O	O
treatment	O	O
arms	O	O
.	O	O
A	O	O
likely	O	O
explanation	O	O
could	O	O
be	O	O
that	O	O
the	O	O
first	O	O
two	O	O
HRQoL	O	O
assessment	O	O
times	O	O
were	O	O
at	O	O
very	O	O
short	O	O
interval	O	O
(	O	O
ie	O	O
,	O	O
at	O	O
randomization	O	O
and	O	O
day	O	O
one	O	O
of	O	O
the	O	O
first	O	O
chemotherapy	O	O
cycle	O	O
)	O	O
and	O	O
this	O	O
may	O	O
have	O	O
caused	O	O
some	O	O
confusion	O	O
between	O	O
these	O	O
two	O	O
time	O	O
points	O	O
at	O	O
the	O	O
time	O	O
of	O	O
data	O	O
collection	O	O
.	O	O
The	O	O
completion	O	O
rate	O	O
over	O	O
time	O	O
was	O	O
close	O	O
to	O	O
those	O	O
observed	O	O
in	O	O
other	O	O
clinical	O	O
trials	O	O
in	O	O
pancreatic	O	O
cancer	O	O
,	O	O
such	O	O
as	O	O
in	O	O
a	O	O
phase	O	O
II	O	O
clinical	O	O
trial	O	O
in	O	O
resectable	O	O
or	O	O
borderline	O	O
resectable	O	O
pancreatic	O	O
cancer	O	O
patients	O	O
using	O	O
also	O	O
the	O	O
QLQ	O	O
-	O	O
C30	O	O
questionnaire	O	O
to	O	O
assess	O	O
HRQoL	O	O
among	O	O
other	O	O
questionnaires	O	O
.	O	O
24	O	O
These	O	O
missing	O	O
data	O	O
also	O	O
had	O	O
a	O	O
direct	O	O
impact	O	O
on	O	O
the	O	O
population	O	O
for	O	O
analysis	O	O
.	O	O
It	O	O
was	O	O
required	O	O
to	O	O
define	O	O
a	O	O
modified	O	O
ITT	O	O
population	O	O
including	O	O
all	O	O
ITT	O	O
patients	O	O
with	O	O
a	O	O
baseline	O	O
HRQoL	O	O
score	O	O
available	O	O
.	O	O
However	O	O
,	O	O
it	O	O
is	O	O
recommended	O	O
that	O	O
the	O	O
ITT	O	O
population	O	O
be	O	O
studied	O	O
in	O	O
order	O	O
to	O	O
best	O	O
reflect	O	O
the	O	O
treatment	O	O
effect	O	O
without	O	O
inducing	O	O
bias	O	O
.	O	O
14	O	O
It	O	O
is	O	O
therefore	O	O
essential	O	O
to	O	O
verify	O	O
that	O	O
the	O	O
modified	O	O
ITT	O	O
is	O	O
representative	O	O
of	O	O
the	O	O
ITT	O	O
population	O	O
.	O	O

0000	O	O
-	O	O
0002	O	O
-	O	O
7749	O	O
-	O	O
7217	O	O
RahulAggarwal	B-authors	B-authors
Rahul	B-authors	B-authors
Aggarwal	I-authors	B-authors
0000	O	O
-	O	O
0002	O	O
-	O	O
7749	O	O
-	O	O
7217	O	O
JeremyCetnar	B-authors	B-authors
JeremyCetnar	B-authors	B-authors
Jeremy	B-authors	B-authors
Cetnar	I-authors	B-authors
CharlesJRyan	B-authors	B-authors
CharlesJRyan	B-authors	B-authors
Charles	B-authors	B-authors
J	I-authors	I-authors
Ryan	I-authors	B-authors
ShaadiTabatabaei	B-authors	B-authors
ShaadiTabatabaei	B-authors	B-authors
Shaadi	B-authors	B-authors
Tabatabaei	I-authors	B-authors
ShawnaBailey	B-authors	B-authors
ShawnaBailey	B-authors	B-authors
Shawna	B-authors	B-authors
Bailey	I-authors	I-authors
ClaireBTurina	B-authors	B-authors
ClaireBTurina	B-authors	B-authors
Claire	B-authors	B-authors
B	I-authors	I-authors
Turina	I-authors	B-authors
DavidAQuigley	B-authors	B-authors
DavidAQuigley	B-authors	B-authors
David	B-authors	B-authors
A	I-authors	I-authors
Quigley	I-authors	B-authors
XiangnanGuan	B-authors	B-authors
XiangnanGuan	B-authors	B-authors
Xiangnan	B-authors	B-authors
Guan	I-authors	I-authors
AdamFoye	B-authors	B-authors
AdamFoye	B-authors	B-authors
Adam	B-authors	B-authors
Foye	I-authors	I-authors
JackFYoungren	B-authors	B-authors
JackFYoungren	B-authors	B-authors
Jack	B-authors	B-authors
F	I-authors	I-authors
Youngren	I-authors	B-authors
JoshuaUrrutia	B-authors	B-authors

Portland	O	O
,	O	O
OR	O	O
97239	O	O
a	O	O
Knight	O	O
Cancer	O	O
Institute	O	O
,	O	O
Oregon	O	O
Health	O	O
&	O	O
Science	O	O
University	O	O
,	O	O
Portland	O	O
,	O	O
OR	O	O
97239	O	O
Portland	O	O
,	O	O
OR	O	O
97239	O	O
b	O	O
Computational	O	O
Biology	O	O
Program	O	O
,	O	O
Oregon	O	O
Health	O	O
&	O	O
Science	O	O
University	O	O
,	O	O

Portland	O	O
,	O	O
OR	O	O
97239	O	O
c	O	O
Molecular	O	O
Microbiology	O	O
and	O	O
Immunology	O	O
Department	O	O
,	O	O
Oregon	O	O
Health	O	O
&	O	O
Science	O	O
University	O	O
,	O	O
Portland	O	O
,	O	O
OR	O	O
97239	O	O
Portland	O	O
,	O	O
OR	O	O
97239	O	O
d	O	O
Biostatistics	O	O
Shared	O	O
Resource	O	O
,	O	O
Knight	O	O
Cancer	O	O
Institute	O	O
,	O	O
Oregon	O	O
Health	O	O
&	O	O
Science	O	O
University	O	O
,	O	O

San	O	O
Francisco	O	O
,	O	O
CA	O	O
94143	O	O
f	O	O
Department	O	O
of	O	O
Medicine	O	O
,	O	O
University	O	O
of	O	O
California	O	O
,	O	O
San	O	O
Francisco	O	O
,	O	O
CA	O	O
94143	O	O
San	O	O
Francisco	O	O
,	O	O
CA	O	O
94143	O	O
g	O	O
Division	O	O
of	O	O
Hematology	O	O
,	O	O
Oncology	O	O
and	O	O
Transplantation	O	O
,	O	O
University	O	O
of	O	O
Minnesota	O	O
Masonic	O	O
Cancer	O	O
Center	O	O
,	O	O

Santa	O	O
Cruz	O	O
,	O	O
CA	O	O
95064	O	O
j	O	O
University	O	O
of	O	O
California	O	O
Santa	O	O
Cruz	O	O
Genomics	O	O
Institute	O	O
,	O	O
University	O	O
of	O	O
California	O	O
,	O	O
Santa	O	O
Cruz	O	O
,	O	O
CA	O	O
95064	O	O
Santa	O	O
Cruz	O	O
,	O	O
CA	O	O
95064	O	O
k	O	O
Department	O	O
of	O	O
Biomolecular	O	O
Engineering	O	O
,	O	O
University	O	O
of	O	O
California	O	O
,	O	O

Cancer	O	O
Receiving	O	O
Enzalutamide	O	B-arm_description
Therapy	O	O
enrolled	O	O
36	O	O
patients	O	O
with	O	O
metastatic	O	O
CRPC	O	O
who	O	O
had	O	O
not	O	O
previously	O	O
received	O	O
enzalutamide	O	B-arm_description
.	O	O
Patients	O	O
with	O	O
prior	O	O
use	O	O
of	O	O
docetaxel	O	B-arm_description
or	O	O
abiraterone	O	B-arm_description
were	O	O
ineligible	O	O
for	O	O
this	O	O
study	O	O
.	O	O
Study	O	O
enrollment	O	O
,	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
and	O	O
analyses	O	O
are	O	O
depicted	O	O
in	O	O
SI	O	O
Appendix	O	O
,	O	O
Fig	O	O
.	O	O
S1	O	O
.	O	O
The	O	O
demographic	O	O
characteristics	O	O
for	O	O
all	O	O
36	O	O
patients	O	O
enrolled	O	O
on	O	O
the	O	O
study	O	O
are	O	O
shown	O	O
in	O	O
SI	O	O
Appendix	O	O
,	O	O
Table	O	O
S1	O	O
.	O	O
Thirty	O	O
-	O	O
four	O	O
patients	O	O
were	O	O
evaluable	O	O
for	O	O
the	O	O
primary	O	O
end	O	O
point	O	O
of	O	O
≥50	O	O
%	O	O
PSA	O	O
decline	O	O
at	O	O
12	O	O
wk	O	O
,	O	O
and	O	O
their	O	O
demographic	O	O
features	O	O
are	O	O
shown	O	O
in	O	O
Table	O	O
1	O	O
.	O	O
There	O	O
were	O	O
9	O	O
nonresponders	O	O
(	O	O
<	O	O
50	O	O
%	O	O
PSA	O	O
decline	O	O
at	O	O
12	O	O
wk	O	O
)	O	O
and	O	O
25	O	O
responders	O	O
(	O	O
≥50	O	O
%	O	O
PSA	O	O
decline	O	O
at	O	O
12	O	O
wk	O	O
)	O	O
(	O	O
Fig	O	O
.	O	O
1	O	O
)	O	O
.	O	O

Targeted	O	O
DNA	O	O
-	O	O
Sequencing	O	O
.	O	O
For	O	O
26	O	O
of	O	O
36	O	O
patients	O	O
,	O	O
there	O	O
was	O	O
sufficient	O	O
DNA	O	O
to	O	O
perform	O	O
targeted	O	O
DNA	O	O
-	O	O
sequencing	O	O
(	O	O
DNA	O	O
-	O	O
seq	O	O
)	O	O
.	O	O
Five	O	O
of	O	O
these	O	O
patients	O	O
were	O	O
nonresponders	O	O
,	O	O
and	O	O
21	O	O
were	O	O
responders	O	O
.	O	O
We	O	O
focused	O	O
on	O	O
TP53	O	O
,	O	O
RB1	O	O
,	O	O
and	O	O
PTEN	O	B-arm_description
as	O	O
those	O	O
genes	O	O
have	O	O
been	O	O
linked	O	O
previously	O	O
to	O	O
poor	O	O
outcomes	O	O
for	O	O
men	O	O
with	O	O
CRPC	O	O
or	O	O
resistance	O	O
to	O	O
AR	O	O
-	O	O
targeting	O	O
therapies	O	O
in	O	O
preclinical	O	O
or	O	O
clinical	O	O
studies	O	O
(	O	O
12,(15)(16)(17)(18	O	O
)	O	O
.	O	O
No	O	O
statistically	O	O
significant	O	O
differences	O	O
were	O	O
detected	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
for	O	O
these	O	O
genes	O	O
(	O	O
Fig	O	O
.	O	O
3	O	O
)	O	O
or	O	O
other	O	O
genes	O	O
examined	O	O
(	O	O
SI	O	O
Appendix	O	O
,	O	O
Fig	O	O
.	O	O
S2	O	O
)	O	O
.	O	O
However	O	O
,	O	O
there	O	O
was	O	O
a	O	O
strong	O	O
trend	O	O
toward	O	O
greater	O	O
likelihood	O	O
of	O	O
TP53	O	O
alterations	O	O
in	O	O
nonresponders	O	O
(	O	O
Fisher	O	O
's	O	O
exact	O	O
test	O	O
P	O	O
=	O	O
0.055	O	O
)	O	O
.	O	O

For	O	O
the	O	O
primary	O	O
analysis	O	O
,	O	O
we	O	O
assessed	O	O
correlations	O	O
between	O	O
baseline	O	O
molecular	O	O
features	O	O
and	O	O
PSA50	O	O
response	O	O
defined	O	O
as	O	O
a	O	O
PSA	O	O
decline	O	O
of	O	O
≥50	O	O
%	O	O
at	O	O
12	O	O
wk	O	O
compared	O	O
with	O	O
baseline	O	O
.	O	O
Secondary	O	O
clinical	O	O
end	O	O
points	O	O
included	O	O
TOT	O	O
,	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
and	O	O
OS	O	O
,	O	O
all	O	O
measured	O	O
from	O	O
the	O	O
date	O	O
of	O	O
enzalutamide	O	O
initiation	O	O
.	O	O

Statistical	O	O
Analysis	O	O
.	O	O
Descriptive	O	O
statistics	O	O
(	O	O
median	O	O
and	O	O
interquartile	O	O
range	O	O
for	O	O
continuous	O	O
variables	O	O
;	O	O
frequencies	O	O
and	O	O
percentages	O	O
for	O	O
categorical	O	O
variables	O	O
)	O	O
were	O	O
used	O	O
to	O	O
summarize	O	O
the	O	O
demographic	O	O
and	O	O
clinical	O	O
data	O	O
by	O	O
response	O	O
group	O	O
.	O	O
Time	O	O
-	O	O
to	O	O
-	O	O
event	O	O
analysis	O	O
was	O	O
performed	O	O
using	O	O
Kaplan	O	O
-	O	O
Meier	O	O
curves	O	O
and	O	O
log	O	O
-	O	O
rank	O	O
tests	O	O
to	O	O
evaluate	O	O
the	O	O
association	O	O
between	O	O
response	O	O
group	O	O
and	O	O
TOT	O	O
,	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
and	O	O
OS	O	O
.	O	O
Cox	O	O
regression	O	O
models	O	O
were	O	O
used	O	O
to	O	O
calculate	O	O
hazard	O	O
ratios	O	O
by	O	O
response	O	O
group	O	O
with	O	O
95	O	O
%	O	O
CIs	O	O
.	O	O
All	O	O
statistical	O	O
analyses	O	O
were	O	O
performed	O	O
using	O	O
R	O	O
:	O	O
A	O	O
Language	O	O
and	O	O
Environment	O	O
for	O	O
Statistical	O	O
Computing	O	O
.	O	O
P	O	O
<	O	O
0.05	O	O
was	O	O
considered	O	O
statistically	O	O
significant	O	O
.	O	O

Analysis	O	O
of	O	O
Baseline	O	O
Biopsy	O	O
Samples	O	O
and	O	O
DNA	O	O
-	O	O
Seq	O	O
.	O	O
At	O	O
the	O	O
time	O	O
of	O	O
consenting	O	O
for	O	O
the	O	O
Genetic	O	O
and	O	O
Molecular	O	O
Mechanisms	O	O
in	O	O
Assessing	O	O
Response	O	O
in	O	O
Patients	O	O
with	O	O
Prostate	O	O
Cancer	O	O
Receiving	O	O
Enzalutamide	O	O
Therapy	O	O
trial	O	O
,	O	O
patients	O	O
also	O	O
consented	O	O
to	O	O
the	O	O
IRB	O	O
-	O	O
approved	O	O
West	O	O
Coast	O	O
Prostate	O	O
Cancer	O	O
Dream	O	O
Team	O	O
tissue	O	O
collection	O	O
protocol	O	O
through	O	O
which	O	O
their	O	O
tumor	O	O
samples	O	O
were	O	O
sequenced	O	O
.	O	O
Results	O	O
in	O	O
Fig	O	O
.	O	O
3	O	O
and	O	O
SI	O	O
Appendix	O	O
,	O	O
Fig	O	O
.	O	O
S2	O	O
are	O	O
based	O	O
on	O	O
a	O	O
37-gene	O	O
targeted	O	O
DNA	O	O
-	O	O
seq	O	O
panel	O	O
described	O	O
previously	O	O
(	O	O
48	O	O
)	O	O
.	O	O
AR	O	O
DNA	O	O
-	O	O
seq	O	O
results	O	O
in	O	O
Fig	O	O
.	O	O
4A	O	O
are	O	O
based	O	O
on	O	O
an	O	O
alternate	O	O
targeted	O	O
DNA	O	O
-	O	O
seq	O	O
panel	O	O
that	O	O
included	O	O
the	O	O
AR	O	O
or	O	O
whole	O	O
-	O	O
genome	O	O
-	O	O
seq	O	O
that	O	O
has	O	O
been	O	O
described	O	O
previously	O	O
(	O	O
21,49	O	O
)	O	O
.	O	O

Characterization	O	O
of	O	O
AR	O	O
Protein	O	O
Expression	O	O
.	O	O
AR	O	O
protein	O	O
expression	O	O
was	O	O
analyzed	O	O
using	O	O
immunohistochemical	O	O
analysis	O	O
.	O	O
The	O	O
AR	O	O
[	O	O
C6F11	O	O
]	O	O
XP	O	O
rabbit	O	O
monoclonal	O	O
antibody	O	O
was	O	O
used	O	O
as	O	O
previously	O	O
described	O	O
,	O	O
and	O	O
AR	O	O
nuclear	O	O
staining	O	O
was	O	O
quantified	O	O
as	O	O
described	O	O
previously	O	O
:	O	O
0	O	O
(	O	O
absent	O	O
)	O	O
,	O	O
1	O	O
+	O	O
(	O	O
low	O	O
)	O	O
,	O	O
2	O	O
+	O	O
(	O	O
intermediate	O	O
)	O	O
,	O	O
and	O	O
3	O	O
+	O	O
(	O	O
strong	O	O
)	O	O
(	O	O
21	O	O
)	O	O
.	O	O

A	O	O
Randomized	B-study_type	B-study_type
Phase	I-study_type	I-study_type
IIa	I-study_type	I-study_type
Trial	I-study_type	I-study_type
with	O	O
Temsirolimus	B-arm_description	B-arm_description
versus	O	O
Sunitinib	B-arm_description	B-arm_description
in	O	O
Advanced	O	O
Non	O	O
-	O	O
Clear	O	O
Cell	O	O
Renal	O	O
Cell	O	O
Carcinoma	O	O
:	O	O
An	O	O
Intergroup	O	B-study_type
Study	O	I-study_type
of	O	O
the	O	O
CESAR	O	O
Central	O	O
European	O	O
Society	O	O
for	O	O
Anticancer	O	O
Drug	O	O
Research	O	O
-	O	O
EWIV	O	O
and	O	O
the	O	O
Interdisciplinary	O	O
Working	O	O
Group	O	O
on	O	O
Renal	O	O
Cell	O	O
Cancer	O	O
(	O	O
IAGN	O	O
)	O	O
of	O	O
the	O	O
German	O	O
Cancer	O	O
Society	O	O

Germany	O	O
Theodor	O	O
-	O	O
Stern	O	O
-	O	O
Kai	O	O
7	O	O
DE	O	O
60590	O	O
Frankfurt	O	O
Germany	O	O
A	O	O
Randomized	B-study_type	B-study_type
Phase	I-study_type	I-study_type
IIa	I-study_type	I-study_type
Trial	I-study_type	I-study_type
with	O	O
Temsirolimus	B-arm_description	B-arm_description
versus	O	O
Sunitinib	B-arm_description	B-arm_description
in	O	O
Advanced	O	O
Non	O	O
-	O	O
Clear	O	O
Cell	O	O
Renal	O	O
Cell	O	O
Carcinoma	O	O
:	O	O
An	O	O
Intergroup	O	B-study_type
Study	O	I-study_type
of	O	O
the	O	O
CESAR	O	O
Central	O	O
European	O	O
Society	O	O
for	O	O
Anticancer	O	O
Drug	O	O
Research	O	O
-	O	O
EWIV	O	O
and	O	O
the	O	O
Interdisciplinary	O	O
Working	O	O
Group	O	O
on	O	O
Renal	O	O
Cell	O	O
Cancer	O	O
(	O	O
IAGN	O	O
)	O	O
of	O	O
the	O	O
German	O	O
Cancer	O	O
Society	O	O
June	O	O
15	O	O
,	O	O
2020	O	O
June	O	O
15	O	O
,	O	O
2020	O	O
June	O	O
15	O	O
,	O	O
2020	O	O
10.1159/000508450	O	O
Received	O	O
:	O	O
February	O	O
27	O	O
,	O	O
2020	O	O
Accepted	O	O
:	O	O
May	O	O
6	O	O
,	O	O
2020	O	O

Direct	O	O
comparisons	O	O
between	O	O
the	O	O
mammalian	O	O
targets	O	O
of	O	O
rapamycin	O	O
(	O	O
mTOR	O	O
)	O	O
inhibitors	O	O
everolimus	O	O
and	O	O
SUN	O	B-arm_description
have	O	O
been	O	O
studied	O	O
in	O	O
two	O	O
small	O	O
randomized	O	O
trials	O	O
showing	O	O
a	O	O
tendency	O	O
towards	O	O
SUN	O	B-arm_description
or	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
efficacy	O	O
,	O	O
but	O	O
still	O	O
the	O	O
numbers	O	O
are	O	O
rather	O	O
small	O	O
to	O	O
draw	O	O
final	O	O
conclusions	O	O
[	O	O
6,7	O	O
]	O	O
.	O	O
Regarding	O	O
the	O	O
mTOR	O	O
inhibitor	O	O
TEM	O	O
,	O	O
the	O	O
subgroup	O	O
analysis	O	O
of	O	O
the	O	O
"	O	O
Advanced	O	O
Renal	O	O
Cell	O	O
Carcinoma	O	O
"	O	O
(	O	O
ARCC	O	O
)	O	O
study	O	O
showed	O	O
a	O	O
comparable	O	O
median	O	O
OS	O	O
(	O	O
mOS	O	O
)	O	O
for	O	O
ccRCC	O	O
and	O	O
nccRCC	O	O
patients	O	O
receiving	O	O
TEM	O	O
in	O	O
comparison	O	O
to	O	O
interferon	O	O
-	O	O
α	O	O
[	O	O
13	O	O
]	O	O
.	O	O
No	O	O
data	O	O
are	O	O
available	O	O
for	O	O
the	O	O
mTOR	O	O
inhibitor	O	O
TEM	O	O
in	O	O
comparison	O	O
to	O	O
SUN	O	B-arm_description
[	O	O
14	O	O
]	O	O
.	O	O

This	O	O
open	B-study_type	B-study_type
-	I-study_type	I-study_type
label	I-study_type	I-study_type
randomized	I-study_type	I-study_type
trial	I-study_type	I-study_type
was	O	O
performed	O	O
in	O	O
9	O	O
centers	O	O
of	O	O
the	O	O
Central	O	O
European	O	O
Society	O	O
for	O	O
Anticancer	O	O
Drug	O	O
Research	O	O
-	O	O
EWIV	O	O
(	O	O
CESAR	O	O
)	O	O
study	O	O
group	O	O
.	O	O
It	O	O
was	O	O
an	O	O
investigator	O	O
-	O	O
initiated	O	O
trial	O	O
.	O	O
Eligible	O	O
patients	O	O
had	O	O
histologically	O	O
confirmed	O	O
nccRCC	O	O
,	O	O
including	O	O
sarcomatoid	O	O
features	O	O
,	O	O
defined	O	O
as	O	O
>	O	O
50	O	O
%	O	O
sarcomatoid	O	O
component	O	O
as	O	O
assessed	O	O
through	O	O
pathological	O	O
examination	O	O
by	O	O
a	O	O
local	O	O
site	O	O
review	O	O
.	O	O
Mixed	O	O
features	O	O
were	O	O
allowed	O	O
if	O	O
the	O	O
nccRCC	O	O
component	O	O
was	O	O
>	O	O
50	O	O
%	O	O
.	O	O
Additional	O	O
eligibility	O	O
criteria	O	O
included	O	O
a	O	O
baseline	O	O
Karnofsky	O	O
perfor	O	O
-	O	O
mance	O	O
status	O	O
of	O	O
70	O	O
or	O	O
higher	O	O
,	O	O
life	O	O
expectancy	O	O
of	O	O
at	O	O
least	O	O
3	O	O
months	O	O
,	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
measurable	O	O
metastatic	O	O
disease	O	O
as	O	O
per	O	O
RECIST	O	O
1.1	O	O
criteria	O	O
.	O	O
Patients	O	O
had	O	O
to	O	O
have	O	O
adequate	O	O
bone	O	O
marrow	O	O
,	O	O
kidney	O	O
,	O	O
and	O	O
liver	O	O
function	O	O
and	O	O
adequate	O	O
laboratory	O	O
parameters	O	O
(	O	O
baseline	O	O
creatinine	O	O
concentration	O	O
≤2	O	O
times	O	O
the	O	O
institutional	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
(	O	O
ULN	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
aspartate	O	O
aminotransferase	O	O
and	O	O
alanine	O	O
aminotransferase	O	O
concentrations	O	O
<	O	O
2•5	O	O
times	O	O
the	O	O
ULN	O	O
.	O	O
The	O	O
patients	O	O
could	O	O
not	O	O
have	O	O
received	O	O
any	O	O
prior	O	O
systemic	O	O
cancer	O	O
treatment	O	O
and	O	O
should	O	O
not	O	O
have	O	O
symptomatic	O	O
brain	O	O
metastases	O	O
.	O	O
Local	O	O
irradiation	O	O
and/or	O	O
surgical	O	O
procedures	O	O
were	O	O
not	O	O
allowed	O	O
within	O	O
4	O	O
weeks	O	O
prior	O	O
study	O	O
inclusion	O	O
.	O	O
Additional	O	O
exclusion	O	O
criteria	O	O
were	O	O
severe	O	O
cardiovascular	O	O
disorders	O	O
,	O	O
poorly	O	O
controlled	O	O
hypertension	O	O
,	O	O
any	O	O
cardiovascular	O	O
event	O	O
within	O	O
6	O	O
months	O	O
of	O	O
randomization	O	O
or	O	O
prolonged	O	O
QTc	O	O
time	O	O
(	O	O
>	O	O
450	O	O
ms	O	O
)	O	O
,	O	O
abnormal	O	O
pulmonary	O	O
function	O	O
(	O	O
DCO	O	O
<	O	O
50	O	O
%	O	O
)	O	O
,	O	O
poorly	O	O
controlled	O	O
diabetes	O	O
mellitus	O	O
,	O	O
patients	O	O
taking	O	O
strong	O	O
CYP3A	O	O
inhibitors	O	O
or	O	O
inducers	O	O
,	O	O
active	O	O
infections	O	O
,	O	O
or	O	O
second	O	O
malignancies	O	O
as	O	O
well	O	O
as	O	O
pregnant	O	O
or	O	O
nursing	O	O
women	O	O
.	O	O

In	O	O
total	O	O
,	O	O
22	O	O
patients	O	O
were	O	O
eligible	O	O
and	O	O
randomized	O	O
.	O	O
Due	O	O
to	O	O
low	O	O
recruitment	O	O
over	O	O
2	O	O
years	O	O
,	O	O
the	O	O
study	O	O
was	O	O
prematurely	O	O
stopped	O	O
.	O	O
Twelve	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
arm	B-arm_description	B-arm_description
A	I-arm_description	I-arm_description
(	I-arm_description	I-arm_description
TEM	I-arm_description	B-arm_description
)	I-arm_description	O
and	O	O
10	O	O
patients	O	O
to	O	O
arm	B-arm_description	B-arm_description
B	I-arm_description	I-arm_description
(	I-arm_description	I-arm_description
SUN	I-arm_description	B-arm_description
)	I-arm_description	O
.	O	O
The	O	O
median	O	O
age	O	O
was	O	O
60.8	O	O
years	O	O
.	O	O
A	O	O
total	O	O
of	O	O
59	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
ECOG	O	O
and	O	O
41	O	O
%	O	O
ECOG	O	O
1	O	O
.	O	O
Further	O	O
,	O	O
86.5	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
a	O	O
metastatic	O	O
disease	O	O
,	O	O
and	O	O
13.5	O	O
%	O	O
a	O	O
locally	O	O
advanced	O	O
stage	O	O
.	O	O
The	O	O
histological	O	O
classification	O	O
was	O	O
done	O	O
by	O	O
the	O	O
local	O	O
pathologists	O	O
.	O	O
Sixteen	O	O
patients	O	O
(	O	O
73	O	O
%	O	O
)	O	O
had	O	O
a	O	O
papillary	O	O
subtype	O	O
,	O	O
2	O	O
patients	O	O
a	O	O
chromophobe	O	O
,	O	O
1	O	O
patient	O	O
a	O	O
renal	O	O
medullary	O	O
and	O	O
3	O	O
patients	O	O
an	O	O
unclassified	O	O
non	O	O
-	O	O
clear	O	O
cell	O	O
carcinoma	O	O
(	O	O
Table	O	O
1	O	O
)	O	O
.	O	O
The	O	O
median	O	O
treatment	O	O
duration	O	O
was	O	O
slightly	O	O
but	O	O
not	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
TEM	B-arm_description	B-arm_description
group	I-arm_description	O
.	O	O
The	O	O
reason	O	O
for	O	O
treatment	O	O
stop	O	O
was	O	O
predominantly	O	O
tumor	O	O
progression	O	O
or	O	O
death	O	O
(	O	O
Table	O	O
1	O	O
)	O	O
.	O	O

Safety	O	O
and	O	O
activity	O	O
of	O	O
ibrutinib	B-arm_description	B-arm_description
in	O	O
combination	O	O
with	O	O
durvalumab	B-arm_description	B-arm_description
in	O	O
patients	O	O
with	O	O
relapsed	O	O
or	O	O
refractory	O	O
follicular	O	O
lymphoma	O	O
or	O	O
diffuse	O	O
large	O	O
B	O	O
-	O	O
cell	O	O
lymphoma	O	O
10.1002	O	O
/	O	O
ajh.25659	O	O

Safety	O	O
and	O	O
activity	O	O
of	O	O
ibrutinib	B-arm_description	B-arm_description
in	O	O
combination	B-arm_description	O
with	I-arm_description	O
durvalumab	I-arm_description	B-arm_description
in	O	O
patients	O	O
with	O	O
relapsed	O	O
or	O	O
refractory	O	O
follicular	O	O
lymphoma	O	O
or	O	O
diffuse	O	O
large	O	O
B	O	O
-	O	O
cell	O	O
lymphoma	O	O
AlexFHerrera	B-authors	B-authors
aherrera@coh.org	O	B-authors

Diffuse	O	O
large	O	O
B	O	O
-	O	O
cell	O	O
lymphoma	O	O
(	O	O
DLBCL	O	O
)	O	O
and	O	O
follicular	O	O
lymphoma	O	O
(	O	O
FL	O	O
)	O	O
are	O	O
the	O	O
most	O	O
common	O	O
subtypes	O	O
of	O	O
non	O	O
-	O	O
Hodgkin	O	O
lymphoma	O	O
in	O	O
adults	O	O
.	O	O
[	O	O
1][2][3][4	O	O
]	O	O
Although	O	O
most	O	O
patients	O	O
respond	O	O
to	O	O
first	O	O
-	O	O
line	O	O
chemoimmunotherapy	O	O
,	O	O
a	O	O
substantial	O	O
proportion	O	O
of	O	O
patients	O	O
with	O	O
DLBCL	O	O
and	O	O
most	O	O
patients	O	O
with	O	O
FL	O	O
will	O	O
eventually	O	O
relapse	O	O
or	O	O
have	O	O
refractory	O	O
disease	O	O
.	O	O
[	O	O
1][2][3][4][5	O	O
]	O	O
The	O	O
treatment	O	O
of	O	O
relapsed	O	O
/	O	O
refractory	O	O
DLBCL	O	O
and	O	O
FL	O	O
remains	O	O
challenging	O	O
,	O	O
with	O	O
a	O	O
minority	O	O
of	O	O
patients	O	O
with	O	O
DLBCL	O	O
achieving	O	O
durable	O	O
remission	O	O
and	O	O
patients	O	O
with	O	O
FL	O	O
experiencing	O	O
decreased	O	O
duration	O	O
of	O	O
remission	O	O
with	O	O
successive	O	O
therapies	O	O
.	O	O
[	O	O
1][2][3][4][5	O	O
]	O	O
Effective	O	O
,	O	O
well	O	O
-	O	O
tolerated	O	O
therapy	O	O
for	O	O
relapsed	O	O
/	O	O
refractory	O	O
DLBCL	O	O
and	O	O
FL	O	O
remains	O	O
an	O	O
unmet	O	O
need	O	O
.	O	O

Key	O	O
eligibility	O	O
criteria	O	O
included	O	O
age	O	O
≥18	O	O
years	O	O
;	O	O
pathologically	O	O
confirmed	O	O
DLBCL	O	O
,	O	O
with	O	O
subtype	O	O
identified	O	O
via	O	O
gene	O	O
expression	O	O
or	O	O
immunohistochemistry	O	O
tests	O	O
,	O	O
or	O	O
FL	O	O
(	O	O
grade	O	O
1	O	O
,	O	O
2	O	O
,	O	O
or	O	O
3A	O	O
)	O	O
according	O	O
to	O	O
World	O	O
Health	O	O
Organization	O	O
criteria	O	O
;	O	O
relapsed	O	O
/	O	O
refractory	O	O
disease	O	O
to	O	O
at	O	O
least	O	O
one	O	O
line	O	O
of	O	O
therapy	O	O
;	O	O
measurable	O	O
disease	O	O
(	O	O
≥1	O	O
lesion	O	O
>	O	O
1.5	O	O
cm	O	O
in	O	O
longest	O	O
dimension	O	O
)	O	O
;	O	O
adequate	O	O
hematological	O	O
function	O	O
independent	O	O
of	O	O
transfusion	O	O
and	O	O
growth	O	O
factor	O	O
support	O	O
;	O	O
adequate	O	O
hepatic	O	O
and	O	O
renal	O	O
function	O	O
;	O	O
prothrombin	O	O
time	O	O
<	O	O
1.5	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
(	O	O
ULN	O	O
)	O	O
and	O	O
activated	O	O
partial	O	O
thromboplastin	O	O
time	O	O
<	O	O
1.5	O	O
times	O	O
ULN	O	O
;	O	O
and	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
performance	O	O
status	O	O
of	O	O
0	O	O
or	O	O
1	O	O
.	O	O
In	O	O
the	O	O
phase	O	O
2	O	O
portion	O	O
of	O	O
the	O	O
study	O	O
within	O	O
the	O	O
DLBCL	O	O
cohort	O	O
,	O	O
patients	O	O
with	O	O
germinal	O	O
center	O	O
B	O	O
-	O	O
cell	O	O
(	O	O
GCB	O	O
)	O	O
and	O	O
non	O	O
-	O	O
GCB	O	O
subtypes	O	O
were	O	O
to	O	O
be	O	O
enrolled	O	O
in	O	O
a	O	O
1:1	O	O
ratio	O	O
.	O	O

This	O	O
was	O	O
an	O	O
open	B-study_type	B-study_type
-	I-study_type	I-study_type
label	I-study_type	I-study_type
,	I-study_type	I-study_type
multicenter	I-study_type	I-study_type
phase	I-study_type	I-study_type
1b/2	I-study_type	I-study_type
study	I-study_type	I-study_type
conducted	O	O
at	O	O
12	O	O
centers	O	O
in	O	O
the	O	O
United	O	O
States	O	O
from	O	O
May	O	O
2015	O	O
to	O	O
February	O	O
2018	O	O
.	O	O

The	O	O
primary	O	O
endpoint	O	O
of	O	O
the	O	O
phase	O	B-study_type
2	O	I-study_type
portion	O	O
of	O	O
the	O	O
study	O	O
was	O	O
the	O	O
ORR	O	O
;	O	O
secondary	O	O
endpoints	O	O
included	O	O
duration	O	O
of	O	O
response	O	O
,	O	O
progression	B-arm_efficacy_metric	B-arm_efficacy_metric
-	I-arm_efficacy_metric	I-arm_efficacy_metric
free	I-arm_efficacy_metric	I-arm_efficacy_metric
survival	I-arm_efficacy_metric	I-arm_efficacy_metric
(	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
)	O	O
,	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
,	O	O
safety	O	O
,	O	O
and	O	O
tolerability	O	O
.	O	O

Response	O	O
evaluations	O	O
were	O	O
performed	O	O
every	O	O
three	O	O
cycles	O	O
until	O	O
cycle	O	O
12	O	O
and	O	O
every	O	O
six	O	O
cycles	O	O
thereafter	O	O
.	O	O
Response	O	O
was	O	O
assessed	O	O
by	O	O
the	O	O
investigator	O	O
according	O	O
to	O	O
revised	O	O
criteria	O	O
for	O	O
malignant	O	O
lymphoma	O	O
described	O	O
by	O	O
the	O	O
International	O	O
Working	O	O
Group	O	O
for	O	O
non	O	O
-	O	O
Hodgkin	O	O
Lymphoma	O	O
.	O	O
26	O	O
Adverse	O	O
events	O	O
(	O	O
AEs	O	O
)	O	O
were	O	O
coded	O	O
using	O	O
the	O	O
Medical	O	O
Dictionary	O	O
for	O	O
Regulatory	O	O
Activities	O	O
(	O	O
version	O	O
20.0	O	O
)	O	O
and	O	O
graded	O	O
according	O	O
to	O	O
the	O	O
National	O	O
Cancer	O	O
Institute	O	O
Common	O	O
Terminology	O	O
Criteria	O	O
for	O	O
AEs	O	O
(	O	O
CTCAE	O	O
)	O	O
,	O	O
version	O	O
4.03	O	O
.	O	O
Treatment	O	O
-	O	O
emergent	O	O
adverse	O	O
events	O	O
(	O	O
TEAEs	O	O
)	O	O
were	O	O
defined	O	O
as	O	O
(	O	O
1	O	O
)	O	O
any	O	O
AE	O	O
occurring	O	O
after	O	O
the	O	O
start	O	O
of	O	O
study	O	O
treatment	O	O
and	O	O
within	O	O
30	O	O
days	O	O
of	O	O
the	O	O
last	O	O
dose	O	O
of	O	O
ibrutinib	B-arm_description	B-arm_description
or	O	O
within	O	O
90	O	O
days	O	O
after	O	O
the	O	O
last	O	O
dose	O	O
of	O	O
durvalumab	B-arm_description	B-arm_description
,	O	O
(	O	O
2	O	O
)	O	O
any	O	O
study	O	O
drug	O	O
-	O	O
related	O	O
AE	O	O
regardless	O	O
of	O	O
start	O	O
date	O	O
,	O	O
or	O	O
(	O	O
3	O	O
)	O	O
any	O	O
AE	O	O
present	O	O
at	O	O
baseline	O	O
that	O	O
worsens	O	O
in	O	O
severity	O	O
of	O	O
frequency	O	O
after	O	O
the	O	O
start	O	O
of	O	O
study	O	O
treatment	O	O
or	O	O
is	O	O
considered	O	O
by	O	O
the	O	O
investigator	O	O
to	O	O
be	O	O
study	O	O
drug	O	O
-	O	O
related	O	O
.	O	O
Treatment	O	O
-	O	O
related	O	O
DLTs	O	O
followed	O	O
guidelines	O	O
provided	O	O
in	O	O
the	O	O
CTCAE	O	O
(	O	O
version	O	O
4.03	O	O
)	O	O
and	O	O
were	O	O
defined	O	O
as	O	O
(	O	O
1	O	O
)	O	O
any	O	O
grade	O	O
3	O	O
or	O	O
higher	O	O
nonhematologic	O	O
AE	O	O
or	O	O
(	O	O
2	O	O
)	O	O
clinically	O	O
relevant	O	O
hematologic	O	O
AE	O	O
.	O	O
and	O	O
white	O	O
(	O	O
90	O	O
%	O	O
)	O	O
(	O	O
Table	O	O
1	O	O
)	O	O
.	O	O
The	O	O
median	O	O
time	O	O
from	O	O
initial	O	O
diagnosis	O	O
to	O	O
the	O	O
first	O	O
dose	O	O
of	O	O
study	O	O
treatment	O	O
was	O	O
26.1	O	O
months	O	O
(	O	O
range	O	O
:	O	O
6.0	O	O
-	O	O
362.5	O	O
)	O	O
.	O	O

HRQoL	O	O
data	O	O
were	O	O
analysed	O	O
in	O	O
the	O	O
subset	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
intention	O	O
-	O	O
totreat	O	O
population	O	O
who	O	O
had	O	O
an	O	O
evaluable	O	O
baseline	O	O
EORTC	O	O
QLQ	O	O
-	O	O
C30	O	O
or	O	O
QLQ	O	O
-	O	O
PAN26	O	O
form	O	O
[	O	O
patient	O	O
-	O	O
reported	O	O
outcome	O	O
(	O	O
PRO	O	O
)	O	O
analysis	O	O
set	O	O
]	O	O
.	O	O
An	O	O
evaluable	O	O
form	O	O
was	O	O
defined	O	O
as	O	O
one	O	O
on	O	O
which	O	O
at	O	O
least	O	O
one	O	O
subscale	O	O
baseline	O	O
score	O	O
could	O	O
be	O	O
determined	O	O
.	O	O
For	O	O
the	O	O
adjusted	O	O
mean	O	O
change	O	O
from	O	O
baseline	O	O
in	O	O
GHS	O	O
score	O	O
analysis	O	O
,	O	O
only	O	O
visits	O	O
with	O	O
at	O	O
least	O	O
25	O	O
%	O	O
non	O	O
-	O	O
missing	O	O
values	O	O
in	O	O
each	O	O
treatment	O	O
arm	O	O
were	O	O
included	O	O
;	O	O
study	O	O
treatment	O	O
discontinuation	O	O
and	O	O
30	O	O
days	O	O
following	O	O
last	O	O
dose	O	O
of	O	O
study	O	O
treatment	O	O
visits	O	O
were	O	O
excluded	O	O
.	O	O
The	O	O
analysis	O	O
was	O	O
carried	O	O
out	O	O
using	O	O
a	O	O
linear	O	O
mixed	O	O
model	O	O
for	O	O
repeated	O	O
measures	O	O
,	O	O
adjusted	O	O
for	O	O
score	O	O
at	O	O
baseline	O	O
,	O	O
time	O	O
,	O	O
and	O	O
treatment	O	O
-	O	O
by	O	O
-	O	O
time	O	O
interaction	O	O
to	O	O
estimate	O	O
the	O	O
cumulative	O	O
effect	O	O
of	O	O
olaparib	B-arm_description	O
versus	O	O
placebo	B-arm_description	B-arm_description
on	O	O
GHS	O	O
.	O	O
Between	O	O
-	O	O
group	O	O
differences	O	O
were	O	O
compared	O	O
using	O	O
adjusted	O	O
mean	O	O
estimates	O	O
for	O	O
each	O	O
treatment	O	O
group	O	O
with	O	O
a	O	O
between	O	O
-	O	O
group	O	O
difference	O	O
of	O	O
!	O	O
10	O	O
points	O	O
defined	O	O
as	O	O
clinically	O	O
meaningful	O	O
,	O	O
based	O	O
on	O	O
published	O	O
literature	O	O
[	O	O
17][18][19	O	O
]	O	O
.	O	O
A	O	O
change	O	O
of	O	O
!	O	O
10	O	O
points	O	O
from	O	O
baseline	O	O
was	O	O
also	O	O
predefined	O	O
as	O	O
clinically	O	O
meaningful	O	O
[	O	O
17][18][19	O	O
]	O	O
.	O	O
TSCMD	O	O
was	O	O
analysed	O	O
by	O	O
log	O	O
-	O	O
rank	O	O
test	O	O
[	O	O
hazard	O	O
ratio	O	O
(	O	O
HR	O	O
)	O	O
<	O	O
1	O	O
favours	O	O
olaparib	B-arm_description	O
]	O	O
in	O	O
all	O	O
patients	O	O
with	O	O
a	O	O
baseline	O	O
score	O	O
!	O	O
10	O	O
(	O	O
GHS	O	O
and	O	O
functioning	O	O
subscale	O	O
analyses	O	O
)	O	O
or	O	O
90	O	O
(	O	O
symptom	O	O
subscales	O	O
)	O	O
.	O	O
HRQoL	O	O
improvement	O	O
rates	O	O
were	O	O
analysed	O	O
using	O	O
a	O	O
logistic	O	O
regression	O	O
model	O	O
[	O	O
odds	O	O
ratio	O	O
(	O	O
OR	O	O
)	O	O
>	O	O
1	O	O
favours	O	O
olaparib	B-arm_description	B-arm_description
]	O	O
.	O	O

Of	O	O
154	O	O
randomized	O	O
patients	O	O
,	O	O
89	O	O
of	O	O
92	O	O
who	O	O
received	O	O
olaparib	B-arm_description	B-arm_description
and	O	O
58	O	O
of	O	O
62	O	O
who	O	O
received	O	O
placebo	B-arm_description	B-arm_description
were	O	O
included	O	O
in	O	O
the	O	O
PRO	O	O
analysis	O	O
set	O	O
;	O	O
the	O	O
remaining	O	O
seven	O	O
patients	O	O
had	O	O
missing	O	O
baseline	O	O
forms	O	O
.	O	O
HRQoL	O	O
scores	O	O
were	O	O
well	O	O
-	O	O
balanced	O	O
between	O	O
treatment	O	O
groups	O	O
at	O	O
baseline	O	O
with	O	O
overall	O	O
high	O	O
scores	O	O
for	O	O
GHS	O	O
and	O	O
physical	O	O
functioning	O	O
scales	O	O
,	O	O
and	O	O
low	O	O
scores	O	O
for	O	O
symptom	O	O
scales	O	O
(	O	O
supplementary	O	O
Figure	O	O
S1	O	O
,	O	O
available	O	O
at	O	O
Annals	O	O
of	O	O
Oncology	O	O
online	O	O
)	O	O
.	O	O

The	O	O
overall	O	O
compliance	O	O
rate	O	O
for	O	O
EORTC	O	O
QLQ	O	O
-	O	O
C30	O	O
was	O	O
high	O	O
,	O	O
100	O	O
%	O	O
at	O	O
baseline	O	O
and	O	O
96.6	O	O
%	O	O
and	O	O
94.8	O	O
%	O	O
overall	O	O
in	O	O
the	O	O
olaparib	B-arm_description	B-arm_description
and	O	O
placebo	B-arm_description	B-arm_description
groups	O	O
,	O	O
respectively	O	O
,	O	O
based	O	O
on	O	O
the	O	O
PRO	O	O
analysis	O	O
set	O	O
(	O	O
supplementary	O	O
Figure	O	O
S2	O	O
,	O	O
available	O	O
at	O	O
Annals	O	O
of	O	O
Oncology	O	O
online	O	O
)	O	O
.	O	O

HRQoL	O	O
was	O	O
preserved	O	O
with	O	O
olaparib	O	B-arm_description
maintenance	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
metastatic	O	O
pancreatic	O	O
cancer	O	O
and	O	O
a	O	O
gBRCAm	O	O
whose	O	O
disease	O	O
had	O	O
not	O	O
progressed	O	O
during	O	O
first	O	O
-	O	O
line	O	O
platinum	O	O
-	O	O
based	O	O
chemotherapy	O	O
,	O	O
with	O	O
no	O	O
meaningful	O	O
difference	O	O
observed	O	O
compared	O	O
with	O	O
placebo	B-arm_description	B-arm_description
.	O	O
Results	O	O
of	O	O
prespecified	O	O
end	O	O
points	O	O
from	O	O
the	O	O
POLO	O	O
trial	O	O
show	O	O
that	O	O
maintenance	O	O
olaparib	O	O
significantly	O	O
Figure	O	O
4	O	O
.	O	O
Best	O	O
overall	O	O
quality	O	O
of	O	O
life	O	O
response	O	O
for	O	O
EORTC	O	O
QLQ	O	O
-	O	O
C30	O	O
Global	O	O
Health	O	O
Status	O	O
,	O	O
physical	O	O
functioning	O	O
and	O	O
symptom	O	O
scales	O	O
.	O	O
Percentages	O	O
are	O	O
calculated	O	O
based	O	O
on	O	O
the	O	O
86	O	O
olaparib	B-arm_description	B-arm_description
-	O	I-arm_description
arm	O	I-arm_description
patients	O	O
and	O	O
55	O	O
placebo	B-arm_description	B-arm_description
-	O	I-arm_description
arm	O	I-arm_description
patients	O	O
(	O	O
54	O	O
for	O	O
the	O	O
diarrhoea	O	O
subscale	O	O
)	O	O
with	O	O
available	O	O
results	O	O
.	O	O
Three	O	O
patients	O	O
in	O	O
each	O	O
arm	O	O
(	O	O
4	O	O
placebo	B-arm_description	B-arm_description
arm	O	I-arm_description
patients	O	O
for	O	O
the	O	O
diarrhoea	O	O
subscale	O	O
)	O	O
were	O	O
included	O	O
in	O	O
the	O	O
PRO	O	O
analysis	O	O
set	O	O
,	O	O
but	O	O
had	O	O
no	O	O
evaluable	O	O
baseline	O	O
or	O	O
post	O	O
-	O	O
baseline	O	O
results	O	O
and	O	O
are	O	O
excluded	O	O
from	O	O
this	O	O
figure	O	O
.	O	O
O	O	O
,	O	O
olaparib	B-arm_description	B-arm_description
;	O	O
P	O	O
,	O	O
placebo	B-arm_description	B-arm_description
.	O	O

Nelfinavir	O	B-arm_description
and	O	O
lenalidomide/	O	B-arm_description
dexamethasone	O	I-arm_description
in	O	O
patients	O	O
with	O	O
lenalidomide	O	B-arm_description
-	O	O
refractory	O	O
multiple	O	O
myeloma	O	O
.	O	O
A	O	O
phase	B-study_type	B-study_type
I	I-study_type	I-study_type
/	I-study_type	I-study_type
II	I-study_type	I-study_type
Trial	I-study_type	I-study_type
(	O	O
SAKK	O	O
39/10	O	O
)	O	O
Nelfinavir	O	B-arm_description
and	O	O
lenalidomide/	O	B-arm_description
dexamethasone	O	O
in	O	O
patients	O	O
with	O	O
lenalidomide	O	B-arm_description
-	O	O
refractory	O	O
multiple	O	O
myeloma	O	O
.	O	O
A	O	O
phase	B-study_type	B-study_type
I	I-study_type	I-study_type
/	I-study_type	I-study_type
II	I-study_type	I-study_type
Trial	I-study_type	I-study_type
(	O	O
SAKK	O	O
39/10	O	O
)	O	O
FHitz	B-authors	B-authors

Patient	O	O
and	O	O
disease	O	O
characteristics	O	O
for	O	O
the	O	O
29	O	O
patients	O	O
are	O	O
presented	O	O
in	O	O
Table	O	O
1	O	O
.	O	O
Most	O	O
(	O	O
93	O	O
%	O	O
)	O	O
had	O	O
undergone	O	O
two	O	O
or	O	O
more	O	O
prior	O	O
lines	O	O
of	O	O
therapy	O	O
,	O	O
and	O	O
24	O	O
(	O	O
83	O	O
%	O	O
)	O	O
had	O	O
prior	O	O
bortezomib	O	O
exposure	O	O
,	O	O
including	O	O
18	O	O
(	O	O
62	O	O
%	O	O
)	O	O
with	O	O
prior	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
and	O	O
10	O	O
(	O	O
34	O	O
%	O	O
)	O	O
who	O	O
were	O	O
double	O	O
-	O	O
refractory	O	O
to	O	O
lenalidomide	O	O
and	O	O
bortezomib	O	O
,	O	O
based	O	O
on	O	O
International	O	O
Myeloma	O	O
Working	O	O
Group	O	O
(	O	O
IMWG	O	O
)	O	O
criteria	O	O
14	O	O
.	O	O

Fifteen	O	O
patients	O	O
completed	O	O
four	O	O
cycles	O	O
of	O	O
study	O	O
treatment	O	O
.	O	O
Fourteen	O	O
of	O	O
29	O	O
patients	O	O
discontinued	O	O
trial	O	O
treatment	O	O
due	O	O
to	O	O
:	O	O
progressive	O	O
disease	O	O
(	O	O
PD	O	O
;	O	O
n	O	O
=	O	O
8)	O	O
,	O	O
unacceptable	O	O
toxicity	O	O
(	O	O
4	O	O
)	O	O
,	O	O
or	O	O
patient	O	O
refusal	O	O
(	O	O
2	O	O
)	O	O
.	O	O

Department	O	O
of	O	O
Internal	O	O
Medicine	O	O
II	O	O
,	O	O
Asklepios	O	O
Klinik	O	O
Altona	O	O
Hamburg	O	O
Germany	O	O
MartinaEmde	O	B-authors
Labor	O	O
für	O	O
Myelomforschung	O	O
Universitätsklinikum	O	O
Heidelberg	O	O
Heidelberg	O	O
Germany	O	O
Medizinische	O	O
Klinik	O	O
V	O	O
Universitätsklinikum	O	O
Heidelberg	O	O
Heidelberg	O	O
Germany	O	O
Labor	O	O
für	O	O
Myelomforschung	O	O
Universitätsklinikum	O	O
Heidelberg	O	O
Heidelberg	O	O
Germany	O	O
Medizinische	O	O
Klinik	O	O
V	O	O
Universitätsklinikum	O	O
Heidelberg	O	O
Heidelberg	O	O
Germany	O	O
UtaBertsch	O	O
Medizinische	O	O
Klinik	O	O
V	O	O
Universitätsklinikum	O	O
Heidelberg	O	O
Heidelberg	O	O
Germany	O	O
Medizinische	O	O
Klinik	O	O
V	O	O
Universitätsklinikum	O	O
Heidelberg	O	O
Heidelberg	O	O
Germany	O	O
ChristinaKunz	B-authors	B-authors

Both	O	O
personalized	O	O
and	O	O
risk	O	O
-	O	O
adapted	O	O
treatment	O	O
strategies	O	O
prerequisite	O	O
the	O	O
feasibility	O	O
of	O	O
prospective	O	O
assessment	O	O
and	O	O
reporting	O	O
of	O	O
targets	O	O
and	O	O
prediction	O	O
of	O	O
survival	O	O
probability	O	O
in	O	O
clinical	O	O
routine	O	O
in	O	O
a	O	O
high	O	O
enough	O	O
percentage	O	O
of	O	O
patients	O	O
.	O	O
For	O	O
phase	O	O
III	O	O
trial	O	O
strategies	O	O
,	O	O
e.g.	O	O
,	O	O
selecting	O	O
an	O	O
add	O	O
-	O	O
on	O	O
treatment	O	O
,	O	O
the	O	O
necessary	O	O
threshold	O	O
based	O	O
on	O	O
power	O	O
calculations	O	O
and	O	O
clinical	O	O
feasibility	O	O
could	O	O
be	O	O
estimated	O	O
as	O	O
80	O	O
%	O	O
of	O	O
the	O	O
actual	O	O
population	O	O
of	O	O
patients	O	O
included	O	O
in	O	O
the	O	O
trial	O	O
.	O	O
It	O	O
is	O	O
interesting	O	O
to	O	O
denote	O	O
that	O	O
,	O	O
despite	O	O
of	O	O
course	O	O
iFISH	O	O
and	O	O
GEP	O	O
have	O	O
been	O	O
used	O	O
in	O	O
an	O	O
academic	O	O
setting	O	O
or	O	O
using	O	O
commercial	O	O
providers	O	O
[	O	O
8,17,[23][24][25][26][27][28	O	O
]	O	O
,	O	O
the	O	O
question	O	O
has	O	O
yet	O	O
not	O	O
been	O	O
answered	O	O
if	O	O
this	O	O
is	O	O
possible	O	O
in	O	O
terms	O	O
of	O	O
a	O	O
prospective	O	O
molecular	O	O
analysis	O	O
and	O	O
reporting	O	O
,	O	O
as	O	O
opposed	O	O
to	O	O
being	O	O
conducted	O	O
in	O	O
a	O	O
prospective	O	O
clinical	O	O
trial	O	O
.	O	O
Our	O	O
study	O	O
group	O	O
sees	O	O
such	O	O
a	O	O
proof	O	O
as	O	O
prerequisite	O	O
for	O	O
indeed	O	O
planning	O	O
a	O	O
clinical	O	O
trial	O	O
based	O	O
on	O	O
molecular	O	O
diagnostics	O	O
such	O	O
as	O	O
GEP	O	O
or	O	O
RNA	O	O
-	O	O
sequencing	O	O
.	O	O

Aims	O	O
of	O	O
this	O	O
study	O	O
were	O	O
thus	O	O
:	O	O
(	O	O
i	O	O
)	O	O
set	O	O
up	O	O
a	O	O
sampling	O	O
,	O	O
experimental	O	O
and	O	O
analysis	O	O
strategy	O	O
to	O	O
perform	O	O
iFISH	B-arm_description	O
in	O	O
≥	O	O
90	O	O
%	O	O
and	O	O
GEP	B-arm_description	O
in	O	O
≥	O	O
80	O	O
%	O	O
of	O	O
patients	O	O
within	O	O
the	O	O
first	O	O
cycle	O	O
of	O	O
induction	O	O
chemotherapy	O	O
.	O	O
(	O	O
ii	O	O
)	O	O
Report	O	O
to	O	O
patients	O	O
and	O	O
physicians	O	O
within	O	O
this	O	O
time	O	O
to	O	O
be	O	O
able	O	O
to	O	O
draw	O	O
a	O	O
clinical	O	O
consequence	O	O
.	O	O
(	O	O
iii	O	O
)	O	O
Prospectively	O	O
validate	O	O
this	O	O
strategy	O	O
in	O	O
the	O	O
randomized	O	B-study_type
phase	O	B-study_type
III	O	I-study_type
multicenter	O	I-study_type
GMMG	O	O
-	O	O
MM5-trial	O	O
including	O	O
assessment	O	O
of	O	O
potential	O	O
targets	O	O
(	O	O
based	O	O
on	O	O
GEP	B-arm_description	O
)	O	O
and	O	O
multimodal	O	O
assessment	O	O
of	O	O
risk	O	O
using	O	O
clinical	O	O
,	O	O
cytogenetic	O	O
,	O	O
and	O	O
gene	O	O
expression	O	O
-	O	O
based	O	O
prognostic	O	O
factors	O	O
and	O	O
their	O	O
integration	O	O
into	O	O
a	O	O
metascore	O	O
in	O	O
clinical	O	O
routine	O	O
.	O	O

Density	O	O
gradient	O	O
centrifugation	O	O
of	O	O
bone	O	O
marrow	O	O
aspirates	O	O
over	O	O
Ficoll	O	O
Hypaque	O	O
(	O	O
Biochrom	O	O
,	O	O
Berlin	O	O
,	O	O
Germany	O	O
)	O	O
was	O	O
performed	O	O
to	O	O
separate	O	O
mononuclear	O	O
cells	O	O
by	O	O
standard	O	O
protocol	O	O
.	O	O
CD138	O	O
+	O	O
plasma	O	O
cells	O	O
were	O	O
isolated	O	O
using	O	O
anti	O	O
-	O	O
CD138	O	O
immunobeads	O	O
and	O	O
an	O	O
autoMACS	O	O
Pro	O	O
Separator	O	O
(	O	O
Miltenyi	O	O
Biotec	O	O
,	O	O
Bergisch	O	O
Gladbach	O	O
,	O	O
Germany	O	O
)	O	O
as	O	O
published	O	O
[	O	O
13,21,[30][31][32][33][34][35	O	O
]	O	O
.	O	O
Purity	O	O
was	O	O
assessed	O	O
by	O	O
flow	O	O
cytometry	O	O
(	O	O
Becton	O	O
Dickinson	O	O
,	O	O
Heidelberg	O	O
,	O	O
Germany	O	O
)	O	O
using	O	O
antibodies	O	O
against	O	O
CD38	O	O
(	O	O
clone	O	O
HB-7	O	O
,	O	O
FITClabeled	O	O
;	O	O
Becton	O	O
Dickinson	O	O
)	O	O
and	O	O
CD138	O	O
(	O	O
clone	O	O
B	O	O
-	O	O
B4	O	O
,	O	O
PElabeled	O	O
;	O	O
Miltenyi	O	O
Biotec	O	O
)	O	O
.	O	O
Aliquots	O	O
of	O	O
CD138	O	O
+	O	O
malignant	O	O
plasma	O	O
cells	O	O
were	O	O
subjected	O	O
to	O	O
cytospin	O	O
preparation	O	O
with	O	O
5000	O	O
cells	O	O
per	O	O
dot	O	O
for	O	O
iFISH	B-arm_description	O
analysis	O	O
(	O	O
n	O	O
=	O	O
556	O	O
patients	O	O
)	O	O
and	O	O
RNA	O	O
/	O	O
DNA	O	O
extraction	O	O
for	O	O
gene	O	O
expression	O	O
profiling	O	O
(	O	O
n	O	O
=	O	O
458	O	O
)	O	O
.	O	O

The	O	O
percentages	O	O
of	O	O
patients	O	O
identified	O	O
as	O	O
being	O	O
of	O	O
high	O	O
risk	O	O
(	O	O
first	O	O
column	O	O
)	O	O
and	O	O
the	O	O
overlap	O	O
of	O	O
the	O	O
respective	O	O
groups	O	O
of	O	O
patients	O	O
are	O	O
shown	O	O
GPI	O	O
,	O	O
gene	O	O
expression	O	O
-	O	O
based	O	O
proliferation	O	O
index	O	O
;	O	O
(	O	O
r)ISS	O	O
,	O	O
(	O	O
revised	O	O
)	O	O
International	O	O
Staging	O	O
System	O	O
aberrantly	O	O
or	O	O
differentially	O	O
expressed	O	O
in	O	O
myeloma	O	O
.	O	O
In	O	O
our	O	O
cohort	O	O
of	O	O
456	O	O
patients	O	O
from	O	O
the	O	O
intention	O	O
-	O	O
to	O	O
-	O	O
treat	O	O
population	O	O
for	O	O
which	O	O
a	O	O
GEP	B-arm_description	O
-	O	O
R	O	O
is	O	O
available	O	O
,	O	O
197	O	O
were	O	O
found	O	O
to	O	O
express	O	O
AURKA	O	B-arm_description
(	O	O
43.2	O	O
%	O	O
)	O	O
,	O	O
151	O	O
IGF1R	O	O
(	O	O
33.1	O	O
%	O	O
)	O	O
,	O	O
and	O	O
50	O	O
FGFR3	O	O
(	O	O
11	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
In	O	O
the	O	O
same	O	O
way	O	O
,	O	O
candidates	O	O
for	O	O
personalized	O	O
treatment	O	O
approaches	O	O
,	O	O
given	O	O
the	O	O
availability	O	O
of	O	O
respective	O	O
inhibitors	O	O
,	O	O
could	O	O
be	O	O
addressed	O	O
.	O	O

Pemetrexed	B-arm_description	B-arm_description
,	O	O
Bevacizumab	B-arm_description	B-arm_description
,	O	O
or	O	O
the	O	O
Combination	B-arm_description	O
As	O	O
Maintenance	O	O
Therapy	O	O
for	O	O
Advanced	O	O
Nonsquamous	O	O
Non	O	O
-	O	O
Small	O	O
-	O	O
Cell	O	O
Lung	O	O
Cancer	O	O
:	O	O
ECOG	O	O
-	O	O
ACRIN	O	O
5508	O	O
Pemetrexed	O	O
,	O	O
Bevacizumab	O	B-arm_description
,	O	O
or	O	O
the	O	O
Combination	O	O
As	O	O
Maintenance	O	O
Therapy	O	O
for	O	O
Advanced	O	O
Nonsquamous	O	O
Non	O	O
-	O	O
Small	O	O
-	O	O
Cell	O	O
Lung	O	O
Cancer	O	O
:	O	O
ECOG	O	O
-	O	O
ACRIN	O	O
5508	O	O
MDSureshSRamalingam	B-authors	B-authors

Eligible	O	O
patients	O	O
received	O	O
carboplatin	O	B-arm_description
(	O	O
dosed	O	O
to	O	O
achieve	O	O
an	O	O
area	O	O
under	O	O
the	O	O
concentration	O	O
versus	O	O
time	O	O
curve	O	O
of	O	O
6	O	B-arm_dosage
mg	O	I-arm_dosage
/	O	I-arm_dosage
mL	O	I-arm_dosage
per	O	I-arm_dosage
minute	O	I-arm_dosage
)	O	O
,	O	O
paclitaxel	O	B-arm_description
(	O	O
200	O	B-arm_dosage
mg	O	I-arm_dosage
/	O	I-arm_dosage
m	O	I-arm_dosage
2	O	I-arm_dosage
)	O	O
,	O	O
and	O	O
bevacizumab	O	B-arm_description
(	O	O
15	O	B-arm_dosage
mg	O	I-arm_dosage
/	O	I-arm_dosage
kg	O	I-arm_dosage
)	O	I-arm_dosage
every	O	I-arm_dosage
3	O	I-arm_dosage
weeks	O	I-arm_dosage
for	O	O
up	O	O
to	O	O
four	O	O
cycles	O	O
(	O	O
induction	O	O
therapy	O	O
)	O	O
.	O	O
Patients	O	O
achieving	O	O
complete	O	O
response	O	O
,	O	O
partial	O	O
response	O	O
,	O	O
or	O	O
stable	O	O
disease	O	O
per	O	O
RECIST	O	O
criteria	O	O
after	O	O
four	O	O
cycles	O	O
were	O	O
then	O	O
randomly	O	O
assigned	O	O
at	O	O
a	O	O
1:1:1	O	O
ratio	O	O
to	O	O
maintenance	O	O
therapy	O	O
with	O	O
bevacizumab	B-arm_description	B-arm_description
(	O	O
15	B-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
kg	I-arm_dosage	I-arm_dosage
)	O	O
,	O	O
pemetrexed	B-arm_description	O
(	O	O
500	B-arm_dosage	B-arm_dosage
mg	I-arm_dosage	I-arm_dosage
/	I-arm_dosage	I-arm_dosage
m	I-arm_dosage	I-arm_dosage
2	I-arm_dosage	I-arm_dosage
)	O	O
,	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
the	O	O
two	O	O
agents	O	O
at	O	O
the	O	O
same	O	O
doses	O	O
as	O	O
in	O	O
the	O	O
monotherapy	O	O
groups	O	O
every	B-arm_dosage	O
3	I-arm_dosage	O
weeks	I-arm_dosage	O
.	O	O
Because	O	O
of	O	O
the	O	O
national	O	O
shortage	O	O
of	O	O
paclitaxel	O	O
in	O	O
2011	O	O
,	O	O
use	O	O
of	O	O
docetaxel	O	O
at	O	O
75	O	B-arm_dosage
mg	O	I-arm_dosage
/	O	I-arm_dosage
m	O	I-arm_dosage
2	O	I-arm_dosage
was	O	O
allowed	O	O
as	O	O
a	O	O
substitution	O	O
for	O	O
a	O	O
short	O	O
duration	O	O
of	O	O
time	O	O
.	O	O
Standard	O	O
premedications	O	O
,	O	O
including	O	O
dexamethasone	O	O
,	O	O
diphenhydramine	O	O
,	O	O
and	O	O
cimetidine	O	O
,	O	O
or	O	O
appropriate	O	O
institutional	O	O
alternative	O	O
options	O	O
were	O	O
used	O	O
during	O	O
the	O	O
induction	O	O
chemotherapy	O	O
phase	O	O
.	O	O
For	O	O
maintenance	O	O
therapy	O	O
,	O	O
premedications	O	O
included	O	O
vitamin	O	O
B12	O	O
injection	O	O
,	O	O
dexamethasone	O	O
,	O	O
and	O	O
folic	O	O
acid	O	O
supplements	O	O
for	O	O
patients	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
the	O	O
pemetrexed	O	O
groups	O	O
.	O	O
Treatment	O	O
cycles	O	O
were	O	O
repeated	O	O
every	O	O
3	O	O
weeks	O	O
.	O	O

In	O	O
the	O	O
induction	O	O
phase	O	O
,	O	O
patients	O	O
who	O	O
did	O	O
not	O	O
make	O	O
it	O	O
to	O	O
the	O	O
fourth	O	O
cycle	O	O
because	O	O
of	O	O
toxicity	O	O
were	O	O
allowed	O	O
to	O	O
proceed	O	O
to	O	O
maintenance	O	O
phase	O	O
after	O	O
cycle	O	O
3	O	O
if	O	O
they	O	O
had	O	O
achieved	O	O
favorable	O	O
response	O	O
or	O	O
stable	O	O
disease	O	O
.	O	O
In	O	O
the	O	O
maintenance	O	O
phase	O	O
,	O	O
treatment	O	O
was	O	O
continued	O	O
until	O	O
documentation	O	O
of	O	O
disease	O	O
progression	O	O
,	O	O
unacceptable	O	O
toxicity	O	O
,	O	O
or	O	O
withdrawal	O	O
of	O	O
informed	O	O
consent	O	O
.	O	O
Dose	O	O
modifications	O	O
were	O	O
made	O	O
for	O	O
patients	O	O
who	O	O
experienced	O	O
treatment	O	O
-	O	O
related	O	O
toxicity	O	O
.	O	O
Delay	O	O
in	O	O
treatment	O	O
of	O	O
up	O	O
to	O	O
3	O	O
weeks	O	O
was	O	O
allowed	O	O
for	O	O
toxicity	O	O
,	O	O
with	O	O
any	O	O
delays	O	O
beyond	O	O
that	O	O
resulting	O	O
in	O	O
discontinuation	O	O
of	O	O
study	O	O
therapy	O	O
.	O	O
All	O	O
appropriate	O	O
supportive	O	O
care	O	O
measures	O	O
were	O	O
instituted	O	O
for	O	O
patients	O	O
who	O	O
experienced	O	O
toxicity	O	O
.	O	O

The	O	O
study	O	O
was	O	O
conducted	O	O
by	O	O
the	O	O
Thoracic	O	O
Malignancies	O	O
Committee	O	O
of	O	O
the	O	O
ECOG	O	O
-	O	O
American	O	O
College	O	O
of	O	O
Radiology	O	O
Imaging	O	O
Network	O	O
(	O	O
ACRIN	O	O
)	O	O
Cancer	O	O
Research	O	O
Group	O	O
;	O	O
monitoring	O	O
was	O	O
performed	O	O
by	O	O
the	O	O
ECOG	O	O
-	O	O
ACRIN	O	O
Data	O	O
Safety	O	O
Monitoring	O	O
Committee	O	O
,	O	O
which	O	O
meets	O	O
twice	O	O
annually	O	O
.	O	O
For	O	O
each	O	O
meeting	O	O
,	O	O
the	O	O
study	O	O
was	O	O
reviewed	O	O
for	O	O
safety	O	O
and	O	O
progress	O	O
toward	O	O
completion	O	O
.	O	O
Interim	O	O
analyses	O	O
were	O	O
conducted	O	O
on	O	O
the	O	O
outcome	O	O
data	O	O
at	O	O
predefined	O	O
time	O	O
points	O	O
.	O	O
Only	O	O
the	O	O
study	O	O
statistician	O	O
and	O	O
members	O	O
of	O	O
the	O	O
Data	O	O
Safety	O	O
Monitoring	O	O
Committee	O	O
had	O	O
access	O	O
to	O	O
interim	O	O
analyses	O	O
of	O	O
the	O	O
outcome	O	O
data	O	O
.	O	O
Toxicity	O	O
reports	O	O
were	O	O
available	O	O
to	O	O
the	O	O
study	O	O
investigators	O	O
throughout	O	O
the	O	O
course	O	O
of	O	O
the	O	O
study	O	O
.	O	O
The	O	O
study	O	O
protocol	O	O
was	O	O
approved	O	O
by	O	O
the	O	O
institutional	O	O
review	O	O
board	O	O
of	O	O
each	O	O
participating	O	O
institution	O	O
and	O	O
by	O	O
the	O	O
National	O	O
Cancer	O	O
Institute	O	O
Central	O	O
institutional	O	O
review	O	O
board	O	O
.	O	O

Fostering	O	O
efficacy	O	O
of	O	O
anti	O	O
-	O	O
PD-1-treatment	O	O
:	O	O
Nivolumab	B-arm_description	B-arm_description
plus	O	I-arm_description
radiotherapy	B-arm_description	I-arm_description
in	O	O
advanced	O	O
non	O	O
-	O	O
small	O	O
cell	O	O
lung	O	O
cancer	O	O
-study	O	O
protocol	O	O
of	O	O
the	O	O
FORCE	O	O
trial	O	O
FarastukBozorgmehr	B-authors	B-authors

However	O	O
,	O	O
when	O	O
radiation	O	O
is	O	O
applied	O	O
as	O	O
a	O	O
sole	O	O
treatment	O	O
modality	O	O
,	O	O
this	O	O
phenomenon	O	O
is	O	O
soon	O	O
suppressed	O	O
by	O	O
regulatory	O	O
signalling	O	O
pathways	O	O
that	O	O
inhibit	O	O
auto−/	O	O
tumor	O	O
-	O	O
immune	O	O
responses	O	O
within	O	O
and	O	O
outside	O	O
the	O	O
tumor	O	O
microenvironment	O	O
[	O	O
13,17,18	O	O
]	O	O
.	O	O
Thus	O	O
,	O	O
the	O	O
clinical	O	O
observation	O	O
of	O	O
any	O	O
abscopal	O	O
effect	O	O
with	O	O
radiation	O	O
alone	O	O
has	O	O
always	O	O
been	O	O
a	O	O
rare	O	O
finding	O	O
.	O	O
With	O	O
the	O	O
advent	O	O
of	O	O
agents	O	O
that	O	O
target	O	O
PD-1	O	O
/	O	O
PD	O	O
-	O	O
L1	O	O
and	O	O
therefore	O	O
disinhibit	O	O
tumor	O	O
-	O	O
directed	O	O
immune	O	O
responses	O	O
,	O	O
the	O	O
potential	O	O
of	O	O
inducing	O	O
an	O	O
abscopal	O	O
effect	O	O
through	O	O
combined	O	O
radio	O	O
-	O	O
immunotherapies	O	O
has	O	O
gained	O	O
renewed	O	O
attention	O	O
.	O	O
Interestingly	O	O
,	O	O
a	O	O
secondary	O	O
analysis	O	O
of	O	O
a	O	O
clinical	O	O
landmark	O	O
trial	O	O
has	O	O
identified	O	O
98	O	O
patients	O	O
,	O	O
who	O	O
had	O	O
received	O	O
photon	O	O
radiotherapy	O	O
prior	O	O
to	O	O
immunotherapy	O	O
[	O	O
19	O	O
]	O	O
.	O	O
These	O	O
patients	O	O
showed	O	O
significantly	O	O
improved	O	O
PFS	O	B-arm_efficacy_metric
and	O	O
OSirrespective	O	O
of	O	O
the	O	O
expression	O	O
of	O	O
PD	O	O
-	O	O
L1	O	O
.	O	O
This	O	O
finding	O	O
hasonce	O	O
again	O	O
nourished	O	O
the	O	O
hope	O	O
that	O	O
the	O	O
combination	O	O
of	O	O
pharmacological	O	O
disinhibition	O	O
of	O	O
the	O	O
immune	O	O
system	O	O
through	O	O
medical	O	O
immunotherapies	O	O
and	O	O
tumor	O	O
-	O	O
antigen	O	O
-	O	O
exposing	O	O
photon	O	O
radiation	O	O
may	O	O
be	O	O
a	O	O
beneficial	O	O
combination	O	O
.	O	O
However	O	O
,	O	O
to	O	O
date	O	O
results	O	O
from	O	O
prospective	O	O
clinical	O	O
trials	O	O
investigating	O	O
this	O	O
hypothesis	O	O
in	O	O
lung	O	O
cancer	O	O
patients	O	O
are	O	O
not	O	O
available	O	O
.	O	O

This	O	O
is	O	O
an	O	O
interventional	B-study_type	B-study_type
two	I-study_type	I-study_type
-	I-study_type	I-study_type
group	I-study_type	I-study_type
,	I-study_type	I-study_type
non	I-study_type	I-study_type
-	I-study_type	I-study_type
randomized	I-study_type	I-study_type
,	I-study_type	I-study_type
open	I-study_type	I-study_type
-	I-study_type	I-study_type
label	I-study_type	I-study_type
phase	I-study_type	I-study_type
II	I-study_type	I-study_type
trial	I-study_type	I-study_type
(	O	O
Fig	O	O
.	O	O
1	O	O
)	O	O
[	O	O
20	O	O
]	O	O
.	O	O

Furthermore	O	O
,	O	O
to	O	O
address	O	O
the	O	O
role	O	O
of	O	O
radiotherapy	B-arm_description	O
in	O	O
the	O	O
context	O	O
of	O	O
immune	O	O
modulation	O	O
,	O	O
several	O	O
aspects	O	O
of	O	O
radiation	O	O
planning	O	O
and	O	O
treatment	O	O
will	O	O
be	O	O
explored	O	O
.	O	O
This	O	O
includes	O	O
both	O	O
the	O	O
location	O	O
and	O	O
composition	O	O
of	O	O
radiation	O	O
targets	O	O
and	O	O
the	O	O
anatomical	O	O
profile	O	O
of	O	O
abscopally	O	O
responding	O	O
lesions	O	O
.	O	O
Therefore	O	O
,	O	O
treatment	O	O
-	O	O
related	O	O
aspects	O	O
characterizing	O	O
the	O	O
irradiated	O	O
targets	O	O
and	O	O
abscopally	O	O
responding	O	O
target	O	O
lesions	O	O
will	O	O
be	O	O
documented	O	O
by	O	O
the	O	O
treating	O	O
radiation	O	O
oncologist	O	O
and	O	O
radiologist	O	O
.	O	O
Documentation	O	O
of	O	O
these	O	O
aspects	O	O
will	O	O
help	O	O
to	O	O
substantiate	O	O
the	O	O
phenomenon	O	O
of	O	O
radiation	O	O
-	O	O
induced	O	O
abscopal	O	O
effects	O	O
and	O	O
to	O	O
improve	O	O
the	O	O
option	O	O
of	O	O
radiation	O	O
triggered	O	O
systemic	O	O
response	O	O
through	O	O
identification	O	O
and	O	O
possible	O	O
prediction	O	O
of	O	O
both	O	O
eligible	O	O
targets	O	O
for	O	O
irradiation	O	O
and	O	O
probable	O	O
lesion	O	O
of	O	O
abscopal	O	O
response	O	O
.	O	O

An	O	O
overview	O	O
of	O	O
all	O	O
study	O	O
procedures	O	O
is	O	O
presented	O	O
in	O	O
Table	O	O
2	O	O
.	O	O
For	O	O
each	O	O
patient	O	O
enrolled	O	O
,	O	O
an	O	O
electronic	O	O
case	O	O
report	O	O
form	O	O
(	O	O
eCRF	O	O
)	O	O
must	O	O
be	O	O
completed	O	O
by	O	O
the	O	O
principal	O	O
investigator	O	O
or	O	O
authorized	O	O
delegate	O	O
from	O	O
the	O	O
study	O	O
staff	O	O
.	O	O
For	O	O
patients	O	O
in	O	O
group	O	B-arm_description
A	O	O
,	O	O
non	O	O
-	O	O
measurable	O	O
and	O	O
measurable	O	O
lesions	O	O
may	O	O
be	O	O
chosen	O	O
for	O	O
irradiation	O	O
.	O	O
However	O	O
,	O	O
in	O	O
order	O	O
to	O	O
allow	O	O
for	O	O
evaluation	O	O
of	O	O
abscopal	O	O
effects	O	O
,	O	O
patients	O	O
in	O	O
group	O	B-arm_description
A	O	O
must	O	O
have	O	O
at	O	O
least	O	O
one	O	O
measurable	O	O
lesion	O	O
beside	O	O
the	O	O
lesion	O	O
planned	O	O
to	O	O
be	O	O
irradiated	O	O
.	O	O
Lesions	O	O
planned	O	O
to	O	O
be	O	O
irradiated	O	O
may	O	O
not	O	O
be	O	O
defined	O	O
as	O	O
a	O	O
measurable	O	O
target	O	O
lesion	O	O
.	O	O
Radiographic	O	O
tumor	O	O
assessment	O	O
must	O	O
be	O	O
performed	O	O
within	O	O
28	O	O
days	O	O
before	O	O
initiation	O	O
of	O	O
study	O	O
treatment	O	O
.	O	O
•	O	O
Target	O	O
Lesions	O	O
may	O	O
be	O	O
located	O	O
in	O	O
a	O	O
previously	O	O
irradiated	O	O
field	O	O
if	O	O
there	O	O
is	O	O
documented	O	O
(	O	O
radiographic	O	O
)	O	O
disease	O	O
progression	O	O
in	O	O
that	O	O
site	O	O
.	O	O

•	O	O
Adequate	O	O
blood	O	O
count	O	O
,	O	O
liver	O	O
-	O	O
enzymes	O	O
,	O	O
and	O	O
renal	O	O
function	O	O
(	O	O
obtained	O	O
no	O	O
later	O	O
than	O	O
14	O	O
days	O	O
prior	O	O
to	O	O
start	O	O
of	O	O
treatment	O	O
)	O	O
:	O	O

Nivolumab	B-arm_description	B-arm_description
will	O	O
be	O	O
given	O	B-arm_dosage
every	B-arm_dosage	I-arm_dosage
two	I-arm_dosage	I-arm_dosage
weeks	I-arm_dosage	I-arm_dosage
at	I-arm_dosage	I-arm_dosage
a	I-arm_dosage	I-arm_dosage
dose	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	I-arm_dosage
240	I-arm_dosage	I-arm_dosage
mg	I-arm_dosage	I-arm_dosage
to	I-arm_dosage	I-arm_dosage
be	I-arm_dosage	I-arm_dosage
administered	I-arm_dosage	I-arm_dosage
as	I-arm_dosage	I-arm_dosage
a	I-arm_dosage	I-arm_dosage
60	I-arm_dosage	I-arm_dosage
min	I-arm_dosage	I-arm_dosage
IV	I-arm_dosage	I-arm_dosage
infusion	I-arm_dosage	I-arm_dosage
.	O	O
Treatment	O	O
regimen	O	O
depends	O	O
on	O	O
study	O	O
group	O	O
:	O	O
in	O	O
study	B-arm_description	O
group	I-arm_description	O
A	I-arm_description	O
,	O	O
nivolumab	B-arm_description	B-arm_description
will	O	O
be	O	O
given	O	O
on	O	B-arm_dosage
day	B-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
of	I-arm_dosage	I-arm_dosage
the	I-arm_dosage	I-arm_dosage
first	I-arm_dosage	I-arm_dosage
cycle	I-arm_dosage	I-arm_dosage
and	I-arm_dosage	O
continued	I-arm_dosage	O
to	I-arm_dosage	O
be	I-arm_dosage	O
given	I-arm_dosage	O
every	I-arm_dosage	O
two	I-arm_dosage	O
weeks	I-arm_dosage	O
.	O	O
The	O	O
first	B-arm_dosage	O
fraction	I-arm_dosage	O
of	O	O
radiotherapy	B-arm_description	O
has	O	O
to	O	O
be	O	O
delivered	B-arm_dosage	O
within	I-arm_dosage	O
72	I-arm_dosage	B-arm_dosage
h	I-arm_dosage	I-arm_dosage
after	I-arm_dosage	I-arm_dosage
cycle	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
day	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
.	O	O

Gross	O	O
tumor	O	O
volumes	O	O
(	O	O
GTV	O	O
)	O	O
are	O	O
contoured	O	O
on	O	O
the	O	O
planning	O	O
CT	O	O
,	O	O
considering	O	O
additional	O	O
co	O	O
-	O	O
registered	O	O
imaging	O	O
techniques	O	O
such	O	O
as	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
or	O	O
positron	O	O
emission	O	O
tomography	O	O
(	O	O
PET	O	O
)	O	O
,	O	O
if	O	O
available	O	O
.	O	O
Derived	O	O
from	O	O
the	O	O
GTV	O	O
,	O	O
clinical	O	O
(	O	O
CTV	O	O
)	O	O
and	O	O
planning	O	O
target	O	O
volumes	O	O
(	O	O
PTV	O	O
)	O	O
are	O	O
created	O	O
using	O	O
common	O	O
institutional	O	O
margins	O	O
to	O	O
confidently	O	O
cover	O	O
radiation	O	O
targets	O	O
and	O	O
simultaneously	O	O
spare	O	O
organs	O	O
at	O	O
risk	O	O
(	O	O
OAR	O	O
)	O	O
.	O	O
Contouring	O	O
of	O	O
relevant	O	O
OAR	O	O
is	O	O
only	O	O
necessary	O	O
in	O	O
cases	O	O
of	O	O
close	O	O
vicinity	O	O
or	O	O
anticipated	O	O
critical	O	O
radiation	O	O
exposure	O	O
.	O	O
In	O	O
case	O	O
of	O	O
thoracic	O	O
target	O	O
volumes	O	O
,	O	O
both	O	O
lungs	O	O
will	O	O
be	O	O
contoured	O	O
to	O	O
monitor	O	O
lung	O	O
dose	O	O
exposure	O	O
,	O	O
which	O	O
is	O	O
required	O	O
to	O	O
be	O	O
as	O	O
low	O	O
as	O	O
reasonably	O	O
achievable	O	O
.	O	O
In	O	O
cases	O	O
of	O	O
subtotal	O	O
lung	O	O
registration	O	O
,	O	O
the	O	O
OAR	O	O
"	O	O
both	O	O
partial	O	O
lungs	O	O
"	O	O
will	O	O
be	O	O
generated	O	O
.	O	O

Routine	O	O
haematological	O	O
analysis	O	O
of	O	O
red	O	O
and	O	O
white	O	O
blood	O	O
cells	O	O
and	O	O
platelets	O	O
are	O	O
part	O	O
of	O	O
the	O	O
scheduled	O	O
patient	O	O
assessments	O	O
under	O	O
therapy	O	O
and	O	O
are	O	O
not	O	O
a	O	O
specific	O	O
part	O	O
of	O	O
the	O	O
exploratory	O	O
biomarker	O	O
program	O	O
.	O	O
However	O	O
,	O	O
their	O	O
results	O	O
are	O	O
mandatory	O	O
baseline	O	O
information	O	O
as	O	O
absolute	O	O
cell	O	O
counts	O	O
for	O	O
further	O	O
investigations	O	O
.	O	O

The	O	O
study	O	O
requires	O	O
n	O	O
=	O	O
50	O	O
subjects	O	O
(	O	O
in	O	O
group	B-arm_description	B-arm_description
A	I-arm_description	O
)	O	O
to	O	O
detect	O	O
whether	O	O
the	O	O
responding	O	O
proportion	O	O
(	O	O
ORR	O	O
)	O	O
is	O	O
higher	O	O
than	O	O
19	O	O
%	O	O
by	O	O
applying	O	O
a	O	O
binomial	O	O
test	O	O
at	O	O
a	O	O
one	O	O
-	O	O
sided	O	O
significance	O	O
level	O	O
of	O	O
0.05	O	O
with	O	O
a	O	O
probability	O	O
of	O	O
1-beta	O	O
=	O	O
0.8	O	O
,	O	O
assuming	O	O
an	O	O
actual	O	O
response	O	O
rate	O	O
of	O	O
35	O	O
%	O	O
.	O	O

P.R.	O	O
China	O	O
Department	O	O
of	O	O
Hematology	O	O
and	O	O
Oncology	O	O
Tianjin	O	O
Clinical	O	O
Research	O	O
Center	O	O
for	O	O
Cancer	O	O
Key	O	O
Laboratory	O	O
of	O	O
Cancer	O	O
Prevention	O	O
and	O	O
Therapy	O	O
Tianjin	O	O
Medical	O	O
University	O	O
Cancer	O	O
Institute	O	O
and	O	O
Hospital	O	O
National	O	O
Clinical	O	O
Research	O	O
Center	O	O
for	O	O
Cancer	O	O
Tianjin	O	O

Diffuse	O	O
large	O	O
B	O	O
-	O	O
cell	O	O
lymphoma	O	O
(	O	O
DLBCL	O	O
)	O	O
is	O	O
an	O	O
aggressive	O	O
non	O	O
-	O	O
Hodgkin	O	O
lymphoma	O	O
with	O	O
extreme	O	O
heterogeneity	O	O
,	O	O
accounting	O	O
for	O	O
30	O	O
-	O	O
40	O	O
%	O	O
of	O	O
newly	O	O
diagnosed	O	O
lymphomas	O	O
[	O	O
1	O	O
]	O	O
.	O	O
Although	O	O
the	O	O
standard	O	O
R	O	O
-	O	O
CHOP	O	O
regimen	O	O
has	O	O
extremely	O	O
good	O	O
therapeutic	O	O
effect	O	O
on	O	O
DLBCL	O	O
patients	O	O
,	O	O
approximately	O	O
30	O	O
-	O	O
40	O	O
%	O	O
of	O	O
patients	O	O
show	O	O
relapse	O	O
and	O	O
10	O	O
%	O	O
have	O	O
refractory	O	O
disease	O	O
[	O	O
2	O	O
]	O	O
.	O	O
In	O	O
the	O	O
past	O	O
decades	O	O
,	O	O
accumulating	O	O
evidences	O	O
have	O	O
shown	O	O
the	O	O
genetic	O	O
,	O	O
microenvironment	O	O
,	O	O
autoimmune	O	O
diseases	O	O
and	O	O
occupational	O	O
exposure	O	O
participated	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
DLBCL	O	O
[	O	O
3][4][5	O	O
]	O	O
.	O	O
With	O	O
gene	O	O
-	O	O
expression	O	O
profiling	O	O
and	O	O
next	O	O
-	O	O
generation	O	O
sequencing	O	O
,	O	O
some	O	O
common	O	O
genetic	O	O
loci	O	O
are	O	O
found	O	O
to	O	O
enmesh	O	O
in	O	O
the	O	O
lymphomagenesis	O	O
of	O	O
DLBCL	O	O
[	O	O
6	O	O
]	O	O
.	O	O
However	O	O
,	O	O
the	O	O
pathogenesis	O	O
of	O	O
DLBCL	O	O
is	O	O
still	O	O
not	O	O
fully	O	O
understood	O	O
.	O	O

Total	O	O
RNA	O	O
was	O	O
isolated	O	O
using	O	O
TRIzol	O	O
reagent	O	O
(	O	O
Invitrogen	O	O
)	O	O
.	O	O
We	O	O
normalized	O	O
the	O	O
levels	O	O
of	O	O
expression	O	O
of	O	O
CREBBP	O	O
relative	O	O
to	O	O
glyceraldehyde	O	O
phosphate	O	O
dehydrogenase	O	O
(	O	O
GAPDH	O	O
)	O	O
,	O	O
and	O	O
2	O	O
−	O	O
C	O	O
t	O	O
indicated	O	O
the	O	O
quantification	O	O
of	O	O
gene	O	O
expression	O	O
.	O	O
The	O	O
primers	O	O
for	O	O
CREBBP	O	O
were	O	O
:	O	O
forward	O	O
5	O	O
-CGGCTCTAGTATCAACCCAGG-3	O	O
and	O	O
reverse	O	O
5	O	O
-TTTTGTGCTT	O	O
GCGGATTCAGT-3	O	O
.	O	O
The	O	O
primers	O	O
for	O	O
0	O	O
:	O	O
italic	O	O
GAPDH	O	O
/0	O	O
:	O	O
italic	O	O
were	O	O
:	O	O
forward5	O	O
-CCACATCGCTCAGACACCAT-3	O	O
andreverse5	O	O
-CCAGGCGCCCAATACG-3	O	O
.	O	O

CREBBP	O	B-arm_description
expression	O	O
was	O	O
detected	O	O
in	O	O
63	O	O
patients	O	O
and	O	O
32	O	O
controls	O	O
.	O	O
The	O	O
results	O	O
showed	O	O
that	O	O
the	O	O
CREBBP	O	O
expression	O	O
was	O	O
remarkably	O	O
down	O	O
-	O	O
regulated	O	O
in	O	O
patients	O	O
as	O	O
compared	O	O
with	O	O
controls	O	O
(	O	O
P<0.001	O	O
,	O	O
Figure	O	O
2A	O	O
)	O	O
.	O	O
The	O	O
CREBBP	O	O
expression	O	O
of	O	O
patients	O	O
with	O	O
GG	O	O
genotype	O	O
was	O	O
down	O	O
-	O	O
regulated	O	O
as	O	O
compared	O	O
with	O	O
the	O	O
patients	O	O
with	O	O
GA	O	O
and	O	O
AA	O	O
genotype	O	O
(	O	O
P=0.016	O	O
and	O	O
0.001	O	O
,	O	O
respectively	O	O
,	O	O
Figure	O	O
2B	O	O
)	O	O
.	O	O
However	O	O
,	O	O
no	O	O
significant	O	O
difference	O	O
was	O	O
detected	O	O
between	O	O
the	O	O
GA	O	O
and	O	O
AA	O	O
subgroups	O	O
(	O	O
P=0.134	O	O
,	O	O
Figure	O	O
2B	O	O
)	O	O
.	O	O
The	O	O
CREBBP	O	O
expression	O	O
was	O	O
down	O	O
-	O	O
regulated	O	O
in	O	O
the	O	O
GA	O	O
/	O	O
AA	O	O
subgroup	O	O
as	O	O
compared	O	O
with	O	O
the	O	O
GG	O	B-arm_description
subgroup	O	O
(	O	O
P=0.002	O	O
,	O	O
Figure	O	O
2C	O	O
)	O	O
.	O	O

Treatment	O	O
-	O	O
related	O	O
toxicities	O	O
during	O	O
PCR	B-arm_description	O
and	O	O
alemtuzumab	B-arm_description	B-arm_description
were	O	O
those	O	O
expected	O	O
in	O	O
patients	O	O
with	O	O
R	O	O
/	O	O
R	O	O
CLL	O	O
receiving	O	O
CIT	O	O
(	O	O
Table	O	O
2	O	O
)	O	O
.	O	O
Anemia	O	O
,	O	O
thrombocytopenia	O	O
and	O	O
neutropenia	O	O
were	O	O
observed	O	O
in	O	O
16	O	O
%	O	O
,	O	O
34	O	O
%	O	O
and	O	O
60	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
during	O	O
PCR	B-arm_description	O
treatment	I-arm_description	O
.	O	O
The	O	O
worst	O	O
-	O	O
degree	O	O
of	O	O
non	O	O
-	O	O
hematologic	O	O
treatment	O	O
-	O	O
related	O	O
toxicities	O	O
during	O	O
PCR	B-arm_description	O
treatment	I-arm_description	O
were	O	O
grades	O	O
3	O	O
-	O	O
4	O	O
in	O	O
47	O	O
patients	O	O
(	O	O
47	O	O
%	O	O
)	O	O
and	O	O
grade	O	O
5	O	O
in	O	O
5	O	O
patients	O	O
(	O	O
5	O	O
%	O	O
)	O	O
.	O	O
These	O	O
included	O	O
fatigue	O	O
(	O	O
9	O	O
%	O	O
)	O	O
,	O	O
nausea	O	O
(	O	O
8	O	O
%	O	O
)	O	O
and	O	O
vomiting	O	O
(	O	O
7	O	O
%	O	O
)	O	O
.	O	O
Metabolic	O	O
abnormalities	O	O
were	O	O
observed	O	O
in	O	O
18(18	O	O
%	O	O
)	O	O
patients	O	O
but	O	O
all	O	O
were	O	O
less	O	O
than	O	O
grade	O	O
4	O	O
.	O	O
Tumor	O	O
-	O	O
lysis	O	O
syndrome	O	O
was	O	O
documented	O	O
in	O	O
six	O	O
patients	O	O
,	O	O
all	O	O
grade	O	O
3	O	O
.	O	O
Febrile	O	O
neutropenia	O	O
occurred	O	O
in	O	O
10	O	O
patients	O	O
(	O	O
10	O	O
%	O	O
)	O	O
.	O	O
Most	O	O
infections	O	O
,	O	O
either	O	O
presumed	O	O
or	O	O
proven	O	O
,	O	O
were	O	O
grades	O	O
1	O	O
-	O	O
3	O	O
.	O	O
These	O	O
included	O	O
respiratory	O	O
tract	O	O
,	O	O
urinary	O	O
tract	O	O
,	O	O
skin	O	O
and	O	O
ocular	O	O
site	O	O
infections	O	O
.	O	O
Colitis	O	O
,	O	O
unrelated	O	O
to	O	O
CMV	O	O
,	O	O
occurred	O	O
in	O	O
two	O	O
patients	O	O
(	O	O
C.	O	O
difficile	O	O
,	O	O
unknown	O	O
)	O	O
.	O	O
Septicemia	O	O
was	O	O
documented	O	O
in	O	O
2	O	O
patients	O	O
,	O	O
one	O	O
of	O	O
whom	O	O
died	O	O
.	O	O
Pneumonia	O	O
,	O	O
attributable	O	O
to	O	O
CMV	O	O
occurred	O	O
in	O	O
2	O	O
patients	O	O
.	O	O
There	O	O
were	O	O
5	O	O
treatment	O	O
-	O	O
related	O	O
deaths	O	O
during	O	O
the	O	O
PCR	B-arm_description	O
therapy	I-arm_description	O
including	O	O
multiorgan	O	O
failure	O	O
(	O	O
1	O	O
)	O	O
,	O	O
ARDS	O	O
,	O	O
non	O	O
-	O	O
CMV	O	O
(	O	O
1	O	O
)	O	O
,	O	O
infection	O	O
(	O	O
1	O	O
)	O	O
,	O	O
pneumonitis	O	O
(	O	O
2	O	O
)	O	O
.	O	O

Greece	O	O
Athens	O	O
Greece	O	O
Adverse	O	O
event	O	O
management	O	O
in	O	O
the	O	O
TOURMALINE	B-study_type	O
-	I-study_type	O
MM3	I-study_type	O
study	I-study_type	O
of	O	O
post	O	O
-	O	O
transplant	O	O
ixazomib	B-arm_description	B-arm_description
maintenance	I-arm_description	O
in	O	O
multiple	O	O
myeloma	O	O
1	O	O
July	O	O
2020	O	O
1	O	O
July	O	O
2020	O	O
1	O	O
July	O	O
2020	O	O
10.1007	O	O
/	O	O
s00277	O	O
-	O	O
020	O	O
-	O	O
04149	O	O
-	O	O
5	O	O
Received	O	O
:	O	O
12	O	O
May	O	O
2020	O	O
/	O	O
Accepted	O	O
:	O	O
14	O	O
June	O	O
2020	O	O
#	O	O
The	O	O
Author(s	O	O
)	O	O
2020	O	O

The	O	O
design	O	O
of	O	O
the	O	O
TOURMALINE	B-study_type	O
-	I-study_type	O
MM3	I-study_type	O
study	I-study_type	O
has	O	O
been	O	O
described	O	O
previously	O	O
[	O	O
14	O	O
]	O	O
.	O	O
Briefly	O	O
,	O	O
eligible	O	O
patients	O	O
were	O	O
adults	O	O
with	O	O
a	O	O
confirmed	O	O
diagnosis	O	O
of	O	O
symptomatic	O	O
MM	O	O
(	O	O
by	O	O
the	O	O
International	O	O
Myeloma	O	O
Working	O	O
Group	O	O
criteria	O	O
)	O	O
who	O	O
had	O	O
achieved	O	O
at	O	O
least	O	O
a	O	O
partial	O	O
response	O	O
after	O	O
receiving	O	O
standardof	O	O
-	O	O
care	O	O
induction	O	O
therapy	O	O
(	O	O
including	O	O
a	O	O
proteasome	O	O
inhibitor	O	O
and/or	O	O
an	O	O
immunomodulatory	O	O
drug	O	O
)	O	O
followed	O	O
by	O	O
high	O	O
-	O	O
dose	O	O
melphalan	O	O
conditioning	O	O
and	O	O
single	O	O
ASCT	O	O
.	O	O
Following	O	O
transplant	O	O
,	O	O
patients	O	O
were	O	O
randomized	O	O
in	O	O
a	O	O
3:2	O	O
ratio	O	O
to	O	O
receive	O	O
either	O	O
oral	B-arm_description	O
ixazomib	I-arm_description	B-arm_description
3	B-arm_dosage	O
mg	I-arm_dosage	O
(	O	O
n	O	O
=	O	O
395	O	O
)	O	O
or	O	O
matching	O	O
placebo	B-arm_description	B-arm_description
(	O	O
n	O	O
=	O	O
261	O	O
)	O	O
on	B-arm_dosage	B-arm_dosage
days	I-arm_dosage	I-arm_dosage
1	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
8	I-arm_dosage	I-arm_dosage
,	I-arm_dosage	I-arm_dosage
and	I-arm_dosage	I-arm_dosage
15	I-arm_dosage	I-arm_dosage
in	I-arm_dosage	I-arm_dosage
28-day	I-arm_dosage	I-arm_dosage
cycles	I-arm_dosage	I-arm_dosage
.	O	O
Stratification	O	O
factors	O	O
were	O	O
induction	O	O
regimen	O	O
,	O	O
pre	O	O
-	O	O
induction	O	O
disease	O	O
stage	O	O
,	O	O
and	O	O
posttransplant	O	O
response	O	O
.	O	O
The	O	O
dose	O	O
of	O	O
ixazomib	B-arm_description	B-arm_description
was	O	O
increased	B-arm_dosage	O
to	I-arm_dosage	O
4	I-arm_dosage	O
mg	I-arm_dosage	O
starting	I-arm_dosage	O
at	I-arm_dosage	O
cycle	I-arm_dosage	O
5	I-arm_dosage	O
if	O	O
ixazomib	B-arm_description	B-arm_description
was	O	O
tolerated	O	O
during	O	O
the	O	O
previous	O	O
4	O	O
cycles	O	O
.	O	O
Treatment	O	O
was	O	O
continued	O	O
for	O	O
up	O	O
to	O	O
26	O	O
cycles	O	O
(	O	O
~2	O	O
years	O	O
)	O	O
or	O	O
until	O	O
progressive	O	O
disease	O	O
or	O	O
unacceptable	O	O
toxicity	O	O
.	O	O

Supportive	O	O
measures	O	O
consistent	O	O
with	O	O
optimal	O	O
patient	O	O
care	O	O
(	O	O
including	O	O
myeloid	O	O
growth	O	O
factors	O	O
,	O	O
erythropoietin	O	O
,	O	O
red	O	O
blood	O	O
cell	O	O
and	O	O
platelet	O	O
transfusions	O	O
,	O	O
prophylaxis	O	O
for	O	O
deep	O	O
vein	O	O
thrombosis	O	O
/	O	O
pulmonary	O	O
embolism	O	O
,	O	O
antibiotics	O	O
,	O	O
intravenous	O	O
immunoglobulin	O	O
,	O	O
antiemetics	O	O
,	O	O
antidiarrheals	O	O
,	O	O
and	O	O
corticosteroids	O	O
)	O	O
could	O	O
be	O	O
given	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O
Unless	O	O
there	O	O
was	O	O
a	O	O
clinical	O	O
contraindication	O	O
,	O	O
prophylactic	O	O
antiviral	O	O
therapy	O	O
to	O	O
prevent	O	O
reactivation	O	O
of	O	O
herpes	O	O
zoster	O	O
infection	O	O
was	O	O
mandatory	O	O
following	O	O
a	O	O
protocol	O	O
amendment	O	O
.	O	O
Use	O	O
of	O	O
concomitant	O	O
medications	O	O
(	O	O
such	O	O
as	O	O
prophylaxis	O	O
or	O	O
symptomatic	O	O
treatment	O	O
)	O	O
,	O	O
including	O	O
blood	O	O
products	O	O
and	O	O
supportive	O	O
therapies	O	O
,	O	O
was	O	O
recorded	O	O
from	O	O
the	O	O
first	O	O
dose	O	O
of	O	O
the	O	O
study	O	O
drug	O	O
through	O	O
30	O	O
days	O	O
after	O	O
the	O	O
final	O	O
dose	O	O
.	O	O
Concomitant	O	O
medications	O	O
were	O	O
classified	O	O
according	O	O
to	O	O
their	O	O
preferred	O	O
term	O	O
in	O	O
the	O	O
World	O	O
Health	O	O
Organization	O	O
Drug	O	O
Dictionary	O	O
.	O	O

All	O	O
safety	O	O
outcomes	O	O
are	O	O
presented	O	O
using	O	O
descriptive	O	O
statistics	O	O
using	O	O
SAS	O	O
version	O	O
9.2	O	O
(	O	O
or	O	O
higher	O	O
)	O	O
.	O	O
TOURMALINE	B-study_type	O
-	I-study_type	O
MM3	I-study_type	O
was	O	O
conducted	O	O
in	O	O
accordance	O	O
with	O	O
the	O	O
International	O	O
Conference	O	O
on	O	O
Harmonisation	O	O
Guidelines	O	O
for	O	O
Good	O	O
Clinical	O	O
Practice	O	O
and	O	O
all	O	O
relevant	O	O
regulatory	O	O
requirements	O	O
.	O	O
The	O	O
protocol	B-study_type	O
was	O	O
approved	O	O
by	O	O
an	O	O
ethics	O	O
committee/	O	O
institutional	O	O
review	O	O
board	O	O
at	O	O
each	O	O
center	O	O
.	O	O
All	O	O
patients	O	O
provided	O	O
written	O	O
informed	O	O
consent	O	O
.	O	O

The	O	O
rate	O	O
of	O	O
new	O	O
-	O	O
onset	O	O
nausea	O	O
was	O	O
highest	O	O
during	O	O
the	O	O
first	O	O
3	O	O
months	O	O
of	O	O
treatment	O	O
and	O	O
then	O	O
decreased	O	O
substantially	O	O
(	O	O
Fig	O	O
.	O	O
3b	O	O
)	O	O
.	O	O
The	O	O
incidence	O	O
rate	O	O
of	O	O
vomiting	O	O
was	O	O
also	O	O
highest	O	O
in	O	O
cycle	O	O
1	O	O
in	O	O
the	O	O
ixazomib	B-arm_description	B-arm_description
arm	O	O
and	O	O
generally	O	O
higher	O	O
versus	O	O
placebo	B-arm_description	B-arm_description
(	O	O
Fig	O	O
.	O	O
4a	O	O
)	O	O
;	O	O
new	O	O
-	O	O
onset	O	O
vomiting	O	O
was	O	O
most	O	O
common	O	O
during	O	O
the	O	O
first	O	O
3	O	O
months	O	O
and	O	O
then	O	O
decreased	O	O
(	O	O
Fig	O	O
.	O	O
4b	O	O
)	O	O
.	O	O
The	O	O
incidence	O	O
rate	O	O
of	O	O
diarrhea	O	O
was	O	O
similar	O	O
between	O	O
groups	O	O
in	O	O
cycles	O	O
1	O	O
-	O	O
2	O	O
and	O	O
then	O	O
higher	O	O
with	O	O
ixazomib	B-arm_description	B-arm_description
versus	O	O
placebo	B-arm_description	B-arm_description
through	O	O
cycle	O	O
9	O	O
(	O	O
Fig	O	O
.	O	O
5a	O	O
)	O	O
;	O	O
the	O	O
rate	O	O
of	O	O
new	O	O
-	O	O
onset	O	O
diarrhea	O	O
was	O	O
low	O	O
and	O	O
similar	O	O
between	O	O
groups	O	O
thereafter	O	O
(	O	O
Fig	O	O
.	O	O
5b	O	O
)	O	O
.	O	O

Thromboprophylaxis	O	O
was	O	O
not	O	O
mandated	O	O
by	O	O
the	O	O
protocol	O	O
but	O	O
could	O	O
have	O	O
been	O	O
administered	O	O
per	O	O
institutional	O	O
guidelines	O	O
,	O	O
and	O	O
19	O	O
%	O	O
of	O	O
patients	O	O
in	O	O
each	O	O
arm	O	O
used	O	O
an	O	O
antithrombotic	O	O
agent	O	O
.	O	O
Based	O	O
on	O	O
the	O	O
SMQ	O	O
for	O	O
venous	O	O
embolic	O	O
and	O	O
thrombotic	O	O
events	O	O
,	O	O
2	O	O
patients	O	O
(	O	O
<	O	O
1	O	O
%	O	O
)	O	O
in	O	O
the	O	O
ixazomib	B-arm_description	B-arm_description
arm	O	O
had	O	O
a	O	O
thrombotic	O	O
event	O	O
.	O	O
One	O	O
of	O	O
these	O	O
patients	O	O
had	O	O
a	O	O
history	O	O
of	O	O
port	O	O
catheter	O	O
implantation	O	O
,	O	O
and	O	O
the	O	O
other	O	O
patient	O	O
had	O	O
a	O	O
history	O	O
of	O	O
pulmonary	O	O
embolism	O	O
and	O	O
was	O	O
receiving	O	O
antithrombotic	O	O
medication	O	O
.	O	O
Each	O	O
of	O	O
these	O	O
patients	O	O
had	O	O
low	O	O
-	O	O
grade	O	O
events	O	O
.	O	O
One	O	O
of	O	O
these	O	O
patients	O	O
experienced	O	O
thromboembolic	O	O
events	O	O
of	O	O
jugular	O	O
vein	O	O
thrombosis	O	O
and	O	O
subclavian	O	O
vein	O	O
thrombosis	O	O
that	O	O
led	O	O
to	O	O
hospitalization	O	O
and	O	O
resulted	O	O
in	O	O
discontinuation	O	O
of	O	O
ixazomib	B-arm_description	B-arm_description
.	O	O
In	O	O
the	O	O
placebo	B-arm_description	B-arm_description
arm	O	O
,	O	O
no	O	O
patient	O	O
had	O	O
a	O	O
venous	O	O
thromboembolic	O	O
event	O	O
.	O	O
Arterial	O	O
thromboembolic	O	O
events	O	O
,	O	O
as	O	O
assessed	O	O
according	O	O
to	O	O
the	O	O
SMQ	O	O
for	O	O
arterial	O	O
embolic	O	O
and	O	O
thrombotic	O	O
events	O	O
,	O	O
were	O	O
reported	O	O
infrequently	O	O
(	O	O
<	O	O
1	O	O
%	O	O
ixazomib	B-arm_description	B-arm_description
,	O	O
1	O	O
%	O	O
placebo	B-arm_description	B-arm_description
)	O	O
.	O	O

Patients	O	O
with	O	O
high	O	O
-	O	O
risk	O	O
solid	O	O
tumors	O	O
reported	O	O
to	O	O
express	O	O
one	O	O
or	O	O
more	O	O
target	O	O
tumor	O	O
antigens	O	O
-	O	O
WT1	O	O
,	O	O
PRAME	O	O
,	O	O
and/or	O	O
survivin	O	O
-	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
published	O	O
literature	O	O
[	O	O
12][13][14][15][16][17][18][19][21][22][23	O	O
]	O	O
were	O	O
eligible	O	O
for	O	O
this	O	O
nonrandomized	O	O
phase	O	B-study_type
I	O	I-study_type
study	O	I-study_type
.	O	O
Informed	O	O
consent	O	O
was	O	O
obtained	O	O
for	O	O
patients	O	O
who	O	O
met	O	O
standard	O	O
eligibility	O	O
requirements	O	O
,	O	O
including	O	O
performance	O	O
status	O	O
and	O	O
organ	O	O
function	O	O
parameters	O	O
,	O	O
before	O	O
cell	O	O
procurement	O	O
and	O	O
TAA	O	O
-	O	O
T	O	O
infusion	O	O
(	O	O
ClinicalTrials.gov	O	O
identifier	O	O
:	O	O
NCT02789228	O	O
;	O	O
Appendix	O	O
Fig	O	O
A1	O	O
,	O	O
online	O	O
only	O	O
)	O	O
.	O	O
This	O	O
study	O	O
was	O	O
approved	O	O
by	O	O
the	O	O
US	O	O
Food	O	O
and	O	O
Drug	O	O
Administration	O	O
(	O	O
IND	O	O
16135	O	O
)	O	O
and	O	O
the	O	O
Children	O	O
's	O	O
National	O	O
Medical	O	O
Center	O	O
(	O	O
CNMC	O	O
)	O	O
institutional	O	O
review	O	O
board	O	O
.	O	O

We	O	O
analyzed	O	O
survival	O	O
data	O	O
,	O	O
including	O	O
PFS	B-arm_efficacy_metric	B-arm_efficacy_metric
,	O	O
median	O	O
,	O	O
and	O	O
95	O	O
%	O	O
CIs	O	O
,	O	O
with	O	O
either	O	O
log	O	O
-	O	O
rank	O	O
test	O	O
to	O	O
compare	O	O
DLs	O	O
or	O	O
sign	O	O
test	O	O
to	O	O
compare	O	O
the	O	O
difference	O	O
between	O	O
TAA	B-arm_description	O
-	I-arm_description	O
T	I-arm_description	O
DL	I-arm_description	O
3	I-arm_description	O
and	O	O
immediate	O	O
prior	O	O
therapy	O	O
.	O	O
Results	O	O
were	O	O
presented	O	O
using	O	O
the	O	O
Kaplan	O	O
-	O	O
Meier	O	O
method	O	O
.	O	O
P	O	O
values	O	O
,	O	O
.05	O	O
were	O	O
considered	O	O
statistically	O	O
significant	O	O
(	O	O
Appendix	O	O
,	O	O
online	O	O
only	O	O
)	O	O
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
was	O	O
investigator	O	O
-	O	O
assessed	O	O
PFS	O	B-arm_efficacy_metric
,	O	O
with	O	O
secondary	O	O
end	O	O
points	O	O
including	O	O
OS	O	O
,	O	O
ORR	O	O
,	O	O
clinical	O	O
benefit	O	O
rate	O	O
,	O	O
safety	O	O
and	O	O
tolerability	O	O
[	O	O
13	O	O
]	O	O
.	O	O
Tumor	O	O
response	O	O
was	O	O
assessed	O	O
per	O	O
RECIST	O	O
,	O	O
version	O	O
1.1	O	O
,	O	O
at	O	O
screening	O	O
,	O	O
every	O	O
8	O	O
weeks	O	O
after	O	O
randomization	O	O
for	O	O
18	O	O
months	O	O
and	O	O
every	O	O
12	O	O
weeks	O	O
thereafter	O	O
until	O	O
disease	O	O
progression	O	O
,	O	O
death	O	O
,	O	O
withdrawal	O	O
of	O	O
consent	O	O
or	O	O
loss	O	O
to	O	O
follow	O	O
-	O	O
up	O	O
[	O	O
13	O	O
]	O	O
.	O	O
ECG	O	O
assessments	O	O
were	O	O
performed	O	O
at	O	O
screening	O	O
,	O	O
on	O	O
day	O	O
15	O	O
of	O	O
cycle	O	O
1	O	O
,	O	O
on	O	O
days	O	O
1	O	O
and	O	O
15	O	O
of	O	O
cycle	O	O
2	O	O
,	O	O
on	O	O
day	O	O
1	O	O
of	O	O
all	O	O
subsequent	O	O
cycles	O	O
up	O	O
to	O	O
cycle	O	O
6	O	O
,	O	O
at	O	O
end	O	O
of	O	O
treatment	O	O
,	O	O
and	O	O
as	O	O
clinically	O	O
indicated	O	O
.	O	O
In	O	O
patients	O	O
with	O	O
a	O	O
QTcF	O	O
≥481	O	O
ms	O	O
at	O	O
any	O	O
time	O	O
before	O	O
cycle	O	O
7	O	O
,	O	O
additional	O	O
ECGs	O	O
were	O	O
performed	O	O
predose	O	O
on	O	O
day	O	O
1	O	O
of	O	O
subsequent	O	O
cycles	O	O
and	O	O
post	O	O
dose	O	O
every	O	O
third	O	O
cycle	O	O
[	O	O
13	O	O
]	O	O
.	O	O

Ribociclib	B-arm_description	B-arm_description
is	O	O
now	O	O
being	O	O
investigated	O	O
as	O	O
a	O	O
potential	O	O
adjuvant	O	O
or	O	O
neoadjuvant	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
breast	O	O
cancer	O	O
.	O	O
These	O	O
trials	O	O
are	O	O
randomizing	O	O
HR+	O	O
,	O	O
HER2-breast	O	O
cancer	O	O
patients	O	O
to	O	O
treatment	O	O
with	O	O
ribociclib	O	O
in	O	O
combination	O	O
with	O	O
ET	O	O
or	O	O
to	O	O
standard	O	O
of	O	O
care	O	O
treatment	O	O
.	O	O
In	O	O
the	O	O
neoadjuvant	O	O
setting	O	O
,	O	O
the	O	O
Phase	O	B-study_type
II	O	I-study_type
FELINE	O	O
trial	O	O
is	O	O
comparing	O	O
ribociclib	B-arm_description	B-arm_description
plus	O	O
letrozole	B-arm_description	O
versus	O	O
placebo	O	B-arm_description
plus	O	O
letrozole	O	O
in	O	O
postmenopausal	O	O
women	O	O
with	O	O
HR+	O	O
,	O	O
HER2early	O	O
breast	O	O
cancer	O	O
(	O	O
NCTT02712723	O	O
)	O	O
[	O	O
41,42	O	O
]	O	O
;	O	O
the	O	O
Phase	O	B-study_type
II	O	I-study_type
NEOLBC	O	O
trial	O	O
is	O	O
comparing	O	O
ribociclib	B-arm_description	B-arm_description
plus	O	O
letrozole	B-arm_description	O
versus	O	O
standard	O	O
chemotherapy	O	O
as	O	O
a	O	O
neoadjuvant	O	O
therapy	O	O
in	O	O
postmenopausal	O	O
women	O	O
with	O	O
HR+	O	O
,	O	O
HER2-luminal	O	O
breast	O	O
cancer	O	O
(	O	O
NCT03283384	O	O
)	O	O
[	O	O
43	O	O
]	O	O
;	O	O
and	O	O
the	O	O
CORALLEEN	O	O
trial	O	O
is	O	O
comparing	O	O
ribociclib	B-arm_description	O
plus	O	O
letrozole	B-arm_description	O
versus	O	O
standard	O	O
chemotherapy	O	O
as	O	O
a	O	O
neoadjuvant	O	O
therapy	O	O
in	O	O
postmenopausal	O	O
women	O	O
with	O	O
luminal	O	O
B	O	O
,	O	O
HER2-breast	O	O
cancer	O	O
(	O	O
NCT03248427	O	O
)	O	O
[	O	O
44,45	O	O
]	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
the	O	O
Phase	O	B-study_type
III	O	I-study_type
NATALEE	O	O
trial	O	O
will	O	O
evaluate	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
ribociclib	B-arm_description	O
plus	O	O
ET	O	O
compared	O	O
with	O	O
ET	O	O
alone	O	O
as	O	O
an	O	O
adjuvant	O	O
treatment	O	O
in	O	O
pre	O	O
/	O	O
perimenopausal	O	O
and	O	O
postmenopausal	O	O
women	O	O
with	O	O
early	O	O
breast	O	O
cancer	O	O
(	O	O
NCT03701334	O	O
)	O	O
[	O	O
46	O	O
]	O	O
.	O	O

